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Abstract 
The impact of iron on the function and composition of the human gut 
microbiota 
Iron-supplements are widely consumed; however, most of the iron is not absorbed and 
enters the colon where potentially pathogenic bacteria can utilise it for growth. Assessing 
iron bioavailability and the effects on bacterial groups is an evolving subject area and 
forms the basis of the research presented in this thesis. 
The growth of Escherichia coli and Salmonella Typhimurium was significantly impaired 
when cultured independently in iron-deficient media (p<0.0001). These observations 
positively correlated with a decrease in water-soluble iron concentrations present in the 
culture. However, depletion of iron did not affect the growth of the beneficial 
species, Lactobacillus rhamnosus. 
Culturing human faecal microbiotas in an in vitro colon model identified changes in the 
growth of different bacterial taxa. 16S rDNA-based metataxonomics indicated that under 
conditions of iron depletion through BPDS, a chemical iron chelator, the relative 
abundance of several taxa decreased, including a 10% and 15% decrease in Escherichia 
and Bifidobacterium, respectively. This was supported by observations of lower viable 
counts of Enterobacteriaceae and bifidobacteria. Analysis using 1H NMR indicated that 
the production of acetate, butyrate and propionate in vitro was reduced under iron-
restricted conditions. Iron chelation through phytin, a dietary compound, illustrated similar 
results with the exception of a 33% increase in the relative abundance of Bifidobacterium 
and 225% increase in Collinsella. Furthermore, increases in propionate and formate 
concentrations were also observed when cultured with phytin. 
A 6-week, crossover double-blinded randomised human dietary intervention trial was 
performed (n=14), where participants were asked to consume encapsulated phytin or 
placebo. Capsules were coated with a specialised formulation, Phloral®, designed to 
release phytin directly in the colon. No conclusions could be made regarding the iron 
chelating properties of phytin as analysis of stool samples collected revealed clumps of 
phytin and therefore, unsuccessful dispersal of phytin within the colonic lumen. This pilot 
human intervention study indicates that the form of phytin is an important factor and this 
should be considered for follow-up studies. 
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1.0  Introduction to iron 
From ancient times, the special role of iron in health and disease has been recognised by 
man [1, 2] and has been used for its medicinal purposes by Greeks, Romans, Hindus and 
Egyptians [3]. During the 17th century, treatment of chlorosis (green disease), a condition 
arising due to iron deficiency, was treated with the administration of iron [4]. However, 
1932 marked the year where the importance of iron was highlighted and it was proved that 
inorganic iron was essential for haemoglobin synthesis [5]. In humans, iron is incorporated 
into proteins as a component of haem (e.g. haemoglobin, cytochrome proteins, myoglobin, 
nitric oxide synthetases, myeloperoxidase), iron sulphur clusters (DNA primase, 
respiratory complexes I-III) or other functional groups [6]. Essential cellular and 
organismal functions are dependent on these iron-containing proteins, some of which 
include the transport of oxygen, mitochondrial respiration, nucleic acid replication and 
repair, cell signalling and host defence [7-12].  
The oxygenation of the Earth’s atmosphere over 2 billion years ago led to the oxidisation 
of the abundant soluble ferrous iron (Fe2+) to insoluble ferric iron (Fe3+), causing iron 
bioavailability to decrease [13]. Simultaneously, the potential toxic nature of iron also 
increased due to the redox cycling of iron under oxygenated environments. This leads to 
catalysis of free radicals by hydrogen peroxide, named the Fenton reaction, and 
subsequently causes damage to DNA, lipids and proteins [14-16]. Subsequently, humans as 
well as other organisms have acquired specialised proteins and strictly regulated 
homeostatic mechanisms for the uptake, transport, storage and export of iron to ensure iron 
availability for vital biological processes, but at the same time regulate the toxicity of 
excess iron. 
1.1 Iron absorption, metabolism, regulation and homeostasis 
1.1.1 Biochemistry and physiology 
Iron is an abundant element on earth and is a biologically essential component of every 
living organism [17-19]. In response to iron scarcity, a variety of cellular mechanisms have 
developed to obtain iron from the surrounding environment in biologically useful forms. 
Such examples are siderophores (further details in section 2.2.2.1), iron-scavenging 
molecules secreted by microbes [20], or mechanisms that involve the reduction of Fe3+ to 
the soluble Fe2+ as in yeasts [21]. Analogous counterparts are also found in higher 
organisms, including humans, where iron is found mostly as complex forms bound to 
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various proteins (haemoprotein) as haem compounds (haemoglobin or myoglobin), haem 
enzymes or non-haem compounds (transferrin, ferritin) [3]. Iron is required for the 
production of oxygen transport proteins, especially haemoglobin and myoglobin, and is 
also necessary for the formation of haem enzymes and other iron-containing enzymes that 
are a part of the electron transfer process as well as oxidation-reductions [3, 22]. 
Approximately two-thirds of the iron within the body is found in haemoglobin present 
within circulating erythrocytes and is recycled in the process of erythrophagocytosis by 
reticuloendothelial macrophages. These iron-recycling macrophages are a major storage 
site of iron, along with liver hepatocytes. In comparison, all other cells in the body contain 
smaller amounts of iron for important cellular processes. A quarter of the iron is present 
within iron storage compartments and the remaining 15% is bound to myoglobin in muscle 
tissue and in a range of enzymes contributing to oxidative metabolism and other cellular 
functions [23].  
1.1.2 Iron absorption and recycling 
The absorption of iron by the epithelial cells of the small intestine is an extremely tightly 
regulated process and any disruption in this process could hinder the body’s iron 
homeostasis [24]. The small intestine is responsible for iron uptake and transport into the 
systemic circulation, under the control of hepcidin (further detail on this protein can be 
found in section 1.1.5.1), and therefore absorption of iron correlates with the body’s iron 
status or requirements when in normal physiological conditions [25]. For this reason, iron 
absorption is increased during hypoxia, iron depletion [25] and pregnancy [26], but is 
reduced in secondary iron-overload conditions. However, conditions such as anaemia of 
chronic disease (ACD) and mutations in genes involved in iron metabolism can have a 
large effect on iron absorption [27].  
Dietary iron has broadly been classified into two types, non-haem and haem iron. Both 
these forms of dietary iron have a separate pathway of uptake by enterocytes. Haem iron is 
a lot more bioavailable and its bioavailability is less influenced by dietary constituents. 
Whilst the molecular mechanism of non-haem iron absorption is clear, the mechanism for 
haem iron absorption is still emerging. 
The first step in the absorption process of non-haem iron is its uptake from the lumen of 
the intestine across the apical membrane and into the enterocyte. Divalent metal transporter 
1 (DMT1), an iron transporter, is responsible for mediating this step, and transports iron as 
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Fe2+. However, the majority of the iron that enters the duodenal lumen from the diet is Fe3+ 
and therefore the iron must first be reduced before it can be taken up by the enterocytes. 
Duodenal cytochrome B (DcytB), a brush border ferric reductase enzyme that is highly 
expressed in the duodenum, is responsible for the reduction of Fe3+ into Fe2+. Once inside 
the enterocyte, the intracellular trafficking of iron from the brush border membrane to the 
basolateral membrane is poorly understood [28]. Intracellular iron may be bound to 
chaperone molecules to maintain its solubility, but to date none have been identified. In 
fact, many proteins have been proposed to be involved in absorption and transport of non-
haem iron (Table 1.1). Iron that is not transported around the body is instead incorporated 
into ferritin, the iron storage molecule, and is lost when the cell is ultimately sloughed at 
the villus tip.  
Ferroportin-1 facilitates the efflux of iron across the basolateral membrane and into the 
circulation. Ferroportin-1 also plays a role in the export of iron from other cell types, 
including monocytes and macrophages [29]. In addition to ferroportin-1, the basolateral 
efflux of iron from enterocytes requires the ferroxidase, hephaestin. Although the exact 
role of this protein has not been defined, it is thought that iron is exported as Fe2+, oxidised 
to Fe3+ by hephaestin and ceruloplasmin, and loaded onto transferrin, the main plasma iron 
carrier [30-33]. 
As mentioned earlier, the recycling of iron through macrophages is the major source of 
iron for haemoglobin synthesis [34]. After a mean lifespan of 120 days, specialised 
macrophages phagocytose old and damaged red blood cells (RBCs). After lysis, iron is 
released from the haemoglobin of RBCs by haemoxygenase 1 and thereafter iron can be 
stored in ferritin and exported to the bloodstream by ferroportin through a similar process 
as described above for duodenal enterocytes. Ferroportin, the only known mammalian iron 
exporter, is therefore a “major gatekeeper controlling iron entry into the bloodstream” [35]. 
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Table 1.1 - Proteins involved in intestinal non-haem iron absorption. Adapted from 
Gulec et al., 2014 [36]. 
Protein Function 
Duodenal cytochrome B (DcytB) Ferric iron reduction for absorption via 
DMT1 
Divalent metal transporter 1 
(DMT1) 
Ferrous iron transporter 
Ferroportin (FPN1) Ferrous iron exporter 
Ferritin Intracellular iron storage 
Hephaestin Ferroxidase 
Hepcidin Liver-derived, iron regulator 
 
Currently, there are two prevailing hypotheses explaining the mechanisms of haem iron 
absorption; firstly, a well-known theory that haem is taken up by receptor mediated 
endocytosis; secondly, the recent discovery of a haem transporter that may have the 
capability of transferring haem from the small intestinal lumen directly into the cytoplasm 
[37]. These pathways are summarised in Figure 1.1 and discussed in detail below.  
The hypothesis of haem uptake by receptor mediated endocytosis originated in 1979 from 
the discovery of a haem binding protein on the microvillus membrane of the upper small 
intestine of both pigs and humans [38]. Haem enters mucosal cells via the brush border 
membrane, possibly by endocytosis, as the intact iron-protoporphyrin complex [37]. Haem 
oxygenase 1 (HO-1) then initiates the release of iron which enters the same pathway as 
non-haem iron and subsequently is influenced by the same factors. 
In recent years, two mammalian haem transporters have been discovered, namely proton-
coupled folate transporter/haem carrier protein 1 (PCFT/HCP1) [39, 40] and feline 
leukaemia virus subgroup C receptor (FLVCR) [41]. These appear to function 
independently of the putative haem receptor and receptor mediated endocytosis in that they 
act as a direct transfer process across plasma membranes [37]. It is hypothesised that 
FLVCR transports intact haem across the basolateral membrane where it then binds 
haemopexin. Alternatively, haem may be catabolised to non-haem iron and biliverdin by 
HO-1 located on the endoplasmic reticulum. Any iron released from haem inside the 
enterocyte, regardless of the mode of uptake, ultimately joins the labile iron pool and is 
transferred to the bloodstream by FPN1 in the same fashion as non-haem iron. 
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Figure 1.1 – Summary diagram of the hypothesised mechanisms of haem iron uptake. DMT1 is 
responsible for the uptake of non-haem iron before joining the labile iron pool in the cytoplasm. 
Fe3+ is first reduced to Fe2+ by DcytB. Fe2+ is then transferred to the circulation by ferroportin, 
which requires hephaestin for oxidation to Fe3+ in order to bind to circulating apotransferrin. 
Haem iron is hypothesised to be taken up by receptor-mediated endocytosis. Internalised haem is 
degraded by haem oxygenase inside the vesicles, releasing non-haem iron and generating 
biliverdin. The non-haem iron is subsequently transported to the cytoplasm by DMT1. Haem iron 
may also be taken up by PCFT/HCP1 directly into the cytoplasm. Intact haem may be transported 
across the basolateral membrane by FLVCR where it binds circulating haemopexin. Alternatively, 
biliverdin may catabolise haem to non-haem iron by HO-1, which is located on the endoplasmic 
reticulum. Irrespective of how iron is taken up in to the cell, the iron which is released from haem 
within the enterocyte joins the labile iron pool. FPN1 then transfers this iron into the bloodstream 
in the same way non-haem iron is transported. Diagram and description taken from West and 
Oates, 2008 [37] 
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1.1.3 Circulating iron 
Under physiological conditions, transferrin-bound iron is the predominant form of iron 
circulating in the bloodstream [18]. Transferrin has the ability to carry up to two iron 
molecules and therefore ensures iron remains in an inert state. Transferrin saturation 
reflects the levels of iron occupation of the iron binding sites on transferrin, which 
typically ranges from 20-40%. Iron is delivered to tissues by transferrin for uptake by 
transferrin receptor 1 (TfR1), a ubiquitously expressed protein [42]. Transferrin receptor 2 
(TfR2) is a homologue of TfR1 and has a much more limited expression. It has been 
thought that TfR2 may be involved in the sensing of transferrin-bound iron levels in other 
tissues, such as erythrocytes and the liver [34, 43]. In circumstances where transferrin is 
fully saturated, non-transferrin bound iron (NTBI) can circulate. This includes highly 
reactive labile plasma iron (LPI) that can lead to cellular damage if taken up by organs 
such as the pancreas, liver and heart [44].  
Blood plasma also contains ferritin, which is mainly derived from macrophages [45]. 
Circulating ferritin is generally reflective of body iron stores, but as it is an acute phase 
protein its levels can be massively influenced by the presence of infection, inflammation, 
liver disease and also malignancy derived from other conditions [44].  
Another protein, neutrophil gelatinase associated lipocalin (NGAL)/lipocalin-2, has also 
been reported to behave as an extracellular iron carrier by binding to siderophores (iron-
binding compounds secreted by microorganisms). Furthermore, haemopexin and 
haptoglobin, which are haem and haemoglobin scavengers, respectively, are also proteins 
known to circulate within the bloodstream [46, 47]. 
1.1.4 Iron storage 
Ferritin concentration, together with that of haemosiderin, reflects the body’s iron stores. 
These proteins store iron in an insoluble form and are present primarily in the liver, spleen, 
and bone marrow [48]. The majority of iron is bound to the ubiquitous and highly 
conserved iron-binding protein, ferritin [49]. Haemosiderin is an iron storage complex that 
does not readily release iron. Under steady state conditions, serum ferritin concentrations 
correlate well with total body iron stores [50]. Thus, serum ferritin is the most convenient 
laboratory test to estimate iron stores. 
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1.1.5 Human iron homeostasis 
The circulating pool of iron is relatively small (approximately 2-4 mg) and turns over 
every few hours to ensure the daily requirement of iron for erythropoiesis (RBC 
production) and other needs of the body (approximately 20-25 mg) are met [35]. On 
average, roughly 1-2 mg of iron is absorbed daily from the diet in the duodenum and 
proximal jejunum [51, 52]. This is balanced by the unregulated loss of iron through 
desquamation of skin, sloughing of intestinal epithelial cells and blood loss. Urinary iron 
excretion is minimal due to the largely protein bound form of circulating iron (transferrin-
bound iron) and other mechanisms for iron retrieval in the kidney [53]. Since the human 
body has no controlled mechanism for the excretion of iron, the major avenues for 
regulating systemic iron balance are in the control of dietary iron uptake as well as the 
release of iron from recycling macrophages and hepatocytes [54]. An overview of systemic 
iron homeostasis is summarised in Figure 1.2. 
 
Figure 1.2 - Systemic iron homeostasis. Transferrin (Tf) bound iron circulates in the bloodstream. 
Most of the iron is transported to the bone marrow for red blood cell synthesis, whilst smaller 
amounts are delivered to other tissues for essential cellular processes. Excess iron is transported to 
the liver for storage. Recycling of RBCs is the main process for ensuring iron homeostasis is 
maintained, whilst lesser levels of iron are provided from the diet through duodenal enterocytes. 
Diagram taken from Dev and Babitt, 2017 [35]. 
Circulating iron is delivered to erythrocytes and other cells within the body through 
specific uptake mechanisms [42]. One key uptake mechanism is that of receptor-mediated 
endocytosis of transferrin-bound iron by TfR1 into clathrin coated pits. Clathrin is a 
protein that plays an important role in the formation of coated vesicles [55]. Once 
endocytosed, iron is then released into the endosome, an acidic environment, therefore 
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initiating the reduction of Fe3+ to Fe2+. This reduction is mediated by the ferrireductase, 
STEAP3. DMT1 then exports Fe2+ out of the endosome and TfR1 undergoes recycling and 
returns to the surface of the cell to repeat this process. Once iron enters the labile-iron pool, 
also known as the ‘chelatable’ iron pool, it can be used immediately, stored in an inert 
form in cytosolic or mitochondrial ferritin, trafficked to the mitochondria for use in the 
iron-sulphur cluster pathways or exported out of the cell [35]. 
1.1.5.1  Systemic iron homeostasis 
The successful functioning of cells and tissues is heavily dependent on maintaining optimal 
levels of iron in the circulation. For instance, too much iron could potentially lead to iron 
overload and related diseases, while too little systemic iron could lead to restricted 
erythropoiesis and consequent anaemia [54].  
Another environment in which iron regulation is crucial is during infections and iron 
removal by the host is important in the innate immune response to pathogens. To ensure 
that the body’s iron requirements are met, the human body has evolved many mechanisms 
to sense and adjust iron levels accordingly. Furthermore, these mechanism are also 
activated under the presence of inflammatory/infectious stimuli as well as hypoxia and 
erythropoietic signals [54]. Hepcidin and ferroportin, two molecules found in the liver, are 
the two major proteins involved in regulating and maintaining systemic iron homeostasis.  
Ferroportin, the only known mammalian iron exporter, is found in various cells, with its 
highest expression being in macrophages, followed by duodenal enterocytes and 
hepatocytes. Ferroportin is also expressed in cells that are involved in iron recycling, 
absorption, storage and regulation [56]. Its expression is controlled at different levels, 
including transcriptional, translational and post-translational levels. The ferroportin mRNA 
contains a functional iron responsive element (IRE) in its 5′ untranslated region (UTR). 
Under low iron conditions, translation of ferroportin is repressed, leading to a decrease in 
cellular iron export [56]. Transcription of the macrophage ferroportin gene can be 
promoted by haem [57] and inhibited by inflammatory stimuli [58]. The complete loss of 
ferroportin expression in mouse models and zebrafish was demonstrated to be lethal due to 
the resultant inability of embryonic trophoblasts to transfer iron from the mother to the 
embryo [29]. New-born mice which lacked ferroportin developed severe iron-deficiency 
anaemia as a result of reduced dietary iron absorption and a faulty release of iron from 
hepatic storage and iron-recycling macrophages [29].  
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The hormone hepcidin is the major protein involved in regulating ferroportin levels at a 
systemic level. Hepcidin is a 25 amino acid polypeptide expressed in the liver and serves 
as an iron-regulatory hormone. It was first identified in urine and plasma as a disulphide 
bonded, liver-expressed antimicrobial peptide [59, 60]. Very soon after, it emerged that 
hepcidin also played a crucial role in iron homeostasis regulation [61-63]. Studies 
illustrated the binding of hepcidin to ferroportin, resulting in reduced cellular iron export 
activity and subsequently leading to the internalisation and degradation of ferroportin [64]. 
Through hepcidin-ferroportin binding, immediate ubiquitination and internalisation of this 
complex occurs and therefore lowers cell surface expression and export of iron [65, 66]. 
Since the discovery of hepcidin in 2000, it has become apparent that its interaction with 
ferroportin is critical for systemic iron regulation and that disturbances in this hepcidin-
ferroportin complex are the foundation for several iron-related disorders [67].  
When chronically overexpressed, hepcidin causes iron-deficient anaemia in both mice and 
humans, which generally presents as microcytic, hypochromic anaemia. On the contrary, 
reduced hepcidin levels in mice and humans results in iron overload with iron deposition in 
the liver and other parenchyma [64, 68]. When completely absent, hepcidin causes juvenile 
haemochromatosis, which is the most severe form of hereditary haemochromatosis.  
Hepcidin homeostasis is regulated by iron and erythropoietic activity. When in excess, iron 
stimulates hepcidin production. Subsequently, dietary iron absorption is reduced and 
therefore prevents further loading. Under iron-deficient environments, hepcidin levels are 
repressed, which allows for increased iron absorption from the diet and subsequently 
leading to the replenishment of iron stores. When erythropoietic activity is heightened, 
hepcidin expression is, in turn, decreased. This allows for increased absorption as well as 
the quick release of macrophage and hepatocyte-stored iron, and therefore increasing the 
supply of iron for erythropoiesis.  
Lastly, inflammation and infection also influence hepcidin. Under these conditions, 
hepcidin levels are upregulated and it is thought that this occurs as a host defence 
mechanism to limit iron availability to microorganisms [69]. Studies investigating this 
further examined the effect of administering IL-6 to human volunteers and showed an 
increase in urinary hepcidin excretion within 2 h of IL-6 administration [70]. Other 
cytokines have also been suggested to influence hepcidin expression and it was shown that 
IL-6 knockout mice still presented with elevated hepcidin mRNA levels compared to wild-
type mice [70]. In this study, IL-1 was shown to upregulate hepcidin mRNA in mouse 
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hepatocytes independently of IL-6. An overview of iron regulation through hepcidin is 
shown in Figure 1.3. 
 
Figure 1.3 – Interaction of hepcidin and ferroportin complex. Intracellular Fe2+approach and 
bind to ferroportin in its inward-facing state, which leads to a change in conformation of 
ferroportin to the outward-facing state, allowing export of iron. Ferroportin then returns to its 
original inward-facing state to transport another intracellular iron molecule. Under high hepcidin 
levels, hepcidin binds ferroportin, which prevents the conformational transition and iron export. 
Conversely, when hepcidin levels are low under low iron environments, hepcidin-ferroportin 
binding does not occur, which in turn allows ferroportin to resume iron transportation. The 
binding of hepcidin also leads to a conformational change, which subsequently uncovers many 
ubiquitination sites. This then triggers the internalisation and degradation of ferroportin. Diagram 
and description adapted from Zhang and Rouault, [71] 
1.1.5.2  Cellular iron homeostasis 
The iron regulatory protein (IRP) system is a major regulator of cellular iron homeostasis 
[72, 73]. In conditions where cellular iron levels are low, the expression of a number of 
iron homeostasis proteins are regulated by IRPs through the binding of these proteins to 
IREs. This occurs in the mRNA 5’ UTR of the IREs to prevent translation of ferroportin 
and ferritin, for example. This could also occur in the mRNA 3’UTR of the IREs to inhibit 
the degradation of TfR1, for example [72]. Through the binding of the UTRs of the IREs, 
an increase in iron uptake is observed whilst iron storage decreases in environments of low 
cellular iron. The reverse is observed when cellular iron levels are high.  
1.2 Iron bioavailability 
Non-haem iron is derived from pulses, cereals, fruits, legumes and vegetables, whilst the 
primary sources for haem iron are haemoglobin and myoglobin from meat, fish and poultry 
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[74-76]. Compared to haem iron absorption, which represents roughly between 15-35% of 
total iron intake, non-haem iron absorption is considerably lower, between 2-20% of total 
iron intake [77]. As haem iron is complexed with globin, its absorption is largely 
unaffected by other dietary factors, whereas non-haem iron is strongly influenced by the 
presence of other food components [22, 77]. Despite its lower bioavailability, non-haem 
iron levels are much greater than that of haem iron in most meals and therefore, in general, 
non-haem iron plays a bigger part in iron nutrition compared to haem iron [78]. The most 
common enhancers of iron absorption are ascorbic acid, which could potentially reduce 
Fe3+ to Fe2+ and subsequently aid the binding of iron in soluble complexes to increase 
absorption, and muscle tissue from which digested peptides are believed to bind any free 
soluble iron [77]. Inhibitors of iron absorption are calcium, polyphenols and phytic acid 
[52, 77, 79, 80].  
1.2.1 Factors enhancing iron absorption 
Many dietary factors have a positive effect on iron absorption. Ascorbate behaves as a 
weak chelator of iron and subsequently increases iron uptake through increasing the 
solubility of iron in the duodenum [81-85]. The enhancing effect of ascorbate is largely 
attributable to its ability to reduce Fe3+ to Fe2+ as well as its ability to form a weak-chelate 
complex with iron. Hallberg et al., (1989) [86] and Siegenberg et al., (1991) [85] 
demonstrated that ascorbic acid is able to reverse the inhibitory effects on iron absorption 
by phytate and polyphenols. Another study reported that the addition of ascorbic acid at 
concentrations of 100 mg/L or higher in cow’s milk supplemented with ferrous sulphate 
(FeSO4) enhanced iron absorption and therefore bioavailability of iron [87]. In fruits and 
vegetables, the enhancing effects of ascorbic acid is often counteracted by the presence of 
polyphenols [88], and as ascorbic acid is the only enhancer of iron-absorption present in 
vegetarian diets, it is suggested that those following a vegetarian or vegan diet should 
include vegetables containing ascorbic acid to optimise iron absorption [84]. 
The enhancing effect of meat, fish, or poultry on iron absorption from non-vegetarian 
meals has been shown [89]. 30 g muscle tissue in meat is considered equivalent to 25 mg 
ascorbic acid [78]. One study reported that the addition of chicken, beef, or fish to a maize 
meal increased non-haem iron absorption 2-3-fold [90]. As with ascorbic acid, it has been 
somewhat more difficult to demonstrate the enhancing effect of meat in multiple meals and 
complete diet studies. One study demonstrated a small improvement in iron absorption 
(35%) in self-selected diets over 5 days when daily muscle tissue intake was increased to 
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300 g/day [91], although, in a similar 5-day study, 60 g pork meat added to a vegetarian 
diet increased iron absorption by 50% [92]. 
1.2.2 Factors inhibiting iron absorption 
Phytate (myo-inositol hexakisphosphate) is the main inhibitor of iron absorption in plant-
based diets [77, 93]. Low concentrations of phytate (2-10 mg/meal) have been 
demonstrated to have a dose-dependent negative effect on iron absorption [85, 94]. To 
significantly improve iron absorption in plant-based foods which do not contain any 
compounds to enhance iron absorption, the molar ratio of phytate to iron should be 1:1 or 
preferably 0.4:1 [95].  
Various animal proteins have been shown to decrease iron absorption. These include 
proteins derived from animal milk and eggs, including albumin and egg whites [96, 97]. 
Whey and casein are the two major bovine milk proteins that have been illustrated to 
inhibit iron absorption in humans [97]. Soybean-derived proteins have also been 
demonstrated to inhibit iron absorption [98].  
Compared to other inhibitors of iron absorption, which affect non-haem iron, calcium 
negatively affects both haem and non-haem iron [99]. Studies have shown that when doses 
of 75-300 mg of calcium is added to wheat bread rolls, a dose-dependent inhibitory effect 
is observed in iron absorption. This study also found that administering 165 mg calcium in 
the form of milk, cheese or calcium chloride also reduced iron absorption in humans by 50-
60%. The same amount of calcium also significantly inhibited haem iron absorption, 
suggesting a role of calcium in the mucosal transfer of iron [100]. 
Polyphenols are dietary constituents obtained through plant-based foods, occurring in tea, 
coffee, wine, fruits, vegetables and some legumes and cereals. Black tea has been shown to 
reduce iron absorption, as have herbal teas but to a lesser extent [101, 102].  
1.3 Iron disorders 
1.3.1 Iron deficiency  
1.3.1.1  Iron deficiency anaemia  
Despite the high abundance of iron in the environment, iron deficiency is extremely 
common in humans. According to the World Health Organisation (WHO), approximately 
30-50% of anaemia in children is due to iron deficiency and as such it is the most prevalent 
cause of anaemia worldwide [103]. It is estimated that two billion people worldwide who 
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are nutritionally iron deficient suffer from iron-deficiency anaemia (IDA) [104]. There are 
many health risks associated with IDA, including impaired cognitive and physical 
development in children, cognitive decline in the elderly, increased risk of mother and 
child mortality as well as a decreased output of physical performance and work 
productivity in adults [104, 105]. 
IDA can be due to various factors, but the main reason is insufficient dietary iron 
absorption. Other reasons include malabsorption, increased blood loss (for instance, 
gastrointestinal losses from ulcers or malignancies) and increased iron requirements during 
pregnancy [105].  
1.3.1.2  Anaemia of chronic disease 
ACD, also known as anaemia of chronic inflammation, is the most common cause of 
anaemia reported in hospitalised patients [106] and is the second most prevalent cause of 
anaemia, after IDA [107-109].  
ACD is characterised by an immune activation with an increase in inflammatory cytokines, 
such as IL-6, and subsequently leads to elevated hepcidin levels. Imbalanced 
erythropoietin levels and the lack of responsiveness to erythropoiesis further contributes to 
ACD. As mentioned previously in this chapter, hepcidin, being the central regulator of iron 
metabolism, plays a crucial role in the pathophysiology of ACD. Hepcidin binds to 
ferroportin present on macrophages, hepatocytes, and enterocytes which then leads to the 
degradation of ferroportin. This, in turn, leads to iron trapping within the macrophages and 
hepatocytes, resulting in functional iron deficiency. ACD is therefore characterised by 
reduced levels of circulating iron despite adequate or high stores of total body iron [108-
110].  
1.3.2 Iron overload  
1.3.2.1  Hereditary haemochromatosis 
Hereditary haemochromatosis (HH) is an autosomal recessive disorder that disrupts the 
body's regulation of iron [111]. HH occurs in approximately 1 in 200-250 individuals, with 
approximately 0.4% of people of northern European descent having the genetic mutation 
and thereby increasing the risk of developing haemochromatosis [112-115]. Men have a 
24-fold increased rate of iron-overload disease compared with women, and occurs 
predominantly in Caucasians [116]. Persons who are homozygous for the HFE gene 
mutation C282Y comprise up to 90% of phenotypically affected persons. In an estimated 
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10% of individuals homozygous for C282Y, end-organ damage or clinical manifestations 
of HH are present. HH symptoms are generally non-specific and are not entirely apparent 
in the early stages of the disorder. Typical symptoms of HH are weakness, joint pain (also 
known as arthralgia) and lethargy [117]. Later stages of HH encompass individuals 
suffering from osteoporosis, cardiomyopathy, diabetes mellitus, cirrhosis, hepatocellular 
cancer, dysrhythmia and hypogonadism [111, 116, 117]. The appropriate interpretation of 
transferrin saturation and serum ferritin results is essential in the diagnosis of iron 
overload, where both transferrin saturation and serum ferritin levels are elevated [117, 
118]. 
Phlebotomy (also known as venesection therapy) is the standard treatment for patients with 
HH, having been implemented for over 60 y. As well as reducing iron levels, phlebotomy 
is also effective in reducing morbidity and mortality of HH [118, 119]. Iron overload 
during HH generally results in tissue injury mainly through the production of reactive 
oxygen species. These molecules are toxic to cell membranes and organelles, which 
subsequently results in cellular death [118]. During venesection therapy, an estimated 250 
mg of iron is removed per 500 mL of blood withdrawal. This iron is released as a means of 
a compensatory process from tissues overloaded with iron, such as the liver. Therefore, 
repeated venesection therapy is required to ensure the complete removal of excess iron in 
the individual [118]. 
Chelation therapy is also another avenue of treatment for HH individuals, however this is 
usually reserved for extreme cases, such as individuals who do not respond to the standard 
therapy of venesection, or when phlebotomies are medically contraindicated (such as poor 
vein conditions) [118]. 
In general, HH universal screening is not implemented, however first-degree relatives of 
HH patients, individuals with abnormally high iron levels and those with evidence of 
active liver disease are tested for potential HH. Only individuals with HH and cirrhosis are 
screened for hepatocellular carcinoma. 
HH patients are recommended to consume a healthy varied diet, avoiding foods with iron 
fortification, such as breakfast cereals. HH individuals are also discouraged from 
consuming iron and vitamin C supplements, as well as reducing alcohol intake and red 
meat consumption [116].  
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1.4 Chelation therapy 
The main aim of iron chelation therapy is to ensure a ‘safe’ iron status is sustained at all 
times. The main situations under which iron chelation therapy should be sought is when 
iron accumulation is to be prevented, and to lessen the extent of iron-related complications 
including hepatic, cardiac and endocrinological dysfunction.  
In practice, chelation therapy is generally utilised to eradicate excess stored iron and 
subsequently correct any complications related to the iron overload. Deferoxamine is a 
chelator used clinically and its use is generally implemented after 2 to 3 y of patients 
undergoing transfusion or when an individual’s ferritin levels exceed 1,000 ng/mL [120].  
Iron chelation therapy is extremely useful in not only treating iron overload but also 
minimising any harmful effects that usually present with iron burden. 
The direct capture of NTBI and LPI via effective chelation therapy may help to prevent the 
adverse consequences of iron overload. Many iron chelators have been used clinically, 
each of which have been designed to remove tissue iron by creating a complex with iron 
which are in turn excreted in the urine and/or faeces. Table 1.2 summarises these iron 
chelators. 
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Table 1.2 – An overview of different iron chelators. Adapted from Poggiali et al., (2012) 
[120] 
Property Deferoxamine Deferiprone Deferasirox 
Stoichiometry 
(chelator:iron) 
Hexadentate (1:1) Bidentate (2:1) Tridentate (3:1) 
Route Subcutaneous, 
intravenous 
Oral tablet/solution Tablets for oral 
suspension 
Excretion Urinary, faecal Mainly urinary Faecal 
Half-life 20-30 m 3-4 h 8-16 h 
Adverse 
effects 
Local skin 
reactions 
Ophthalmological 
Allergic reactions 
Growth retardation 
Bone 
abnormalities 
Pulmonary (high 
doses) 
Neurological (high 
doses) 
Gastrointestinal 
Agranulocytosis/neutropenia 
Arthralgia 
Elevated liver enzymes 
Gastrointestinal 
Rash 
Creatinine 
increase 
Proteinuria 
Ophthalmological 
Auditory 
Elevated liver 
enzymes 
Status Licensed Licensed in USA and 
Europe 
Licensed in USA 
and Europe 
 
1.5 The human gut microbiota 
Humans represent a framework upon which wide varieties of microbial ecosystems are 
established. Previously it was believed that all mammals are subjected to a life-long 
process of colonisation instantly after birth [121], however, recent research proposes that 
colonisation of the gastrointestinal tract begins in utero [122]. After many years of 
evolution, an environment of mutualism has been created whereby many host-bacterial 
associations have become relationships.  
The latter part of the gut (colon) is home to our highest number of microbes (over 100 
trillion bacteria) [123]. Symbiotic bacteria of the mammalian gut have long been 
recognised for the advantages they confer to the host. Some of these benefits include 
defence against opportunistic pathogen colonisation, metabolism of indigestible 
compounds, provision of necessary nutrients, such as iron, and involvement in the 
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development of the intestinal structure. The human gut microbiota also contributes towards 
the basic developmental features and functions of the immune system [124]. Conversely, 
perturbations (e.g. antibiotic treatment and/or overgrowth of pathogenic bacteria) in these 
symbiotic relationships, termed dysbiosis, can lead to a negative impact on the host’s 
health [125]. Dysbiosis can lead to a range of human disease states, such as autoimmune 
disorders [126, 127], increased vulnerability to cancers [128], irritable bowel syndrome 
[129-132] and obesity [133]. Furthermore, the number of studies examining the 
relationship between diet and the gut microbiota has increased over the past years and they 
have shown that the gut microbiota composition and metabolic activity is affected by diet 
[134]. Currently, it is not clearly defined whether the type of diet significantly contributes 
to host health or disease through the shaping of the gut microbiota. Elucidating the 
relationships between human health and the associated microbiota presents us with a new 
challenge, and, if successful, will provide an invaluable tool for diagnostics and possible 
mechanisms for human therapeutic interventions [135]. 
1.6 Factors that affect the gut microbiota 
After birth, factors like type of feeding (either breast-feeding or formula feeding) and 
hospitalisation continues to influence the gut microbiota [136]. Hygiene, diet and illness 
then play a role in later life [134]. Genetic factors also play a role in influencing the gut 
microbiota and have a contribution to an individual’s microbial composition.  
Historically, culture-based analysis has suggested that the gut microbiota of healthy people 
share bacterial species, which are common among the majority of individuals. More 
recently, large-scale studies for identifying and characterising different microbial 
communities have been carried out (Human Microbiome Project, HMP [137] and 
Metagenomics of the Human Intestinal Tract MetaHIT). These studies have highlighted 
that the vast diversity of the human gut microbiota poses a significant challenge when 
analysing human microbiota data. Each individual’s microbiota is dynamic and ever 
changing in response to diet, environment and host behaviour [138] and therefore this 
hinders our ability to make generalisations that are relevant across human populations. It 
has, however, been established that there is a high overall temporal stability of the 
microbial community amongst unrelated individuals, whereby a large collection of 
microbial genes are shared, encoding metabolic traits that pose an advantage to the host.  
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1.6.1 The effects of nutritional and metabolic stress on gut pathogens 
Unabsorbed iron from the diet travels to the colon, and there is accumulating evidence to 
suggest that this can facilitate the growth of intestinal pathogens [139]. The vast majority 
of bacteria in the gut require iron for growth and development, and they have formulated 
many strategies to acquire this nutrient, which in its more common state (Fe3+) has low or 
zero solubility. Potentially pathogenic bacteria make use of a continuous supply of 
micronutrients, such as iron, for metabolism and replication. Thus, there is constant 
competition for iron between various bacteria, many of which have developed 
mechanisms, such as siderophore production, to acquire iron, particularly when availability 
is limited. Unlike most bacteria, members of the Bifidobacteriaceae and Lactobacilliaceae 
families (two families that are believed to be beneficial to the host [140-143]) have a very 
limited need for iron [135]. Lactobacilli do not produce siderophores to sequester iron, and 
their growth is similar in media with and without iron [144]. The human body has created 
many ways to promote the growth of these beneficial bacteria, such as the presence of 
lactoferrin in breast milk which travels intact to the large intestine [145-147], which with 
its high affinity for iron, renders the iron unavailable to potentially pathogenic bacteria 
[148]. Along with high amounts of dietary iron in the gut lumen, the oral administration of 
iron supplements also results in freely available ‘unbound’ iron in the colon [149-151]. 
This disturbs iron homeostasis consequently modifying the gut microbial composition 
[152-154]. 
An emerging link between the gut microbiota and iron availability has been observed, 
however several studies that have investigated the effects of iron on the human gut 
microbiota are mainly focussed on the infant microbiota [150-152, 155-158].  
1.6.2 The effect of redox stress on bacteria 
Iron’s inherent redox cycling properties makes it a good metal for electron carrying and as 
a biocatalyst in proteins [20, 139]. Fe3+ is mostly present under aerobic conditions and is 
virtually insoluble. It is only soluble in water when it is complexed in a strong acidic 
solution, making its bioavailability very low despite it being present in such copious 
amounts on earth. Fe2+ is mainly found when oxygen levels are low as well as in acidic 
environments and is more soluble than Fe3+. Through the Fenton Reaction, reactive oxygen 
species (ROS) can be formed in the presence of free redox active iron under aerobic 
conditions, which can prove to be extremely toxic. The hydroxyl ion OH- is one of the 
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most reactive ROS species and can have detrimental effects on biological molecules and 
cells.  
Only a very small number of bacterial species do not require iron, such as those within the 
Lactobacillaceae family, which have acquired alternative metabolic solutions via evolution 
[159]. Lactobacillus plantarum was the first identified iron-independent microbial strain, 
which contains a maximum of 2 iron atoms – “a level that is considered to be too low to 
provide iron with any conceivable function” [160]. This property further justifies their 
presence in the natural gut microbiota and milk, a highly iron-restricted environment due to 
the lactoferrin [161]. 
Borrelia burgdorferi is a well-known pathogen that causes Lyme disease, transmitted to 
humans through the bite of infected ticks of the genus, Ixodes. This pathogen has advanced 
in an environment rich in manganese but poor in iron through the replacement of iron with 
manganese in their metalloproteins. This substitution is a vital trigger for bacterial 
virulence as well as the activation of superoxide dismutase (SodA) [162]. The lack of iron 
requirement by this bacterial species may facilitate infection conditions that strictly restrict 
iron bioavailability within the host systemic compartment [163]. 
Bacteria that utilise iron for their metabolism face the problem of having to overcome the 
stresses of the toxicity derived from free redox active iron molecules. To tackle this 
problem, many bacterial species have developed mechanisms to directly detoxify oxidative 
stress or iron itself. Catalase is a well-known enzyme that has the ability to neutralise ROS. 
This enzyme catalyses the reaction of two hydrogen peroxide molecules into the non-toxic 
products, oxygen and water.  
Another method to deal with oxidative stress is to directly counteract the oxidative stress 
molecules. SodA is an enzyme produced by many bacterial species and is involved in 
catalysing the dismutation of superoxide into a less toxic hydrogen peroxide and oxygen. 
Interestingly, different members of the SodA family utilise different metals as cofactors. 
For example, SodA members that use manganese and zinc are unable to perform the 
dismutation process if these metals are sequestered by the host under inflammatory 
conditions, consequently making the bacteria more susceptible to oxidative stress. Finally, 
alkylhydroperoxide reductase (Ahp) and glutathione peroxidase are peroxidases that can 
rapidly detoxify hydroperoxides, hydrogen peroxides or peroxynitrite [164].  
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1.6.3 Iron detoxification 
When iron is present in very high amounts, bacterial species are able to export iron to the 
outside of the cell. One example of this is a haem export mechanism (HrtAB), which 
reduces the haem-based iron stress in certain bacterial species, such as Staphylococcus 
aureus. Orthologues of the HrtAB system have been identified in Bacillus anthracis, 
Listeria monocytogenes, Enterococcus faecalis, and Streptococcus agalactiae [165].  
Bifidobacteria have the ability to bind iron to their surface, preventing the formation of 
radicals in the surrounding environment as well as sequestering iron inside the colonic 
lumen, preventing pathogenic bacteria from acquiring iron [166].  
Ferric iron can be bound to three types of bacterial high-affinity storage proteins [139]. 
These are ferritin (similar to eukaryotic ferritin), DNA binding protein from starved cells 
(DPS) and bacterioferritin. DPS has a dual role; it acts as a detoxification/iron storage 
protein but also binds DNA. For this reason, it is involved in the protection of bacterial 
DNA from redox stress [20]. By lowering the amount of intracellular free iron through the 
storage of iron in a non-toxic and soluble form, bacterial species are able to protect 
themselves from redox stress. When residing in the mammalian blood stream or host cells, 
for instance, iron levels are scarce and under these conditions, bacterial species are able to 
release the stored iron for utilisation.  
1.7 Iron exploitation by gut bacteria 
1.7.1 Bacterial uptake of iron 
Many bacterial species have developed mechanisms to acquire iron, even when availability 
is sparse. On average, bacteria need 10-7 – 10-5 M iron for optimal growth [139]. E. coli, for 
example is able to take up both forms of iron. One study describes the Feo-uptake system 
that E. coli uses to achieve this [20], which is involved in the transport of Fe2+ (under 
anaerobic conditions). Alternatively, most bacterial species are able to acquire iron through 
the reduction of Fe3+ into Fe2+ with the help of an extracellular reductase, and this can then 
be transported into the cell [167]. Furthermore, bacterial siderophores act as iron chelators 
with a very high affinity for iron [168]. Haemophores are another specialised method in 
which haem iron is directly taken up.  
Pathogenic bacteria using iron to thrive [169, 170] and conversely, decreasing in numbers 
when iron is limited, is a long-known concept. In vivo knockout studies on mice have 
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shown that particular iron uptake mechanisms, such as the Feo-uptake system, are essential 
in the survival and virulence of some bacterial species, such as E. coli [171, 172]. Bacteria 
upregulate or downregulate their virulence genes depending on the amount of iron that is 
available in the surrounding environment. For example, adhesion of Salmonella 
Typhimurium to enterocytes is increased in the presence of high amounts of iron [173]. 
Conversely, under iron-limiting conditions, bacterial toxins are decreased while bacterial 
siderophores are increased [174]. Either way, whether the iron availability is low or high, 
bacteria are able to alter different aspects of their virulence to adapt to the environment.  
1.7.2 The battle for iron 
One of the main reasons why free-iron concentrations are extremely low in the gut 
(approximately 10-24 M) is due to the toxic properties of iron, and for this reason iron is 
bound to high-affinity host proteins, preventing ROS formation [175]. These high-affinity 
proteins include transferrin, ferritin, lactoferrin and haemoproteins, such as haemosiderin. 
With bacterial species always competing for iron, the high-affinity binding of host proteins 
to iron is a form of innate defence against these microorganisms. Infection further boosts 
this defence mechanism. Under inflammatory conditions, the pro-inflammatory cytokine 
IL-6 is upregulated, as described earlier in this chapter. Once induced, hepcidin binds to 
ferroportin, and subsequently degrades and internalises it [69, 176, 177]. This leads to a 
reduced intestinal iron uptake and a concurrent increase in the iron stores belonging to the 
reticulo-endothelial system (RES). Consequently, extracellular pathogens have reduced 
access to iron. Therefore, being able to overcome these host iron-withdrawal mechanisms 
is an extremely important virulence trait that bacteria must possess or else they fail to 
thrive.  
1.7.2.1  Siderophores 
The more established method of bacterial iron acquisition is the secretion of iron-
scavenging siderophores [20, 178]. Siderophores are small organic molecules produced by 
microorganisms under iron-limiting conditions which enhance the uptake of iron to the 
microorganisms. Siderophores can be split into three key classes depending on the 
chemical nature of the moieties that donate the oxygen ligands for Fe3+ co-ordination 
[168]. These are hydroxamates, catecholates or carboxylates. However, new ‘mixed-type’ 
siderophores identified recently leads to more complex classifications (Figure 1.4). 
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Figure 1.4 - Different structural families of siderophores. Siderophores can be classified into 
three main structural families. These are catecholates, hydroxamates and carboxylates. The 
binding moieties are shown in green (catecholate), blue (hydroxamate) and red (carboxylate). 
Illustration taken from Holden and Bachman, 2015 [179].  
Siderophore production is the most common mechanism used by bacterial families such as 
Enterobacteriaceae, Streptomycetaceae, and Bacillaceae, in order to scavenge inorganic 
iron from the environment [180]. They are produced in high amounts by bacteria exposed 
to iron-limiting environments, due to their high ferric ion-specific chelating capacities [20, 
181].  
Pathogenic bacteria need to proliferate once inside the host for them to survive. Bacteria 
such as E. coli, S. Typhimurium and Klebsiella pneumoniae synthesise enterochelin [182, 
183], which binds to Fe3+ very strongly (association constant of 1052 M-1), unlike the host 
protein transferrin, which has an association constant that is much lower at 1022 M-1 [184]. 
The strong binding between enterochelin and iron can be exploited to scavenge even very 
low concentrations of iron in the surrounding environment. The iron is released from the 
siderophore once it is transported inside the bacterial cell through the action of reductases, 
which reduce siderophore-bound Fe3+ into Fe2+, thereby enabling it to be incorporated 
directly into metallo-enzymes. If there is an excess of iron, it can then be stored as 
bacterioferritin, or in the related DPS proteins [185]. The ferric uptake regulator (Fur) 
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repressor protein is then responsible for the shutdown of iron uptake once the bacteria have 
accumulated enough iron, by preventing the biosynthesis of the iron transport system 
(Figure 1.5). Moreover, some bacterial species have evolved even further and are able to 
extract Fe3+ directly from transferrin or even use haem as an iron source [186, 187].  
 
Figure 1.5 – Schematic representation of Fur-mediated repression. Taken from Crichton, 2008 
[188]. 
An example of haem utilisation can be observed in Bacteroides fragilis. These bacteria are 
able to take up haem by either expressing high-affinity haem outer membrane transporters 
or producing haemophores [189]. Under conditions of iron-depletion, the availability of 
iron is likely to be limited in the gastrointestinal tract [190] and therefore, the 
bioavailability of iron greatly influences the composition of the gut microbiota.  
1.7.2.2  Host counteraction of iron acquisition by bacteria 
The host has developed another counteracting mechanism to protect iron levels via the 
sequestration of some bacterial siderophores with lipocalin-2, an innate defence peptide 
[191, 192]. Lipocalin-2 binds bacterial siderophores, preventing the bacteria from taking 
up the Fe3+-enterobactin complex. However, some bacterial species overcome even this 
host response via ‘stealth siderophores’ [193, 194]. To illustrate, E. coli and S. 
Typhimurium can produce a C-glucosylated form of enterobactin, and salmochelin, which 
escapes the binding of lipocalin-2 [195]. Aerobactin is another example of a ‘stealth 
siderophore’ that also evades the binding of lipocalin-2. Shigella and Klebsiella are some 
bacterial genera that produce aerobactin. Some pathogenic E. coli strains and Salmonella 
serovars also produce this siderophore [196]. 
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1.8 Iron speciation and mechanisms of iron uptake  
1.8.1 Iron speciation 
Most of the iron that reaches the intestine is in the form of Fe3+. This is due to the acidic 
and high oxygen environment in the stomach, as well as the nature of foods itself. 
However, in the small intestine, the pH rises, rendering Fe3+ insoluble. This increase in pH 
facilitates the oxidation of any Fe2+ into Fe3+. However, in the colon, Fe3+ could be 
potentially reduced into Fe2+ by certain bacterial species, most of which are acidophiles  
[197]. Studies looking at the effect of pH on siderophore activity have illustrated that mice 
with a higher colonic pH have increased siderophore production. This suggests that the 
iron availability is scarce in high pH environments and therefore bacteria upregulate their 
iron-scavenging mechanisms [198]. However, this study used phosphate buffer at different 
pHs to induce the colonic pH and iron is prone to form complexes with phosphate, which 
could have influenced their results. Another study carried out by Salovaara et al., (2003) 
[199] supported the finding that Fe2+ uptake was increased by a lowering of the pH.  
Many factors can influence iron speciation and solubility and it is notoriously difficult to 
measure the different species of iron in the gut lumen. This therefore makes it difficult to 
predict how much iron is readily available for potentially pathogenic as well as commensal 
bacteria to use in the colon. As well as pH and oxygen, dietary components also have a 
huge influence on iron speciation and, in turn, its availability, as described earlier in this 
chapter.  
Other species of iron, including iron carbonates, iron hydroxides, iron phosphates and iron 
oxides, can also be found in the intestinal lumen, as the pH of the lumen enables 
precipitation with hydroxides as well as formation of complexes with proteins, amino acids 
and food components [139]. However, it not known to what extent bacteria are able to use 
these forms of insoluble iron. Several ways in which bacteria could possibly make these 
forms of iron more accessible is by reducing the pH of the surroundings through the 
production of different acids, such as lactic acid, binding to siderophores or directly 
reducing Fe3+ [200].  
1.8.2 Interaction between phytates and bacteria 
Phytates (the salt form of phytic acid) are derived from cereals and legumes. This 
compound has a very high iron-binding capacity and certain gut microorganisms 
(Bifidobacteriaceae and coliforms), are able to break down phytates. This mechanism 
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could have evolved as a way by which bacterial species can free the phytate-bound iron 
and use it for their growth [201]. One study showed that the highest phytate degrading 
activity belonged to Lactobacillus reuteri, Lactobacillus salivarius and Bifidobacterium 
dentium [201], which suggests that phytate-bound iron could potentially be a relevant 
source of iron for colonic microorganisms. Notably, phytate-bound irons found in the 
colon are present in the insoluble form making it difficult to degrade [52, 202]. A study 
that strengthens the idea of phytate degradation in the colon was carried out by Schlemmer 
et al., 2009 [203] who showed that degradation products of phytate were only seen in 
conventional rats when compared to germ-free rats, suggesting that phytate degradation 
occurs in the colon by the microbiota.  
1.8.3 Interaction between polyphenols and bacteria 
Tea and coffee are commonly consumed drinks that are high in polyphenolic compounds, 
including catechols and tannins. Polyphenols are known to reduce iron absorption in the 
small intestine due to their extremely strong iron-binding capacity. Strong binding between 
polyphenols and iron stops both the host and bacterial species from absorbing iron. 
However, bacterial species may have an advantage in these situations through siderophore 
production to compensate for low iron availability. Certain bacteria (Staphylococcus 
lugdunensis or Streptococcus gallolyticus), have been shown to be able to degrade tannate 
and in turn free the iron from the tannate-iron complex [204].  
1.9 Prebiotics  
1.9.1 Induction of beneficial bacterial growth through prebiotics 
According to the International Scientific Association for Probiotics and Prebiotics, 
prebiotics are defined as “a substrate that is selectively utilised by host microorganisms 
conferring a health benefit”, such as bifidobacteria and lactobacilli, which have the 
potential to improve host health. Prebiotics are, simply speaking, the ‘food’ for beneficial 
bacteria.  
Prebiotics have been shown to alter the microbial composition and metabolism, and in the 
process, potentially create an environment that favours iron bioavailability [205]. Common 
prebiotics include non-digestible oligosaccharides (NDOs) such as inulin and its partial 
hydrolysate fructo-oligosaccharides. Other identified prebiotics include galacto-
oligosaccharides and lactulose [206]. Tako et al., (2008) demonstrated that there was 
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significant variation in relative amounts of bifidobacteria and lactobacilli in the intestinal 
content between the treatment groups, with generally more bifidobacteria being present 
with increased prebiotic content [207]. 
Also known as, ‘colonic foods’, prebiotics resist digestion by gastric acid and pancreatic 
enzymes in vivo but are preferentially fermented by beneficial intestinal bacteria once they 
reach the colon. Studies have shown that provision of diets with inulin enhanced surface 
counts of bifidobacteria and lactobacilli in biopsy samples taken from the cecum, 
transverse and descending colon, and rectum of human subjects during colonoscopy [208]. 
Some reported benefits of beneficial bacteria include a decrease in toxic metabolites and 
detrimental enzymes secreted by pathogenic bacteria, strengthening the intestinal flora’s 
ability to defend against invasion by potentially pathogenic bacteria and repressing the 
onset of constipation. It should be noted that both inulin and fructo-oligosaccharides are 
‘generally-regarded-as-safe’ and their acceptable intake levels depend on the sensitivity of 
the consumer, ranging from <10 g/d to >30 g/d [209].  
As an effect of prebiotics, a change of microbial composition can lead to a change in the 
production of short chain fatty acids (SCFAs). SCFAs have also been shown to induce the 
proliferation of epithelial cells, therefore increasing the absorptive surface, whereas 
prebiotics or their fermentation products may enhance the presence of iron regulatory 
genes such as DMT1 in both the duodenum and the colon [207, 209]. One study illustrated 
that iron absorption genes in the colon of mice were highly expressed in iron-deficient 
mice compared with healthy controls [210]. It also showed that Dcytb was present in low 
amounts in the colon of iron-deficient mice. As mentioned earlier, Dcytb facilitates the 
reduction of Fe3+, which is necessary for the uptake of iron. Combined, this may indicate 
that it is not necessary for colonocytes to be able to produce Dcytb because the microbiota 
have other ways to elicit reductase activity that already contributes to the reduction of Fe3+ 
[210]. Another study examined the effects of iron absorption in gnotobiotic rats compared 
to conventionally raised rats [211]. It was found that the gnotobiotic rats had a much lower 
iron uptake activity in comparison to the conventionally raised rats, once again suggesting 
that microbial communities influence the ability of the host to absorb iron.  
1.9.2 Short chain fatty acids 
Humans lack the enzymes to degrade the bulk of dietary fibres which therefore pass the 
upper gastrointestinal tract unaffected and are fermented in the cecum and the large 
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intestine by the colonic bacteria. Fermentation of these indigestible fibres leads to the 
production of multiple groups of metabolites [212] of which SCFAs are the major group 
[213]. To the microbial community, SCFAs are an essential waste product, as they are 
needed to balance redox equivalent production in the anaerobic environment of the gut 
[214]. Also, SCFAs have been shown to exert multiple beneficial effects on mammalian 
energy metabolism. SCFAs are saturated aliphatic organic acids that consist of one to six 
carbons of which acetate (C2), propionate (C3), and butyrate (C4) are the most abundant 
(≥95%) [156]. Acetate is mainly used as an energy source in colonocytes [215]. Recently, 
a study suggested that the protection from enteropathogenic infection by bifidobacteria is 
partially attributed to the production of acetate [216]. The impact of butyrate on gut health 
has been examined comprehensively and has been associated with anti-cancerogenic 
effects and anti-inflammatory properties [217-219]. Furthermore, it has been shown that 
butyrate acts as an energy source for intestinal cells [220]. Lastly, propionate has been 
shown to be involved in cholesterol- and lipid-lowering mechanisms [221]. However, not 
all metabolites have beneficial effects on gut health. The accumulation of lactate in faeces 
has been correlated with inflammatory bowel disease and ulcerative colitis, and lactate 
concentrations increased during low iron availability conditions [156]. 
One study, with the use of in vitro colonic fermentations, carried out investigations looking 
at the relationship between iron availability and the effect it had on colonic metabolites 
[156]. A significant decrease of acetate, butyrate and propionate was observed under iron-
restricted conditions. These results could potentially be attributed to the fact that many 
iron-dependent enzymes are required for the production of these SCFAs, mainly acetate 
and butyrate. An estimated one third of acetate production is through the acetyl-CoA 
pathway, a pathway that depends on iron behaving as a co-factor for many enzymes. In the 
same manner, the production of butyrate also requires iron-dependent pathways at certain 
stages. It is therefore justified to assume that SCFA production is consequently lowered in 
iron-limiting environments. However, it is important to note that as the host can very 
quickly absorb SCFAs, caecal, colonic or faecal metabolite levels do not automatically 
equate to the levels produced by bacteria. 
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1.10 Animal and human studies in the context of iron and the gut 
microbiota 
A number of studies in animals and humans have investigated the effect of iron deficiency 
and/or supplementation on the composition of the gut microbiota, in animals and in 
humans. These studies have illustrated a fairly well-defined pattern of microbial alterations 
in the gut which correlate with conditions of either iron-limited or iron-supplemented diets. 
1.10.1 Animal studies  
Experimental animal studies provide a good foundation upon which hypotheses can then 
be tested in humans. Benoni et al., (1993) administered iron at different doses to rats and 
found that Clostridium difficile enterotoxin increased after 24 h along with the number of 
Clostridium spp. after 4 w, with the high-iron dose [222]. E. coli and Lactobacillaceae 
numbers were also increased after 2 weeks of iron administration, with numbers of 
Bacteroides spp. and enterococci reduced. Another study reported that total anaerobes, 
Enterococcus spp. as well as lactobacilli were elevated in iron-deprived mice and that iron 
supplementation generally perturbed the gut microbiota [223]. Lee et al., (2008) 
investigated weanling pigs that were put on an iron-supplemented diet, which resulted in 
no effect on clostridia, Lactobacillaceae, Bifidobacteriaceae and total anaerobic bacteria; 
however, increased numbers of coliform bacteria were observed [224].  
Another mouse study which encompassed a genetic modification of iron metabolism in 
mice illustrated that the relative abundance of five lactic acid bacteria were significantly 
different among the mouse lines, suggesting that the deletion of iron metabolism-related 
genes in the host can affect the intestinal gut composition [225]. 
Constante et al., (2017) performed a study investigating the effects of iron supplementation 
in dextran sulphate sodium (DSS) -induced mice illustrated that iron supplementation at 
different doses induced shifts in the gut microbial communities and inferred metabolic 
pathways. The most noticeable taxonomic changes included an increase in the relative 
abundance of Proteobacteria, and a decrease in the abundance of Firmicutes [226].  
Dostal et al., (2012) observed the effect of iron deficiency and subsequent iron repletion on 
the gut microbiota composition and metabolic activity in young Sprague-Dawley rats 
[151]. Iron deficiency led to an increase in Enterobacteriaceae and Lactobacillus but 
reduced counts of Bacteroides spp. and Roseburia spp./Eubacterium rectale members. 
Moreover, changes in metabolites were also seen, with decreases in butyrate and 
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propionate during iron-deficient conditions. Iron supplementation with FeSO4 and 
electrolytic iron re-established the original gut microbiota composition to an extent and led 
to a full recovery of metabolic activity in the rats, suggesting that iron is required for these 
populations to survive adequately. Similarly, another in vivo study which investigated the 
influence of SCFAs on iron absorption in the proximal colon in rats displayed low levels of 
butyrate and propionate during environments of luminal iron deficiency [227].  
Unsurprisingly, iron can promote the replication and virulence of gut enteric pathogens, 
including Shigella, Campylobacter and Salmonella [228]. Generally, the amount of iron in 
the gut can influence the infection cycle of a pathogen. The increased luminal iron and 
intracellular iron in enterocytes could potentially exaggerate or attenuate the virulence of 
enteric pathogens. However, thus far, relatively little is known about a potential link 
between iron and intestinal infection and this merits more research. 
1.10.2 Human studies 
Numerous studies have looked at the effect of iron fortification and iron depletion on the 
human gut microbiota. One of the oldest studies dating back to 1985, provided infants with 
an iron-fortified cow's milk preparation and investigated the changes in the gut microbial 
composition using culture-based methods [148]. These children had reduced counts of 
bifidobacteria but higher counts of E. coli and Bacteroides spp. compared to the infants 
receiving an unfortified cow's milk preparation.  
Zimmermann et al., (2010) examined the gut microbiota of schoolchildren from Côte 
d'Ivoire using molecular methods, such as quantitative polymerase chain reaction (qPCR) 
[229]. These children were given iron-fortified biscuits for a period of 6 months and they 
found that compared to the control group, which were receiving unfortified biscuits, 
isolation frequencies of lactobacilli were lower and Enterobacteriaceae were higher in 
their faecal samples. Conflicting results were seen in a study of iron-deficient women in 
India [230] where low levels of lactobacilli were observed. 
Jaeggi et al., (2015) examined the effects of low and high doses of in-home iron 
supplementation on the gut microbiota of Kenyan children [157]. In this setting, provision 
of iron-fortified porridge led to an increase in pathogen abundance, with numbers of 
enterobacteria, clostridia and pathogenic E. coli increasing whilst numbers of 
bifidobacteria decreased. Furthermore, in comparison to the control group (receiving 
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unfortified porridge), the children with iron-fortified porridge had elevated levels of faecal 
calprotectin, a marker of gut inflammation.  
A lack of knowledge of host factors such as diet fluctuation, the immune system and iron 
status in the gut might be drawbacks to studying iron and the microbiota. Nevertheless, in 
vitro studies on microbial metabolism in the presence of iron and nutrients support the 
findings of in vivo studies. Dostal et al., (2013) examined the effects of reduced iron 
availability in continuous in vitro colonic fermentations [156]. During very low iron 
conditions, a reduction in the counts of Roseburia spp./E. rectale, Clostridium cluster IV 
members and Bacteroides spp. were observed while Lactobacillus spp. and 
Enterobacteriaceae increased. Decreases in the main metabolites (propionate and butyrate) 
were also observed during iron-deficient conditions. 
The role of iron and its influence on the replication and virulence of gut enteric pathogens 
has also been investigated. Olakanmi et al., (2007) investigated the infectivity of 
Mycobacterium tuberculosis (M.Tb) in subjects with HH. This study showed that there was 
a reduced growth of M.Tb in HH subjects compared to control subjects as M.Tb 
acquisition of iron was much lower in the former, suggesting that cellular iron 
concentration is one of the critical determinants for infectivity [231]. 
In vivo studies have produced varying outcomes when studying the effect of iron on 
specific bacterial groups of the human gut microbiota. This could potentially be in part due 
to the intricate interactions between the host iron status, the response the host has to 
differing dietary iron levels, or the iron concentration in the gut lumen. Furthermore, other 
factors such as intestinal immune function, environmental changes, host physiology and 
dietary habits can also influence the gut microbial composition. In vitro gut fermentation 
models allow the gut microbiota to be examined without any influence from the host, as 
well as other environmental factors, through tightly controlled parameters [232]. The in 
vitro continuous colonic fermentation model [233] utilising immobilised child gut 
microbiota represents a good technological platform to investigate the impact of dietary 
changes on the gut microbiota [232]. 
1.11 Thesis aims 
1. To grow pure cultures of bacteria in order to investigate: 
i. The effects of iron addition on bacterial growth 
ii. The effects of iron chelation on bacterial growth 
  Chapter 1 
 
32 
 
 
2.  To use an in vitro batch fermentation model to culture human faecal microbiota in a 
nutritive media simulating the colon, to investigate: 
i. Changes in viable counts of common bacterial groups under iron-supplemented and 
iron-chelated conditions 
ii. Changes in bacterial composition caused by iron-chelated conditions 
iii. Changes in bacterial metabolites caused by iron-chelated conditions 
 
3. To optimise a delivery system to enable release of an iron chelator in the colon 
 
4. To implement the colonic delivery system in a human trial investigating the effects of 
an iron chelator on the human gut microbiota 
1.12 Hypotheses 
The hypotheses to be tested in relation to the aims outlined in the previous section are: 
1. Growth of pure cultures of bacteria in iron chelated media will lead to the decrease of 
bacterial growth, whilst addition of iron will encourage bacterial growth 
 
2. In vitro batch fermentation models will indicate: 
i. A reduction in viable counts of common bacterial groups under iron-chelated 
conditions 
ii. Bacterial composition of bacteria that have the potential to display pathogenic 
phenotypes will reduce under iron-restricted conditions 
iii. A change in different bacterial taxa will subsequently alter the production of 
SCFAs 
 
3. An optimised coating formulation will allow for successful delivery of an iron chelator 
to the colon 
 
4. The consumption of an encapsulated chelator by healthy participants will reduce the 
relative abundance of potentially pathogenic groups of bacteria through the reduction in 
water-soluble iron concentrations 
 
  
 
CHAPTER TWO 
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2.1 General Reagents 
Unless stated otherwise, all chemicals were purchased from Sigma (UK) and were of the 
purest grade available. A 20% nitric acid (HNO3) solution was generated by adding 714 
mL deionised water to 286 mL 70% HNO3, to achieve a total volume of 1 L. All glassware 
and equipment were acid-washed with 20% HNO3 before iron quantification analysis. 
A 1 M hydrochloric acid (HCl) solution was prepared by diluting 36.46 mL 37% HCl 
(Fischer Scientific, UK) with distilled water to a total volume of 1 L.  
A 1 M sodium hydroxide (NaOH) solution was generated by dissolving 40 g NaOH pellets 
in 250 mL distilled water and then diluting the solution further to reach a total volume of 1 
L.  
The following chemicals were diluted to the desired concentration using ultrapure water 
and then subsequently added to pure or/and mixed bacterial cultures to assess the impact of 
either iron addition or chelation on bacterial growth: ammonium iron (II) sulphate 
hexahydrate; bathophenanthroline disulphonic acid; 2,2 Dipyridyl; phytic acid salt sodium 
hydrate; tannic acid; lactoferrin from human milk and sodium alginate (provided by Chris 
Tselepis, Birmingham). 
Phytin mineral salt (TSUNO Rice Fine Chemicals, Japan) was diluted to the desired 
concentration using 0.1 M HCl and then subsequently added to mixed bacterial cultures to 
assess the impact of phytin dependent iron chelation on bacterial growth. 
2.2 Bacterial strains and growth conditions 
2.2.1 Media used for bacterial growth 
The following bacterial strains were used: Escherichia coli 1BO4 (isolated from human 
faeces), Bifidobacterium longum B78 F110564 (isolated from human faeces), 
Lactobacillus rhamnosus GG F111027, Salmonella Typhimurium (ATCC SL1344), 
Clostridium perfringens (NCTC 3110) and Bacteroides thetaiotaomicron VP1-5482 
(ATCC 29148). All bacteria were grown anaerobically at 37oC. 
Table 2.1 outlines the composition of media used for the growth of the bacterial strains 
mentioned above. 
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Table 2.1 - Composition of bacterial culture media 
Media Compositions in 1 L H2O pH Bacteria 
BHI 12.5 g brain infusion solids, 5 g beef 
heart infusion solids, 10 g protease 
peptone, 5 g sodium chloride, 2 g 
glucose, 2.5 g disodium phosphate 
7.4 ± 
0.2 
B. longum 
BHI + 
haemin 
(BHI-H) 
Same as BHI + 0.5% w/v haemin 7.4 ± 
0.2 
B. thetaiotaomicron 
BHI + 
complement 
(BHI-C) 
Same as BHI + 0.01 mL vitamin K [10 
mM], 0.01 mL haemin [0.5% w/v], 4 mL 
resazurin  
[0.02 %], 0.5 g L -cysteine 
7.4 ± 
0.2 
C. perfringens 
LB 10 g tryptone, 5 g yeast extract, 10 g 
NaCl 
7.0 ± 
0.2 
E. coli and S. 
Typhimurium 
MRS + 
glucose 
8 g peptone, 5 g yeast extract, 5 g 
CH3COONa.3H2O, 2 g K2HPO4, 2 g 
C6H17N3O7, 5 mL salt solution (0.2 g 
CaCl2 anhydrous, 0.2 g MgSO4, 1 g 
K2HPO4, 1 g KH2PO4, 10 g NaHCO3, 2 
g NaCl in 1 L), 1 mL Tween 80, 20 g 
glucose 
6.5 ± 
0.2 
L. rhamnosus 
M9 Solution A: 6 g Na2HPO4 [40 mM], 3 g 
KH2PO4 [20 mM], 0.5 g NaCl [8 mM], 1 
g NH4Cl [20 mM], 790 mL dH2O; 
Solution B: 0.147 g CaCl2.2H2O [10 
mM], 100 mL dH2O; Solution C: 0.246 g 
MgSO4.7H2O [10 mM], 100 mL dH2O; 
Solution D: 11 mL leucine, 6.5 mL 
histidine, 1.7 mL thiamine, 1.5 mL 
threonine, 0.23 g proline, 0.13 g 
arginine, 2 g glucose, 100 mL dH2O 
7.3 ± 
0.2 
E. coli, S. 
Typhimurium 
Nutritive 
media 
2 g peptone water, 2 g yeast extract, 0.01 
g NaCl, 0.04 g K2HPO4, 0.04 g KH2PO4, 
0.01 g MgSO4.6H2O, 0.01 g 
CaCl2.6H2O, 2 g NaHCO3, 0.5 g 
cysteine.HCl.H2O, 0.5 g bile salts, 2 mL 
Tween80 and 10 μL vitamin K1  
7.0 ± 
0.2 
in vitro colonic 
fermentations 
 
2.2.2 Selective agar plates used for enumeration of bacterial groups 
Table 2.2 outlines the different agar plates used to visualise viable counts of different 
bacterial groups analysed during in vitro colonic fermentation studies. All media, except 
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bifidobacteria agar plates, were first autoclaved and cooled before pouring into petri 
dishes. All media were purchased from Oxoid, except Brucella, which was purchased from 
Difco.  
Antibiotics were purchased from Sigma and diluted to required stock concentration using 
ultrapure water.  
 
Table 2.2 – Composition of agar plates used for enumeration of different bacterial 
groups 
Bacterial group Compositions in 1 L H2O Antibiotic 
Total anaerobes 43 g Wilkin chalgren - 
Enterobacteriaceae 51.5 g MacConkey #3 - 
Lactobacilli 15 g agar, 52 g MRS broth powder - 
Clostridia 43 g Wilkin chalgren 8 mL novobiocin 
and colistin (1 
mg/mL) 
Bacteroides 28 g Brucella, 15 g agar, 10 mL haemin 
solution (0.5 mg/mL), 200 µL vitamin 
K solution and 50 mL laked horse 
blood (Oxoid) 
3 mL kanamycin 
(25 mg/mL) and 
7.5 mL 
vancomycin (1 
mg/mL) 
Bifidobacteria 39 g Columbia agar, 5 g glucose, 0.5 g 
cysteine.HCl and 5 g agar. 
5 mL propionic acid to be added after 
cooling and adjusted to pH 5 with 6 M 
NaOH 
- 
 
2.3 Quantification of iron from stool samples 
2.3.1 Measurement of total iron 
Flame atomic absorption spectrophotometry (FAAS) was used to determine the 
concentration of iron in faecal samples. All glassware and equipment used were acid-
washed with 20% 16 M HNO3. Fresh faecal samples were weighed and then dried at 110
oC 
in an oven. The sample was re-weighed to calculate water content, transferred into glass 
crucibles and ashed in a muffle furnace for 48 h at 600oC. The ashed sample was dissolved 
in 20% 16 M HNO3 and crucibles were then placed on a hot plate until almost dry. The 
residue was dissolved with 1 M HCl and then diluted further to a final volume of 25 mL of 
1 M HCL. The spectrophotometer (Perkin Elmer Atomic Absorption Spectrophotometer 
Model 3300) was calibrated against a range of iron standards (0-6 ppm) and samples were 
measured at an absorption wavelength of 248 nm. 
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2.3.2 Measurement of water-soluble iron in stool samples 
A 0.2 g aliquot of a fresh faecal sample was homogenised with a 0.2 g of ultrapure water, 
mixed on a rotator stirrer (300 rpm) for 30 mins at room temperature, and centrifuged at 
3,200 xg for 15 mins at 4oC. Supernatants were then analysed using the Ferrozine assay 
(Abcam, Cambridge, UK), where ferric iron in the sample is reduced to ferrous iron using 
an iron reducer provided in the kit, after which the iron reacts with Ferene S (an iron 
chromogen) to produce a stable coloured complex with an absorbance at 593 nm. 
2.4 Assessing the impact of either iron chelation or addition on pure 
bacterial cultures 
A range of pure bacterial cultures were grown overnight in the desired media at 1% 
inoculation. Cultures were seeded in 100-well honeycomb plates, and the cells were then 
exposed to the chemical of interest. Samples were analysed using a Bioscreen C, which 
monitors the growth of microorganisms by measuring the turbidity (optical density, OD) of 
the liquid growth medium. The experiments were run for 24 h – 48 h, with measurements 
at OD600, taken every 10 mins. The temperature of all experiments was set at 37
oC. 
Depending on the type of organism, these studies were carried out under either aerobic or 
anaerobic conditions.  
2.5 Culturing human faecal microbiota 
2.5.1 Donor recruitment for in vitro colonic fermentation experiments 
Faecal samples used in the colon model experiments were obtained from participants 
recruited onto the Quadram Institute Bioscience (QIB) Colon Model study. Men and 
women aged 18 y or older who live or work within 10 miles of the Norwich Research Park 
were recruited onto the QIB Colon Model study if they satisfied the following criteria. 
Participants who were assessed to have a normal bowel habit, regular defecation between 
three times a day and three times a week, with an average stool type of 3 – 5 on the Bristol 
Stool Chart, and not diagnosed with chronic gastrointestinal health problems, such as 
irritable bowel syndrome, inflammatory bowel disease, or coeliac disease were eligible to 
enrol onto the study. Demographic information was collected, and a brief health 
questionnaire was completed during the eligibility screening. Participants were asked 
additional questions immediately prior to donating a stool sample to confirm that they had 
not taken antibiotics or probiotics within the last four weeks, had not experienced a 
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gastrointestinal complaint, such as vomiting or diarrhoea, within the last 72 h, were not 
currently pregnant or breast-feeding, had not recently had an operation requiring general 
anaesthetic, and were not taking iron or multivitamin supplements. The study was 
approved by the Quadram Institute Bioscience (formally Institute of Food Research) 
Human Research Governance committee (IFR01/2015), and London - Westminster 
Research Ethics Committee (15/LO/2169). The informed consent of all participating 
subjects was obtained, and the trial is registered at http://www.clinicaltrials.gov 
(NCT02653001). 
2.5.2 Culturing human faecal microbiota in nutritive media 
All samples were processed within 4 h of stool collection. A 10 g portion of faecal material 
was placed into a Seward stomacher bag using a sterilised spatula. Deoxygenated 1x PBS 
was added to the stomacher bag to obtain a mass of 100 g. The stomacher bag was placed 
into the Stomacher 400 circulator and the faecal matter was homogenised at 230 rpm, for 
45 seconds. A 15 mL aliquot of the homogenised faecal suspension was transferred into a 
150 mL sterile vessel. The working volume of each vessel was set at 150 mL of which 135 
mL was nutritive media (composition of nutritive media can be found in Table 2.1). The 
pH was maintained between 6.6 – 7.0 and the temperature of the vessels were kept at 37oC. 
Conditions tested were either nutritive media with faecal inocula only (control), or with 
faecal inocula supplemented with the reagent of interest. For each donor, one vessel was 
used for each condition. Samples were taken at 0, 4, 8, and 24 h and spun at 3200 xg, 4oC 
for 15 mins. A 100 µL aliquot of the supernatant suspension was serially diluted in PBS 
(900 µL) and enumerated on selective agar plates (Table 2.2). The remaining supernatant 
was aliquoted and used for 1H nuclear magnetic resonance (NMR) analysis (section 2.7). 
The resulting pellet was frozen and later used for bacterial DNA extraction (section 2.6).   
2.6  Phylogenetic analysis of cultured human faecal microbiota  
2.6.1 Extraction of bacterial DNA 
The bacterial pellets were thawed at room temperature and the DNA was extracted using a 
FastDNA SPIN Kit for Soil (MP Biomedicals, UK) with an additional modification 
incorporated into this method [234].  Sodium phosphate buffer (978 μL) and MT buffer 
(122 μL) were added to the thawed bacterial pellets and vortexed until the pellet was 
completely homogenised. This mixture was then incubated at 4˚C for 1 h, with the sample 
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being mixed using a vortex every 15 mins. After vortexing, samples were transferred to 
Lysing Matrix E tubes, and mechanically disrupted three times with a FastPrep instrument 
(MP Biomedicals, UK) at 6.5 ms-1 for 60 s. The supernatant was transferred to a sterile 
tube containing 250 μL protein precipitation solution (PPS), inverted 10 times by hand and 
centrifuged at 14,800 xg for 5 mins. The supernatant was transferred to a sterile tube 
containing 1 mL Binding Matrix suspension, inverted by hand for 2 mins, then incubated at 
room temperature for 3 mins to allow for the binding matrix to settle. Carefully, 1 mL of 
the supernatant was discarded, and samples were vortexed, prior to 600 μL of the mixture 
being added to a SPIN filter tube. Samples were centrifuged at 14,800 xg for 1 min, then 
underwent three 500 μL DNase-free salt/ethanol wash solution (SEWS-M) wash steps, 
with centrifugation at 14,800 xg for 1 min between each step. Samples were spun for a 
further 2 mins to allow for the removal of any remaining ethanol. DNA was eluted with 50 
μL of DNase/Pyrogen free DNA elution solution (DES) and stored at -20˚C.  
2.6.2 Assessing bacterial DNA extraction  
A 1% (w/v) agarose solution was generated by adding 0.5 g agarose powder to 500 mL 0.5 
mM Tris/borate/ethylenediaminetetraacetic acid (TBE) buffer, then dissolved by heating in 
a microwave at 800 watts for approximately 3 mins at full power until clear. The 1% (w/v) 
agarose solution was added to an electrophoresis gel tray in a horizontal gel electrophoresis 
system (Life Technologies, Inc.), with a toothed comb fitted (to a depth of ~8 mm) and left 
to set at room temperature (approx. 40 m). 2 μL Hyperladder I (Bioline) was added to the 
outer well to act as a molecular weight marker, and 1 μL DNA were mixed with 1 μL 10x 
loading dye before being added to the remaining wells. The gel was run at 100 volts (PPV 
300/200.4, Northumbria Biologicals Ltd) in 5mM TBE until the samples had migrated 
towards the end of the gel. The gels were stained in an ethidium bromide solution (5 μg-10 
μg/mL ethidium bromide in water) for 30 mins and rinsed with water. DNA fragments 
were visualised and photographed using the AlphaImager HP system (Alpha Innotech) 
under UV trans-illumination. Total DNA was quantified using the NanoDrop ND-1000 
UV/vis spectrophotometer (NanoDrop Technologies, Inc., USA) and the ND-1000 
computer software. The nucleic acid, DNA-50 settings were selected, DNase/Pyrogen free 
water (1 μL) was used as a blank, and 1 μL of each sample was analysed. 
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2.6.3 Bioinformatic analysis of 16S rDNA 
DNA extracted from in vitro batch fermentation models were sent to Novogene for 
sequencing. Sequencing reads were analysed using the Quantitative Insights Into Microbial 
Ecology (QIIME) pipeline and Ribosomal Database Project (RDP) classifier. All 
sequences were filtered to meet the following criteria: read length within 200 and 1,000 bp; 
a maximum of 6 ambiguous bases; a minimum average quality score of 25 within a 50 bp 
window; and exact match to primer sequences. ChimeraSlayer was used to filter trimmed 
reads for chimeric sequences, and RDP classifier (version 2.10) was used for bacterial 
taxonomy assignment with a confidence value threshold of 50%, with trimmed reads 
clustered into operational taxonomic units (OTUs) at 97% identity level. Observed species 
(number of unique OTUs) and the Shannon Index (species richness and evenness) were 
used to compute alpha (α)-diversity and rarefaction plots. Weighted and unweighted 
UniFrac distances were used to generate beta (β)-diversity principle co-ordinate analysis 
(PCoA) plots, which were visualised using the Emperor tool. Primers U515F (5’- 
GTGCCAGCMGCCGCGGTAA) and U806R (3’-GGACTACHVGGGTWTCTAAT) 
were used to amplify the V4 region of the 16S rDNA. 
2.7  Short chain fatty acid quantification  
Faecal water was prepared to quantify short chain fatty acids in stool. Briefly, samples (13 
mL) taken from colonic batch fermentations were centrifuged at 3220 xg for 15 mins at 
4oC. 100 μL NMR buffer (0.26 g NaH2PO4 and 1.41 g K2HPO4 made up in 100 mL 
deuterium oxide (D2O), containing 0.1% NaN3 (100 mg), and 1 mM sodium 3-
(Trimethylsilyl)-propionate-d4, (TSP) (17 mg) as a chemical shift reference) was added to 
900 µL supernatant and analysed using 1H NMR spectroscopy (this mixture is defined as 
‘faecal water’). The 1H NMR spectra were recorded at 600 MHz on a Bruker Avance 
spectrometer (Bruker BioSpin GmbH, Germany) running Topspin 2.0 software and fitted 
with a cryoprobe and a 60-slot autosampler. Each 1H NMR spectrum was acquired with 
256 scans, a spectral width of 12,300 Hz, and an acquisition time of 2.67 s. The 
“noesypr1d” pre-saturation sequence was used to suppress the residual water signal with a 
low-power selective irradiation at the water frequency during the recycle delay and a 
mixing time of 10 ms. Spectra were transformed with a 0.3 Hz line broadening, and were 
manually phased, baseline corrected, and referenced by setting the TSP methyl signal to 0 
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ppm. The metabolites were quantified using the software Chenomx® NMR Suite 7.0TM. 
NMR analysis was performed by Dr Gwenaelle Le Gall (UEA). 
2.8 Effects of phytin on the human gut microbiota dietary intervention 
study 
Full details can be found in the Appendix in the form of annexes. Briefly, the study method 
was as follows. 
2.8.1 Study Recruitment 
Fourteen participants were recruited onto the ‘Effect of Phytin on the Human Gut 
Microbiome’ (EPoM) human study (ClinicalTrials.gov: NCT03917693) and gave written 
informed consent for their biological samples to be used as described in the study protocol 
(Appendix). The EPoM study protocol was approved by the Human Research Governance 
Committee at Quadram Institute Bioscience and the East of England – Cambridge Central 
Research Ethics Committee (19/EE/0005). All study participants were assessed for 
eligibility on the basis of a screening health questionnaire and the results of clinical 
laboratory tests sent to Norfolk and Norwich University Hospital (NNUH). All participants 
produced a urine sample for urinalysis which was screened for protein, blood, leukocytes, 
nitrites, glucose and ketones via a dipstick urine test (Multistix® 8SG; Siemens). The 
following exclusions applied: 
• Failing screening test 
• Pregnant, or have been pregnant in the last year or are lactating and/or breast 
feeding 
• Currently suffering from, or previously suffered from, any diagnosed 
gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and 
constipation (excluding hiatus hernia unless symptomatic), and/or gastrointestinal 
surgery 
• Diagnosed with any long-term medical condition that may affect the study outcome 
(e.g. cancer, diabetes, haemophilia, cardiovascular disease, glaucoma, anaemia), as 
assessed on an individual basis 
• Diagnosed with any long-term medical condition requiring medication that may 
affect the study outcome 
• Regularly taking over the counter medications for digestive/gastrointestinal 
conditions 
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• Long-term antibiotic therapy (at least 4 weeks since end of a course of antibiotics, 
assessed on an individual basis) 
• Regular laxatives (once a month or more) 
• User of dietary supplements or herbal remedies and unwilling to stop taking them 
for one month prior to and during study period (assessed on an individual basis) 
• Consumer of pre- or pro-biotic drinks &/or yoghurts on an irregular basis. 
• On a diet programme that may affect the study outcome (e.g. 5:2 fasting diet)  
• Recently returned to the UK following a period abroad and suffered gastric 
symptoms during the period abroad or on return to the UK (assessed on an 
individual basis). 
• Regular/recent (within 3 months) use of colonic irrigation or other bowel cleansing 
techniques 
• Involvement in another research project that includes dietary intervention or blood 
sampling 
• Blood seen in stools or two or more episodes of constipation or diarrhoea (type 1, 
2, or 7 stools) during the study 
• Unwilling to provide GPs contact details 
• Unable to provide written informed consent 
• Regularly consume more than 15 units (women) or 22 units (men) of alcohol a 
week 
• Regularly taking iron supplements 
• Unable to swallow capsules 
• Abnormal blood pressure measurements (i.e. 160/100 or higher, or low blood 
pressure) 
• Related to someone in the study (e.g. spouse, partner, immediate family member). 
Details of the participants that were enrolled onto the study are displayed in Table 2.3. 
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Table 2.3 – Age, gender, Body Mass Index (BMI) of EPoM study participants. All 
participants were non-smokers. 
Participant Code Age (y) Gender BMI (kg/cm2) 
EPoM114 27 Male 19.7 
EPoM120 32 Female 27.0 
EPoM125 33 Female 19.5 
EPoM129 27 Female 26.5 
EPoM134 26 Male 25.9 
EPoM139 25 Female 25.0 
EPoM148 28 Female 28.3 
EPoM150 23 Female 21.4 
EPoM151 29 Male 28.5 
EPoM155 24 Male 20.9 
EPoM156 23 Male 21.4 
EPoM163 18 Male 25.8 
EPoM169 25 Male 24.9 
EPoM191 30 Female 23.8 
 
2.8.2 EPoM study design 
Recruited participants (n=14) were asked to maintain their habitual diet throughout the 
length of the study. Following randomisation (see Appendix: Study Protocol, 
‘Randomisation process’), half of the participants (dependent on randomisation results) 
consumed two capsules, each containing 0.4 g phytin (test capsule), three times a day with 
a meal for a period of two weeks. The remaining participants consumed two placebo 
capsules, each containing 0.4 g microcrystalline cellulose, three times a day with a meal 
for a period of two weeks. Phase 1 was followed by a 2-week washout period, where all 
participants ceased capsule consumption. After the washout period, the alternative 
treatment was given (Figure 2.1).  
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Figure 2.1 - Summary of EPoM study design. The diagram represents a two-phase crossover, 6-
week dietary intervention trial, where participants consumed a randomly allocated set of capsules 
during each phase. Phases were separated by a washout period, during which no capsule 
consumption took place. Habitual diet was maintained throughout the study period. Faecal 
samples were collected three times during each phase, at the start, middle and end. During each 
phase, stool charts, food frequency questionnaires and capsule checklists were completed for a 
consecutive period of time. 
Participants were asked to maintain their habitual diet during the entirety of the study 
period. Three faecal samples were collected per participant per phase, following the 
instructions provided, at the following stages in the study: before commencing the phase, 
seven days after starting the phase and upon completion of the phase. Faecal samples were 
used to analyse the composition of the human gut microbiota (detailed method in section 
2.8.3.1) . Participants were asked to complete stool charts to assess any effects of the 
capsule content on gut function, and to complete a food frequency questionnaire. These 
were completed in consecutive 7-day periods during each intervention phase. Finally, all 
participants were asked to complete a capsule checklist throughout the entire study as a 
measure of compliance.  
2.8.3 EPoM study sample analysis 
2.8.3.1  Phylogenetic analysis of human faecal microbiota 
Aliquots of faecal samples were collected from each sample, using sterilised spatulas and 
stored at -80˚C. Bacterial DNA was extracted, visualised, and the DNA concentration was 
quantified following the method described in section 2.6.1. Bacterial DNA concentration 
was normalised to 5 ng/μL by dilution with ultra-pure water to produce a final volume of 
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50 μL. Normalised DNA samples were sequenced in-house for 16S rRNA gene using 
paired-end Illumina sequencing (2x 250 bp) on the MiSeq platform. In-house sequencing 
was performed by Dave Baker (QIB). 
Sequencing data were analysed by Dr Andrea Telatin (QIB), using the QIIME (version 
1.9.1) pipeline and RDP 16S rDNA sequence database, as described in section 2.6.3. 
2.8.3.2  Metabolite analysis of human faecal waters  
Human faecal waters were prepared simultaneously with pellets for bacterial DNA 
extraction. Approximately 0.2 g of thawed or fresh faecal samples were added to sterile 
tubes. NMR buffer (2.4 mL) was added to the faecal sample and homogenised before 
centrifuging at 3,220 xg for 15 mins at 4oC. The supernatant (‘faecal water’) was 
transferred into sterile tubes and analysed for metabolite profiling following the method 
outlined in section 2.7.  
2.9  Statistical analysis 
Data from pure culture experiments and in vitro colonic fermentations were expressed as 
means ± standard errors of the means (SEM). Pure culture data were analysed using one-
way ANOVA followed by Bonferroni post-tests with GraphPad Prism software (Version 
5.04), whilst in vitro colonic batch fermentations were analysed using unpaired t-tests 
assuming unequal variances on Microsoft Excel. p<0.05 was considered statistically 
significant. PCA plots illustrated in Chapter 7 were generated using the XLSTAT package 
in Microsoft Excel. 
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3.0 Summary 
The requirement for iron in bacterial growth and survival has been observed for a wide 
range of bacterial species. This chapter focuses on the impact of iron addition to a range of 
independently cultured bacteria as well as mixed cultures derived from human faecal 
microbiota. The data outlined in this chapter highlights the positive effect that iron has on 
the growth of E. coli and S. Typhimurium when cultured independently, whilst varying 
results are observed in the gut microbial composition when iron is added to human faecal 
microbiota. 
3.1 Introduction 
Iron availability is typically very limited to the microorganisms due to host iron-
withholding mechanisms and can therefore stop pathogenic organisms from growing [235]. 
An established method of iron acquisition is the secretion of iron-scavenging siderophores 
(also known as enterobactin and enterochelin) and haemophores, molecules that are 
synthesised by bacteria and released into the extracellular medium in order to scavenge 
inorganic iron or haem iron [20, 178].  
Siderophores can be split into three key classes depending on the chemical nature of the 
moieties that donate the oxygen ligands for Fe3+ co-ordination [168]. These are 
hydroxamates, catecholates or carboxylates. Pathogenic bacteria need to proliferate once 
inside the host for them to survive. The high affinity of the bacterial siderophores helps 
them to compete with host proteins for iron; bacterial siderophores have an iron-
association constant of approximately 1051 M-1 whilst the host protein transferrin has an 
association constant that is much lower, at 1022 M-1.  The iron is released from the 
siderophore once it is transported inside the bacterial cell through the help of reductases, 
which reduce siderophore-bound Fe3+ into Fe2+. As a result, Fe2+ can now be incorporated 
directly into metallo-enzymes. If there is an excess of iron, it can then be stored as 
bacterioferritin, or in the related DPS proteins [185]. The Fur repressor protein is then 
responsible for the shutdown of iron uptake once the bacteria have accumulated enough 
iron, by preventing the biosynthesis of the iron transport system. Moreover, some bacterial 
species have evolved even further and are able to extract Fe3+ directly from transferrin or 
even use haem as an iron source [186, 187].  
Haemophores are another specialised method in which haem-iron is directly taken up. 
However, haem iron is more readily available for humans, compared to non-haem iron [236, 
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237]. On average, iron in omnivorous diets consists of approximately 90% non-haem iron 
and 10% haem iron. 
On average, bacteria need 10-7 – 10-5 M iron for optimal growth [139]. E. coli, for example 
is able to take up both forms of iron (ferrous and ferric). One study describes the Fe-uptake 
system that E. coli uses for the transport of Fe2+ under anaerobic conditions [20]. Most 
bacterial species are able to acquire iron through the reduction of Fe3+ into Fe2+ with the 
help of an extracellular reductase and this form can then be taken up into the cell [167].  
Bacteria have also developed mechanisms to reduce iron-induced toxicity. One example of 
this is a haem export mechanism (HrtAB), which reduces the haem-based iron stress in 
certain bacterial species, such as Staphylococcus aureus. Orthologues of the HrtAB system 
have been identified in Bacillus anthracis, Listeria monocytogenes, Enterococcus faecalis, 
and Streptococcus agalactiae [165]. Bifidobacteriaceae have the ability to bind iron to 
their surface, thereby preventing the formation of free radicals in the surrounding 
environment as well as sequestering iron from the colonic lumen and preventing 
pathogenic bacteria from acquiring iron [166].  
Animal studies have highlighted the importance of iron within the gut microbial 
community. One study administered iron at different doses to rats and found that 
Clostridium difficile enterotoxin increased after 24 h, as did the number of Clostridium 
spp. after 4 weeks, with the high-iron dose [222]. E. coli and Lactobacillaceae numbers 
also increased after 2 weeks of iron administration, with a reduction in the numbers of 
Bacteroides spp. and enterococci. Another study reported that the numbers of anaerobes, 
Enterococcus spp. and lactobacilli were elevated in iron-deprived mice, and that iron 
supplementation generally perturbed the gut microbiota [223]. This study examined the 
effects of an iron-deficient diet on healthy mice and found that numbers of 
Lactobacillaceae were higher in the mice fed with an iron-deficient diet compared to the 
standard diet control group. Moreover, the numbers of total anaerobes were also higher in 
the mice on an iron-deficient diet. A more recent study observed the effect of iron 
deficiency and subsequent iron repletion on the gut microbiota composition and metabolic 
activity in young Sprague-Dawley rats [151]. Iron deficiency led to an increase in 
Enterobacteriaceae and Lactobacillus but reduced counts of Bacteroides spp. and 
Roseburia spp./E. rectale members. Moreover, changes in metabolic profiles were also 
seen, with decreases in butyrate and propionate under iron-deficient conditions. Iron 
supplementation with FeSO4 and electrolytic iron partially re-established the original gut 
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microbiota composition, suggesting that iron is required for these populations to survive 
adequately. 
Given the importance of iron, the aim of the experiments described in this chapter was to 
investigate the effect of added iron on various bacterial species.  
3.2 Objectives 
Prior to the series of experiments to examine the effects of iron on various groups of 
bacteria (both independently and in mixed cultures), it was first important to determine 
baseline levels of iron present in human faeces. This would allow the administration of 
appropriate concentrations of iron (or chelator) to investigate any potential effects of iron 
on the bacteria tested. Next, pure and mixed cultures of bacteria were supplemented with 
iron and subsequently examined to see what impact iron had on bacterial growth. 
3.3 Materials and Methods 
3.3.1 Human faecal microbiota 
Faecal samples used in the colon model experiments were obtained from participants 
recruited onto the QIB Colon Model study. Men and women aged 18 y or older who live or 
work within 10 miles of the Norwich Research Park were recruited onto the QIB Colon 
Model study if they satisfied the following criteria. Further details on donor recruitment 
can be found in chapter 2, section 2.5.1.  
3.3.2 Measuring total iron concentrations in stool samples 
FAAS was used to determine the concentration of iron in faecal samples. All glassware 
and equipment used were acid-washed with 20% 16 M HNO3. Further detail on faecal 
sample preparation and processing can be found in chapter 2, section 2.3.1.   
3.3.3 Measuring water-soluble iron in stool samples 
A 0.2 g aliquot of a fresh faecal sample was homogenised with a known volume of 
ultrapure water, mixed on a rotator stirrer (300 rpm) for 30 mins at room temperature and 
centrifuged at 3,000 xg for 15 mins at 4oC. Further detail on sample analysis can be found 
in chapter 2, section 2.3.2.  
3.3.4 The effect of adding ferrous iron to pure cultures of bacteria 
A range of pure bacterial cultures were grown overnight in M9 minimal media at 1% 
inoculation. Cultures were seeded in 100-well honeycomb plates and cells were then 
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exposed to 250 µM FeSO4. Samples were analysed using a Bioscreen C machine, which 
monitors the growth of microorganisms by measuring the turbidity (OD) of the liquid 
growth medium. The experiments were run for 24 h, with measurements at OD600, taken 
every 10 mins. The temperature of all experiments was set at 37oC. Depending on the type 
of organism, these studies were carried out under either aerobic or anaerobic conditions.  
3.4 Results 
3.4.1 Iron quantification from human faecal microbiota 
Table 3.1 – Iron concentrations in healthy human faecal microbiota 
Donor Water-soluble iron 
(mg/g) 
Total Iron 
(mg/g) 
CM031 0.113 0.270 
CM036 0.067 0.244 
CM075 0.064 0.271 
 
Table 3.1 shows the iron concentrations quantified from three healthy human microbiota. 
On average, the faeces of these three healthy humans contained an average of 0.081 ±0.02 
mg/g water-soluble iron (unbound iron that is freely available for use in the colonic 
environment) and 0.258 ±0.03 mg/g (dry weight) total iron (both water-soluble and 
insoluble iron, including any iron within the bacterial structure). The total iron was very 
similar between the three donors, but the water-soluble iron varied, with one donor having 
a much higher level than the other two. 
3.4.2 Iron addition in pure bacterial cultures 
For pure culture experiments, a wide range of gut bacteria that are known to be affected or 
unaffected by iron were tested. The selection of bacteria to be tested was, to some extent 
dependent on availability in the laboratory. 
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Figure 3.1 - The impact of FeSO4 on the growth of E. coli and S. Typhimurium. FeSO4 added at 
various concentrations, ranging from 0 – 100 µM to E. coli (a) and S. Typhimurium (b) grown 
anaerobically in minimal M9 media, at 1% inoculation, with a total working volume of 300 µL.                  
Iron, in the form of FeSO4, was added to pure cultures of E. coli (Figure 3.1a) and S. 
Typhimurium (Figure 3.1b) and left overnight to grow at 37oC. When analysed, the 
addition of FeSO4 from 10 – 100 µM resulted in a significant increase in the growth of 
both bacteria (p<0.0001) compared to the culture with no iron addition.  
To confirm that the effects seen on these bacteria were iron-dependent, a reverse saturation 
assay was conducted, whereby bacteria were first grown in iron-chelated media and later 
supplemented with FeSO4. 
 
Figure 3.2 – The impact of iron saturation on the growth of E. coli and S. Typhimurium. E. coli 
(a) and S. Typhimurium (b) were cultured overnight under anaerobic conditions at 37oC in iron-
chelated media (achieved through BPDS) at 1% inoculation, with a total working volume of 300 
µL. After a period of 12 h, FeSO4 was added to the culture and growth was monitored for a further 
12 h. *p<0.05, **p<0.01 and ****p<0.0001.               
E. coli (Figure 3.2a) and S. Typhimurium (Figure 3.2b) were cultured overnight in iron-
chelated media, achieved with the chemical iron chelator, BPDS. At 12 h post-culture, 
FeSO4 was added to the culture and the effects on growth were determined after a total 
period of 24 h (indicated by arrows on both graphs). For both bacterial species, growth was 
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significantly reduced in the presence of BPDS (blue line; p<0.0001 E. coli and p< 0.001 S. 
Typhimurium). However, when FeSO4 was added to the culture at 12 h, the growth of both 
bacteria increased and was comparable to the growth of the control. The growth of E. coli 
was significantly higher when iron was added to the culture in comparison to the growth of 
E. coli under iron-chelated conditions (p<0.01), and the same was true for S. Typhimurium 
(p<0.0001). In the case of E. coli, although when supplemented with iron the growth was 
still significantly less than the control (p<0.05), it was still much higher compared to E. 
coli cultured under iron-chelated conditions. 
3.4.3 Iron addition in in vitro colonic fermentations 
Faecal samples used in the colon model experiments were obtained from participants 
recruited onto the QIB Colon Model study (refer to section 3.3.1 and chapter 2 for further 
details). Aliquots of fresh faecal samples obtained from the healthy volunteers were diluted 
in deoxygenated phosphate buffered saline (pH 7.7), and homogenised using a Stomacher 
400 (Seward, United Kingdom) at 230 rpm for 45 s. The pH was maintained between 6.6 – 
7.0 and temperature of vessels were kept at 37oC. All samples were processed within 4 h of 
stool collection. Details of the donors (denoted by a code number in the format of CM0xx) 
are outlined in Table 3.2. All donors were non-smokers. 
Table 3.2 - Age, gender and BMI status of faecal donors 
Donor ID Age (y) Gender BMI (kg/m2) 
CM011 51 M 25.7 
CM031 33 M 22.4 
CM065 34 M 21 
CM075 70 M 18 
 
Conditions tested were either nutritive media with faecal inocula only (Control), or with 
faecal inocula supplemented with FeSO4 (0 – 250 µM). For each donor, 1 vessel was used 
for each condition. Samples were taken at 0, 4, 8, and 24 h from each vessel, serially 
diluted in PBS and enumerated on selective agar plates.  
  Chapter 3 
 
53 
 
 
Figure 3.3 – The effect of iron addition on Enterobacteriaceae viable counts from in vitro 
colonic fermentations. Iron was added to in vitro colonic fermentations, at concentrations of 50 
µM and 250 µM. Significant differences were seen between the control and treatments at the 
respective time-points, as analysed by one-way ANOVA analysis. *p<0.05, ***p<0.001 and 
****p<0.0001. 
Results vary between individual donors when investigating the effect of iron addition on 
the growth of Enterobacteriaceae (Figure 3.3), a group which contains bacterial species 
with the potential to display pathogenic phenotypes. 2 out of the 4 donors (CM031 and 
CM065, Figure 3.3b and 3.3c, respectively) had displayed higher counts of 
Enterobacteriaceae in the presence of additional iron (250 µM FeSO4 - CM031 8 h and 24 
h p<0.001 and p<0.0001, respectively, and CM065 8 h and 24 h p<0.0001). 
Enterobacteriaceae counts from donor CM011 (Figure 3.3a) remained unaffected by the 
presence of additional iron, whilst donor CM075 (Figure 3.3d) displayed significant 
decreases under iron-supplemented conditions (50 µM FeSO4 – p<0.05 4h, p<0.0001 8 h 
and 24 h; 250 µM FeSO4 – 8 h p<0.0001 and 24 h p<0.05). 
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Figure 3.4 – The effect of iron addition on bifidobacteria viable counts enumerated from in vitro 
colonic fermentations. Iron was added to in vitro colonic fermentations, at concentrations of 50 
µM and 250 µM. Significant differences were seen between the control and treatments at the 
respective time-points, as analysed by one-way ANOVA analysis. *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
As with Enterobacteriaceae, the viable counts for bifidobacteria varied amongst 
individuals (Figure 3.4). From these observations, the most common finding amongst 
majority of the donors was that of the viable counts at 8 h. For 3 out of the 4 donors, the 
addition of 250 µM FeSO4 was accompanied with a significant increase in the counts of 
bifidobacteria at 8 h (p<0.0001 for donors CM011, CM031 and CM075, Figure 3.4a, 3.4b 
and 3.4d, respectively). The faecal microbiota of donor CM075 (Figure 3.4d) was the only 
community which exhibited higher counts of bifidobacteria by the end of the 24 h 
fermentation, with significant increases seen at both concentrations of iron (p<0.0001 at 50 
µM and 250 µM FeSO4). No effect of iron addition, at either concentration, was observed 
for the remaining 3 donors at 24 h.  
Bacteroides and Clostridium, another set of bacterial genera which can harbour potentially 
pathogenic bacteria, remained largely unaffected in the presence of additional iron, with 
results varying largely between individuals. Finally, Lactobacillus counts were also 
observed to fluctuate between individuals, leading to an inconclusive pattern in relation to 
iron addition.  
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3.5 Discussion 
Any excess dietary iron that has not been absorbed in the duodenum passes through to the 
colon and is therefore available for colonic bacteria. This is indicated by the presence of 
iron in faecal samples of weaning infants as well as British adults on a standard Western 
diet; studies have shown that approximately 1.8 mM of iron is passed through to the colon, 
which is in excess of the iron requirements of the majority of the gut bacteria (10-7 – 10-5 
M) [139].  
Several animal studies have looked into the effects of iron on the bacterial communities. 
Physiologically, pigs have gastrointestinal tracts that are the most closely comparable to 
humans. Lee et al., (2008) performed a study in which weanling pigs were given an iron-
supplemented diet had no effect on clostridia, Lactobacillaceae, Bifidobacteriaceae and 
total anaerobic bacteria; however, increased numbers of coliform bacteria were observed 
[224]. Our findings are comparable to the results in the experiments performed in pigs, 
where clostridia and Lactobacillaceae remained largely unaffected by the presence of 
additional iron. Similarly, we also observed an increase in Enterobacteriaceae, which 
contains species such as Escherichia, a coliform member. 
A few studies have examined the effect of iron fortification and iron depletion on the 
human gut microbiota. One study provided infants with an iron-fortified cow's milk 
preparation and investigated the changes in the gut microbial composition using culture-
based methods [148]. These children had reduced counts of bifidobacteria but higher 
counts of E. coli and Bacteroides spp. compared to the infants receiving an unfortified 
cow's milk preparation. In the experiments detailed in this chapter, similar to the study 
mentioned above, a general increase in the viable counts of Enterobacteriaceae was also 
observed, the group to which E. coli belongs. Additionally, an increase in viable counts of 
bifidobacteria was observed, which is contrary to the study above, suggesting the 
differences in bacterial composition seen between children and adults. It is also worth 
noting that the study carried out by Mevissen-Verhage et al., (1985) was investigating the 
effects of iron on neonatal gut flora. It has long been known that neonatal microbiota are 
vastly different to the adult microbiota as the gut microbiota is not fully established until 
the later years of life and is instead dominantly populated by bifidobacteria [238-240]. 
Zimmermann et al., (2010) examined the gut microbiota of school children (aged 6-14 y) 
from Côte d'Ivoire using molecular methods, including faecal DNA extractions and 
classification, PCR and qPCR [229]. These children, who belonged a rural area of Côte 
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d'Ivoire with a high infectious disease burden, were given iron-fortified biscuits for a 
period of 6 months and it was observed that compared to the control group, who were 
receiving unfortified biscuits, lactobacilli abundance was lower and Enterobacteriaceae 
was higher in their faecal samples. Conflicting results were seen in a study of iron-
deficient women in India [230] where low levels of lactobacilli were observed. Our results 
are in line with the Côte d'Ivoire study as we also observed higher counts of 
Enterobacteriaceae under iron-supplemented conditions. The inconsistency in lactobacilli 
levels in the studies in Côte d'Ivoire and India further strengthen the notion that predicting 
how the gut microbial composition is altered when exposed to additional iron is a 
challenging task due to the high variability amongst individuals. This is also the case with 
our results, where an inconclusive pattern was observed amongst our donors when 
investigating the effects of additional iron on the relative abundance of lactobacilli. 
Dostal et al., (2013) examined the effects of reduced iron availability in continuous in vitro 
colonic fermentations [156]. Samples were acquired from three healthy 6-10 y old 
children. During very low iron conditions, a reduction in the counts of Roseburia spp./E. 
rectale, Clostridium cluster IV members and Bacteroides spp. were observed while 
Lactobacillus spp. and Enterobacteriaceae increased. Decreases in propionate and butyrate 
were also observed during iron-deficient conditions. Our study demonstrated higher counts 
of Enterobacteriaceae, whilst the study mentioned above displayed higher counts of this 
bacterial group under low iron conditions. This highlights the scavenging ability that this 
bacterial group may possess when iron availability is sparse. Interestingly, their study also 
showed a strong increase of previously subdominant families like Bifidobacteriaceae under 
low iron conditions. Contrary to their study, we observed high bifidobacteria counts from 
the faecal microbiota of 2 out of 3 donors when iron was added to the fermentation 
medium.  
Jaeggi et al., (2015) examined the effects of low and high doses of in-home iron 
supplementation on the gut microbiota of Kenyan children [157]. In this setting, provision 
of iron-fortified porridge led to an increase in pathogen abundance, with numbers of 
enterobacteria, Clostridium and pathogenic E. coli increasing whilst numbers of 
bifidobacteria decreased. Furthermore, in comparison to the control group (receiving 
unfortified porridge), the children with iron-fortified porridge had elevated levels of faecal 
calprotectin, a marker of gut inflammation.  
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These contradictory results suggest that changes in bacterial numbers might not only be 
due to iron concentration in the gut lumen but also the result of host responses to iron and a 
number of other environmental factors. For example, in the Côte d'Ivoire study, 
calprotectin, a marker of intestinal inflammation, was increased in children provided with 
iron-fortified biscuits, and mucosal inflammation can give Enterobacteriaceae a growth 
advantage [229]. In in vitro fermentations, however, environmental and host factors are 
excluded. Thus, the absence of host variables, in particular inflammatory factors, might 
also contribute towards the differences observed between in vivo and in vitro studies.  
In vivo studies on the effect of iron on specific bacterial groups have produced inconsistent 
findings in both the human and animal gut microbiota. This could potentially be, in part, 
due to the intricate interactions between the host iron status, the host response to differing 
dietary iron levels, and/or the iron concentration in the gut lumen. Another factor is the 
inter-individual differences in the gut flora, which are host-specific. Furthermore, other 
factors such as intestinal immune function, environmental changes, host physiology and 
dietary habits can also influence the gut microbial composition. In vitro gut fermentation 
models allow the gut microbiota to be examined without the influence of the host, as well 
as other environmental factors, through tightly controlled parameters [232]. The in vitro 
continuous colonic fermentation model established in the 90’s [241, 242] represents a good 
technological platform to investigate the impact of dietary changes on gut microbiota 
activity. The advantage of an in vitro colonic model is that it allows for long-term stability 
and biodiversity, making it possible to examine the effects of the compound of interest on 
different bacterial populations [232]. However, the inoculation and colonisation of in vitro 
fermentation systems influences the reproducibility of the studies and constitute a 
challenge of the models [232]. In order to facilitate the reproducibility of experiments, 
recent developments are addressing the inoculation of fermentation models with defined 
populations of human gut microorganisms represented by common saccharolytic and 
amino acid-fermenting populations in the large intestine [243]. 
3.6 Conclusions 
Supplementing bacteria with iron confirmed the positive effect it had on the growth of the 
bacterial species, E. coli and S. Typhimurium. This was further strengthened by 
supplementing iron to E. coli and S. Typhimurium cultured in iron-depleted conditions, 
resulting in comparable growth as compared to the control. Results varied when iron was 
supplemented to mixed bacterial cultures derived from human faecal microbiota, 
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suggesting the influence of neighbouring bacterial taxa. To further investigate the effects 
of iron, the next chapter details the impact on pure and mixed bacterial cultures when iron 
is chelated from the environment. 
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4 Iron chelators: The effect of iron chelation on the growth of specific 
groups of bacteria 
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4.0  Summary 
This chapter investigates how a range of iron chelators, both chemical and those present in 
the diet, affects the growth of a range of independently cultured bacteria. Bacterial cultures 
that have the potential to display pathogenic phenotypes, such as E. coli, S. Typhimurium, 
C. perfringens and B. thetaiotaomicron declined in growth when cultured independently in 
media supplemented with iron chelators. When the beneficial species B. longum and L. 
rhamnosus were cultured in the presence of iron chelators, their growth remained largely 
unaffected. 
4.1 Introduction 
The microbial community relies on proteins, complex carbohydrate and micronutrients that 
pass through undigested from the small intestine into the colon for metabolism and 
replication and there is constant competition for micronutrients [139, 244-246]. Iron is one 
of the micronutrients that the majority of the gut bacterial species need for their growth and 
metabolism [20]. Previous studies have shown that on average, bacteria need 10-7 – 10-5 M 
iron for optimal growth, and total iron in the colon far exceeds this value [139].  
Many bacterial species have developed mechanisms to acquire iron [247], even when iron-
availability is sparse, suggesting the importance of this nutrient for successful growth and 
development. Therefore, despite iron bioavailability being low in the colon, with strong 
bacterial iron-uptake mechanisms, the ability of potentially pathogenic bacteria to exploit 
this nutrient is relatively high. Only a very small number of bacterial species do not require 
iron, such as Lactobacillus, a genus of bacteria known to have beneficial properties. 
Instead, bacterial species belonging to this genus depend on alternative metals such as 
manganese for its metabolism [144]. 
Food safety studies have demonstrated the requirement of iron by Salmonella species for 
successful growth in the tomato fruit [248]. To test whether iron acquisition was essential 
for Salmonella growth in tomatoes, a mutant, which lacked the ability to import iron-
associated siderophores was investigated. Compared to the wild type, the growth of the 
mutant was significantly reduced within tomatoes. Furthermore, when exogenous iron was 
provided to the fruit, the defect of the mutant was fully reversed, demonstrating the 
requirement for bacterial iron scavenging. These studies also suggest a role for iron 
chelation in the farming industry.  
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Dietary compounds also have natural iron-chelating properties. For example, tannins are 
present in a wide variety of fruits and vegetables. Anti-microbial activity of tannins 
through iron deprivation has been suggested as it acts as a siderophore to chelate iron, 
rendering it unavailable for other micro-organisms [249]. Another example of a dietary 
iron chelator is phytic acid, also known as inositol hexakisphosphate and is the principle 
storage form of phosphorus in many plant tissues. Phytic acid is a very potent iron chelator 
and its iron-chelating properties have been found to be similar to desferrioxamine (a 
clinically used iron chelator). When iron binds to phytic acid, it forms an insoluble 
precipitate and is unavailable for absorption in the intestine [52, 79, 203, 250-252]. 
When examining the effects of iron on independently cultured bacteria, the bacterial media 
used in pure culture studies are designed to contain all the essential nutrients for bacterial 
growth. For example, E. coli and S. Typhimurium grow successfully in Luria broth, whilst 
L. Rhamnosus grows well in de Man, Rogosa and Sharpe (MRS) broth. Various types of 
bacteria require different compositions of media for optimal growth, and one of the key 
nutrients contributing towards successful bacterial growth is iron. Therefore, removing iron 
from the media with the addition of an iron chelator enables the effects on bacterial growth 
associated with a particular nutrient to be examined. 
4.2 Objectives 
The research included in this chapter reports the effect of chemical iron chelators on single 
cultures of bacteria that are known to require iron for growth. This chapter also examines 
the effects of iron chelators found in foods on bacteria cultured independently. The 
hypothesis being tested was that a reduction in iron availability through iron chelation 
would exert a negative impact on the growth of iron-dependent bacteria. 
4.3 Materials and Methods 
The bacterial strains and their growth conditions tested in this section are outlined in 
chapter 2, section 2.2.1. A range of pure bacterial cultures were grown overnight in 
selective rich media at 1% inoculation. Compositions of bacterial culture media can be 
found in chapter 2 (section 2.2.1, Table 2.1). No external source of iron was added to the 
cultures, and any iron present in the culture originated from the rich media. Cultures were 
seeded in 100-well honeycomb plates and cells were then exposed to a range of iron 
chelators. Bacterial growth was analysed using a Bioscreen C machine, which monitors the 
cell growth by measuring the turbidity (OD) of the liquid growth medium. The 
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experiments were run for 24 h – 48 h, depending on the bacteria of interest, with 
measurements at OD600, taken every 10 mins. The temperature of all experiments was set 
at 37oC. Depending on the type of organism, these studies were carried out under either 
aerobic or anaerobic conditions. The final concentration of chelators was decided based on 
previously published literature. 
Table 4.1 indicates which media was used for specific bacteria. Further details on media 
composition can be found in chapter 2. 
Table 4.1 - Media used for different bacterial species 
Bacterial species Media used 
E. coli LB 
S. Typhimurium LB 
C. perfringens BHI-C 
B. thetaoiotaomicron BHI-H 
B. longum BHI 
L. rhamnosus MRS +glucose 
 
4.4 Results 
4.4.1 Evaluating the growth of independently cultured bacteria under 
conditions of iron chelation using chemical iron chelators 
Small-scale experiments were performed to elucidate whether independently cultured 
bacteria would achieve optimal growth under chelated-iron conditions. For these 
experiments, the bacteria selected to investigate the effects of iron chelation were a range 
of bacteria that can be found in the colon. 
4.4.1.1  Bathophenantrholine Disulphonic Acid (BPDS) and 2,2-dipyridyl 
(22D) 
BPDS and 22D both act as metal chelators, with a very strong affinity for iron. They both 
form a complex with iron, rendering it unavailable to the surrounding environment. Taking 
this into consideration, a range of bacteria were cultured with and without BPDS or 22D. 
Figure 4.1 illustrates the impact of BPDS and 22D on potentially pathogenic bacteria, 
whilst Figure 4.2 demonstrates how the potentially beneficial bacteria are affected by the 
chelation of iron.  
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Figure 4.1 – The effects of BPDS and 22D on the growth of potentially pathogenic bacteria. 
BPDS and 22D was added at various concentrations, ranging from 0 – 100 µM to E. coli (a and b, 
respectively), S. Typhimurium (c and d, respectively), C. perfringens (e and f, respectively) and B. 
thetaiotaomicron (g) grown anaerobically, at 1% inoculation, with a total working volume of 300 
µL. One-way ANOVA was performed to analyse growth curves, comparing each curve to the 
control (0 µM chelator). **p<0.01 and ****p<0.0001. 
The presence of either BPDS or 22D in the medium had a marked influence on the growth 
of the majority of the bacteria cultured. Both E. coli (Figure 4.1a and 4.1b) and S. 
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Typhimurium (Figure 4.1c and 4.1d) displayed a dose-dependent decrease that was 
statistically significant when cultured in LB media containing either of the iron chelators. It 
was concluded that for E. coli, a concentration of 50 μM BPDS was deemed sufficient for 
significant growth impairment (p<0.0001), whilst for S. Typhimurium, a lower 
concentration of 20 μM BPDS was sufficient to exert significant growth-limiting effects 
(p<0.01). Water-soluble iron (Fe2+) was also quantified in from the pure culture, and 
results showed that the presence of both chelators in the solution led to a decrease in iron 
in comparison to the control (no chelator) for both E. coli and S. Typhimurium. Fe2+ levels 
in the control media were 0.11 nmol and 0.531 nmol for E. coli and S. Typhimurium, 
respectively, whilst negligible amounts of Fe2+ were found in the presence of both BPDS 
and 22D for both bacteria. 
Although not dose-dependent, similar results were observed for C. perfringens when 
cultured in the presence of 22D (Figure 4.1f), but this was not observed when grown with 
BPDS (Figure 4.1e). Interestingly, when Fe2+ was quantified, the presence of both 
chelators led to a decrease in iron in comparison to the control (0.645 nmol in control and 
negligible amounts in the presence of both chelators). For C. perfringens, a minimum 
concentration of 50 μM 22D elicited a statistically significant decrease in growth 
(p<0.0001). Finally, the growth of B. thetaiotamicron was negatively impacted by BPDS 
(Figure 4.1g), causing a statistically significant reduction in its growth at all concentrations 
of this chelator (p<0.0001). 
Next, the effects of the same chelators were investigated on bacteria that are considered as 
beneficial for gut health. In general, beneficial bacteria, such as members of the 
Lactobacillus genera, are unaffected by a lack of iron and can grow optimally even when 
iron is scarce. Figure 4.2 illustrates the effects of both iron chelators on two beneficial 
species, B. longum and L. rhamnosus.  
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Figure 4.2 – The effects of BPDS and 22D on the growth of beneficial bacteria. BPDS and 22D 
was added at various concentrations, ranging from 0 – 100 µM to B. longum (a and b, 
respectively) and L. rhamnosus (c and d, respectively) grown anaerobically, at 1% inoculation, 
with a total working volume of 300 µL. One-way ANOVA was performed to analyse growth curves, 
comparing each curve to the control (0 µM chelator). **p<0.01. 
There has been some research which suggests that some Bifidobacterium species do not 
require iron for its growth [253], and interestingly, when B. longum was cultured in the 
presence of BPDS, there was a significant decrease in its growth (p<0.01 for both 10 µM 
and 20 µM) in comparison to the control (0 µM) (Figure 4.2a). This decrease correlated 
with a reduction in Fe2+ in the culture in the presence of BPDS. 22D illustrated no 
significant impact on B. longum growth (Figure 4.2b). As expected, the growth of L. 
rhamnosus was unaffected when cultured with either chelator, despite Fe2+ levels reducing 
in the presence of both chelators (Figure 4.2c and 4.2d). B. longum presented with Fe2+ 
levels of 0.026 nmol in the control culture, whilst negligible amounts of Fe2+ were found in 
the presence of both chelators. 
4.4.1.2  Effects of BPDS on the growth of different species of bifidobacteria 
Given the interesting decrease in B. longum growth observed when cultured with BPDS, a 
range of different Bifidobacterium species and B. longum strains were cultured with BPDS 
to confirm whether similar effects were observed. Figure 4.3 shows the influence of BPDS 
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on the growth of the following bacteria – B. longum subsp. longum; B. longum subsp. 
infantis (x2 different strains); B pseudocatenulatum and B. adolescentis.  
 
Figure 4.3 – The effects of BPDS on different species and strains of Bifidobacterium. BPDS was 
added at various concentrations, ranging from 0 – 50 µM to B. longum subsp. Longum 20219 (a); 
B. longum subsp. Infantis 20090 and 20088 (b and c, respectively); B pseudocatenulatum 20438 
(d) and B. adolescentis 20083 (e) grown anaerobically, at 1% inoculation, with a total working 
volume of 300 µL. One-way ANOVA was performed to analyse growth curves, comparing each 
curve to the control (0 µM BPDS). *p<0.05 and **p<0.01. 
No decrease in growth was observed when any of the B. longum species were cultured in 
BHI media with BPDS (Figure 4.3a, 4.3b and 4.3c). Conversely, in the presence of BPDS 
at a concentration of 20 μM, both B. pseudocatenulatum (Figure 4.3d) and B. adolescentis 
(Figure 4.3e) exhibited a statistically significant reduction in growth (p<0.01 and p<0.05, 
respectively), with 10 μM BPDS being sufficient to also significantly impair the growth of 
B. adolescentis (p<0.05). These observations suggest that the iron-limiting effects of the 
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iron chelator is species/strain dependent, and reliant on the iron-regulatory genes, if any, 
that the different species/strains express.  
4.4.2  Evaluating the growth of cultured bacteria under conditions of iron 
chelation achieved by naturally-derived iron chelators 
There are many naturally-occurring compounds within our diet that have the ability to 
strongly bind iron and withhold it from bacteria present in the colonic environment. A 
range of naturally-derived iron chelators identical to those outlined in section 4.4.1, were 
added to media used to independently culture bacteria. The next series of figures displays 
the impact of the following chelators, sodium alginates, lactoferrin, tannic acid and phytic 
acid on the growth of different bacteria. 
4.4.2.1  Sodium alginate 
Alginates have been reported to inhibit the growth of a range of bacteria, and therefore 
Manucol LD (mwt 145 kDa; G:M ratio 38:62), a sodium alginate was added at a final 
concentration of 0.3% (w/v) to pure cultures of bacteria to investigate this. 
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Figure 4.4 – The effects of Manucol LD on the growth of potentially pathogenic bacteria. 
Manucol LD was added at a final concentration of 0.3% (w/v) to pure cultures of E. coli (a), S. 
Typhimurium (b), C. perfringens (c) and B. thetaiotaomicron (d) grown anaerobically, at 1% 
inoculation, with a total working volume of 300 µL. One-way ANOVA was performed to analyse 
growth curves, comparing each curve to the control (no alginate). **p<0.01 and ****p<0.0001. 
From these data, it was clear that the growth of most of the pure cultures tested (S. 
Typhimurium, C. perfringens and B. thetaiotaomicron, Figure 4.4b, 4.4c and 4.4d, 
respectively) were significantly impaired in the presence of Manucol LD (p<0.01, 
p<0.0001 and p<0.0001, respectively), correlating with lower Fe2+ levels in the media 
when compared to the control (S. Typhimurium - 0.531 nmol and 0.199 nmol from control 
and chelator cultures, respectively; C. perfringens – 0.645 nmol and 0.254 nmol from 
control and chelator cultures, respectively). E. coli growth was unaffected by Manucol LD 
(Figure 4.4a), as has been reported in other studies, where E. coli displayed the most 
resistance to the antibacterial effects of the alginates tested [254]. This is also further 
strengthened by the unaffected levels of Fe2+ concentrations in the presence of Manucol 
LD (0.105 nmol present in control culture compared to 0.274 nmol present in chelator 
culture), suggesting strong iron-scavenging properties of E. coli.  
The next set of figures illustrate the effects of Manucol LD on the beneficial species, B. 
longum and L. rhamnosus (Figure 4.5a and 4.5b, respectively). 
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Figure 4.5 – The effects of Manucol LD on the growth of beneficial bacteria. Manucol LD was 
added at a final concentration of 0.3% (w/v) to pure cultures of B. longum (a) and L. rhamnosus 
(b) grown anaerobically, at 1% inoculation, with a total working volume of 300 µL. One-way 
ANOVA was performed to analyse growth curves, comparing each curve to the control (0% 
Manucol LD). *p<0.05 and ****p<0.0001. 
As seen in Figures 4.5, the addition of Manucol LD had a detrimental effect on the 
beneficial species, B. longum (Figure 4.5a), with its growth being significantly impaired 
(p<0.0001). This correlated with a decrease observed in Fe2+ levels in the culture compared 
to the control (0.026 nmol from control culture compared to negligible amounts of Fe2+ in 
the presence of Manucol LD). L. rhamnosus growth was also significantly stunted (p<0.05) 
(Figure 4.5b). Fe2+ levels show no reduction in concentrations when cultured with Manucol 
LD. 
These data suggest that although removal of iron could reduce the pathogenic profile of the 
gut microbiota, as illustrated by the pure cultures in Figure 4.5, it may be important to 
ensure that the beneficial bacterial population are not negatively affected by iron removal.  
4.4.2.2  Human lactoferrin 
Human lactoferrin (Lf) is a key protein in host defences, with its iron-binding capabilities 
contributing towards this [255-257]. The same bacterial species from the previous 
experiments were cultured independently with and without human Lf (apolactoferrin) 
(Figure 4.6).  
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Figure 4.6 – The effects of lactoferrin on the growth of potentially pathogenic bacteria. Lf was 
added at various concentrations (0 – 12 µM) to pure cultures of E. coli (a), S. Typhimurium (b), C. 
perfringens (c) and B. thetaiotaomicron (d) grown anaerobically, at 1% inoculation, with a total 
working volume of 300 µL. One-way ANOVA was performed to analyse growth curves, comparing 
each curve to the control (0 µM Lf). ***p<0.001 and ****p<0.0001. 
Statistically significant effects were only observed for E. coli (p<0.0001, Figure 4.6a) and 
S. Typhimurium (p<0.001 and p<0.0001 at 6 μM and 12 μM, respectively, Figure 4.6b), 
where concentrations of 6 μM and 12 μM Lf impaired the growth of these bacteria, though 
not in a dose-dependent manner. For C. perfringens and B. thetaiotaomicron, (Figure 4.6c 
and 4.6d, respectively) no effect on their growth was observed when Lf was present in the 
media, suggesting Lf may not be as potent an iron chelator as some of the previously 
investigated chelators in this Chapter.  
The next set of figures illustrate the effects of human Lf on the beneficial species, B. 
longum and L. rhamnosus (Figure 4.7). 
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Figure 4.7 – The effects of lactoferrin on the growth of beneficial bacteria. Lf was added at 
various concentrations (0 – 12 µM) to pure cultures of B. longum (a) and L. rhamnosus (b) grown 
anaerobically, at 1% inoculation, with a total working volume of 300 µL. One-way ANOVA was 
performed to analyse growth curves, comparing each curve to the control (0 µM Lf).  
Interestingly, no statistically relevant effect of Lf was observed on the growth of B. longum 
(Figure 4.7a), as was also the case with L. rhamnosus (Figure 4.7b), where its growth 
remained unaffected in the presence of Lf in comparison to the control. 
4.4.2.3  Tannic acid 
As briefly discussed in the introduction of this Chapter, tannins (a compound present in a 
wide variety of fruits and vegetables) also have iron-chelating properties. Therefore, tannic 
acid (TA) (final concentration of 60 μM), the salt form of tannins, was cultured with the 
same set of bacteria outlined in the previous sections, to investigate its effects on bacterial 
growth.  
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Figure 4.8 – The effects of tannic acid on the growth of potentially pathogenic bacteria. TA was 
added at a final concentration of 60 µM to pure cultures of E. coli (a), S. Typhimurium (b), C. 
perfringens (c) and B. thetaiotaomicron (d) grown anaerobically, at 1% inoculation, with a total 
working volume of 300 µL. One-way ANOVA was performed to analyse growth curves, comparing 
each curve to the control (0 µM TA). *p<0.05 and ****p<0.0001. 
The growth of all bacterial cultures was impacted by the presence of TA (Figure 4.8). E. 
coli growth was significantly impaired when TA was present in the culture media (p<0.05, 
Figure 4.8a), however, this growth was not as significant as observed for the growth of S. 
Typhimurium (p<0.0001, Figure 4.8b), C. perfringens (p<0.0001, Figure 4.8c) and B. 
thetaiotaomicron (p<0.0001, Figure 4.8d). E. coli and C. perfringens displayed comparable 
levels of Fe2+ to the control when in the presence of TA whilst Fe2+ concentrations in the 
control culture of S. Typhimurium was 0.531 nmol compared to 0.194 nmol when in the 
presence of TA.  
Following this, the effects of TA were investigated on the beneficial bacteria, B. longum and 
L. rhamnosus. 
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Figure 4.9 – The effects of tannic acid on the growth of beneficial bacteria. TA was added at a 
final concentration of 60 µM to pure cultures of B. longum (a) and L. rhamnosus (b) grown 
anaerobically, at 1% inoculation, with a total working volume of 300 µL. One-way ANOVA was 
performed to analyse growth curves, comparing each curve to the control (0 µM TA). ***p<0.001. 
As expected, the growth of L. rhamnosus (Figure 4.9b) was unaffected when cultured in 
media containing TA. A positive effect on B. longum was observed (Figure 4.9a), where the 
addition of TA significantly increased its growth in comparison to the control (p<0.001). 
Iron quantification showed comparable levels of Fe2+ to the control for both bacterial species.  
4.4.2.4  Phytic acid 
Phytic acid (PA) is also a very potent iron chelator found in plant-based foods. For this 
reason, a range of bacteria were independently cultured with and without PA to observe its 
effects, if any, on bacterial growth.  
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Figure 4.10 – The effects of phytic acid on the growth of potentially pathogenic bacteria. PA was 
added at various concentrations (0 mM – 21.8 mM) to pure cultures of E. coli (a), S. Typhimurium 
(b), C. perfringens (c) and B. thetaiotaomicron (d) grown anaerobically, at 1% inoculation, with a 
total working volume of 300 µL. One-way ANOVA was performed to analyse growth curves, 
comparing each curve to the control (0 mM PA). ***p<0.001 and ****p<0.0001. 
The highest concentration of PA tested (21. 8 mM) elicited a statistically negative effect on 
all potentially pathogenic bacteria investigated (E. coli, S. Typhimurium and C. 
perfringens p<0.0001, Figure 4.10a – 4.10c, respectively) in comparison to the control, 
with C. perfringens’ growth also being impaired at a lower PA concentration of 10.9 mM 
(Figure 4.10c). In the presence of PA, Fe2 concentrations were lower in comparison to 
when no chelator was cultured with these bacterial species. Fe2+ concentrations were 
present at 0.006 nmol in the presence of PA in comparison to 0.105 nmol obtained from 
the control culture of E. coli. For S. Typhimurium, PA reduced the levels of Fe2+ to 0.071 
nmol from 0.531 nmol. Finally, Fe2+ levels were reduced to 0.318 nmol from 0.645 nmol 
in the presence of PA for C. perfringens. 
Interestingly, for B. thetaiotaomicron after an initial significant decrease in growth 
observed in the presence of 21.8 mM PA (up to 24 h, p<0.001, Figure 4.10d), a resumption 
of growth occurred after approximately 24 h, after which the growth of B. 
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thetaiotaomicron is comparable to that of the control. Many bacteria have been found to 
have outer-membrane vesicles, which contain phytate-binding enzymes [258], so this 
effect may be due to phytate degradation releasing iron back into the media.  
Finally, the growth of beneficial bacteria was also observed in the presence of PA, as seen 
in Figure 4.11. 
 
Figure 4.11 – The effects of phytic acid on the growth of beneficial bacteria. PA was added at 
various concentrations (0 mM – 21.8 mM) to pure cultures B. longum (a) and L. rhamnosus (b) 
grown anaerobically, at 1% inoculation, with a total working volume of 300 µL. One-way ANOVA 
was performed to analyse growth curves, comparing each curve to the control (0 mM PA). 
*p<0.05. 
The addition of 21.8 mM PA to the media led to a statistically relevant increase in the 
growth of B. longum (p<0.05, Figure 4.11a), whilst L. rhamnosus growth was unaffected 
when PA was added to the culture (Figure 4.11b). Iron levels in the presence of PA when 
cultured with L. rhamnosus was comparable to the control (4.394 nmol control vs 4.127 
nmol PA), whilst iron levels were considerably reduced when B. longum was cultured in 
the presence of PA (0.026 nmol control vs negligible concentrations in the presence of 
PA). 
Table 4.2 summarises the effects of all the chelators tested on the different bacterial 
species presented in this chapter. 
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Table 4.2 - Effects of iron chelators on different bacterial species. Significance shown for 
highest concentration of chelator tested (- p<0.05, -- p<0.01 and ---- p<0.0001 and + 
p<0.05, +++ p<0.001. ‘-’ indicates a significant decrease and ‘+’ indicates a significant 
increase 
Species BPDS 22D Manucol 
LD 
Lf TA PA 
E. coli ---- ---- No effect ---- - ---- 
S. Typhimurium ---- ---- -- --- ---- ---- 
C. perfringens No effect ---- ---- No 
effect 
---- ---- 
B. thetaiotaomicron ---- No growth ---- No 
effect 
---- ---- 
B. longum -- No effect ---- No 
effect 
+++ + 
L. rhamnosus No effect No effect - No 
effect 
No 
effect 
No 
effect 
 
4.5 General Discussion 
The main objective of these experiments was to establish whether the growth of 
independently cultured bacteria would be affected by the addition of a range of iron 
chelators to the media. Before inoculation with bacteria, nutrient rich media was placed in 
an anaerobic cabinet for a minimum of 12 h to ensure deoxygenated media was used in the 
experiments. It was found that for all bacteria tested, the lag phase ended approximately 
between 6-8 h, after which the exponential phase commenced, and therefore, running the 
experiments for a period of 24 – 48 h was deemed sufficient for the observations. 
A range of iron chelators was used for these experiments in order to assess the impact of 
iron withdrawal on various bacterial species. The chelators were divided into two groups, 
chemical and dietary, and both sets of chelators were tested on bacteria that have the 
potential to be pathogenic as well as those that are beneficial for gut health. The 
concentrations of chelators to be used in these pure culture experiments were based on 
previously published literature to ensure that concentrations were low enough to elicit 
inhibitory effects and at the same time not cause toxic effects on the bacteria [254, 259, 
260]. All iron chelators elicited an iron-reduced environment when cultured with majority 
of the bacteria, with Fe2+ concentrations being considerably lower in the media when 
compared to the control. Firstly, when cultured with the chemical iron chelators, BPDS and 
2,2-Dipyridyl, the growth of all potentially pathogenic bacteria was significantly impaired, 
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except for C. perfringens when cultured with BPDS. Similar results were seen in another 
study, which investigated the survival of bacteria derived from lake water when treated 
with bathophenanthroline, a chemical iron chelator [261]. This study showed that the 
administration of bathophenanthroline strongly inhibited E. coli growth by up to 88%. Our 
data also showed BPDS significantly reducing the growth of B. longum, whilst 2,2-
Dipyridyl had no effect on its growth. As expected, the growth of L. rhamnosus was 
unaffected by either of the chelators. It can be seen from the control culture (i.e. cultures 
that were grown without the addition of any chelator) that the growth of all bacteria 
progressed without any restriction and it can therefore be inferred that the reduction in the 
growth of the bacterial species tested was mediated through lack of iron.  
Likewise, when bacterial species were cultured with dietary iron chelators, a similar trend 
was observed. Phytic and tannic acid both decreased the growth of all potentially 
pathogenic bacteria to a significant extent, whilst simultaneously increasing the growth of 
B. longum and L. rhamnosus. Interestingly, the addition of PA led to a temporary reduction 
in the growth of B. thetaiotaomicron until 24 h, after which growth resumed. B. 
thetaiotaomicron have been shown to have outer membrane vesicles, which contain 
phytate degrading enzymes [258, 262]. These enzymes allow the phytate to enter the cell 
for nutrient processing whilst also preventing it from being destroyed by the hosts own 
protein degrading enzymes. In the case of B. thetaiotaomicron, it has been reported that it 
produces a histidine acid phosphatase, which is characterised by a subtle change in amino 
acid structure, therefore, providing this enzyme with catalytic properties. From Figure 
4.10d, it could be speculated that this enzyme takes approximately 24 h to be produced, as 
before that time, the growth of B. thetaiotaomicron is significantly impaired, possibly due 
to undigested phytate. When comparing phytic and tannic acid together, PA appears to 
have an overall higher significant impact on the growth of potentially pathogenic bacteria, 
whereby PA reduced the growth of E. coli to a greater extent than TA (Figure 4.10a and 
4.8a, respectively).  
Lactoferrin only decreased the growth of E. coli and S. Typhimurium, whilst the growth of 
all other bacterial species tested remained unaffected in the presence of lactoferrin, 
suggesting it may not be as strong a chelator compared to the ones previously discussed. 
The decrease observed in E. coli and S. Typhimurium has been observed in other studies 
also. Iron binding related growth inhibition or cell death has been regarded as a major 
antibacterial activity of lactoferrin. For instance, human apo lactoferrin (iron free 
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lactoferrin) has a bactericidal effect on a variety of microorganism (gram-positive/negative 
bacteria, rods and cocci, facultative anaerobes and aerotolerant anaerobes) [147, 263]. 
Some studies have described lactoferrin as consistently exhibiting bactericidal activity 
against gram-negative bacteria [264, 265], whilst other studies have suggested the use of 
lactoferrin in the control of Salmonella food poisoning as an additive to dry foods [266]. 
Over the recent years, studies have shown that lactoferrin not only chelates and sequesters 
iron, it also binds to the lipid A portion of lipopolysaccharide (LPS), found on the bacterial 
cell wall and therefore disrupting the surface [267, 268]. The binding of lactoferrin to the 
lipid A section of LPS can therefore reduce the virulence of some of the major 
enteropathogens [269, 270]. 
Finally, Manucol LD significantly decreased the growth of all bacteria, apart from E. coli, 
including the beneficial species, to a statistically significant extent. Our results reflect what 
has been seen in another study, which had the aim of culturing a panel of bacteria, 
including E. coli and S. Typhimurium, with various concentrations of alginate, followed by 
assessment of bacterial growth [254]. As with our study, the growth of Salmonella was 
significantly reduced by the addition of alginate, whilst E. coli displayed the most 
resistance to the antibacterial properties of the alginates. Again, given the successful 
growth of bacteria cultured without any chelator present in the media, it can be inferred 
that these effects observed are mediated by the depletion of iron.  
One can speculate the direct interaction of the sodium alginate with the bacterial species, in 
regard to L. rhamnosus. For all chelators tested, Fe2+ levels were reduced in comparison to 
the control, except for when cultured with Manucol LD. However, the presence of 
Manucol LD subsequently led to a significant decrease in the growth of this bacteria. This 
suggests that the reduction in growth observed may not be linked to the levels of iron, but a 
direct effect of sodium, which has been reported to be toxic to the Lactobacillus genus 
[271]. 
4.6 Conclusions 
Using a variety of independently cultured bacteria, the effects on growth were observed 
with and without iron chelators. It was confirmed that the addition of a range of iron 
chelators, both dietary and chemical, restricted the growth of many potentially pathogenic 
bacterial species, such as E. coli, S. Typhimurium, C. perfringens and B. longum. 
However, this effect was not observed for all chelators tested. Furthermore, it was also 
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observed that the growth of beneficial bacterial species, such as B. longum and L. 
rhamnosus was largely unaffected in the presence of an iron chelator, and in some cases, 
the growth of these bacteria was positively impacted. Furthermore, the reduction in the 
potentially pathogenic bacteria was positively correlated with the amount of Fe2+ available 
in the media, suggesting that the decreases observed in various bacterial species was iron-
dependent. When choosing which chelator to use with the objective to improve gut health, 
the impacts on all groups of bacteria have to be considered. Out of the naturally-derived 
chelators, phytic acid appeared to have the most positive impact overall. Therefore, to 
further complement these results, the next chapter will look at how the chelation of iron 
with phytin (calcium magnesium salt of phytic acid) and BPDS (a commonly used 
chemical iron chelator) impacts the function and composition of the human gut microbiota 
when iron chelators are cultured with human faecal microbiota in a colonic batch 
fermentation model.  
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5.0 Summary 
The previous chapter described the effect of a range of iron chelators on bacteria that were 
cultured independently. It was observed that the growth of many pure cultures of bacteria 
were negatively impacted in the presence of an iron chelator. However, bacteria are largely 
present as a mixed community, therefore, the next step was to examine what effect iron 
chelation has on human faecal microbiota derived from apparently healthy donors. The 
relative abundance of different groups of bacteria which have the potential to display 
pathogenic phenotypes, such Enterobacteriaceae, were reduced in the presence of an iron 
chelator, whilst the presence of alternative chelators also led to an increase in the relative 
abundance of bacterial groups beneficial for the host, such as bifidobacteria. Part of the 
work described in this chapter has been published previously [272].  
5.1 Introduction 
Dietary components have a large influence on iron availability. Organic acids, such as 
citrate, have been demonstrated to form a weak, soluble chelate with iron, which 
potentially prevents the precipitation of iron, keeping it in its soluble form, once it has left 
the acidic conditions of the stomach and entered the duodenum at a higher pH [51]. A 
well-known enhancer of iron absorption is ascorbic acid (Vitamin C) that can chelate iron 
and also reduce Fe3+ to Fe2+, the species that is absorbed in the duodenum [82, 84]. As well 
as increasing the absorption of iron, there are many dietary components that restrict this 
process. PA, also known as inositol hexakisphosphate (InsP6), or phytate when present as 
the calcium-magnesium salt, is the principle storage form of phosphorus in many plants, 
such as seeds, nuts, cereals and legumes [250]. Beneficial properties of PA have been 
reported, including anti-cancer and anti-oxidant activities [273, 274]. However, in vivo and 
in vitro studies have shown that it forms insoluble complexes with several divalent 
minerals such as Ca2+, Fe2+, Zn2+ and Mg2+, thereby preventing absorption [275, 276] and 
it has therefore been referred to as an anti-nutrient. Inorganic phosphate is released as a 
result of PA degradation, resulting in the production of PA’s lower inositol forms (penta-, 
tetra-, tri-, di- and mono-myo-inositol phosphates; InsP5, InsP4, InsP3, InsP2 and InsP1, 
respectively) [277]. Of these lower inositol phosphates, only InsP5 and InsP4 has anti-
nutritional properties, thereby decreasing mineral availability [251, 278]. Other derivatives 
of PA display no anti-nutritional activity. 
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Degradation of PA can occur during the processing of foods [279], through the actions of 
enzymes called phytases, derived from plant-based foods. Any ingested PA will enter the 
gastrointestinal tract but no substantial PA degradation is achieved due to the absence of 
phytase activity in human intestinal cells [280]. Enzymatic degradation of PA, however, is 
achievable via intrinsic plant-based phytases or via the colonic microbiota [278].  
Certain gut micro-organisms (Bifidobacteriaceae and coliforms) are able to break down 
phytates. One study showed that the highest phytate degrading activity belonged to 
Lactobacillus reuteri, Lactobacillus salivarius and Bifidobacterium dentium [201]. 
Notably, phytate-bound iron found in the colon is present in the insoluble form making it 
difficult to degrade [52, 202], suggesting a potential role for phytate in the withholding of 
iron from potentially pathogenic bacteria.  
Few studies have examined the effects of iron chelation on the gut microbiota of healthy 
individuals, and therefore, the aim of the experiments detailed in this chapter was to 
investigate the effects of limiting the availability of iron to mixed cultures of bacteria 
obtained from the gut microbiota. For the experiments outlined in this chapter, BPDS and 
PA were used as examples of iron chelators to examine the hypothesis that iron-chelation 
in the colonic environment would alter the composition of the gut microbiota, with 
potentially pathogenic groups of bacteria reducing in abundance.  
5.2 Objectives 
The aim of the research presented in this chapter was to investigate the hypothesis that 
culturing human faecal microbiota with an iron chelator will decrease the relative 
abundance of those bacteria which are potentially pathogenic, whilst simultaneously 
increasing the relative abundance of beneficial bacteria. This chapter will be split into two 
sections: the effect on human faecal microbiota by ⅰ) the chemical iron chelator, BPDS, 
and ⅱ) the natural iron chelator, phytin (calcium magnesium salt of phytic acid).  
5.3 Materials and Methods 
The data presented in this chapter was obtained from experiments using faecal material 
from 6 healthy donors, details for whom are given in Table 5.1. This table also outlines for 
which chelator the faecal microbiota were used.  
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Table 5.1 – Age, gender and BMI status of faecal donors 
Donor 
ID 
Age Gender BMI 
(kg/m2) 
Chelator 
CM031 33 M 22.4 BPDS 
CM036 31 F 23.2 BPDS 
CM075 70 M 18 BPDS 
CM011 51 M 25.7 Phytin 
CM026 27 F 25.1 Phytin 
CM052 25 F 25.4 Phytin 
 
5.3.1 In vitro colonic fermentations 
Faecal samples used in the colon model experiments were obtained from participants 
recruited to the QIB Colon Model study. Further details regarding the criteria for 
participants recruited, all of which were non-smokers, can be found in chapter 2, section 
2.5.1. Aliquots of fresh faecal samples obtained from the healthy volunteers were diluted in 
deoxygenated phosphate buffered saline (pH 7.7), and homogenised using a Stomacher 
400 (Seward, United Kingdom) at 230 rpm for 45 s. Further details regarding the 
processing of the homogenised faecal samples can be found in chapter 2, section 2.5.2.  
Conditions tested were either nutritive media (composition can be found in chapter 2) with 
faecal inocula only (control), or with faecal inocula supplemented with either BPDS (70 
μM) or phytin (50 μM). Chelator concentrations tested were feasible for human intake 
levels. For each donor, 1 vessel was used for each condition. Samples were taken at 0, 4, 8, 
and 24 h, serially diluted in PBS and enumerated on selective agar plates (described 
previously in chapter 2, section 2.5.2). 
5.3.2 Extraction of microbial DNA from human faecal microbiota 
From the fermentation samples collected during the in vitro colonic batch fermentation 
model experiments, microbial DNA was extracted using the commercially available kit, 
FastDNA SPIN Kit for Soil. An additional bead-beating step was incorporated into this 
method, as detailed in chapter 2, section 2.6.1. Following extraction, the QIIME 1.9.0 
pipeline was implemented to perform bioinformatic analysis on the sequencing output 
files, with RDP as the reference sequence database (chapter 2, section 2.6.3). 
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5.4 Results – Bathophenanthroline disulphonic acid 
5.4.1 Evaluating the impact of BPDS-mediated iron chelation on the viable 
counts of some bacterial groups 
For the experiments in this section, the range of bacterial groups enumerated were a 
selection of beneficial bacteria and those that have the potential of displaying pathogenic 
phenotypes. Table 5.2 depict the effects of BPDS on the viable counts of a variety of 
bacterial groups derived from the human faecal microbiota of three individual healthy 
donors (CM031, CM036 and CM075). The viable counts for the ‘control’ vessel (i.e. this 
vessel contained nutritive media and faecal inocula only) were first normalised to 100% 
and thereafter, viable counts from the iron-chelated vessels (‘+BPDS’) were shown as 
percentages in relation to the control at the corresponding time point (‘T8’ and ‘T24’). 
Significant changes of viable counts in comparison to the control are marked at the 
relevant timepoints for each bacterial group. 
Table 5.2 – Viable counts (%) of different bacterial groups derived from the human 
faecal microbiota of donors after iron chelation with BPDS. **p<0.01, ***p<0.001 and 
****p<0.0001. Control normalised to 100%. 
Bacterial Group T8 +BPDS T24 +BPDS 
 
CM031 CM036 CM075 CM031 CM036 CM075 
Total Anaerobes 34 **** 10 **** 42 **** 38 **** 14 **** 36 **** 
Bacteroides 103 6 **** 99 8 *** 15 **** 69 
Bifidobacteria 7 **** 5 **** 4 4 **** 4 **** 324 ** 
Clostridia 75 15 **** 103 1012 **** 10 **** 278 **** 
Lactobacilli 2 **** 18 **** 5 **** 39 **** 24 **** 44 **** 
Enterobacteriaceae 2 **** 44 *** 16 **** 2 ****  48 *** 3 **** 
  
Numerous trends can be seen that are consistent in the donors. For example, the faecal 
material from all three donors displayed a significant reduction (p<0.0001) in the viable 
counts of three bacterial groups at both 8 h and 24 h when cultured in the presence of 
BPDS, in comparison to the control at the respective timepoints. These three groups of 
bacteria are (ⅰ) total anaerobes, (ⅱ) the beneficial group lactobacilli and (ⅲ) 
Enterobacteriaceae, a family containing potentially pathogenic bacterial species. 
Decreases as high as 98% were observed for the viable counts of Enterobacteriaceae at 24 
h of the fermentation period in the presence of BPDS. 
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The viable counts of Bacteroides, a genus of bacteria that are also known to contain 
bacterial species with pathogenic phenotypes, displayed a statistically significant decrease 
from the faecal material of two of the three donors at 24 h (CM031, p<0.001 and CM036, 
p<0.001). Both donors displayed decreases in viable counts ranging from 85% - 92%. 
Faecal material from donor CM075 displayed a non-significant decrease in the viable 
counts of Bacteroides when their human faecal microbiota was cultured with BPDS.  
Bifidobacteria, a group of bacteria that is linked to a healthy gut profile, were observed to 
decrease in viable counts at both 8 h and 24 h when the human faecal microbiota of two of 
the three donors were cultured with BPDS. Faecal material from donor CM031 displayed 
decreases of 92% and 96% at 8 h and 24 h (p<0.0001 at both timepoints), respectively, 
whilst faecal material from donor CM036 illustrated reductions of 95% and 96% at 8 h and 
24 h (p<0.0001 at both timepoints), respectively. Interestingly, although faecal material 
from donor CM075 showed no change in viable counts of bifidobacteria when in the 
presence of BPDS at 8 h, by the end of the fermentation period, viable counts had 
significantly increased in comparison to the control (p<0.01). 
For clostridia, another group of bacteria that may contain species of a pathogenic nature, 
faecal material from two of the three donors exhibited no change in viable counts in the 
presence of BPDS after 8 h of the fermentation. However, at the end of the 24 h 
fermentation period, statistically significant increases were observed for both donors in 
comparison to the control. The viable counts from the faecal material of donor CM031 
increased by 912% (p<0.0001) by 24 h, whilst viable counts in the faecal material from 
donor CM075 increased by 178% by the end of the fermentation cycle, compared to the 
control vessel. Such substantial increases could suggest that clostridia were presented with 
a competitive advantage due to other bacterial groups rapidly declining in the neighbouring 
environment. However, the opposite effect was observed in the faecal material from donor 
CM036 when cultured in the presence of BPDS. By 8 h, the viable counts of clostridia had 
significantly reduced by 85% (p<0.0001) and by the end of the fermentation cycle, 
clostridia counts had further reduced to 90% (p<0.0001) in comparison to the control 
vessel.  
5.4.2 Extraction of microbial DNA from human faecal microbiota 
From the fermentation samples collected during the in vitro colonic batch fermentation 
model experiments, microbial DNA was extracted. Extraction effectiveness was confirmed 
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using gel electrophoresis (Figure 5.1) and the yield and purity quantified using a NanoDrop 
Spectrophotometer.  
 
Figure 5.1 – Representative image of a 1% agarose gel containing extracted microbial DNA 
from fermented human faecal microbiota.  
5.4.3 Compositional analysis of cultured human faecal microbiota 
The V4 variable region of the 16S rDNA of the extracted microbial DNA obtained from 
the cultured faecal microbiota was investigated using high throughput 16S rRNA gene 
sequencing using the Illumina Miseq platform, followed by data analysis using the 
Quantitative Insights into Microbial Ecology (QIIME, V1.9) pipeline. Faecal samples from 
3 healthy humans (CM031, CM036 and CM075; Table 5.1) aged between 31-70 y (mean 
age of 45 y; mean BMI of 21.2 kg/m2) were collected, microbial DNA extracted and 
sequenced. Sequencing produced 103,954 high-quality reads. 
5.4.3.1  Compositional analysis of cultured human faecal microbiota – 
phylum level 
For each sample sequenced, the relative abundance of the bacterial taxa is illustrated as a 
proportion of each taxonomic unit within the human faecal microbiota. Both phylum and 
genus levels have been displayed to illustrate the differences observed between the 
taxonomic groups within the microbiota under both control and iron-chelated conditions.   
Tables 5.3a-c display the relative abundances (%) for the 4 main phyla present in the 
human gut microbiota sequenced for each donor. These phyla are Actinobacteria, 
Bacteroidetes, Firmicutes and Proteobacteria. 
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Table 5.3 – Relative abundances (%) of phyla sequenced from human faecal microbiota 
of donor CM031(a), CM036 (b) and CM075 (c) 
a. 
CM031 
Phyla T0 T8 control T8 BPDS T24 control T24 BPDS 
Actinobacteria 4 37 13 53 12 
Bacteroidetes 31 28 49 3 12 
Firmicutes 62 20 32 36 72 
Proteobacteria 2 15 6 8 3 
b. 
CM036 
Phyla T0 T8 control T8 BPDS T24 control T24 BPDS 
Actinobacteria 13 25 4 46 27 
Bacteroidetes 3 9 11 5 1 
Firmicutes 34 44 82 38 65 
Proteobacteria 50 22 2 11 6 
c. 
CM075 
Phyla T0 T8 control T8 BPDS T24 control T24 BPDS 
Actinobacteria 3 2 2 2 6 
Bacteroidetes 17 7 7 2 2 
Firmicutes 60 2 9 14 15 
Proteobacteria 1 89 80 81 76 
 
Tables 5.3a-c illustrate the large differences observed in the human faecal microbiota at the 
phylum level when the microbiota were cultured in the presence of BPDS. However, 
consistent trends were observed for 4 of the major phyla found in the human gut.  
Actinobacteria are a phylum of Gram-positive bacteria that are generally associated with 
species contributing towards a healthy gut profile. For two of the three donors, when 
cultured with BPDS, the human faecal microbiota displayed a reduction in the relative 
abundance of Actinobacteria at both 8 h and 24 h. 
The phylum Bacteroidetes is composed of Gram-negative bacteria and comprises bacterial 
species that exhibit pathogenic behaviour but also contain species that contribute positively 
towards gut health. All three donors illustrated an increase in the relative abundance of 
Bacteroidetes at 8 h when iron was chelated. 
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Firmicutes are a phylum of mostly Gram-positive bacteria. It includes many well-known 
genera, which can either be beneficial or harmful to gut health. When BPDS was cultured 
with the human faecal microbiota, all three donors showed an increase in the relative 
abundance of Firmicutes in comparison to the control at the respective time-points at 8 h 
and 24 h.  
Finally, Proteobacteria were adversely also affected by the presence of BPDS in the 
cultured human faecal microbiota. Proteobacteria are a major phylum of Gram-negative 
bacteria and include a wide variety of pathogens that can lead to a negative microbial 
profile. When iron was chelated from the fermentation, all three donors exhibited a 
decrease in the relative abundance of Proteobacteria at 8 h and 24 h in relation to the 
respective control. 
5.4.3.2  Compositional analysis of cultured human faecal microbiota – genus 
level 
Figure 5.2 illustrates the differences observed in the same human faecal microbiota at the 
genus level when the microbiota were cultured in the presence of BPDS. As with the 
phyla, consistent trends can be observed throughout all donors for many of the genera 
when iron chelation occurs via BPDS.  
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Figure 5.2 – Bar chart representing relative abundances (%) of different genera sequenced 
through 16S rDNA. Human faecal microbiota derived from donors CM031 (a), CM036 (b) and 
CM075 (c). 
Similar to that seen at the phyla level, genera identified from the human faecal microbiota 
of the three donors highlighted similar trends when cultured in the presence of BPDS.  
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Streptococcus is a genus of Gram-positive bacteria belonging to the phylum Firmicutes. 
Streptococcus species can contribute towards both negative and positive host health with S. 
thermophilus being exploited industrially as a probiotic [281-284]. For all three donors, 
upon chelation of iron from the fermentation through BPDS, subtle increases in the relative 
abundance of Streptococcus were seen in the faecal material at 8 h of the fermentation. 
However, by the end of the 24 h fermentation, a notable bloom in Streptococcus was 
observed in comparison to the 24 h control vessel for donors CM031 (59% T24 BPDS vs 
0.2% T24 control) and CM036 (43% T24 BPDS vs 1% T24 control). 
Bifidobacterium, a beneficial genus of bacteria belonging to the phylum Actinobacteria, 
decreased in relative abundance for two of the three donors when the faecal microbiota 
were cultured in the presence of BPDS. Faecal material from donor CM031 had relative 
abundances of 8% at T8 BPDS in comparison to 24% at T8 control. Similarly, the relative 
abundance of Bifidobacterium also decreased at 24 h (9% T24 BPDS vs 41% T8 control). 
Likewise, the faecal material from donor CM036 also displayed lower levels of 
Bifidobacterium in the presence of BPDS. At 8 h, the BPDS vessel contained 2% 
Bifidobacterium compared to 19% in the control. By the end of the fermentation, the 
relative abundance of Bifidobacterium was 27% (T24 BPDS) compared to 43% (T24 
control).  
Another genus belonging to Actinobacteria is Collinsella whose levels decreased in all 
donors when BPDS was added. Faecal material from donor CM031 had relative 
abundances of 4% at T8 BPDS compared to the T8 control, which displayed a relative 
abundance level of 24%. Similarly, at 24 h, Collinsella relative abundance was 9% 
compared to 41% (T24 control). Faecal material from donor CM036 also showed a similar 
trend though not to the same extent as CM031; 2% T8 BPDS vs 6% T8 control and 0.4% 
T24 BPDS vs 3% T24 control. However, negligible decreases were observed in the faecal 
material from donor CM075 (0.04% T8 BPDS vs 0.3% T8 control and 0.02% T24 BPDS 
vs 0.3% T24 control).  
The genus Bacteroides generally increased in the presence of BPDS for two of the three 
donors. For donor CM031, the relative abundance of Bacteroides at T8 BPDS and T24 
BPDS was 38% and 10%, respectively, in comparison to 17% and 2% at T8 control and 
T24 control, respectively.  
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Escherichia, a genus associated with negative health belonging to the Proteobacteria phyla, 
decreased in relative abundance in two of the three microbiota in which it was identified 
(CM031 and CM036) when cultured with the iron chelator. For donor CM031, when the 
faecal material was cultured with BPDS, the relative abundance of Escherichia was 1% 
and 0.4% at 8 h and 24 h, respectively, in comparison to 11% and 6% in the control vessels 
at 8 h and 24 h, respectively. Likewise, when the faecal microbiota of donor CM036 was 
cultured with BPDS, the relative abundance of Escherichia was lower in comparison to the 
control vessel at both timepoints (0.4% vs 21% T8 and 6% vs 9% T24). For the microbiota 
of donor CM075, the community displayed relatively high levels of Enterobacteriaceae, 
the family to which Escherichia and other pathogenic species belong. Relative abundances 
of Enterobacteriaceae decreased when the faecal microbiota was cultured with BPDS at 
both T8 and T24 in comparison to the respective control (77% vs 84% T8 and 72% vs 77% 
T24). The sample obtained from donor CM075 was the only of the three faecal samples 
that was found to contain measurable levels of Enterobacteriaceae at T0.  
The compositional data from all three donors combined to illustrate the overall trends 
observed when iron was chelated from the culture media through BPDS is described in 
Table 5.4. 
Table 5.4 – Average viable counts (%) of different bacterial groups before and after 
BPDS-mediated iron chelation derived from the human faecal microbiota of donors 
(+SEM). Control normalised to 100%. 
  Viable Counts % (‘control’ 
normalised to 100%, ±SEM) 
Bacterial Group T8 T24 
  (+)BPDS (+)BPDS 
Total Anaerobes 28 ±10 * 29 ±8 * 
Bacteroides 69 ±32 30 ±19 
Bifidobacteria 5 ±1*** 110 ±106 
Clostridia 64 ±26 433 ±299 
Lactobacilli 8 ±5 ** 36 ±6 ** 
Enterobacteriaceae 19 ±11 * 18 ±15 * 
 
Compared to when the human faecal microbiota were analysed individually (Table 5.2), 
only four bacterial groups displayed statistically different viable counts data at the same 
timepoint, when analysed as an average of the human faecal microbiota (Table 5.4). The 
viable counts for total anaerobes (p<0.05), lactobacilli (p<0.01) and Enterobacteriaceae 
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(p<0.05) showed a statistically significant reduction at both 8 h and 24 h when cultured 
under iron-chelated conditions. Similar observations were seen for the viable counts for 
bifidobacteria at 8 h, where a reduction was observed in viable counts under iron-chelated 
conditions (p<0.001). The increase in viable counts observed at 24 h for bifidobacteria is 
attributed entirely to one donor, CM075 (Table 5.2).  
After combining and averaging the abundance values from the three individual 
experiments, the data revealed that most abundant genera at 0 h were Escherichia (16%), 
followed by Bacteroides (9%) (Figure 5.3). 
 
Figure 5.3 – Microbial community profiles assessed by 16S rRNA gene analysis illustrating 
relative abundances of different genera from the three donors averaged 
High-throughput paired-end sequencing of the 16S rRNA gene (V4 region) was performed 
on fermentation samples using the Illumina Miseq platform, and microbial communities 
present in relative abundances ≥0.5% are illustrated in Figure 5.3. After combining and 
averaging the abundance values from the three individual experiments, the data revealed 
that the most abundant genera at 0 h were Escherichia (16.1%), followed by Bacteroides 
(8.7%). It is worth noting that the relative abundance of Escherichia was entirely attributed 
to one donor only, as the remaining two donors had no more than 0.1% Escherichia 
present at T0. 
Briefly, the relative abundance of Escherichia was reduced substantially in the iron 
chelated fermentation vessel in comparison to the control vessel at 8 h (0.8% vs 10.7%) 
and 24 h (2.3% vs 5.3%). This correlates well with the reduction in the viable counts for 
Enterobacteriaceae (Table 5.4). Again, it is worth noting that the high relative abundance 
of Enterobacteriaceae at T8 and T24 for both control and chelator conditions, is entirely 
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attributed to the levels observed in one donor only, since in the other two donors, the levels 
were below the detectable limit. A similar trend was observed for Bifidobacterium, where 
the relative abundance was much lower at T8 and T24 under iron-chelated conditions 
(4.1% vs 15% and 14% vs 29%, respectively), which is also reflected in the viable counts 
results for bifidobacteria at 8 h. Interestingly, 16S rDNA analysis indicated that at 24 h, the 
relative abundance of Streptococcus increased to 36% in the iron chelated condition 
compared to the starting proportion of 4.7%. Iron-depleted conditions have been shown to 
proportionally decrease many bacterial groups, and this may provide other bacteria, such as 
Streptococcus, with a competitive advantage resulting in their increased growth. This could 
also be true for Bacteroides, as the relative abundances of this genus increased at both 8 h 
(10.6% to 18.1%) and 24 h (2.7% to 4.4%) under iron chelated conditions. Finally, 16S 
rDNA analysis indicated that Clostridium abundance was largely unaffected by iron 
removal, and this was reflected in the viable counts for clostridia (Table 5.4). 
5.4.3.3  Microbial diversity within human faecal microbiota 
α-and β- diversity was measured for all in vitro colonic fermentation samples tested.  
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Figure 5.4 – Bacterial diversity profiles of colonic fermentation samples cultured with BPDS. (a) 
α- diversity analysis of batch fermentation samples with and without iron chelator (BPDS) using 
the Shannon index and (b) β- diversity analysis of batch fermentation samples portraying weighted 
analysis of samples with (BPDS) and without (X) iron chelator using the UniFrac metric and 
presented as a PCoA plot. Data shown is the average Eigenvalues from the 3 individual 
experiments using 3 independent donors. Each colour represents a different donor. Analysis was 
performed using QIIME (V1.9) and visualised using the XLSTAT add-on package in Microsoft 
Excel. 
The Shannon index, which is a measure of α- diversity, did not indicate a difference in 
diversity within the population in the absence of the chelator, between 8 h and 24 h (Figure 
5.4a). However, an increase in population diversity was observed at 8 h in the presence of 
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BPDS, compared to the control vessel at the same timepoint. The PCoA plot, using the 
weighted UniFrac metric, which depicts β- diversity, indicates that the microbiota of the 
subjects before and after iron chelation did not have a large range of taxa in common, 
(Figure 5.4b). Interestingly, at both 8 h and 24 h, a shift in β-diversity was observed upon 
iron chelation when compared to the control at the respective time points, depicted by the 
dashed line. 
5.4.3.4  Metabolite profiling in human faecal microbiota cultured with BPDS 
1H NMR spectroscopy was used to determine the levels of over 70 metabolites from 
samples taken from the fermenters at 0, 8, and 24 h. The three metabolites which showed 
the most substantial changes between treatments, SCFAs, acetate, propionate and butyrate 
(Figure 5.5). 
 
Figure 5.5 - Metabolite concentrations of batch fermentation samples cultured with BPDS. Short 
chain fatty acid concentrations in both vessels (Control ‘X’ and BPDS ‘BPDS’) were measured 
using 1H NMR spectroscopy, with samples being screened for multiple metabolites against a spiked 
standard (TSP) and a validated reference library. Data shown is the average ±SEM metabolite 
concentrations from the individual experiments from 3 independent donors (microbiota of donors 
CM031, CM036 and CM075). 
Acetate concentrations was ~25.3 mM under control conditions (i.e. 0 μM BPDS) at 8 h with 
lower levels (~6.3 mM) found when iron was chelated (with 70 µM BPDS) at the same time-
point. The same trend was observed at 24 h where acetate concentrations were ~33.3 mM in 
the control vessel whereas under iron-limitation, its levels were reduced to ~25.6 mM. Levels 
of propionate and butyrate exhibited the same pattern under control and iron-chelated 
conditions. In the control condition, ~1.1 mM (8 h) and ~6.8 mM (24 h) of butyrate was 
measured whereas under iron-chelation, butyrate levels were reduced (~0.4 mM at 8h and 
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~3.6 mM 24 h) representing 47% reduction at 24 h. This is reflected in the reduction 
observed for the relative abundances of the members of the Ruminococcus (3.9% to 1.5%) 
genera, which are common butyrate producers.  
Although similar propionate levels were observed between the different conditions at 8 h, 
propionate concentrations were lower in the iron-chelated vessel compared to the control at 
24 h (~10.5 mM vs ~3.5 mM). This represents a 67% decrease in production at 24 h under 
iron-limiting conditions. This is in line with the 70% decrease observed in the viable 
counts of Bacteroides (a genus containing propionate producers) under low iron conditions 
(Table 5.4). 
5.5 Results - Phytin 
5.5.1 Evaluating the impact of phytin-mediated iron chelation on the viable 
counts of a variety of bacterial groups 
For the experiments in this section, the range of bacterial groups enumerated were a 
selection of beneficial bacteria and those that have the potential of displaying pathogenic 
phenotypes.  
Table 5.5 depicts the effect of phytin on the viable counts of a variety of bacterial groups 
derived from the human faecal microbiota of three individual healthy donors (CM011, 
CM026 and CM052). The viable counts for the ‘control’ vessel (i.e. this vessel contained 
nutritive media and faecal inocula only) were first normalised to 100% and thereafter, 
viable counts from the iron-chelated vessels (‘+Phy’) were shown as percentages in 
relation to the control at the corresponding time point (8 and 24 h, ‘T8’ and ‘T24’, 
respectively). Significant changes of viable counts in comparison to the control are marked 
at the relevant timepoints for each bacterial group. 
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Table 5.5 – Viable counts (%) of different bacterial groups derived from the human faecal 
microbiota of after iron chelation with phytin. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Control normalised to 100%. 
Bacterial Group T8 +Phy T24 +Phy 
 
CM011 CM026 CM052 CM011 CM026 CM052 
Total Anaerobes 268 * 97 101 184.2 13 **** 137 
Bacteroides 1588 * 337 *** 65 185 39 233 
Bifidobacteria 147 553 * 91 144 623 * 55.4 
Clostridia 840 *** 769 **** 51 **** 170 22 133 *** 
Lactobacilli 139 47 **** 189 *** 136 37 **** 22.2 *** 
Enterobacteriaceae 83 17 **** 61 * 295 *** 4 **** 38 ** 
 
As with BPDS, trends can be observed for two bacterial groups in the viable counts of 
various bacterial groups when cultured in the presence of phytin. 
In general, Enterobacteriaceae, to which many potentially pathogenic species belong to, 
exhibited decreases in its viable counts when the human faecal microbiota were cultured 
with phytin. The faecal materials from donors CM026 and CM052 displayed significant 
decreases in viable counts at both 8 h and 24 h when compared to the control at the 
respective timepoint (CM026 p<0.0001 at T8 and T24; CM052 p<0.05 and p<0.01 at T8 
and T24, respectively). The microbiota of donor CM011 showed a decrease, though not 
significant, at 8 h, however this was reversed at 24 h, where a significant increase in counts 
was observed (p<0.001).  
The faecal materials from two of the three donors displayed increases in the viable counts 
of bifidobacteria when cultured with phytin. At 8 h and 24 h, the viable counts of 
bifidobacteria for the microbiota of donors CM011, increased to 147% and 144%, 
respectively, compared to the control vessel at these timepoints. A similar trend was 
observed for the microbiota of donor CM026 where viable counts at 8 h and 24 h were 
553% (p<0.05) and 623% (p<0.05) in comparison to the control.  
5.5.2 Compositional analysis of cultured human faecal microbiota 
The sequencing and bioinformatic analyses of the extracted microbial DNA obtained from 
the cultured faecal microbiota was performed as described in section 5.4.3. Faecal samples 
from 3 apparently healthy humans (CM011, CM026 and CM052; Table 5.1) aged between 
25-51 y (mean age of 34 y; mean BMI of 25.4 kg/m2) were collected, microbial DNA 
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extracted and sequenced using the Illumina Miseq platform. Sequencing produced 103,954 
high-quality reads. 
5.5.2.1  Compositional analysis of cultured human faecal microbiota – 
phylum level 
For each sample sequenced, the relative abundance of the bacterial taxa is illustrated as a 
proportion of each taxonomic unit within the human faecal microbiota. Both phylum and 
genus levels have been displayed to illustrate the differences observed between the 
taxonomic groups within the microbiota under control and iron-chelated conditions. 
Tables 5.6a-c display the relative abundances (%) for each of the phyla sequenced for each 
donor. 
Table 5.6 – Relative abundances (%) of phyla sequenced from the human faecal 
microbiota of donor CM011 (a), CM026 (b) and CM052 (c). 
a. 
 CM011 
Phyla T0 T8 control T8 Phy T24 control T24 Phy 
Actinobacteria 11 44 30 61 51 
Bacteroidetes 22 14 12 1 1 
Firmicutes 58 36 52 36 45 
Proteobacteria 9 6 6 3 3 
b. 
 CM026 
Phyla T0 T8 control T8 Phy T24 control T24 Phy 
Actinobacteria 21 11 31 16 32 
Bacteroidetes 10 4 11 6 2 
Firmicutes 60 18 4 2 35 
Proteobacteria 6 68 13 57 30 
c. 
 CM052 
Phyla T0 T8 control T8 Phy T24 control T24 Phy 
Actinobacteria 5 9 35 19 65 
Bacteroidetes 7 11 4 4 2 
Firmicutes 82 36 36 22 16 
Proteobacteria 3 43 24 51 17 
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As with the BPDS experiments, consistent trends can be observed throughout all donors 
for 4 of the major phyla found in the human gut: Actinobacteria, Bacteroidetes, Firmicutes 
and Proteobacteria.  
Unlike BPDS, the presence of phytin increased the relative abundance of Actinobacteria, a 
phylum associated with a healthy gut profile. When the faecal microbiota of donors 
CM026 and CM052 were cultured with phytin, an increase in Actinobacteria was observed 
at both 8 h and 24 h (11% to 31% and 16% to 32% T8 and T24, respectively, CM026; 9% 
to 35% and 19% to 65% T8 and T24, respectively, CM052). The microbiota of donor 
CM011 exhibited decreases in the relative abundance of Actinobacteria at both timepoints 
in the presence of phytin (44% to 30% and 61% to 51% T8 and T24, respectively). 
Another difference between the iron chelators tested was that phytin addition led to a 
decrease in the relative abundance of Bacteroidetes, a phylum which has the potential to 
contain pathogenic species. The microbiota of donors CM011 and CM052 illustrated 
decreases in Bacteroidetes abundance, although CM011 displayed decreases to a reduced 
extent than CM052 (14% vs 12% and negligible decrease T8 and T24, respectively, 
CM011; 11% vs 4% and 4% vs 2% T8 and T24, respectively, CM052).  
Similar to BPDS, an increase in the relative abundance of Firmicutes was observed in the 
presence of phytin for two of the three donors. At 8 h and 24 h, there was an increase 
observed in the relative abundance of Firmicutes in the faecal materials of donors 
CM011(36% vs 52% and 36% vs 45% T8 and T24, respectively) and CM026 (18% vs 
45% and 22% vs 35% T8 and T24, respectively).  
Finally, as with BPDS, when cultured with phytin, a decrease in the relative abundance of 
the Proteobacteria phyla was observed for two of the three donors. The microbiota of 
donors CM026 and CM052 displayed decreases in Proteobacteria at both 8 h (CM026 68% 
vs 13%; CM052 43% vs 24%) and 24 h (CM026 57% vs 30%; CM052 51% vs 17%).  
5.5.2.2  Compositional analysis of cultured human faecal microbiota – genus 
level 
Figures 5.6a-c illustrate the differences observed in the same human faecal microbiota at 
the genus level when the microbiota were cultured in the presence of phytin.  
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Figure 5.6 – Bar chart representing relative abundances (%) of different genera sequenced 
through 16S rDNA. Human faecal microbiota derived from donors CM011 (a), CM026 (b) and 
CM052 (c). 
As with the phyla, consistent trends can be observed throughout all donors tested for many 
of the genera when iron chelation occurs through the addition of phytin. 
A consistent pattern observed is that of Collinsella, a genus associated with positive gut 
profiles. The relative abundance of Collinsella increased in all donors when the human 
faecal microbiota were cultured with phytin, in comparison to the control. These increases 
were seen at both 8 h and 24 h (CM011 4% vs 6% and 4% vs 14%; CM026 0.5% vs 9% 
and 2% vs 9%, respectively; CM052 8% vs 24% and 18% vs 35%, respectively).  
Another genus belonging to Actinobacteria is Bifidobacterium. For donors CM026 and 
CM052, increases in the relative abundance of Bifidobacterium was observed throughout 
the fermentation process (CM026 10% to 22% and 13% to 23% T8 and T24, respectively, 
CM052 no change at T8 and 1% to 35% at T24). Donor CM011 displayed opposite results, 
where at 8 h and 24 h, decreases were observed in the abundance of Bifidobacterium, 
which could be a reflection of the decrease observed in Actinobacteria relative abundance 
for donor CM011. 
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16S rDNA sequencing was unable to resolve some members of the Enterobacteriaceae 
family down to the genus level. However, from the microbiota of donors CM026 and 
CM052, a noticeable decrease in Enterobacteriaceae abundance was observed in the 
presence of phytin throughout the fermentation. For the faecal material from donor 
CM026, the relative abundance changed from 74% to 28% (T8) and 68% to 45% (T24), 
whilst for donor CM052, the relative abundance of Enterobacteriaceae in the faecal 
material remained the same at T8 but changed from 49% to 6% at T24.  
The next table (Table 5.7) shows the viable counts data from all three donors combined to 
illustrate the overall trends observed when iron was chelated from the culture through 
phytin. 
Table 5.7 – Average viable counts (%) of different bacterial groups before and after 
phytin-mediated iron chelation derived from the human faecal microbiota of donors 
(+SEM). Control normalised to 100%. 
 T8 T24 
 Bacterial Group (+) Phytin (+) Phytin 
Total Anaerobes 143 ±45 105 ±48 
Bacteroides 546 ±370 147 ±61 
Bifidobacteria 259 ±147 212 ±119 
Clostridia 538 ±244 104 ±42 
Lactobacilli 123 ±41 65 ±36 
Enterobacteriaceae 50 ±19 108 ±88 
 
Unlike the data for BPDS, when the viable counts for the three faecal microbiota are 
combined and the control data normalised to 100%, although overall trends are defined, no 
significant differences in the counts are seen when comparing the control microbiota to 
those cultured with phytin. This highlights the variability of the human gut microbiota in 
each of the donors and despite significant changes being present when analysed 
individually, these may be masked when combined with human faecal microbiota of other 
donors.  
In general, similar trends are observed in the averaged data as with the individuals. Most 
importantly, the viable counts for bifidobacteria noticeably increase in the presence of 
phytin throughout the fermentation period when compared to the control microbiota.   
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Secondly, the growth of Enterobacteriaceae is reduced, at least at the 8 h time point, when 
cultured in the presence of phytin. When analysed individually, this is also true for 24 h, 
however, due to such high variability amongst the donors, this is not reflected in the data 
when combined. 
Next, high-throughput paired-end sequencing of the 16S rRNA gene (V4 region) was 
performed on fermentation samples using the Illumina Miseq platform, and microbial 
communities present in relative abundances ≥0.5% from the three donors are illustrated in 
Figure 5.7. 
 
Figure 5.7 – Microbial community profiles assessed by 16S rRNA gene analysis illustrating 
relative abundances of different genera from the three donors combined 
After combining and averaging the abundance values from the three individual 
experiments, the data revealed that the most abundant taxa at 0 h were Enterobacteriaceae 
(14%), followed by Bifidobacterium (8%) and Prevotella (8%), (Figure 5.7).  
As with the individual analysis of the human faecal microbiota, the most noticeable 
changes were observed in the following three taxa: Collinsella, Bifidobacterium and 
Enterobacteriaceae. 
On average, the relative abundance of Collinsella increased to 13% compared to 4% at 8 h. 
This was again observed at 24 h, where the relative abundance of Collinsella in the 
microbiota cultured with phytin was 19% compared to the control microbiota, which 
displayed an abundance of 8%. 
Similarly, the relative abundance of Bifidobacterium also increased in the presence of 
phytin at 24 h (32% compared to 24%). This increase is well correlated with the increase in 
average viable counts observed for bifidobacteria (Table 5.7). The relative abundance of 
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Bifidobacterium was unchanged at 8 h when comparing the control microbiota to those 
cultured with phytin. 
Lastly, Enterobacteriaceae relative abundance displayed a general decrease when the 
microbiota were cultured with phytin. At 8 h, the relative abundance of Enterobacteriaceae 
decreased to 24% from 39%, and at 24 h, the relative abundance decreased to 18% from 
40%. This decrease is reflected in the average viable counts data (Table 5.7), for at least 
the 8 h timepoint.  
5.5.2.3  Microbial diversity within human faecal microbiota 
Alpha (α) and beta (β) diversity was analysed for in vitro colonic fermentation samples at 
0, 8 and 24 h. Unlike BPDS, results for this section are presented for individual donors as 
opposed to combined data, due to the high variability observed throughout the donors’ 
microbiota. 
 
Figure 5.8 – α- diversity analysis of microbiota cultured with phytin. α- diversity analysis of batch 
fermentation samples with (Phytin) and without iron chelator (control) using the Shannon index. 
Donor CM011 (a), CM026 (b) and CM052 (c). 
The Shannon index, a form of α-diversity, showed a shift in diversity within the population 
in the presence of phytin for two of the three donors in comparison to the control 
fermenter. The microbiota of donor CM026 illustrated a noticeable increase in population 
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diversity in the presence of phytin at both 8 and 24 h (Figure 5.8b), whilst for donor 
CM011, when phytin was added to the fermentation (Figure 5.8a). 
PCoA plots, which illustrates β- diversity, was also performed on all three faecal 
microbiota. 
 
Figure 5.9 – β- diversity analysis of microbiota cultured with phytin. β- diversity analysis of batch 
fermentation samples portraying weighted analysis of samples with (Phy) and without (X) iron 
chelator using the UniFrac metric and presented as a PCoA plot. Donor CM011 (a), CM026 (b) 
and CM052 (c). 
The PCoAs indicates that for all three donors, microbiota of the subjects after iron 
chelation through the addition of phytin, did not have a large range of taxa in common. 
Moreover, at both 8 and 24 h, for all three donors, a shift in β- diversity was observed upon 
phytin addition when compared to the control at the respective time points, depicted by the 
dashed. 
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5.5.2.4  Metabolite profiling within human faecal microbiota cultured with 
phytin 
1H NMR spectroscopy was used to determine the levels of over 70 metabolites from 
samples taken from the fermenters at 0, 8, and 24 h. 
 
Figure 5.10 - Metabolite concentrations of batch fermentation samples cultured with phytin. 
Short chain fatty acid concentrations in both vessels (Control ‘X’ and Phytin ‘Phy’) were measured 
using 1H NMR spectroscopy, with samples being screened for multiple metabolites against a spiked 
standard (TSP) and a validated reference library. Figure a and b represent the microbiota of donor 
CM026 and Figure c and d represent the microbiota of donor CM011. 
 
In two of the three donors, formate and propionate showed the most substantial changes 
between treatments, (Figure 5.10). For donor CM026, concentrations of propionate 
increased from 0.6 mM to 9.4 mM and 7.3 mM to 18 mM at 8 and 24 h, respectively, in 
the presence of phytin in comparison to the control (Figure 5.10a). Similarly, levels of 
propionate increased from 20 mM to 26 mM at 24 h for donor CM011 in the presence of 
phytin when compared to the control fermenter (Figure 5.10c).  
Similar trends were observed for formate. Donor CM026 displayed a 150% and 100% 
increase in formate concentrations at 8 and 24 h, respectively when phytin was present 
(Figure 5.10b), whilst donor CM011 illustrated increases of 92% and 721% at 8 and 24 h, 
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respectively (Figure 5.10d). This is reflected in the increase observed for the relative 
abundance of Collinsella (Figures 5.6a-b), a genus well-recognised to ferment glycogen to 
produce formate [285].  
5.6 Discussion 
5.6.1 BPDS 
This study was designed to assess the effects of colonic iron chelation on the human gut 
microbiota in an in vitro colon model system. 
The net effects of iron on the gut microbial composition are unclear and need further 
research as the results reported are inconsistent [6, 39, 44, 45]. The experiments detailed in 
this chapter showed a marked effect on the global microbiota composition when iron was 
chelated in the fermentation vessels with BPDS. BPDS acts as a chelator of various metals 
and, in particular, it has been shown to bind iron with very high affinity and has therefore 
been used as an iron chelator in many studies [286, 287].  Comparison of the relative 
abundance of bacterial taxa between the two conditions (control and BPDS) illustrated that 
the most apparent differences were the decreased relative abundance of the potentially 
pathogenic Escherichia. The observed decrease of Bifidobacterium is interesting as other 
studies have reported different outcomes, which could be due to strain specificity, inter-
individual variability of the host, as well as the effects of neighbouring taxa and 
metabolites. However, the relative abundance of Clostridium remained relatively stable, 
which has been observed in other studies. Notably, Streptococcus, a member of the lactic 
acid bacteria group to which Lactobacillus also belongs, was seen to increase upon iron 
removal, and this could potentially lead to restricted growth of other bacteria in the gut 
environment. 
Studies investigating the effects of iron supplementation report comparable results to those 
found in this study in relation to the relative abundance of various bacterial taxa, including 
Escherichia. Jaeggi et al., (2015) examined the effects of low and high doses of in-home 
iron supplementation on the gut microbiota of Kenyan children [157]. In this setting, 
provision of iron-fortified porridge led to an increase in the abundance of known/potential 
pathogens, with proportions of enterobacteria, Clostridium and E. coli increasing, whilst 
bifidobacteria decreased. In addition, children given iron-fortified porridge had elevated 
levels of faecal calprotectin, a marker of gut inflammation, which is likely to reflect an 
increased pathogenic profile.  
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Much of the published literature focuses on the effects of iron on the infant microbiota 
which differs in composition to that of adults. In addition, geographical location is likely 
an important factor, as studies have shown that individuals from developing countries tend 
to have a greater pathogenic microbial profile due to the lack of clean food and water, and, 
in turn, a compromised gut function. This is reflected in two studies, where one 
investigated the effects of iron addition on the gut microbiota of children from Cote 
d’Ivoire [229], the second study focused on children from South Africa [155]. No 
detrimental effects of iron supplementation were observed in those that had access to clean 
water and food, yet the children that did not have access to clean water had adverse side 
effects.  
α- diversity analysis using the Shannon index, which accounts for the distribution and 
richness of OTUs within a population, showed an increase in population diversity at 8 h in 
the presence of the iron chelator.  It can be speculated that the chelation of iron may lead to 
certain taxa exploiting other metals as a means of replacing iron, and therefore temporarily 
facilitating growth in a micronutrient-restricted environment. However, by 24 h, a 
substantial decrease in diversity was observed under iron-chelated conditions, suggesting 
an exhaustion of these metals and nutrients. β-diversity analysis demonstrated that there 
was not a large range of taxa in common when comparing the control samples to those that 
were cultured in iron-limiting conditions. Interestingly, at both 8 h and 24 h, there was a 
shift in β-diversity between the two groups for all three of the cultured donor samples. This 
is in line with a study performed by Dostal et al., (2015) [288], which investigated the 
effect of iron on butyrate production in the child gut microbiota, where altering the iron 
concentration in the medium affected microbial community structure as well as causing a 
shift in β-diversity. 
Microbial metabolic activity contributes to human health. When iron was chelated, there 
was a decrease in the three main SCFAs that are produced in the gut, which presumably 
reflects poor growth of fermentative microbes. Based on the 16S rRNA gene sequencing 
data from this study and those published elsewhere, we can infer the potential mechanisms 
behind certain metabolic changes. Firstly, iron-dependent enzymes are critical operators of 
many metabolic pathways, and therefore these processes can be affected by differing iron 
concentrations. Moreover, any microbial fermentation that takes place requires the redox 
balance to be sustained. Due to the dual role of iron as an electron donor and acceptor, we 
speculate that changes in iron levels could have a large effect on redox balance. During the 
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batch fermentation, the most prominent effect observed on metabolite production was that 
of acetate levels. Many gut bacteria produce acetate by either the reductive acetyl-CoA 
pathway, which uses H2 and CO2 [289], or via the regular glycolytic pathway through 
pyruvate metabolism [290]. The former pathway consists of numerous iron-dependent 
enzymes and can account for >25% of acetate produced in the gut [291]. It is therefore 
plausible to speculate a lack of conversion of H2 and CO2 to acetate under iron-limiting 
conditions, resulting in an overall decrease in acetate levels. This observation also 
correlated with the viable counts and 16S rRNA gene analysis, where a decrease in the 
members of Bifidobacterium, a prominent bacterial group which produces acetate, was 
observed under iron-limiting conditions. Although correlations of metabolite levels with 
the relative abundance of bacterial taxa do not provide a causal relationship, it may still 
provide some indications as to which taxa are responsible for any observed differences. 
5.6.2 Phytin 
Experiments were designed to assess the effects of the dietary compound, phytin, and its 
iron-chelating abilities in the human colonic environment. It was found that the addition of 
phytin, the salt form of phytic acid, significantly reduced the viable counts of 
Enterobacteriaceae in two of the three donors that were tested. This is in line with our 
previously published study, which illustrated a significant reduction in this group of 
potentially pathogenic bacteria in the presence of the chemical iron chelator BPDS [272]. 
Interestingly, contrary to our previous study, the viable counts for bifidobacteria 
significantly increased in the presence of phytin for two of the three donors, suggesting 
that the effects of iron chelation on other bacterial groups could have a subsequent effect 
on neighbouring taxa.  
Next, a closer look at the effect of phytin on the composition and function of the human 
gut microbiota revealed a marked reduction in the relative abundance of 
Enterobacteriaceae for two of the three donors. Similar observations have been reported in 
other studies looking at the effects of iron supplementation on the gut microbiota, where an 
increase in iron led to a rise in the potentially pathogenic genus, Escherichia [157, 229]. 
Although other studies have not been performed with the aim of observing the effects of 
phytic acid’s iron-chelating capabilities on the human gut microbial composition, several 
studies have looked at the effects of whole grain foods, a major source of phytic acid, on 
the human gut microbiota. Three studies reported the decrease in Enterobacteriaceae 
levels when volunteers were provided with foods rich in whole grain content [292-294]. 
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Other studies have looked at the impact of phytic acid on pure bacterial cultures. One study 
carried out in Korea examining the protective role of sodium phytate against E. coli in 
meats revealed similar observations, whereby sodium phytate exhibited bactericidal effects 
on E. coli in a dose-dependent manner [295]. In another study, phytic acid from rice bran 
was reported to inhibit the growth of both S. Typhimurium and E. coli, species belonging 
to the Enterobacteriaceae family [296].  
Interestingly, 16S rDNA analysis revealed an increase in the relative abundance of the 
beneficial genus, Bifidobacterium, in the presence of phytin in two of the three donors, 
which was also reflected in the viable counts data for bifidobacteria. One study 
investigated the effects of dietary sodium phytate on the colonic luminal environment of 
rats fed a high-fat diet and found that bifidobacterial profiles increased in the presence of 
sodium phytate [297], which is in line with the results illustrated in our study. Furthermore, 
Bifidobacteria have recently been recognised as a group of bacteria with phytate-degrading 
abilities. Numerous studies have reported that various strains of bifidobacteria to possess 
phytase-producing properties, whereby phytate is degraded to its lower inositol forms [201, 
298-300]. Many of these studies indicated the conservation of InsP6 as well as the 
production of both InsP5 and InsP4 [201, 298, 299]. This suggests that though phytate is 
being degraded into forms lower than InsP5, therefore releasing micronutrients from 
phytate-bound complexes, with InsP6 present and InsP5 still being generated, phytic acid’s 
iron-chelating capabilities are still active. Another study looked at how diet can influence 
the ability of human intestinal microbiota to degrade phytate [277], which showed that 
unlike previous studies, gram-positive anaerobes had in fact the least effective hydrolysing 
properties, with no more than 20% of the phytic acid being degraded. However, it is 
important to note two crucial differences in this study: (ⅰ) the faecal material was 
separately inoculated in media selective for specific bacterial groups, thereby negating any 
community effects and (ⅱ) faecal material was derived from volunteers on different diets. 
In light of this, results of studies on the impact of phytic acid on the gut microbiota 
demonstrate that regardless of the dietary group of the volunteers, lactobacilli and gram-
positive anaerobes had the least phytate-degrading ability, whereas proteobacteria-
bacteroides cultures and coliforms displayed the highest phytate-degrading potential. The 
authors concluded that a community environment with both aerobic and anaerobic bacteria 
is vital for the degradation of phytate to take place.  
A study carried out by Steer et al., (2004) [260] investigated the biodiversity of human 
faecal bacteria that had been cultured in continuous in vitro fermentations in the presence 
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of phytic acid. This study found that, unlike the data presented in this chapter, 
bifidobacteria were less able to maintain viable counts when derived from phytic acid 
enriched chemostat fermenters. This was further reflected in the decrease observed for 
Bifidobacterium relative abundance. However, this study also showed that lactobacilli 
viable counts and Lactobacillus relative abundance decreased when cultured with phytic 
acid, and this is in line with the data presented in this chapter. 
Another interesting observation was that of the genus, Collinsella, which increased in 
relative abundance in all three donors when the faecal inocula was supplemented with 
phytin. Collinsella is the most dominant of the group Coriobacteriales and is frequently 
detected in the human colonic microbiota [301-303]. Previous studies have reported similar 
effects on Collinsella, whereby the provision of phytate-rich whole grain foods to 
volunteers increased the levels of Collinsella [304, 305]. Moreover, Collinsella have been 
observed to ferment a vast range of different carbohydrates, such as glycogen, resulting in 
the production of metabolites such as formate. This is reflected in the metabolite analysis 
performed in this study, where formate concentrations, along with propionate, are 
increased in the presence of phytin. From these data, it can be speculated that the increase 
in formate could be as a result of the rise in Collinsella relative abundance under phytin-
supplemented conditions. 
The diversity of the microbial population was also affected by the presence of phytin 
(Figures 5.11 – 5.16). It was found that when iron was chelated through phytin, α- diversity 
was altered. α- diversity measures the richness and distribution of OTUs within a 
population, and the results illustrated that the presence of phytin led to an increase in 
population diversity in two of the donors. A similar observation was reported in our 
previous study looking at the effects of BPDS on the gut microbiota [272]. β-diversity 
analysis, which looks at the similarity of taxa between different populations, displayed a 
shift in diversity at both 8 and 24 h upon the addition of phytin. This agrees with a study 
performed by another group using a continuous colonic fermentation system, where a shift 
in β-diversity was observed as well as an alteration in the microbial community structure in 
response to a change in iron concentrations [288].  
5.7 Conclusions 
These results highlight the potential role that iron chelators can play in relation to 
decreasing the growth of potentially pathogenic bacteria in the human gut. Data presented 
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in this chapter have shown that iron chelation through BPDS or phytin resulted in a 
decrease of Enterobacteriaceae, a group to which pathogenic bacteria belong. 
Simultaneously, the addition of phytin, but not BPDS, resulted in a rise of Bifidobacterium 
relative abundance¸ a genus with properties beneficial to intestinal health. The results from 
these in vitro colonic fermentations suggest the importance of iron to bacterial growth, as 
well as the potential use of a dietary component that has iron chelating properties, in 
having a positive impact on gut health and homeostasis. Based on the results detailed in 
this chapter, the next step was to see whether these observations could be replicated in 
vivo. The next chapter details the first step towards reproducing these results in vivo. 
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6.0 Summary 
The results detailed in chapter 5 illustrate the iron-chelating properties of phytin and the 
subsequent alteration in gut microbial composition. The next step was to see whether the 
same effects could be observed in vivo. However, to achieve this, it was vital to ensure that 
phytin was only active once it reached the colon. The concept of targeted drug delivery has 
been well established and has been used in the treatment of cancers and inflammatory 
bowel disorders. It was hypothesised that the same approach could be used to deliver 
encapsulated compounds with iron-chelating properties into the colon. This chapter 
examines the use of a specialised coating formulation, known as Phloral®, to deliver 
encapsulated compounds to the colon. Through dynamic dissolution assays, it was found 
that Phloral® successfully maintained its dissolution properties until it had reached the 
colon. 
6.1 Introduction 
The benefits of delivering a drug directly to the desired organ or compartment in a human 
has long been recognised. During the last decades, research and technology in controlled 
drug delivery has advanced and has the potential to contribute significantly towards the 
clinical treatment of patients [306].  
Phloral® is a technology invented by Intract Pharma, a research-based company, which 
specialises in oral drug delivery and hold a range of licensable technologies for targeted 
delivery and drug release into the gastrointestinal tract. Phloral® specifically provides 
precise and consistent delivery to the colon by exploiting both the alterations in 
gastrointestinal pH and the enzymatic activity of the colonic microbiota: this allows a 
complementary-based release mechanism to provide site-specific release. 
One of the properties of Phloral® is the pH-dependent release of the desired drug achieved 
through a polymer coating. However, spatial pH differences are found throughout the 
colon. The pH of the proximal colon is 6.4 ± 0.8, this gradually increases to 6.6 ± 0.8 in the 
traverse colon, and finally reaches a pH of 7 ± 0.7 in the distal colon [307]. pH sensitive 
systems aim to exploit the changes that are observed in the different regions of the human 
gut to enable a successful colonic delivery. One way in which this system is developed is 
through the use of enteric polymers, which are designed to resist low pH levels found in 
the stomach and exhibit properties allowing for dissolution at higher pH values [308]. 
These enteric polymers can be used to coat the active pharmaceutical ingredient (API), 
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Once the coated capsule enters an environment with an appropriately high pH, the coating 
is broken down and dissolved, releasing the API in the desired section of the GIT. 
Eudragit® is one of the most widely used polymers, which contains derivatives of acrylic 
acid [309] and  cellulose, such as cellulose acetate phthalate and hypromellose cellulose 
(HPMC) acetate phthalate. Eudragit® polymers vary in the properties they exhibit. For 
example, some Eudragit® polymers that are utilised in colonic drug delivery are water 
soluble whilst others are water insoluble. Eudragit® S 100 and FS30D are examples of 
polymers which dissolve at a pH of 7 [310, 311], and utilisation of this acrylic based 
polymer was proposed by Dew et al., (1982) [312]. Capsules were filled with sulfapyridine 
(5 aminosalicylic acid) before being coated with Eudragit® S 100, which is a copolymer of 
methacrylic acid and methyl methacrylate with a high dissolution threshold (pH>7). X-ray 
imaging confirmed that the capsules ruptured in either the distal small intestine or the 
colon [312]. This led to the availability of mesalazine drugs, such as Asacol MR, Ipocol 
and Mesren, which have been indicated for treatment of ulcerative colitis (UC) [313]. In 
addition, mesalazine were also formulated with Eudragit L which dissolves at a pH>6. 
Furthermore, diffusion mediated drug release has also been developed. Pentasa, a product 
of mesalazine, is released from the ethylcellulose coated film via diffusion along the GI 
tract. Two marketed products of Budesonide (Entocort EC and Budenofalk) are also 
available. Entocort is formulated by the combination of ethylcellulose granules and 
Eudragit L 100-55. On the other hand, Budenofalk has been developed from budesonide 
pellets coated with a mixture of Eudragit L and S. This fusion of two polymers allows for 
drug release at pH> 6.4 and delivers the drug to the colon. Both Budesonide products are 
indicated for the treatment of acute Crohn’s disease [313]. However, Eudragit S 100 
showed poor site specificity in many experimental assays. The colonic pH in patients of 
UC can be low, and the pH drop increases with the severity of the disease [314]. If a pH 
responsive delivery system does not meet the desired intestinal pH, it will fail to dissolve 
in the required site of action. Consequently, due to the varying nature of the gut 
environment, not only within individuals but also between individuals, a coating consisting 
of only a single mechanism polymer system is unreliable due to the uncertainty of where 
the API will be released [315]. 
Another consideration when developing coating suspensions is the exploitation of the 
natural microbial system that resides within the gut. The large intestine is home to trillions 
of bacteria and are responsible for the fermentation of many proteins and polysaccharides, 
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which evade degradation in the upper gastrointestinal tract, subsequently forming SCFAs. 
For the purpose of colonic targeted delivery, naturally occurring polymers which also have 
properties that allow them to avoid any degradation prior to reaching the colon are 
preferred. There are many naturally occurring polymers, such as chondroitin sulphate, 
pectin, chitosan, guar gum, locust bean gum, alginate, dextran, inulin and amylose [316]. 
Bacteria dependant systems are of two types: delivery of prodrugs and a universal system. 
A prodrug is an inactive form of therapeutics which undergoes bio-transformation to 
become a pharmacologically active ingredient.  
In vitro dissolution assays are a critical tool to control the quality of pharmaceutical 
products and guide formulation development. However, traditional approaches are often 
crude, with inaccurate measures of actual intestinal release behaviour in humans. The 
Dynamic Dissolution Model builds upon conventional apparatus but incorporates a unique 
bicarbonate-based media controlled by a patented Auto pH System™. These innovative 
features reflect the dynamic environment of the GI tract and modulate parameters crucial 
to dissolution and drug release. This provides a greater ability to predict which coating 
formulations are most likely to release the API at the desired site of action within the 
human GI tract. 
A universal delivery system was required to be developed that can carry any drug to the 
colon without being specific to a particular group of enzymes. Pectin was used as a direct 
compression coat on tablets and an in-vivo experiment on human subjects confirmed drug 
release in the colon [317]. Further investigations on this polysaccharide demonstrated 
pectin as a potential element for colonic drug delivery [318]. CODES is a bacteria-
triggered system that includes three layers of polymers coated on the core tablet. First, the 
core tablet is coated with an acid soluble polymer which is further coated with a 
hydrophilic polymer and enteric layer, respectively. The two outer layers dissolve in the 
small intestine and though the innermost acid soluble layer remains intact, it allows slow 
diffusion of water into the core tablet. When the tablet reaches the colon, the 
polysaccharide of the core tablet is fermented by the microflora and organic acids are 
formed. This lowers the pH of the surrounding gut milieu and dissolves the acid soluble 
layer, which initiates drug release [319]. Amylose is a widely used polysaccharide for 
colon targeted delivery and is the starch component of Phloral®. It is known as resistant 
starch because it escapes degradation in the upper gut but is fermented by the colonic 
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microflora. However, when used individually as a coating material, it sometimes swells in 
the stomach. Therefore, it is necessary to add a water insoluble or pH sensitive polymer.  
Starch is the most abundant storage polysaccharide in plants and is made of two fractions, 
amylopectin and amylose. Phloral® consists of amylose (Figure 6.1), which is made of 
glucose and is a linear α-1,4 linked D-glucan. 
 
Figure 6.1 - Chemical structure of amylose. Source: https://www.ncbi.nlm.nih.gov/pccompound 
 
Starch occurs as granules in the chloroplast of green leaves and the amyloplast of seeds, 
pulses and tubers [320]. Crystallinity of the starch granule is an extremely vital property 
that contributes towards the formation of resistant starch. When in crystallised form, starch 
granules have been shown to confer resistance to hydrolysis by enzymes, therefore 
increasing the formation of resistant starch. This is reversed when crystallised starch is 
treated to remove crystallinity and a subsequent decrease in resistant starch is observed 
[321]. It has been reported that when the content of amylose is high, the digestibility of the 
starch is reduced [322]. Moreover, through a hydration process, starch crystallinity can be 
increased [323]. 
Retrogradation is a process by which resistant starch can be prepared and involves a two-
step process [324] (Figure 6.2). The first step, gelatinisation, which causes the release of 
the starch into solution. Once suspended in solution, the starch granules are then heated to 
a high temperature (usually between 60oC – 70oC). Once heated, irreversible swelling of 
the granules causes the starch to be released into the solution, in the form of a random coil 
[325]. The second stage of retrogradation is the recrystallisation of the starch granules. 
This occurs once the granules have cooled down from the first step. During this process, 
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the polymer chains of the starch granules start to reform as double helices, which are 
stabilised by hydrogen bonds.  
  
Figure 6.2 - Retrogradation process of amylose starch granules. Amylose is leached from the 
granules into solution as a random coil polymer. Upon cooling, the polymer chains begin to re-
associate as double helices, stabilised by hydrogen bonds. The individual strands in the helix 
contain six glucose units per turn. Upon further retrogradation the double helices pack in a 
hexagonal unit cell (taken from Haralampu (2000) [326]).  
Resistant starches are classified further into four fractions, I-IV. Resistant starch Type I is 
enclosed in a non-digestible matrix and therefore evades digestion. Type II is ungelatinised 
starch, whilst Type III is retrograded amylose starch. Finally, resistant starch Type IV is 
starch that has been chemically modified. Type III is completely resistant to the enzymatic 
activity exhibited by pancreatic amylases due to its retrograded properties [321].  
In previous chapters, various types of iron chelators were investigated with the aim of 
finding ones which have the most positive impact on gut microbial function and 
composition. From the panel of chelators previously tested, phytin was chosen for further 
in vivo analysis. The next step was to create a delivery system whereby phytin could be 
delivered to the colon in order to exert its iron-chelating properties directly in the 
environment where high levels of iron are present.  
6.2 Objectives 
The research presented in this chapter examines the optimisation of an already existing 
formulation, Phloral®. Phloral® allows colon-specific delivery of the desired agent, in 
either tablet or capsule form. The aim of this chapter was to explore how changing 
parameters of the ingredients used in Phloral® affects the delivery of the desired agent, 
including pharmacokinetics and to establish the best procedure for encapsulating phytin for 
use in a human clinical trial. 
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6.3 Materials and Methods 
6.3.1 Calculating coating thickness of capsules 
The calculation of the amount of coating required for the capsules was based on the 
measurements of an average size 00 HPMC capsule. Surface areas of the body and caps 
were measured, and these values were then used to calculate final weight gain per 
body/cap to achieve required coating thickness. Figure 6.3 depicts the surface area of size 
00 HPMC capsules, whilst Table 6.1 outlines the range of final weights required for 
different coating thicknesses per capsule. 
 
Figure 6.3 – Surface area of size 00 HPMC capsule. The body and cap of size 00 HPMC capsules 
were measured to obtain a surface area value for both parts. These were then combined to achieve 
a total surface area, which was then used to calculate coating thickness. 
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Table 6.1 – Final weight gain required for different coating thicknesses 
Weight gain 
required (mg/cm2) 
Weight gain per 
body/cap (mg) 
 Body Cap 
3 15.6 9.3 
4 20.8 12.4 
5 26.0 15.5 
6 31.1 18.6 
7 36.3 21.7 
8 41.5 24.8 
 
6.3.2 Phloral® coating suspension 
Phloral® is a coating suspension made of two main components, starch and polymer. Two 
suspensions of Phloral® were investigated – semi-organic and fully organic. 
6.3.2.1  Semi-organic Phloral® coating suspension 
A semi-organic coating suspension of Phloral® was made (this suspension is identical to 
the fully-organic suspension, outlined in the next section, with the addition of butanol). For 
the starch dispersion, amylo-maize starch N-400 (Roquette, France) was added gradually 
to butanol. Next, deionised water was added to the starch/butanol suspension under 
agitation. This mixture was boiled for exactly 3 mins at 300oC. The suspension was then 
transferred to a cold plate and left to stir overnight. For the polymer dispersion, absolute 
ethanol and deionised water were mixed to achieve a final ethanol concentration of 95%, 
before the polymer Eudragit® S 100 (Evonik, Germany) was very slowly added to the 
ethanol solution. Using the starch moisture factor (SMF), the amount of starch dispersion 
prepared the night before required was calculated (difference in weight before and after 
starch dispersion preparation, ∆W, multiplied by SMF, 0.879). Once calculated, the 
required amount of starch dispersion was slowly added to the polymer dispersion and left 
to stir for 30 mins. Next, triethyl citrate was added to the above mixture whilst still stirring, 
and finally, PlasACRYL™ T20 was added. This was left to stir for a minimum of 60 m, 
after which it was immediately used to coat the HPMC capsules.  
6.3.2.2  Fully organic Phloral® coating suspension 
A fully-organic coating suspension of Phloral® was made (6 g amylo-maize starch N-400, 
14 g Eudgragit® S100, 20 g PlasACRYL™ T20, 3g triethyl citrate, 210.6 g absolute 
ethanol and 8.8 g deionised water). Absolute ethanol and deionised water were mixed to 
achieve a final ethanol concentration of 95%. Next, the polymer Eudragit® S 100 was very 
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slowly added to the ethanol solution. Amylo-maize starch N-400 was then slowly added to 
the polymer/ethanol solution. This was left to stir at a brisk pace for a minimum of 30 mins 
to ensure no aggregates developed. Next, triethyl citrate was added to the above mixture 
whilst still stirring and finally, PlasACRYL™ T20 was added. This was left to stir for a 
minimum of 60 m, after which it was immediately used to coat the capsules.  
6.3.3 Capsule coating 
HPMC capsules were filled with a known dose of prednisolone either before (Group 1) or 
after (Group 2) using a coating machine Aeromatic AG Strea-1 bottom spray fluidised bed 
coater (Aeromatic AG, Bubendorf, Switzerland). Prednisolone was chosen due to its 
known absorbance from previously performed experiments with this drug in the laboratory. 
Caps and bodies were coated separately to ensure capsules were coated with Phloral® 
evenly. Phloral® was left to stir throughout the coating process, at a consistent pace to 
ensure homogeneity of the suspension whilst simultaneously ensuring no bubbles were 
formed. The coating suspension was delivered into the coating machine via a peristaltic 
pump. Once the coating machine parameters were set up (Table 6.2), a known number of 
either bodies or caps (also known as cores) were added to the coating chamber. This 
chamber was then sealed to ensure it was void of atmospheric air and pressure. The 
temperature within the chamber was set to a minimum of 35oC and the compressed air was 
set to 0.3 bar. To begin the coating process, the peristaltic pump was activated to start the 
flow of Phloral® into the coating chamber, and the cores were exposed to Phloral® until 
the required coating thickness was achieved (section 6.3.1). Once coated, the cores were 
placed in a sieve and dried overnight at room temperature to be subsequently used in the 
dissolution systems. 
Table 6.2 – Parameters for Aeromatic AG coating machine 
Parameter Condition 
Atomising air pressure 0.3 bar 
Inlet temperature 30-40°C 
Fan speed Dependent on batch size 
Pump speed Pump speed set to 1 rpm for 15 mins to 
form initial coat and then increased to 1.5 
rpm for the rest of the coating process 
Curing conditions Fluidised in coater for 5 mins and left to 
dry overnight at room temp 
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6.3.4 Static and dynamic dissolution assays 
USP-II apparatus (Model PTWS, Pharmatest, Hainburg, Germany) was used to perform 
static and dynamic dissolution assays to record the release of prednisolone within the 
coated capsule and, by doing so, testing the efficiency of the coating prepared by exposing 
it to similar conditions to that of the human GI tract. The dynamic dissolution system was 
pH controlled by the Auto pH system™. In brief, two buffers were prepared for the 
dissolution assays. First, a 0.1M HCl buffer was prepared to simulate conditions in the 
stomach. Capsules coated with Phloral® were then submerged into the acidic buffer for a 
period of 2 h, known as the ‘acidic phase’. Capsules were then transferred into a second 
buffer (Hank’s buffer; 0.441 mM KH2PO4, 0.337 mM Na2HPO4.2H2O, 136.9 mM NaCl, 
5.37 mM KCl, 0.812 mM MgSO4.7H2O, 1.26 mM CaCl2.2H2O and 4.17 mM NaHCO3, pH 
6.8) to simulate small intestinal conditions. The pH of the buffer was set to gradually 
increase from pH 5.6 to 6.8 for the first 35 mins. Following this, Pre-Krebs bicarbonate 
buffer (6.9 mM KH2PO4 and 400.7 mM NaHCO3, pH 7.4) was added to Hank’s buffer to 
increase the pH (Table 6.3) The release of prednisolone was measured at Abs247 for a 
period of 210 mins.  
Table 6.3 – pH settings for dynamic dissolution system 
Time (mins) pH 
0 5.6 
5 6.0 
10 6.5 
20 6.8 
36 7.0 (pre-krebs buffer added at 35 mins) 
50 7.2 
80 7.4 
210 6.5 CO2 flow increased to rapidly drop 
pH) 
6.4 Results 
6.4.1 Testing Phloral® efficiency on Group 1 capsules 
Size 00 HPMC capsules were filled with 10 mg prednisolone prior to coating with semi-
organic Phloral®. The remainder of the capsule was filled with a chemically inactive filler 
to provide weight to the capsules. Pre-filled capsules were placed in the coating chamber 
of the coater machine, and batches of capsules were coated with a semi-organic Phloral® 
suspension until a range of coating thicknesses were attained. These capsules were then 
subjected to static and dynamic dissolution assays.  
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Figure 6.4 – Disintegration of semi-organic Phloral® pre-filled capsules. This figure illustrates 
the opened capsule after exposure to acidic phase during static dissolution  
When capsules that were pre-filled with prednisolone were subjected to the conditions of 
the human gastrointestinal tract, it was found that the capsules disintegrated within 1 h of 
the acidic (static) phase of the dissolution assay. This was indicated by an increase in 
absorbance values after 50 mins. Figure 6.4 depicts a disintegrated capsule that was 
removed from the static dissolution system, with no content left within. The dissolution 
assay was stopped at this stage. These results suggested that coating capsules in its entirety 
(i.e. coating closed capsules as opposed to coating the cores separately) most likely led to 
inefficient coating and therefore caused early release of the drug. Therefore, the next set of 
results show the drug release profile of prednisolone when placed within capsules that had 
their cores coated separately first and then filled with the drug and inert filler.  
6.4.2 Testing Phloral® efficiency on Group 2 capsules 
Size 00 HPMC capsules were coated with either a semi-organic (Figure 6.5a) or fully 
organic (Figure 6.5b) Phloral® coating suspension. Capsules were then filled with 10 mg 
prednisolone and inert filler. The capsules were then subjected to static and dynamic 
dissolution assays. 
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Figure 6.5 – Dissolution assay illustrating semi-organic and fully organic Phloral® efficiency of 
pre-coated capsules. Figure a illustrates the prednisolone drug release profile for capsules coated 
with a semi-organic Phloral® suspension, with coating thickness ranging between 3 – 8 mg/cm2. 
Figure b illustrates the prednisolone drug release profile for capsules coated with a fully organic 
Phloral® suspension, with coating thickness ranging between 4 – 6 mg/cm2 
Figure 6.5 shows the results of dynamic dissolution assays on capsules that were coated 
with either a semi or fully organic Phloral® suspension. As illustrated in figure 6.5a, 
coating thicknesses of 3 and 4 mg/cm2 were insufficient at retaining the capsule integrity 
for the required amount of time to reach the colon. Both coating thicknesses led to the 
release of the drug between approximately 2 and 3 h. This is too rapid as ideally drug 
release should occur roughly 4 to 5 h after exposure to the acidic conditions of the stomach 
to ensure drug release occurs in the colon. This ideal drug release time is reflected in the 
profile for capsules coated to a thickness of 5 mg/cm2.
 Although coating thicknesses of 6 – 
8 mg/cm2 retained the drug for an extended period of time, a reduced release of 
prednisolone was observed compared to those coated to 5 mg/cm2.  
As illustrated in Figure 6.5b, all three coating thicknesses tested (4 – 6 mg/cm2) exhibited 
similar release profiles of prednisolone. All three coating thicknesses indicate that drug 
release began at approximately 4 h. However, coating thicknesses of 5 and 6 mg/cm2 show 
that prednisolone release is inhibited to an extent compared to capsules coated to a 
thickness of 4 mg/cm2 and starts to plateau at approximately 6 h. Conversely, capsules 
coated to a thickness of 4 mg/cm2 had an overall higher release of prednisolone over the 
course of the dissolution assay, as well as releasing the drug gradually at a consistent rate, 
illustrating the required delay in release. 
6.5 Discussion 
Due to the varying nature of the physiological gastrointestinal conditions in individuals, it 
is quite difficult to attain the ideal level of therapeutic efficiency by conventional methods. 
For example, mesalazine tablets (used in the treatment of inflammatory bowel disorders, 
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such as Crohn’s disease) are coated with Eudragit® S 100, a coating that is subject to 
dissolution through pH [327]. In some cases, this pH triggered formulation has been 
reported to allow mesalazine tablets to reach the colon intact [328]. However, when 
consumed by healthy subjects, mesalazine tablets have also evaded dissolution [329-331], 
suggesting that besides pH, there must be other factors which impact the mechanism of 
delivery systems. Such factors could include feeding status, the duration of the delivery 
system at the ileo-caecal junction and gastrointestinal fluid composition [330].  
To avoid relying on a single mechanism system, the formulation Phloral® was invented, 
which encompasses a dual coating system, thereby relying on both the pH conditions and 
enzymatic activity of the colon. Phloral® has been shown to successfully release the API at 
the ileo-caecal junction or the colon in eight healthy human volunteers [330]. This study 
investigated the in vivo targeting performance of Phloral®, which is made of a mixture of a 
pH-responsive enteric polymer (Eudragit® S 100) and biodegradable polysaccharide, 
amylo-maize (resistant starch), in a single layer matrix film. Briefly, tablets were film-
coated with Phloral® and administered to eight healthy volunteers, with the site of 
intestinal disintegration assessed using gamma scintigraphy. It was found that the coated 
tablets were able to resist breakdown in the stomach and small intestine. Consistent 
disintegration of the dosage form was seen at the ileo-caecal junction/large intestine.  
The aim of Phloral® is to protect the API from degradation in its transit through the gut 
and efficiently release the drug in the colon by using two triggering mechanisms which are 
independent, complementary, and act as a failsafe for each other: as a polysaccharide, 
starch can be hydrolysed by amylolytic enzymes which can cut one or both types of 
glycosidic bonds. The main enzyme involved in the hydrolysis of α-1,4 bonds is α-amylase 
[332, 333]. The rate and extent of hydrolysis depends on the physio-chemical form of the 
starch. It has been proven that retrograded amylose escapes degradation by pancreatic α-
amylase which will avoid premature release of the API, but is susceptible to hydrolysis by 
colonic microflora [334]. For this reason, the amylose component in Phloral® adds an 
extra element of site-specificity to the system, since bacterial amylases can specifically 
digest resistant starch, as they are more efficient than mammalian pancreatic enzymes, and 
over fifty percent of the bacteria in the colon produce this enzyme [335]. When the 
amylose is degraded by bacterial amylases, it leaves small pores in the coating through 
which the drug can be released. This will ensure drug release even if the pH-sensitive 
polymer fails to dissolve. The polymer is also needed to control the swelling of the starch 
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[331], as this polysaccharide has the ability to form films through gelation which are very 
fragile and have a tendency to swell in water [336]. Due to this, Eudragit® S 100 is also 
used as a structuring agent in the pharmaceutical industry. 
Formulating Phloral® coating is a very delicate and time-consuming process, since for the 
system to function the amylose should be randomly distributed throughout the structure of 
the mixed films, and without any degree of miscibility with the Eudragit® S 100 as this 
could alter the characteristics of the amylose, in particular its susceptibility to digestion by 
colonic bacterial enzymes [337]. This random distribution takes time, and the preparation 
of the starch suspension comprises many steps which are not well understood. For this 
reason, it is important to have a good knowledge of the transitions that occur regarding the 
physical form of starch during processing in order to try to achieve a form that will be 
resistant to pancreatic α-amylase but not to bacterial amylolytic enzymes, that is, type III 
resistant retrograded starch. 
6.6 Conclusions 
Two different types of Phloral® suspensions (semi and fully organic) were tested in order 
to attain the optimal coating suspension which provided the test drug with the most 
resistance to gastrointestinal conditions prior to reaching the colon. A fully organic 
Phloral® suspension displayed high resistant properties when the test drug was exposed to 
gastrointestinal conditions via dissolution systems. The dissolution systems also showed 
that a coating thickness of 4 mg/cm2 was deemed sufficient in terms of drug release. To 
translate these in vitro assays, the coating system developed here was subsequently used in 
a human trial, detailed in the next chapter.
  
 
CHAPTER SEVEN 
 
 
7 The Effect of Phytin on the Human Gut Microbiome (EPoM) – a 
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7.0 Summary 
Previous chapters have measured the effect of different chelators on gut bacteria. Chapter 6 
illustrated a successful targeted delivery system whereby, according to in vitro tests, 
compounds should be protected from gastric acid and GI digestive enzymes and only 
released when they reach the colon. This chapter describes a clinical trial in which 
volunteers were recruited to participate in a double-blind, randomised crossover dietary 
intervention trial. Participants were asked to consume encapsulated phytin or placebo for 2 
weeks, followed by a 2-week wash-out, and then the alternative treatment was given. 
However, due to the lack of phytin dispersion in the colon, as indicated by white clumps of 
powder in the stool samples, it cannot be concluded whether the iron chelating properties 
of phytin had any effect on the composition of the gut microbiota.   
7.1 Introduction 
Phytic acid (Figure. 7.1), also known as inositol hexakisphosphate (IP6) or phytate (when 
in salt form), is the principal storage form of phosphorus in many plants, such as legumes, 
seeds, nuts and cereals [250]. Phytic acid content varies greatly among plants and is due to 
different factors, such as the type of seed, climate, and environmental conditions. 
 
Figure 7.1 - Structure of phytic acid 
Studies in humans report that between 37-66% of dietary phytate is degraded during 
digestion in the stomach and small intestine when the diet is rich in plant food phytases 
[278, 338, 339], a type of phosphatase enzyme that catalyses the hydrolysis of phytic acid.  
Beneficial properties of phytic acid have been proposed, including antioxidant [252] and 
anticancer [273, 274] activities, but phytate is generally regarded as an antinutrient. In vitro 
and in vivo studies have demonstrated that phytic acid forms insoluble complexes with 
several divalent minerals, thereby preventing absorption, and can potentially result in zinc 
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and iron deficiencies [275, 276, 340, 341]. Once these insoluble complexes are formed, the 
mineral cannot be absorbed in the small intestine and therefore pass into the colon. 
Although phytic acid also binds the metals that the beneficial bacteria use, at pH 6-7 
(representative of the colon), phytic acid preferentially binds iron, suggesting a protective 
role of phytic acid in preventing iron acquisition by potentially pathogenic bacteria. 
Several published studies have found that the degradation of phytate in the gut varies 
between individuals and is largely based on the type of diet consumed. As most plant foods 
such as legumes, cereals and whole grain products, are processed or heat-treated during 
food production and the preparation of meals, many of the phytases present in these foods 
are likely to be inactivated. In individuals whose diets consist of high amounts of wheat or 
rye bran i.e. foods that contain native phytases, strong phytate hydrolysis occurs in the 
stomach, with the remaining small portion of non-degraded phytate being hydrolysed in 
the colon [203]. Notably, phytate-bound iron found in the colon is present in the insoluble 
form making it difficult to degrade [52, 202] suggesting a potential role for phytate in the 
withholding of iron from gut bacteria.  
Despite numerous studies on the effects of iron supplementation on the gut microbiota, 
only a few studies have investigated the effects of reducing the level of iron in the gut 
lumen on the gut microbiota of healthy individuals. The earlier in vitro colonic 
fermentation experiments (chapter 5) investigated reducing the availability of iron to gut 
bacteria by means of iron-chelating compounds found in foods. The relative abundance of 
potentially pathogenic bacterial taxa, such as Escherichia and Bacteroides, decreased, and 
simultaneously increased the abundance of beneficial bacterial taxa, such as 
Bifidobacterium.  
7.2 Objectives 
The hypothesis tested in this trial was that the consumption of encapsulated phytin will 
cause a change in the composition of the colonic gut microbiota, and specifically decrease 
the proportions of potentially harmful Enterobacteriaceae, when compared to the faecal 
microbiota after consuming placebo capsules, as well as compared to the baseline faecal 
samples of individuals. It was considered that the consumption of phytin would alter the 
microbial metabolite profile and that the presence of phytin in the colon would reduce the 
concentration of faecal free iron in the individuals. 
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7.3 Materials and methods 
Fourteen participants were recruited onto the ‘Effect of Phytin on the Human Gut 
Microbiome’ (EPoM) study, which investigated the differential effects of consuming 
encapsulated phytin on the composition of the gut microbiota. A detailed protocol on 
participant recruitment and the EPoM study design can be found in the Appendix, in the 
form of a study protocol and annexes.  
Figure 7.2 summarises the EPoM study design and Table 7.1 presents participant 
information. The bacterial composition of faecal samples was determined using 16S rDNA 
paired-end sequencing (2x 250 bp) on the Illumina MiSeq platform, performed by Dave 
Baker (QIB), and bioinformatic analyses were performed by Dr Andrea Telatin (QIB) 
using the QIIME pipeline (section 2.8.3.1). Dr Gwenaelle Le Gall (UEA) performed 1H 
NMR spectroscopy analysis (section 2.8.3.2 ) on faecal waters to investigate changes to 
microbial metabolic profiles associated with consumption of encapsulated phytin. MCC, 
which behaved as the placebo, was purchased from DFE Pharma and encapsulated in equal 
amounts as phytin. 
 
Figure 7.2 - Summary of EPoM study design. The diagram represents a two-phase crossover, 6-
week dietary intervention trial, where participants consumed a randomly allocated set of capsules 
during each phase. Phases were separated by a washout period, during which no capsule 
consumption took place. Habitual diet was maintained throughout the study period. Faecal 
samples were collected three times during each phase, at the start, middle and end. During each 
phase, stool charts, food frequency questionnaires and capsule checklists were completed by each 
participant. 
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Table 7.1 – Age, gender, Body Mass Index (BMI) of EPoM study participants. All 
participants were non-smokers. 
Participant Code Age (y) Gender BMI (kg/cm2) 
EPoM114 27 Male 19.7 
EPoM120 32 Female 27.0 
EPoM125 33 Female 19.5 
EPoM129 27 Female 26.5 
EPoM134 26 Male 25.9 
EPoM139 25 Female 25.0 
EPoM148 28 Female 28.3 
EPoM150 23 Female 21.4 
EPoM151 29 Male 28.5 
EPoM155 24 Male 20.9 
EPoM156 23 Male 21.4 
EPoM163 18 Male 25.8 
EPoM169 25 Male 24.9 
EPoM191 30 Female 23.8 
 
7.4 Results 
7.4.1 Serum ferritin and C-reactive protein measurements of EPoM samples 
To confirm that the release of encapsulated phytin did not take place before it reached the 
colon, serum ferritin levels of EPoM participants were measured at the beginning and end 
of each phase. Blood results showed that serum ferritin levels remained stable for all 
participants throughout the duration of the trial when consuming either capsule.  
C-reactive protein (CRP) was also measured, and as with serum ferritin, CRP levels also 
remained stable throughout the duration of the study in all participants, confirming the lack 
of systemic inflammation. 
7.4.2 Community analysis of human faecal microbiota 
Faecal samples were collected during the study from 14 healthy participants, aged 18 – 33 
y with a mean age of 26 y, and an average BMI of 24.2 kg/m2. The DNA was extracted 
(section 2.6.1) and normalised to 5 ng/μl. The normalised DNA samples were sequenced 
in-house at QIB, where the variable region, V4, of the 16S rRNA gene was amplified using 
PCR, and sequenced using the paired-end Illumina MiSeq platform, for downstream 
analysis using the QIIME pipeline (section 2.6.3). This produced 4,751,049 high-quality 
reads, with an average of 59,948 ± 10,024 reads per sample. 
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Performing the unweighted (Figure 7.3) and weighted (Figure 7.4) Unifrac β-diversity 
analysis with samples colour-coded for each participant, indicated that the samples 
obtained from each individual clustered together. 
 
       
Figure 7.3 - Unweighted β-diversity analysis shows clustering of faecal microbiota based on the 
individual. Unweighted β-diversity analysis of faecal microbiota from fourteen study participants; 
each participant collected a total of six faecal samples, three during each treatment phase. 
Analysis was performed using the UniFrac metric and visualised as a 3D PCoA plot. β-diversity 
analysis was performed using QIIME 1.9.1 and plotted using Emperor. The EPoM code in the key 
refers to different participants. 
EPoM 114 
EPoM 120 
EPoM 125 
EPoM 129 
EPoM 134 
EPoM 139 
EPoM 148 
EPoM 150 
EPoM 151 
EPoM 155 
EPoM 156 
EPoM 163 
EPoM 169 
EPoM 191 
  Chapter 7 
 
132 
 
  
Figure 7.4 - Increased variation within individuals is observed when relative abundance of 
bacteria within the microbiota is considered. Weighted β-diversity analysis of faecal microbiota 
from fourteen study participants; each participant collected a total of six faecal samples, three 
during each treatment phase. Analysis was performed using the UniFrac metric and visualised as a 
3D PCoA plot. β-diversity analysis was performed using QIIME 1.9.1 and plotted using Emperor. 
The EPoM code in the key refers to different participants. 
Figure 7.3 suggests that the greatest degree of similarity between faecal microbiota can be 
found amongst the samples that originated from each individual. The faecal microbiota of 
EPoM148 appears to differ and are less similar to the microbiota of the other 13 
participants, due to a lower number of shared bacterial taxa. Furthermore, EPoM129, 
EPoM151 and EPoM169 appear to have similar microbiota to one another but are less 
similar to the microbiota of the other 11 participants, due to a lower number of shared 
bacterial taxa.  
Weighted Unifrac β-diversity analysis considers the similarity between the relative 
abundance of the bacterial taxa, alongside which taxa are shared between microbiota. 
Figure 7.4 indicates an increased variability amongst the faecal microbiota of individuals 
due to small fluctuations in the relative abundance of bacterial taxa. 
EPoM 114 
EPoM 120 
EPoM 125 
EPoM 129 
EPoM 134 
EPoM 139 
EPoM 148 
EPoM 150 
EPoM 151 
EPoM 155 
EPoM 156 
EPoM 163 
EPoM 169 
EPoM 191 
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7.4.3 Lack of phytin dispersion in the colon 
Treatment A was encapsulated phytin and treatment B was encapsulated MCC (placebo). 
Faecal samples were collected from all participants and aliquoted for further analysis. 
   
Figure 7.5 – Image of white, powdered clump in the faeces of EPoM participants when 
consuming encapsulated phytin. The images above are faecal samples collected from two different 
participants consuming encapsulated phytin. These images are representative of all faecal samples 
collected when participants were consuming encapsulated phytin. 
When faecal samples were collected from participants consuming treatment A (i.e. 
encapsulated phytin), clumps of white powder were found in all faecal samples (Figure 
7.5), indicating lack of dispersion in the colon. Furthermore, when these participants 
switched over to treatment B (i.e. placebo), no clumps of white powder were observed. 
Further examination indicated that the capsule outer layer had broken down and therefore 
only the content remained in the faeces. 
As phytin did not mix in with the faecal material, any further conclusions could not be 
made in regard to whether phytin had any effect on water-soluble iron concentrations, 
faecal metabolites and gut microbial composition. This is reflected in the analysis 
performed on the faecal materials obtained from the trial participants, as shown in the 
following sections. 
7.4.4 Water-soluble iron concentrations in faecal samples 
Water-soluble iron concentrations were quantified from the stool samples of participants, 
collected at the start (pre), middle (mid) and end of each phase.  
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Figure 7.6 – Quantification of faecal water-soluble iron from both treatment arms of EPoM 
study. Figure (a) illustrates water-soluble iron concentrations quantified from stool samples of 
participants when consuming encapsulated phytin, and figure (b) shows water-soluble iron 
concentrations quantified from stool samples of participants when consuming encapsulated MCC 
(placebo). 
As expected, due to lack of phytin dispersion, no difference was observed in water-soluble 
iron concentrations when quantified from the faecal waters of both treatment arms (Figure 
7.6).  
7.4.5 Short-chain fatty acid quantification in faecal samples  
Acetate, butyrate and propionate concentrations were quantified from the stool samples of 
EPoM participants during both treatments. 
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Figure 7.7 – Between-individual variation of the metabolite profile is generally stronger than the 
within-individual variation over time. An aliquot of 84 faecal samples were each analysed using 
1H NMR spectroscopy. Representation of metabolite profiles from stool samples of participants 
consuming encapsulated phytin are shown in blue, whilst encapsulated MCC (placebo) is shown in 
green. The plot was generated using XLSTAT in Excel.  
The metabolite profiles of the 84 faecal waters showed a tendency to cluster based on the 
participant, indicating a low level of intra-individual variability over time (Figure 7.7). 
Furthermore, no association between the treatment arms and the faecal metabolite profile 
were detected due to the unsuccessful mixing of phytin with the faecal material. 
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Figure 7.8 – Quantification of short-chain fatty acids from both treatment arms of EPoM study. 
Acetate (a and b), butyrate (c and d) and propionate (e and f) levels were quantified from faecal 
samples of participants when consuming encapsulated phytin and MCC. 
Quantification of short-chain fatty acids confirmed no observable difference in the levels 
of acetate (Figures 7.8a and 7.8b), butyrate (Figures 7.8c and 7.8d) and propionate (Figures 
7.8e and 7.8f), when comparing both treatment arms due to the lack of phytin dispersion in 
the faeces.  
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7.4.6 β-diversity analysis of faecal samples 
The unweighted Unifrac β-diversity analysis calculates the similarities between samples, 
based on which bacterial taxa are shared amongst the microbiota. As phytin was not 
dispersed in the colon, no associations were observed between the consumption of either 
encapsulated phytin or encapsulated MCC (placebo).  
 
Figure 7.9 - Consumption of either phytin or placebo did not correlate with a common gut 
microbiota composition. Unweighted β-diversity analysis of faecal microbiota from fourteen study 
participants; each participant collected a total of six faecal samples, three during each treatment 
phase. Analysis was performed using the UniFrac metric and visualised as a 3D PCoA plot. β-
diversity analysis was performed using QIIME 1.9.1 and plotted using Emperor. 
Phytin 
Placebo 
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Figure 7.10 - No association between gut microbiota composition and phytin consumption was 
observed when accounting for bacterial relative abundance. Weighted β-diversity analysis of 
faecal microbiota from fourteen study participants; each participant collected a total of six faecal 
samples, three during each treatment phase. Analysis was performed using the UniFrac metric and 
visualised as a 3D PCoA plot. β-diversity analysis was performed using QIIME 1.9.1 and plotted 
using Emperor. 
In line with previous findings, the unsuccessful mixing of phytin with the faecal material 
lead to no alteration of the faecal microbiota of the participants towards a common 
composition, as illustrated by the unweighted (Figure 7.9) and weighted (Figure 7.10) 
Unifrac β-diversity analysis. 
α-diversity was performed to see if there was a difference in diversity within the 
population between the treatment arms (Figure 7.11). 
Phytin 
Placebo 
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Figure 7.11 - α-diversity analysis indicates no difference in population diversity between 
treatment arms. α-diversity rarefaction plot of species richness within the human faecal microbiota 
samples grouped for each of the fourteen individuals. The y-axis is a measure of diversity within 
each community, whilst the x-axis represents the number of sequences used per sample in the 
diversity calculation. Rarefaction plots were generated using QIIME 1.9.1.  
α-diversity analysis of samples derived from both treatment arms further confirms no 
difference in diversity within the population when consuming either encapsulated phytin or 
placebo (Figure 7.11). 
7.4.7 Compositional analysis of the human gut microbiota 
As phytin did not mix in with the faecal material, no changes were observed in the 
bacterial composition from the faecal samples derived from both treatment arms. 
7.5 Discussion 
Serum ferritin was measured to test whether the phytin affected iron status through 
reduction of iron absorption. In order to do this, it is important to rule out inflammation as 
this will increase ferritin levels and make it difficult to interpret whether phytin has 
affected body iron status. Without this measurement, the effect of phytin on iron 
absorption cannot be tested. CRP was therefore measured at the same time as serum 
ferritin throughout the duration of the study (before and after the start of each phase). 
Phytin 
Placebo 
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Blood tests revealed stable levels of serum ferritin and CRP in all participants during each 
phase of the trial. 
When the microbiota profiles of all 84 faecal samples collected throughout the study were 
analysed, samples tended to cluster based on the participant (Figure 7.3), highlighting the 
unique nature and inherent stability of an individual’s gut microbiota. Inter-individual 
differences in the composition of gut bacterial communities have been observed in other 
studies [342]. Weighted β-diversity analysis suggested that the microbiota clustered, but 
that there was variation in the abundances of bacteria within the communities over time 
(Figure 7.4). This potentially reflects the dynamic nature of the gut microbiota, which is 
able to adapt to environmental alterations, such as a change of dietary habits, while 
retaining its core structure.  
Aliquoting of the stool samples collected by the EPoM participants revealed clumps of 
white powder in the samples derived from those consuming encapsulated phytin (Figure 
7.5). No clumps were observed in the faeces of those consuming MCC. Further 
examination revealed that the capsule outer layer had broken down, suggesting the 
Phloral® coating (properties of which were tested in vitro) on the capsules worked 
successfully and allowed the encapsulated material to bypass and withstand the 
gastrointestinal conditions before being released in the colon. However, the content of the 
capsule remained in the faeces, and therefore it is not possible to conclude whether phytin 
had an effect on the parameters tested. The lack of phytin dispersion in the faecal material 
is reflected in the lack of effect of phytin on water-soluble iron concentrations (Figure 7.6), 
faecal metabolite profiles (Figures 7.7-7.8) and gut microbial composition (Figures 7.9-
7.11). 
The lack of phytin dispersion highlights the importance of the form of phytin to be 
administered in any future studies. For example, a liquid form of phytic acid could be 
encapsulated, which would allow for better dispersion in the gut.  
7.6 Conclusions 
A human dietary intervention study was performed to investigate the effects of 
encapsulated phytin on the human gut microbiota. It was shown that each participant had a 
unique bacterial community with small fluctuations in the relative abundances of bacterial 
members. β-diversity analysis suggested samples appeared to cluster when derived from 
the same participant over time. Due to the lack of successful dispersion of phytin in the 
  Chapter 7 
 
141 
 
colon once released from the capsule, phytin appeared to clump in the stool and therefore 
did not mix with the faecal material, and subsequently was unable to bind iron. Therefore, 
it is not possible to make any conclusions on whether the iron chelating properties of 
phytin had any effect on the gut microbial composition. 
  
 
CHAPTER EIGHT 
 
 
8 Gut microbiota changes following systemic iron reduction in 
haemochromatosis patients 
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8.0 Summary 
Hereditary haemochromatosis (HH) is an autosomal recessive genetic disease in which 
intestinal absorption of iron is increased resulting in accumulation of iron in tissues, 
primarily the liver, which can sometimes lead to liver damage. Currently, the line of 
treatment for HH is therapeutic iron reduction by phlebotomy (venesection therapy). 
However, during the course of repeated phlebotomy treatments, it is likely that intestinal 
iron absorption is enhanced to compensate for the iron loss during phlebotomy, and 
therefore may lead to alteration of the gut microbial composition due to changes in colonic 
luminal iron bioavailability. The aim of the work outlined in this chapter was to see 
whether iron removal through venesection reduced systemic and faecal iron levels in HH 
patients and whether iron removal had a subsequent effect on the composition of the gut 
microbiota. Results showed that a majority of the HH patients enrolled on this study 
displayed higher levels of iron removal after phlebotomy, as indicated by lower serum 
ferritin levels, along with changes in gut microbial composition towards a healthier profile. 
8.1 Introduction 
HH is an autosomal recessive disorder in which the regulation of iron is disrupted, leading 
to the toxic accumulation of iron in important organs, such as the liver, and the 
development of cirrhosis, bone and joint disease, diabetes mellitus, and heart disease [111]. 
HH occurs in approximately 1 in 250 individuals, with approximately 0.4% of people of 
northern European descent having the genetic mutation and thereby increasing the risk of 
developing haemochromatosis [112-114]. Most patients with HH are homozygous for the 
C282Y mutation in the HFE gene (HFE-HH), comprising up to 90% of phenotypically 
affected persons [111]. Disorders of iron excess, such as HH, have been suggested to effect 
gut microbial profiles [159]. HH patients have a higher risk of infection due to the 
increased availability of iron to potentially pathogenic bacterial species in the colon.  
Therapeutic venesection has been the standard of care for patients with haemochromatosis 
for at least 60 y [343]. Venesection typically involves the removal of 500 mL of blood 
(equivalent to 250 mg of iron) weekly from patients until normal iron levels are achieved. 
Iron depletion is associated with an improvement in liver function tests, insulin resistance, 
liver fibrosis, enhanced quality of life, increased energy levels and a reduction in mortality 
and risk of several malignancies [344-348]. The mechanisms underlying these benefits are 
unknown. Paradoxically, venesection promotes iron absorption from the gut, and reduced 
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faecal iron levels have been reported during treatment. As iron is critical to the growth and 
proliferation of numerous gut microbes, and excess colonic iron has been implicated in 
inflammation of gut epithelium and carcinogenesis, changes in faecal iron levels during 
venesection could favourably alter the gut microbiota. 
Oral iron supplementation has been shown to adversely affect the composition and 
function of the human gut microbiota [157], while differences in gut bacteria have been 
demonstrated when comparing iron deficient with iron replete individuals [349].  
8.2 Objectives  
In collaboration with Dr John Ryan at Oxford University Hospitals NHS Foundation Trust 
(OUHT)/Beaumont Hospital, we aimed to determine the relationship between gut bacteria 
and faecal iron levels before and during phlebotomy. Stool samples were collected from 20 
patients before and after initiating venesection (characteristics outlined in Table 8.1), with 
paired samples obtained from 11 of these patients during follow up. Faecal iron levels were 
measured, and their relationship with the gut microbiota was assessed by faecal 
metataxanomic and metabolomic analyses. 
Table 8.1 – Patient characteristics  
Baseline Characteristics Venesection Cohort (n=20) 
Female (%) 8 (40%) 
Age (y) 56 (11) 
Weight (kg) 80.3 (16.9) 
BMI (kg/m2) 27.2 (4.5) 
Serum ferritin (μg/L) * 717 (4500) 
Transferrin Saturation (%) 71.9 (27.6) 
Serum iron (µg/dL) 31 (9) 
HFE Genotype 
C282Y/C282Y 
C282Y/H63D 
Carrier/Negative 
 
10 (50%) 
4 (20%) 
6 (30%) 
Haemoglobin (g/L) 144 (14) 
ALT (IU/mL) 40 (19) 
AST (IU/mL) 38 (19) 
CRP (mg/L) 3.2 (5.6) 
HbA1c (mmol/mol) 32 (6) 
^Mean+/- standard deviation in brackets unless indicated otherwise. *median 
(range). Alanine aminotransferase (ALT); aspartate aminotransferase (AST); 
C-reactive protein (CRP); haemoglobin A1c (HbA1c) 
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8.3 Materials and Methods 
8.3.1 Study design and cohort information 
This study has been ethically approved by Yorkshire & The Humber - Sheffield Research 
Ethics Committee, reference number 16/YH/0247. This study was funded by Oxford 
comprehensive Biomedical Research Centre (OxBRC). 
The Gastroenterological cohort was assembled from patients attending Oxford University 
Hospitals service, including those being referred for an endoscopic, radiological, or 
surgical procedure, including percutaneous biopsy or aspiration, as part of the normal care. 
Patients were recruited from the OUHT including the John Radcliffe hospital, the 
Children’s Hospital, the Churchill Hospital and the Horton Hospital. Control and non-GI 
patient relatives were also invited to donate blood samples or a mucosal swab. 
Patient recruitment took place from various locations and backgrounds. These included: 
• Patients under the care of the gastroenterology unit; 
• Patient relatives to allow for investigations of genetic influences; 
• Patients undergoing tonsillectomy, adenotonsillectomy, laparoscopy, laparotomy, 
heart surgery, thymectomy, skin biopsy or appendectomy; 
• Healthy blood donors to be used as controls. 
Patients were presented with verbal and written information about this project along with a 
consent form. Family members of patients who were recruited as a ‘healthy control’ 
received information leaflets and consent forms as per patients (Adult, Child and Young 
Person information leaflets and consent forms). Healthy controls who were colleagues or 
students were recruited by advert and provided with the university guidelines.  
Intended study duration is indefinite and planned to last for the duration of the disease or 
until patients withdraw consent. Continuing informed consent is necessary for participation 
and can be withdrawn by patients at any time, without giving a reason and without 
affecting the quality of future medical care. Samples and data collected and shared with 
other researchers up to the point of withdrawal of consent may still be used. 
The inclusion criteria for this study is outlined below: 
• patients attending the Gastroenterology service at Oxford University Hospitals, and 
referred for endoscopy, or radiology, percutaneous liver biopsy, genetic disorders 
and, or surgery; 
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• patients undergoing surgery such as tonsillectomy, adenectomy, or heart 
surgery/thymectomy or appendectomy, or skin biopsy; 
• healthy controls and, in exceptional circumstances patient relatives, were invited to 
participate and donate a blood sample or oral mucosal swab and/or urine and stool 
samples; 
• patients under the age of 16 y were offered participation using specially amended 
documentation, and consent was obtained from parents or guardians for those who 
were younger than 10 y old; 
• for patients aged older than 10, and younger than 16 y old, their assent was sought 
using age-appropriate materials, in addition to consent from parents or guardians. 
8.3.2 Microbial DNA extraction 
Faecal samples collected from patients were frozen and sent to QIB for analysis. DNA was 
extracted from all samples using a commercially available kit (FastDNA spin kit for soil; 
MP Biomedicals, USA, Cat No. 6560200). Samples were thawed on ice, homogenised, and 
approximately 200 mg of each were used to extract DNA following the manufacturer's 
instruction, with an additional bead beating step using FastPrep (MP Biomedicals, USA), 
as detailed previously described (chapter 2, section 2.6.1). 
 
8.3.3 16S rRNA gene amplification and sequencing 
The impact of therapeutic venesection on the composition of the human gut microbiota 
was investigated using high throughput 16S rRNA gene (V4 region) sequencing using the 
Illumina Miseq platform, followed by data analysis using the Quantitative Insights into 
Microbial Ecology (QIIME, V1.9) pipeline. Details for this method can be found in chapter 
2, section 2.6.3. 
 
8.3.4 Short chain fatty acid quantification in stool samples 
Faecal water was prepared to quantify short chain fatty acids in stool. Briefly, 0.2 g of 
faecal sample was mixed with 12x volume of NMR buffer (0.26 g NaH2PO4 and 1.41 g 
K2HPO4 made up in 100 mL D2O, containing 0.1% NaN3 (100 mg), and 1 mM sodium 3-
(Trimethylsilyl)-propionate-d4, (TSP) (17 mg) as a chemical shift reference). The samples 
were then centrifuged at 3220 xg for 15 mins at 4oC and the 1H NMR spectra were 
recorded as detailed in chapter 2, section 2.7.  
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8.3.5 Measurement of total iron concentrations in stool samples 
FAAS was used to determine the concentration of total iron in faecal samples. Faecal 
samples were weighed and then dried at 110oC in an oven and then further processed for 
total iron analysis as outlined in chapter 2, section 2.3.1.  
8.3.6 Measurement of water-soluble iron iron in stool samples 
A 0.2 g faecal sample was homogenised with 0.2 g of Milli-Q water, mixed on a rotator 
stirrer for 30 mins at room temperature and centrifuged at 3,000 xg for 15 mins at 4oC. 
Supernatants were then analysed using the Ferrozine assay, as outlined in chapter 2, 
section 2.3.1. 
8.3.7 Bacterial species profiling using qPCR 
Profiling of gut bacterial species was performed at the laboratories at the John Radcliffe 
Hospital, Oxford using the Metabolic Disorders qPCR array for microbial DNA testing 
(Qiagen) and Microbial DNA qPCR Assay for Hs.GAPDH. Data was analysed using the 2-
ΔΔCt method with (glyceraldehyde 3-phosphate dehydrogenase) GAPDH as an internal 
control gene and using the mean of the control duplicates as control. 
8.3.8 Serum ferritin and liver enzyme quantification 
Routine haematological and biochemical tests were performed in the clinical laboratories 
of the John Radcliffe Hospital, Oxford. 
8.4 Results 
8.4.1 Effects of venesection on serum ferritin, faecal free iron and liver 
enzymes 
Free iron levels in stool samples were significantly higher in HH patients at baseline when 
compared with those of healthy controls (Figure 8.1). 
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Figure 8.1 – Faecal free iron levels in healthy controls and HH patients. Patients with iron 
overload had significantly higher faecal free iron levels compared to healthy controls. Data 
available on 16 HH patients. ****p<0.0001, data represented as mean ±SEM. 
As expected, treatment with venesection was associated with a significant reduction in 
serum ferritin levels, and an improvement in the levels of the liver enzyme, alanine 
aminotransferase (ALT) (Figure 8.2a and 8.2b).  
 
Figure 8.2 – Serum ferritin and liver ALT of HH patients before and after venesection. 
Significant reductions in (a) serum ferritin (a; p<0.0001) and (b) liver ALT (b; p<0.05) were 
observed in paired samples after treatment with venesection. 
Faecal free iron levels were measured in 11 HH patients (Figure 8.3). 
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Figure 8.3 – Faecal free iron levels in HH patients before and after venesection. Faecal free iron 
levels were measured in 11 HH patients. 6 patients (green line) presented with significant 
decreases in faecal free iron levels (p<0.001), whilst faecal free iron levels remained unchanged in 
5 patients (red line). 
Overall, amongst the 11 HH patients, a variability in response to venesection is observed, 
with a majority displaying a reduction in iron and a minority showing no change (Figure 
8.3). Upon venesection, 6 HH patients showed significant reductions in faecal free iron 
levels whilst faecal free iron levels remained unchanged in 5 HH patients. On average, 
baseline faecal free iron levels of those patients whose faecal free iron levels reduced upon 
venesection, was 0.78 ±0.4 mg/g. This was reduced to 0.31 ±0.2 mg/g after venesection. 
The 5 HH patients in which no reduction in faecal free iron was observed had faecal free 
iron levels of 0.64 ±0.2 mg/g and 0.62 ±0.2 mg/g at baseline and after venesection, 
respectively.  
The patients in which iron was reduced after venesection, had significantly more iron 
removed by phlebotomy compared to those whose iron levels were unchanged [2.7 g (+/-
0.8) vs. 1.1 g (+/-0.7), respectively], and experienced significant reductions in ALT [43 
(+/-11) IU/mL to 28 (+/-4) IU/mL, vs. 39 (+/-28) IU/mL to 22 (+/-9) IU/mL respectively] 
and HbA1c levels [33 (+/-4) mmol/mol to 27 (+/-4) mmol/mol, vs. 33 (+/-4) mmol/mol to 
34 (+/-1) mmol/mol, respectively] (Table 8.2). Patients who had significantly more iron 
removed by phlebotomy presented a positive correlation with faecal free iron levels, which 
was also observed to decrease (Figure 8.3).  
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Table 8.2 – Alterations in various observed parameters for 11 HH patients 
Parameter^ Patients in which iron 
reduced post 
treatment 
(n=6) 
Patients in which iron 
remained unchanged post 
treatment 
(n=5) 
p 
value 
Age (y) 50 (6) 54 (13) 0.35 
Female (%) 2 (40) 4 (80) 0.1 
Weight (kg) 86 (15) 67 (14) 0.15 
HFE C282Y/C282Y 
(%) 
6 (100) 2 (40) 0.09 
Baseline ferritin 
(μg/L) * 
747 (4367) 441 (484) 0.24 
Treatment ferritin 
(μg/L) * 
156 (3939) 116 (460) 0.75 
Baseline faecal free 
iron (mg/g) 
0.78 (0.4) 0.64 (0.2) 0.42 
Treatment faecal free 
iron (mg/g) 
0.31 (0.2) 0.62 (0.2) 0.08 
Total venesections 
(n) 
10 (3) 6 (3) 0.048 
Iron removed (g) 2.7 (0.8) 1.1 (0.7) 0.03 
Baseline ALT 
(IU/mL) 
43 (11) 39 (28) 0.69 
Treatment ALT 
(IU/mL) 
28 (4) £ 22 (9) £0.03 
Baseline HbA1c 
(mmol/mol) 
33 (4) 33 (4) 0.97 
Treatment HbA1c 
(mmol/mol) 
27 (4) £ 34 (1) £0.03 
^Mean+/- standard deviation in brackets unless otherwise indicated. £ baseline vs. 
treatment 
*median (range). Alanine aminotransferase (ALT); international units per litre (IU); 
haemoglobin A1c (HbA1c). Significant findings highlighted in bold 
 
8.4.2 Effects of venesection on the human gut microbiota 
The effect of treatment on the gut microbiota was compared between the patients who 
showed lower levels of faecal free iron and those whose levels did not change after 
treatment in order to assess the impact of changes in faecal free iron on gut bacteria. While 
no difference in phylogenetic diversity was evident between baseline and treatment in both 
sets of patients, significant changes in bacterial genera and species were noted, but only in 
those who presented with lower faecal free iron levels upon venesection. Specifically, 
these patients experienced significant increases in the bacterial genus Faecalibacterium 
and decreases in the genera Finegoldia, Adlercreutzia and Bacteroides. Furthermore, 
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qPCR revealed that the levels of the bacterial species Faecalibacterium prausnitzii, Dorea 
formicigenerans and Collinsella aerofaciens (Figures 8.4a, c and e) were significantly 
increased in these patients but remained unchanged in patients with unaffected faecal free 
iron levels post-treatment (Figures 8.4b, d and f).  
 
Figure 8.4 – Metagenomic profile of HH patients. Alterations in different bacterial species for 
patients presenting with lower faecal free iron levels post-venesection (n=6; a, c and e) and those 
whose faecal free iron levels remained unaffected post-venesection (n=5; b, d and f). 
Metabolomic profiling of the patients was also carried out in tandem to metataxonomic 
analysis. Although significant changes were not observed between patients who had higher 
levels of iron removed through phlebotomy compared to those with lower levels of iron 
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removal, slightly raised concentrations of acetate and butyrate were noted in the former 
group (Figure 8.5a and b, respectively). 
 
Figure 8.5 – Metabolite levels from patients with higher levels of iron removal post-phlebotomy. 
Figure a shows levels of (a) butyrate in patients who presented with higher levels of iron removal 
through phlebotomy, whilst figure (b) displays levels of acetate. 
Furthermore, a visible shift in the metabolome of those patients presenting with higher iron 
removal post-treatment was observed. For these patients, if individual patient data is 
investigated, a greater separation in the metabolome is illustrated, where a shift is observed 
after treatment compared to baseline (Figure 8.6a). A less distinct shift in the metabolomic 
profile is observed for patients with lower levels of iron removal post-treatment when 
comparing baseline profiles to those with treatment (Figure 8.6b).  
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Figure 8.6 – Metabolomic profile of HH patients. Figure (a) represents the metabolomic profile of 
HH patients (n=6) who presented with higher levels of iron removal post-phlebotomy, whilst figure 
(b) represents the metabolomic profile of HH patients (n=5) who presented with lower levels of 
iron removal post-phlebotomy.  
8.5 Discussion 
Haemochromatosis is a disease which is caused by excessive iron absorption, which leads 
to iron overload. The majority of hereditary HH cases are associated with mutations in the 
HFE gene. Generally, this becomes clinically apparent during adulthood and can cause 
damage to many organs, including the skin, pancreas, liver and heart. HH patients who 
displayed higher levels of iron removal post-venesection had more iron removed at the 
time of analysis- this indicates that they were more overloaded at baseline and therefore 
tolerated phlebotomy better, and all were C282Y/C282Y HFE homozygotes, in whom the 
benefit of phlebotomy is most apparent.  
Strikingly, in the study by Lee et al., (2017) examining the effect of oral and intravenous 
iron supplementation on patients with inflammatory bowel disease, oral iron was 
associated with decreased abundances of the bacterial species Faecalibacterium 
prausnitzii, Dorea formicigenerans and Collinsella aerofaciens. Similarly, in the present 
study the reduction in colonic iron was associated with an increase in these species. Lee et 
al., (2017) demonstrate a decrease in the relative abundance of Faecalibacterium 
prausnitzii in response to iron addition through oral administration of iron sulphate [349]. 
Our study supports this finding and illustrates an inverse correlation between iron and 
  Chapter 8 
 
154 
 
Faecalibacterium prausnitzii whereby its relative abundance was observed to increase in 
patients who presented with higher levels of iron removal post-phlebotomy. 
Faecalibacterium prausnitzii is one of the main inhabitants of the human gut microbiota 
and has been reported to be one of the major butyrate producing species in the human 
colon. Literature so far shows that this species of bacteria behaves as a bioindicator of 
human health as in the context of disease, such as inflammatory bowel disease, this species 
decreases [350, 351].  
An interesting observation was that of the genus Collinsella. We saw a significant increase 
in the relative abundance of Collinsella in patients who had higher levels of iron removed 
through phlebotomy. Collinsella is the dominant genus of the group Coriobacteriales and 
is frequently detected in the human colonic microbiota [301-303]. Moreover, Collinsella 
have been illustrated to ferment a vast range of different carbohydrates, such as glycogen, 
resulting in the production of metabolites such as butyrate and acetate. This may be 
reflected in the metabolite analysis performed in this study where concentrations of both 
these SCFAs, although not statistically significant, are observed to increase in patients who 
had higher levels of iron removed through phlebotomy. From these data, we can speculate 
that the increase observed in acetate and butyrate could result from the rise in relative 
abundance of Collinsella.  
8.6 Conclusions 
Results from this study highlight the importance of iron not only systemically but also in 
the gut microbiota. Overall, a general shift towards a healthier systemic and metabolic 
profile was observed within HH patients who had more iron removed through phlebotomy. 
This was accompanied with an increase in beneficial bacterial species in the large intestine 
as well as subtle changes in metabolomic profiles, suggesting the removal of iron led to an 
increase in potentially beneficial bacteria. Tightly regulating the availability of iron in 
individuals presenting with HH may represent a novel therapy and merits further 
investigation. 
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9.1 Summary of findings 
The overall aim of the research presented in this thesis was to investigate the effects of iron 
on the function and composition of the human gut microbiota, using in vitro colonic batch 
fermentation models and a human intervention study. It has already been reported that the 
presence or absence of iron is able to alter the composition of the human gut microbiota. 
The work presented in this thesis aimed to utilise both chemical and dietary iron chelators 
to the impact of iron on the  composition of the bacterial community present in the human 
colon either at the level of individual bacteria or in a more complex gut microbial 
community level. These results formed the basis of a human study investigating what 
effects an encapsulated dietary iron chelator (phytin)  may produce in vivo, with a focus on 
changes to the composition of the gut microbiota. 
9.1.1 Bacterial growth under iron-supplemented conditions 
The growth of pure bacterial cultures has been reported to be affected by different levels of 
iron. The data presented in chapter 3 indicated that when supplemented with iron, in the 
form of FeSO4, the growth of pure cultures of E. coli and S. Typhimurium significantly 
increased in comparison to the non-supplemented control. These findings were further 
investigated through the addition of iron to the same bacteria grown under iron-chelated 
conditions. Results indicated that the growth of E. coli and S. Typhimurium were 
significantly impaired when cultured in iron-chelated media, but growth resumed once an 
external source of iron was added to the culture. 
9.1.2 Bacterial growth under iron-chelated conditions 
The removal of iron via iron chelators from the media in which bacteria are cultured 
resulted in the reduction of bacterial growth, including those that have the potential to 
display pathogenic phenotypes (chapter 4). These bacterial species include E. coli, S. 
Typhimurium, C. perfringens and B.thetaiotaomicron. Some chelators inhibited the growth 
of the bacteria to a greater extent, however, in general, the pattern remained the same. 
Beneficial species such as B. longum and L. rhamnosus were unaffected by all the iron 
chelators tested (BPDS, 22D, Lf, TA and PA), except for Manucol LD, a form of sodium 
alginate. This was speculated to be down to the toxic effects of sodium, as has been 
previously reported [271]. The removal of iron has been reported to decrease the growth of 
some of these bacteria in previous studies [248] and our results show that for all the 
bacterial species examined, iron concentrations were observed to decrease in the presence 
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of the iron chelator tested. This indicates that the reduction in growth is potentially related 
to the lower levels of iron. 
9.1.3 Effect of iron on the human gut microbiota composition examined in 
vitro 
The latter part of chapter 3 determined the effect of iron supplementation on a mixed 
community of bacteria, derived from the faecal microbiota of healthy volunteers through in 
vitro colonic fermentations. Previous studies have examined the effect of iron fortification 
on the human gut microbiota, but varying results were observed [148, 229, 230], as also 
observed in our in vitro studies. The viable counts of common bacterial families, 
Enterobacteriaceae and Bifidobacteriaceae, differed between individual donors, 
suggesting that the effect of iron on gut microbial composition is highly variable. 
The effects of iron chelation on the composition of the human gut microbiota, however, are 
slightly more pronounced. In vitro colonic fermentations (chapter 5) showed a decrease in 
viable counts of three bacterial groups, when the microbiota belonging to three healthy 
donors were cultured in the presence of BPDS a chemical chelator. These three groups 
were total anaerobes, lactobacilli and Enterobacteriaceae. Compositional analysis further 
illustrated a decrease in the relative abundance of Escherichia in two out of three donors, 
presumably reflecting the reduction of viable counts of Enterobacteriaceae, to which 
Escherichia belongs. Similarly, a reduction in the counts of the beneficial bifidobacteria in 
the faecal microbiota of all the donors was observed, and this was further confirmed with 
the decrease of Bifidobacterium relative abundance estimated via 16S-metataxonomic 
analysis.   
The culturing of human faecal microbiota in the presence of phytin also led to similar 
results (chapter 5). The biggest difference observed between phytin and BPDS was the 
increase in relative abundance of Bifidobacterium and viable counts of bifidobacteria in the 
presence of phytin. The positive impact of phytin on the beneficial genus bifidobacteria led 
to the design of a human trial, outlined in chapter 7, in which encapsulated phytin was 
consumed by participants. 
9.1.4 Influence of iron chelation on SCFA production 
Metabolite analysis via 1H NMR spectroscopy indicated a variation in the concentrations 
of SCFAs produced by the cultured human faecal microbiota (chapter 5). Although 
correlations of metabolite levels with the relative abundance of bacterial taxa did not 
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provide a causal relationship, it may still provide some indications as to which taxa are 
responsible for the observed differences. When cultured with BPDS, a decrease was 
observed for three metabolites, acetate, butyrate and propionate, which are usually 
associated with positive effects on human health, [142, 213, 217, 290, 352, 353], 
suggesting low iron levels could potentially have a negative effect on the host. Decreases 
in relative abundances of Bifidobacterium, Ruminococcus and Bacteroides could 
potentially be linked with the decreases in acetate, butyrate and propionate concentrations, 
respectively, since members of these genera have been associated with the production of 
these SCFAs. 
Propionate and formate levels were increased in the presence of phytin. The increase in 
formate concentrations could be linked to the rise seen in the relative abundance for 
Collinsella, a genus well-recognised to ferment glycogen to produce formate [285].  
9.1.5 Effects of iron on the human gut microbiota in vivo 
Dynamic dissolution assays were used for investigations into the optimal conditions for a 
colonic delivery system. Capsules were sprayed with a coating suspension with a dual-
action mechanism whereby the release of the content within the capsule was triggered by 
the colonic luminal pH and colonic starch-fermenting properties of the gut microbiota. To 
find the optimal coating thickness of the suspension, static and dynamic dissolution assays 
were implemented to record time of capsule content release under physiological 
conditions. Capsules with the optimal thickness were then prepared for use in a human 
dietary intervention trial investigating the effect of phytin on the gut microbiota.  
Chapter 7 presented a double-blinded, randomised, 2-phase crossover, human dietary 
intervention study, in which the effects of encapsulated phytin on the gut microbiota of 14 
participants was investigated.  
Serum ferritin was measured as a marker of capsule release and the results from the human 
trial indicated stable serum ferritin levels in all participants throughout the entire duration 
of the trial. This suggests that phytin was not released before it reached the colon and that 
the Phloral® coating kept the capsule intact and therefore withstood the gastrointestinal 
conditions.  
Results from the human trial also indicated stable C-reactive protein levels in all 
participants, and therefore confirming the absence of systemic inflammation. 
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When aliquoting faecal samples for analysis, white, powdered clumps were present in the 
faeces of those consuming encapsulated phytin. Further analysis revealed that the outer 
shell of the capsule had dissolved, leaving only the content in the faeces. This observation 
indicated that phytin was not dispersed in the colonic lumen and was therefore unable to 
implement its iron-chelating properties in the colonic environment. Therefore, it was not 
possible to make any conclusions regarding the iron chelating properties of phytin. Due to 
this, as expected no treatment effect was observed and results were comparable to the 
control, when examining water-soluble iron concentrations, faecal metabolite profiles and 
bacterial composition. 
Although any conclusions on the iron chelating abilities of phytin cannot be made due to 
unsuccessful dispersion, community analysis of the faecal microbiota showed that samples 
tended to cluster based on the participant, and that there was variation in the abundances of 
bacteria within the communities over time. 
It was also confirmed that acetate levels were present in much higher concentrations in 
comparison to propionate and butyrate regardless of study arm, suggesting the presence of 
numerous acetate-producing bacterial species. Higher levels of acetate in comparison to 
other SCFAs have previously been reported in other studies, where one reports that acetate, 
propionate and butyrate are produced in approximate molar ratios of 60:20:20 [354, 355]. 
9.2 Limitations of the research 
The bacterial species investigated in chapters 3 and 4 for the impact of changes in iron 
concentration on growth could have been further investigated by the measurement of 
potential siderophore activity. A well-defined protocol has already been established, 
known as the chrome azurol sulphonate assay. This would have helped to understand the 
underlying mechanism of growth behaviour in different bacterial species when cultured 
under various concentrations of iron. 
A limitation of the in vitro studies using human faecal microbiota to assess the effect of 
iron chelation on microbial composition was the small number of donors used. This made 
it difficult to draw any conclusions due to the high level of inter-individual heterogeneity 
in the faecal microbiota.  
One limitation in the iron chelation experiments carried out in chapter 5 was the lack of 
isolation of bacterial species enumerated from the in vitro batch fermentation model. 
Although the in vitro batch fermentation models provided good representation of bacterial 
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groups affected by the removal of iron, through viable counts data, isolation of bacterial 
species would have given information on the species that were  most affected. Further 
analysis could then have been carried on bacterial species that were more sensitive to iron 
bioavailability and those that were more robust. Subsequently, as mentioned in the 
paragraph above, these isolates could have been further targeted for siderophore activity to 
confirm that the effects observed were linked to iron bioavailability.  
The sequencing data from the human trial did not identify the presence of bacteria 
belonging to the Enterobacteriaceae family in proportions higher than 4.8%. This is 
surprising since Enterobacteriaceae is a large family of Gram-negative bacteria, with 
many of its members being present in the core gut microbiota in humans. Some of these 
members include Salmonella, Escherichia, Klebsiella and Shigella. Microbial profiling 
data detected levels of Enterobacteriaceae in all donors tested and therefore it is surprising 
that only low levels of identification of this family was made from the human faecal 
microbiota of the human trial participants.  
As mentioned earlier, the lack of dispersion of phytin in the faecal material meant it was 
not possible to make any conclusions. However, the next section suggests ways in which 
this trial could have been carried out successfully in relation to phytin dispersion. 
Regardless of the lack of phytin dispersion in the human trial, one limitation of this trial 
was the diet consumed by participants. It was originally thought to impose a diet restriction 
on participants whereby phytin-rich foods would be restricted, however, it was later 
decided that this restriction could negatively affect the trial and therefore participants were 
asked to maintain their habitual diet. Not taking habitual diet into consideration when 
recruiting participants and the lack of dietary control during the study were weaknesses of 
the study. 
9.3 Future research 
The data presented in this thesis identified many different groups of bacteria that were 
altered in their growth patterns when cultured in the presence of an iron chelator in in vitro 
batch fermentation studies. However, it is unclear which bacterial species are mainly 
affected by the change in iron bioavailability. For the purpose of future research, specific 
species and strains of bacteria could be isolated from these in vitro colonic batch 
fermentation models, and using molecular methods, investigated further for the presence of 
iron regulatory genes. The identification of these genes would help elucidate further the 
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impact of iron bioavailability on the cellular mechanisms of various bacterial species. 
Furthermore, this could be followed by gene knockout experiments to identify which 
gene(s) may be responsible for the change in growth of the bacterial isolates.  
As mentioned in the previous section, siderophore activity of bacterial species would add 
invaluable information on the interrelationship between bacterial activity and iron 
bioavailability. The identification of genes involving siderophore biosynthesis is predictive 
of high or low virulence activity and therefore targeting these genes through knockout 
experiments could help observe if bacterial virulence is attenuated when these specific 
genes are removed.  Once identified, competition assays could further categorise which 
bacterial isolates have stronger iron-scavenging properties when cultured in the presence of 
host siderophore proteins.  
For pure culture growth assays using iron chelators, a range of phylogenetically diverse 
human gut isolates could be used, which would be associated with the colonic lumen or 
mucosa. This could potentially help to elucidate whether the ability to scavenge iron by 
bacteria is widespread amongst the human gut microbiota or restricted to a single 
phylogenetic group, as presently, many of the colonic bacteria have been shown to utilise 
iron in one way or the other for growth purposes. 
A three-stage continuous culture system could be used to culture human faecal microbiota. 
The data presented in chapters 4 and 5 used an in vitro model which is only suitable for 
short-term and experiments usually last a maximum of 24 h before nutrients are exhausted. 
A continuous fermentation model would allow for the constant replenishment of nutrients, 
a longer duration of fermentation and therefore be more physiologically representative of 
the human colon. This model could also be used to further investigate and identify 
prebiotics, which encourage the growth of probiotic bacteria, such as lactobacilli and 
Bifidobacterium strains, in iron-chelated media. Should probiotic bacteria bloom upon the 
addition of prebiotics, the potential administration of a prebiotic and an iron chelator could 
be tested in human intervention studies with the possible aim of commercialisation.  
The white, powdered clumps that were present in the faeces of those consuming 
encapsulated phytin indicated lack of phytin dispersion and therefore suggesting that a 
better form of phytic acid should be used in future studies. A liquid form of phytic acid 
could be encapsulated to allow for better mixing with the faecal material. 
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If phytin dispersion was indeed successful, many other lines of investigations could have 
then been carried out. For example, high performance liquid chromatography (HPLC) 
analysis of phytin could be used to determine the form of phytin that is active in the colon. 
Phytic acid can be present in lower inositol forms than inositol hexakisphosphate. The 
lower forms (tetra-, tri-, di-, and mono) do not have iron chelating abilities. This would 
then confirm any observations seen. 
Another potential line of research involves the identification of any phytase activity that 
could take place in the gut microbiota of participants when consuming encapsulated 
phytin. The presence of phytase activity would indicate the breakdown of phytin and 
therefore the release of iron from the phytin-iron complex. 
In line with the previous suggestion, identification of bacterial species which are known to 
possess phytate-degrading properties could also prove useful. Species belonging to 
Bifidobacterium and Lactobacillus have been reported to have the ability to degrade phytic 
acid. To confirm this, specific species of bacteria could be isolated from the stool samples 
of participants from both treatment arms and examined for genes related to phytase 
activity.  
9.4 Conclusion 
In conclusion, the research presented in this thesis provides evidence that the removal of 
iron through iron chelators could reduce potentially pathogenic bacteria and increase those 
that are deemed beneficial, such as Bifidobacterium, which have been reported to represent 
a more healthy gut microbiota [140]. The use of an in vitro model, where phylogenetic and 
metabolite analysis can be extrapolated, provided interesting findings in the importance of 
iron on the behaviours of mixed bacterial communities, especially when compared to pure 
cultures of bacteria. Phytin was shown to clump in the faeces of the human trial 
participants and was therefore unable to bind iron. Due to this, it was not possible to make 
any conclusions on the iron chelating abilities of phytin. The human intervention trial, 
therefore, highlighted that further research is required in implementing a better form of 
phytin to achieve successful dispersion in the colon. 
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Background  
During recent years it has become apparent that the gastrointestinal tract (GIT) plays 
a crucial role in the metabolism of dietary compounds. This is due, in part, to the 
complex microbial ecosystem in the human intestine and its major role in human 
health, largely related to its metabolic activity. The human colon contains 
approximately 200 g of living microbial cells, at a concentration of roughly 1011-1012 
cells/mL [1]. However, the large number of bacteria present in the colon is not a 
direct reflection of microbial diversity, as >90% of the intestinal microbiome belongs 
to members of the Firmicutes and Bacteroidetes phyla [2]. In spite of this, it is 
estimated that the microbial gene catalogues existing in the colon consists of 
approximately 3 million genes, which is approximately 100 times greater than those 
encoded by the host genome [3].  
The bacterial genes present in the gut are highly diverse, in particular the genes that 
code for metabolic enzymes [4]. This is largely due to the range of non- or 
partlydigested food components that reach the colon, including carbohydrates, 
proteins and phytochemicals. Undigested carbohydrates undergo bacterial 
fermentation in the colon, generating bacterial products, such as short-chain fatty 
acids. This bacterial community relies on the continuous provision of micronutrients 
for metabolism and growth [5]. As a result, there is constant competition for essential 
micronutrients, which is reflected in their requirements and uptake mechanisms [6]. 
One of these micronutrients, iron, is highly abundant in colonic contents, and is an 
essential nutrient for virtually all organisms, including most bacterial species [5]. Iron 
is a component of haemoglobin, and is also necessary for cellular growth, 
development, normal functioning, and synthesis of some hormones and connective 
tissue [7]. Dietary iron has two forms: haem and non-haem [8]. Meat, seafood, and 
poultry contain both forms of iron, whereas plants and iron-fortified foods contain 
only non-haem iron. On average, 15 mg of iron is consumed daily in the diet, 
however, iron absorption is strictly regulated because there is no mechanism for 
excreting iron that is surplus to requirements. The quantity that is required to 
maintain iron balance is absorbed in the small intestine, and this is generally 
approximately 15% of the total dietary intake [9]. Due to the low absorption, relatively 
large quantities of iron reach the colonic lumen, and this is illustrated by the relatively 
high concentrations of iron that is recovered in the faeces of British adults on a 
standard Western diet [5, 10].   
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However, the iron supply is typically very limited to the micro-organisms as a result of 
the host iron-withholding mechanisms that can help stop pathogenic organisms from 
growing [11]. Therefore, despite high quantities of dietary iron in the gut lumen, many 
micro-organisms of the gut have developed mechanisms to acquire iron, even when 
available iron is sparse. A well-known example of these mechanisms is the 
production of bacterial siderophores, molecules which are able to scavenge both 
ferrous (Fe2+) and ferric (Fe3+) forms of iron, even in iron-limited environments. On 
average, bacteria need 10-7 – 10-5 M iron for optimal growth [5]. E. coli, a potentially 
pathogenic species of bacteria belonging to the Enterobacteriaceae family, for 
example can take up both forms of iron. Pathogenic bacteria use iron to promote 
growth and, conversely, these bacteria decrease in numbers when iron is limited [12, 
13]. In vivo knockout studies using mice have shown that specific iron uptake 
mechanisms are essential in the survival and virulence of some bacterial species, 
such as E. coli [14, 15]. Unlike most bacteria, members of the Bifidobacteriaceae 
and Lactobacilliaceae families (two families that are seen as beneficial to the host) 
have a very limited need for iron, if any at all [16]. Lactobacilli do not produce 
siderophores to sequester iron, and their growth is similar in media with and without 
iron. It is known that Lactobacillus does not require iron for growth as there is lack of 
haem-containing enzymes but can substitute other metals for iron, such as cobalt 
and manganese [17, 18], which may give these bacteria a competitive advantage in 
low-iron conditions. Bifidobacterium breve, a crucial Bifidobacterium species in 
breast-fed infants, can acquire luminal iron with the help of a divalent metal 
permease, however, many of the Bifidobacterium species do not make siderophores 
or other forms of iron-carriers.   
The host has developed numerous mechanisms to curb the acquisition of iron by 
pathogenic species of bacteria, such as the sequestering of iron by lipocalin-2, a 
protein belonging to the innate immune system. Dietary components also have a 
large influence on iron availability. Organic acids, such as citrate, have been shown 
to form a weak soluble chelate with iron which potentially prevents the precipitation 
of iron, keeping it in its soluble form, once it has left the acidic conditions of the 
stomach and entered the duodenum at a higher pH [19]. Ascorbic acid, (Vitamin C), 
is able to chelate iron and also initiate the reduction of iron, and is a well-known 
enhancer of iron absorption [20, 21].   
Together with dietary components that increase the availability of iron, there are 
several compounds which decrease iron availability. Phytic acid (Figure. 1), also 
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known as inositol hexakisphosphate (IP6) or phytate (when in salt form), is the 
principal storage form of phosphorus in many plants, such as legumes, seeds, 
nuts and cereals [22]. Phytic acid content varies greatly among plants and is due 
to different factors, such as the type of seed, climate, and environmental 
conditions.  
  
Figure 1. Structure of phytic acid  
  
Studies in humans report that between 37-66% of dietary phytate is degraded during 
digestion in the stomach and small intestine when the diet is rich in plant food 
phytases [23-25], a type of phosphatase enzyme that catalyses the hydrolysis of 
phytic acid.   
Beneficial properties of phytic acid have been proposed, including antioxidant [26] 
and anticancer [27, 28] activities, but phytate is generally regarded as an 
antinutrient. In vitro and in vivo studies have demonstrated that phytic acid forms 
insoluble complexes with several divalent minerals, thereby preventing absorption, 
and can potentially result in zinc and iron deficiencies [29-32]. Once these insoluble 
complexes are formed, the mineral cannot be absorbed in the small intestine and 
therefore pass into the colon. Although phytic acid also binds the metals that the 
beneficial bacteria use, at pH 6-7 (representative of the colon), phytic acid 
preferentially binds iron, suggesting a protective role of phytic acid in preventing iron 
acquisition by potentially pathogenic bacteria.  
 
Several published studies have found that the degradation of phytate varies between 
individuals and is largely based on the type of diet consumed. As most plant foods 
such as legumes, cereals and whole grain products, are processed or heat-treated 
during food production and the preparation of meals, many of the phytases present 
in these foods are likely to be inactivated. In individuals whose diets consist of high 
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amounts of wheat or rye bran i.e. foods that contain native phytases, strong phytate 
hydrolysis occurs in the stomach, with the remaining small portion of non-degraded 
phytate being hydrolysed in the colon [33].   
Certain gut micro-organisms (Bifidobacteriaceae and coliforms), have been shown to 
be able to break down phytates. One study showed that the highest phytate 
degrading activity belonged to Lactobacillus reuteri, Lactobacillus salivarius and 
Bifidobacterium dentium [34]. Notably, phytate-bound iron found in the colon is 
present in the insoluble form making it difficult to degrade [35, 36] suggesting a 
potential role for phytate in the withholding of iron from potentially pathogenic 
bacteria.   
As well as playing a major role in human nutrition, our gut bacteria also have a 
profound influence on human physiology and immunology. It is believed that 
changes in the composition of our gut bacteria, known as gut dysbiosis, may be 
associated with some diseases, such as inflammatory bowel disease and colon 
cancer, as well as metabolic disorders such as obesity [37, 38]. Currently, it is 
believed that preserving the appropriate compositional balance of the gut 
microbiome may help to maintain the health of the host. Consequently, there has 
been an increase in research relating to probiotic bacteria. The World Health  
Organization defines probiotics as “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host”, the most common of which 
are Lactobacillus and Bifidobacterium strains [39]. A link between iron and the gut 
microbiome has been observed. Several studies have investigated the effects of 
iron-fortified foods on the infant microbiome, and have reported increased relative 
abundances of potentially pathogenic bacterial taxa associated with higher 
concentrations of iron [40-42]. Other studies have examined the role of iron in the gut 
microbiome in individuals with iron disorders and have speculated that there is a link 
between high iron levels and increased severity of disease.  
Anaemia (iron deficiency) is a severe problem in lesser developed countries, such as 
Africa, particularly amongst children. Alongside anaemia, many children in Africa 
suffer from a disrupted gut microbiome due to lack of clean water and food. This 
unfortunately results in gut microbiomes that tend to skew towards a more 
pathogenic profile, such as high abundances of Enterobacteriaceae, and less of the 
beneficial bacteria, such as Bifidobacterium. In an attempt to resolve or significantly 
diminish the issues related to anaemia, many children are given iron supplements, in 
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the form of iron-fortified foods. These are foods that contain a bioavailable form of 
iron to allow for better iron absorption in the small intestine. However, as discussed 
earlier on, absorption of iron itself is relatively poor. Therefore, providing these 
children with more iron is in fact counter-productive as more iron is now available for 
the already pathogenic-heavy microbiome of these children. This, in turn, 
exacerbates the severity of their already compromised guts [42-44]. This scenario is 
a good example of where the use of iron chelators in the colon may help alleviate gut 
microbiome dysbiosis.   
However, despite numerous studies measuring the effects of iron supplementation, 
only a limited number of studies have investigated the effects of iron chelation on the 
gut microbiome of healthy individuals. Our in vitro colonic fermentation experiments  
(data not published, however, data has been included in a manuscript for 
resubmission in 1 week) have indicated that limiting the availability of iron to gut 
bacteria by means of iron-chelating compounds found in foods (e.g. phytin; a calcium 
magnesium salt of phytic acid, and dominant form of phytate in plants). The relative 
abundance of potentially pathogenic bacterial taxa, such as Escherichia and 
Bacteroides, decreases, whilst simultaneously increasing the abundance of 
beneficial bacterial taxa, such as Bifidobacterium (Figure 2, 3 individual experiments 
with relative abundances defined in the adjacent bar chart).   
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Figure 2. The effect of phytin (Phy) on Enterobacteriaceae and Bifidobacterium.  
‘X’ denotes control, ‘Phy’ denotes phytin, ‘T0/8/24’ denotes time in hours. This 
diagram illustrates the effects of phytin (an iron-chelator) on the relative abundance 
of  
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Enterobacteriaceae (pathogenic bacteria) and Bifidobacterium (beneficial bacteria). In 
the presence of phytin, the relative abundance of Enterobacteriaceae decrease whilst 
that of Bifidobacterium increases, suggesting the importance of iron for pathogenic 
bacteria  
Hypothesis  
Consumption of encapsulated phytin will cause a change in the composition of the 
colonic gut microbiome, and specifically it will decrease the proportions of potentially 
harmful Enterobacteriaceae, compared to the faecal microbiome after consuming the 
placebo capsule as well as compared to the baseline faecal samples of individuals.  
  
Objectives:  
  
Primary  
To investigate whether consuming phytin for two weeks will cause a proportional 
decrease in human gut Enterobacteriaceae compared to the number of  
Enterobacteriaceae present in the participants’ gut microbiome after consuming the 
control capsule.  
  
Secondary  
• To investigate whether the delivery of phytin to the colon for a period of two 
weeks will be associated with an increase in human gut bifidobacteriaceae 
through the chelation of iron, compared to the number of 
bifidobacteriaceae present in the participants' baseline gut microbiota, as 
determined by faecal bacteria phylogenic analysis  
• To ascertain whether consuming phytin modulates the gut microbial 
community as a whole, as compared to the consumption of a placebo 
capsule  
• To determine whether the consumption of phytin causes a change in short 
chain fatty acid levels in the faeces, via changes in the gut microbiome 
function  
• To determine whether the consumption of phytin causes a change in the 
available iron present in the faeces  
• To ascertain the extent of phytin degradation that takes place in the colon 
based on the known concentration of phytin administered via the capsule  
• To determine levels of calprotectin as a marker of gut inflammation  
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• To determine levels of C-Reactive Protein (CRP) as a marker of systemic 
inflammation2  
• To measure serum ferritin levels as a marker of the time of capsule release  
  
Study design  
The study will be led by Professor Arjan Narbad (QIB Research Leader). All aspects 
of the study will be managed by Miss Bhavika Parmanand (QIB PhD student) with 
assistance from Dr Lee Kellingray (QIB scientist) and Professor Susan 
FairweatherTait (UEA Professor). A delegation log will be used for recording the 
roles and responsibilities of the local research team and the authorisation of the 
Principal Investigator. The study will be carried out in collaboration with the Clinical 
Research Facility (CRF) at the Quadram Institute (QI). The QI CRF is an NHS-
governed facility and all clinical procedures for this study will be carried out by the QI 
CRF team following NNUH standard operating procedures. Clinical assessment and 
procedures will be performed by two members of the CRF team when research 
participants are attending the CRF. This will include a registered nurse and another 
member of staff who is trained in NNUH emergency procedures. When no clinical 
assessment or interventions are to be performed (for example in the case of an 
appointment for consent), two members of the CRF team will also be present. This 
will include a Healthcare professional who is trained n NNUH emergency procedures 
and a second designated member of staff to provide support.  
  
Participants (n=14) will be recruited into a randomised, double-blind, two-phase 
crossover dietary intervention. The study team will recruit male and female aged 
between 18 and 50 years, as this was the number deemed sufficient to observe 
changes in Enterobacteriaceae and Bifidobacteriaceae within the gut microbiome 
based upon power calculations (detailed on pages 34-35 of this protocol. An age 
range of 18-50 was decided upon as it is believed that the gut microbiota shows a 
stable form throughout the adulthood (classified as 18-50, which include young and 
middle-aged adults), but it accumulates changes during the aging process [45, 46].  
  
                                            
2 We will be measuring serum ferritin to test whether the phytin affects iron status through reducing 
iron absorption. In order to do this, it’s important to rule out inflammation as this will increase 
ferritin levels and make it impossible to interpret whether phytin has affected body iron status. 
Without it we cannot test for an effect of phytin on iron absorption. CRP has to be measured at the 
same time as serum ferritin as the latter will increase rapidly in response to infection or 
inflammation, so baseline values alone will not be informative.  
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Recruited participants (n=14) will be asked to maintain their habitual diet throughout 
the length of the study. Following randomisation (see ‘Randomisation process’), 7 
participants (dependent on randomisation results) will consume 2 capsules, each 
containing phytin (test capsule), 3 times a day with a meal for a period of 2 weeks. 
The remaining 7 participants will consume 2 placebo capsules, each containing 
microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks. Phase 1 
will be followed by a 2-week washout period, where all participants will cease 
capsule consumption. After the washout period, Phase 2 will begin where 
participants that were initially consuming the test capsule will instead consume the 
placebo capsule, and vice-versa. Again, for both groups, 2 capsules will be taken 3 
times a day with a meal for a total period of 2 weeks. A summarised diagram of this 
study design can be found in Figure 3.  
  
 
Figure 3. Summary of study design  
  
The participants will be asked to provide blood and faecal samples, and complete a 
capsule checklist, stool charts (noting the frequency and consistency of their bowel 
movements) and food frequency questionnaires at various stages throughout the 
intervention. A flowchart summarising this approach can be found below (Figure 4). 
Participants who do not have a BMI between 19.5 (underweight) and 30 (obese) 
kg/m2 will be excluded on the grounds that their gut microbiome may be affected, as 
studies have shown that the gut microbiome of individuals with a BMI between 18.5 
and 30 kg/m2 are significantly different to obese or underweight individuals [37, 47].  
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Figure 4: Flow diagram of EPoM study  
   Pre-study talk (Visit 1, QI CRF, ~1 hr)  
- Member of study team will discuss Participant Information sheet and answer any questions  
- Potential participants supplied with container for urinalysis, and a copy of Bristol Stool Chart -
 Minimum 72 hr consideration period, participant to contact study team if interested  
Eligibility screening (Visit 2, QI CRF, ~1.5 hr)  
- Participant to sign 2 consent forms (study participation and sample storage), and a medical declaration form -
 Copies of each given to participant  
- Screening questionnaire completed with participant by QI CRF Research Nurse  
- Measurements for pulse, blood pressure, height, weight and BMI taken, Multistix® urine dipstick test performed  
- Blood test for serum ferritin, HbA1c, full blood count and CRP  
Faecal sample collection kit pick-up (Visit 3, QI CRF, ~20 min)  
- If successful at eligibility screening, participant will be asked to collect a faecal sample collection kit  
Faecal sample drop-off (Visit 4, QI CRF, ~10 min)  
- Participant to drop off faecal sample in kit provided during Visit 3; date and time arranged for start of study   
Phase 1 (Visit 5, QI CRF, ~1 hr) Days 1-14  
- If participant has not yet provided a faecal sample, opportunity will be given here to do so  
- Confirm participant is happy to proceed with the study and assessment day questionnaire filled  
- QI CRF to take 15 mL blood sample to assess CRP and serum ferritin  
- 2x capsules to be consumed 3 times a day with a meal for a period of 14 days  
- First 2 capsules (either study arm AB or BA) must be consumed at the QI CRF (food provided)  
- Participant will be provided with the rest of the capsules required for Phase 1 (bottle will include extra capsules)  
- Participant will be provided with new faecal collection kit, along with a Bristol Stool Chart, food frequency 
questionnaire and capsule checklist  
Mid-Phase 1 faecal sample drop-off (Visit 6, QI CRF, ~10 min) Day 7  
- Participant to drop off faecal sample in kit provided during Visit 5, new faecal collection kit provided  
  
End of Phase 1 (Visit 7, QI CRF, ~30 min) Day 14  
- Participant to drop off faecal sample in kit provided during Visit 6  
- Blood sample taken by QI CRF Research Nurse (bloods used for iron and CRP measurements)  
- Participants to return the following: (i) stool chart; (ii) food frequency questionnaire; (iii) capsule checklist and (iv) 
capsule bottle, including any capsules that have not been consumed  
- New faecal collection kit provided  
Washout Phase (Days 15-28)  
- Normal diet continued with no capsule consumption  
- Stool sample to be provided at end of this phase, delivered when the participant next visits the QI CRF   
Phase 2 (Visit 8, QI CRF, ~45 min) Days 29-42  
- Participant to provide faecal sample in kit provided during Visit 7, QI CRF Nurse to take blood sample (iron and CRP) 
- Refer to Phase 1 for remaining details  
- Exceptions: (i) Alternative capsules to Phase 1 provided  
Mid-Phase 2 faecal sample drop-off (Visit 9, QI CRF, ~10 min) Day 35  
- Same as ‘Mid-Phase 1 faecal sample drop-off’  
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End of Phase 2 (Visit 10, QI CRF, ~30 min) Day 42  
- Participant to drop off faecal sample in kit provided during Visit 9, blood sample taken by QI CRF Research Nurse 
(bloods used for iron and CRP measurements)  
- Participants to return the following: (i) stool chart; (ii) food frequency questionnaire; (iii) capsule checklist and (iv) 
16 capsule bottle, including any capsules that have not been consumedIRAS ID 251932    
- End of study  
Recruitment strategy  
The study population will consist of men and women between the ages of 18 and 50 
who meet the study inclusion criteria, and recruitment will continue until 14 
participants complete the study.   
  
The QIB Volunteer Database will be accessed by the QIB Volunteer Database 
Manager, Wendy Hollands, and it is anticipated that this will be the prime source of 
participant recruitment for the study. Apparently healthy potential participants from 
the QIB Volunteer database, who meet the basic inclusion criteria, will be sent a 
letter of invitation (Annex 1) to participate in the study. This will be supported by the 
Participant Information Sheet (PIS, Annex 2) and a response slip, with a pre-paid 
envelope included for returning the slip if they are interested and wish for further 
information. The QIB Volunteer database contains names and contact details of 
approximately 1271 people above the age of 18 years who have registered an 
interest for participating in human studies at QIB (The QIB Volunteer Database 
complies with the new EU General Data Protection Regulation (GPDR), which came 
into force in the UK on 25 May 2018, and the UK Data Protection Act (DPA) 2018). 
Identification of potential participants will be carried out by the QIB database 
manager (Wendy Hollands), with initial contact with potential participants from the 
database, including the posting of the invitation letter and PIS, carried out solely by 
Wendy Hollands. The available numbers for recruitment on the database are subject 
to variation as a result of the recruitment of participants by other studies.  
  
Along with using the database as a source of recruitment, advertisements (Annex 3a  
& 3b) will be placed around the Norwich Research Park (University of East Anglia 
(UEA), John Innes Centre (JIC), Earlham Institute (EI) and Quadram Institute (QI)) 
and other appropriate locations for example, supermarkets, social clubs, church 
newsletters, golf and other sporting clubs, gymnasiums and leisure facilities within 
the local area (a 40-mile radius of QI). The posters advertising this study may have 
tear off contact slips attached to the poster to facilitate participant recruitment. If 
required, we will also obtain radio (and television) coverage. Social networking sites 
like Facebook and Twitter may also be used to either display the ethically approved 
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advert for the study, or to direct potential participants to a QI website containing the 
ethically approved advertisement and contact details of members of the study team. 
A member of the study team will send interested responders a letter of invitation  
(Annex 4) and a copy of the PIS (Annex 2) with accompanying response slip and 
pre-paid envelope in which to return the completed response slip to the study 
manager, if interested in taking part in the study.  
  
If a potential participant registers an interest in taking part in the study, and 14 
participants are currently recruited onto the study, the potential participant may be 
asked if they would be happy to be placed on a standby list. Those placed on the 
standby list will neither be consented nor screened until they are recruited onto the 
study and will be notified if their participation is not required. Those on the standby 
list may ask to be removed from the list at any time.   
  
Study Talk at QI CRF – Visit 1  
Following an expression of interest, potential participants will be contacted by 
telephone or e-mail by a member of the study team (study manager or study 
scientist) to arrange an appointment for a study talk at the QI CRF. The QI CRF is an 
NHS facility located within the QI building. This talk will be carried out by a member 
of the study team and all aspects of the study will be discussed. The potential 
participants will be encouraged to ask questions at this point, prior to making any 
commitment. At the end of the talk all potential participants will be given a minimum 
of 72 h to consider whether they wish to participate in the study, and during this 
consideration period they will not be contacted. If, following this period of 
consideration, the participant still wishes to take part they will be asked to contact the 
investigator named on the PIS. If, however, potential participants have decided after 
the talk that they are keen to take part in the study and request to book their eligibility 
screening appointment, the screening appointment will be made for a minimum of 72 
h after the study talk. Before leaving the QI CRF, all potential participants will be 
supplied with a small clean container and a copy of the Bristol Stool Chart. Should 
the potential participant wish to take part in the study, the container will be used for a 
midstream urine sample from within 2 h of their eligibility screening appointment. The 
potential participant will be told that should they decide to take part in the study, the 
QI CRF Research Nurse will go through the Bristol Stool Chart with them at their 
eligibility screening appointment and ask them what their typical stool type is using 
the Bristol Stool Chart as a guide. Thereafter, the potential participants will be 
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advised that they will need to assess their typical stool type, referring to the Bristol 
Stool Chart, prior to their eligibility screening appointment. The potential participant 
will be informed that should they decide against taking part in the study, they may 
dispose of these in general waste. On booking an eligibility screening appointment, a 
member of the study team will post an appointment card (Annex 5) to the potential 
participant.   
  
Eligibility screening at QI CRF – Visit 2  
All those responding positively following this period of consideration will be invited to 
attend the QI CRF for an eligibility screening with a member of the QI CRF team, 
and the screening will be carried out following relevant QI CRF standard operating 
procedures. When using the QI CRF, if clinical assessments are to be performed, 
two members of the CRF team will be present when any study participants are 
attending. Participants will be reminded to bring a midstream sample of urine in the 
container supplied to them following their pre-study talk. Participants will need to 
collect their urine sample from within 2 h prior to the screening appointment as this is 
a required specification for the validity of the urine dipstick test (this will not be tested 
until after the consent forms for study participation and sample storage has been 
signed). Participants will also be reminded to bring with them details of any 
prescribed medication, herbal remedies or dietary supplements (i.e. name of 
medication, dose taken).   
  
On arrival at the QI CRF the participant will be taken into a confidential room where a 
member of the study team (study manager or study scientist) or the QI CRF 
Research Nurse will go through 2 consent forms, one for written informed consent 
for study participation, and another for the long-term storage of samples at the 
Norwich Biorepository (Annex 6 and Annex 7, respectively) with the participant and 
encourage any questions they may have at this stage. Participants will then be 
asked to sign both the consent forms outlined above. The participants will also be 
asked to sign a medical declaration form (Annex 8) agreeing to inform the study 
team of any medication they may have to take, illnesses suffered, or if they become 
pregnant during the study. A signed copy of both the consent forms and medical 
declaration form will be given to the participant to keep.   
Following consent, the QI CRF Research Nurse will perform a Multistix® urine 
dipstick test. The urine dipstick results will be known immediately. In the event of a 
flagged urinalysis indicating a re-screen is appropriate, the QI CRF Research Nurse 
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will speak to the participant regarding their results and they will be advised to visit 
their GP/practice nurse prior to returning for a re-screen. The re-screen will be 
postponed until results from the GP are known. If the urinalysis results are flagged 
on the second occasion the participant may be excluded depending on the tests 
flagged, and this decision will be made at the discretion of the QI medical advisor. If 
blood is flagged in the urine sample of female participants they will be asked if they 
are menstruating or have just finished menstruating, if they answer yes to either they 
will be asked to provide a second urine sample for testing 5 days after finishing 
menstruation. In the event of a flagged result on the second occasion, which 
indicates they may be re-screened, the QI CRF Research Nurse will speak to the 
participant and they will be advised to speak to their GP regarding their results prior 
to coming back to the QI CRF for a re-screen. Again, the re-screen will be postponed 
until results from the GP are known. All abnormal results will be referred to the QI 
medical advisor. In an event of flagged urinalysis result, the decision to exclude the 
participant from the study will be taken by the QI medical advisor.   
  
The QI CRF Research Nurse will then complete a screening questionnaire with the 
participant (Annex 9), measure and record blood pressure (BP), pulse, height (cm) 
and weight (kg) and calculate Body Mass Index (BMI, kg/m2). The screening 
questionnaire contains specific questions pertaining to stools, the QI CRF Research 
Nurse will explain the Bristol Stool Chart and should the participant indicate that their 
typical stool type is abnormal (type 1, 2, or 7), they may be referred to their GP and 
will be excluded from the study.  
  
A blood test (20 mL volume) will also be performed to confirm serum ferritin and  
HbA1c (this test will give an indication of the participant’s average glucose levels 
over a period of approximately 2-3 months). A full blood count and CRP (a marker of 
systemic inflammation) measurements will also be performed (bloods taken for 
eligibility screenings will be sent to NNUH for analysis).   
  
If the flagged urine and blood results indicate exclusion from the study is appropriate 
(refer to inclusion and exclusion criteria), the decision to exclude the participant from 
the study will be taken by the QI medical advisor and the participant will be advised 
to speak to their GP regarding their results. Copy of all the eligibility screening 
results (blood test, blood pressure, pulse, weight, BMI, and urinalysis results) will be 
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sent to the GP (Annex 10), and this will be supported with a letter to their GP 
detailing their clinical results (Annex 11).   
  
The GPs of those successfully recruited onto the study will be informed of their 
patient’s participation in the study by letter (Annex 12) along with a study description 
(Annex 13). It is expected that all participants who successfully pass the screening, 
and who wish to continue, will commence on the study within three months of their 
screening appointment otherwise a re-screen will be necessary.  
  
Note: Participants who do not commence the study within three months of a 
successful eligibility screening will need to be re-screened if they wish to partake in 
the trial.  
  
Randomisation Process – allocation of test or placebo group  
It is important that the groups are balanced in number because of possible order effect, 
and so given the small sample size, block randomization will be used to allocate 
participants to the two treatment arms, with 2 blocks of 4 participants and 3 blocks 
each of 2 participants making 14 participants in total. Blocks will be ordered at random. 
The allocation sequence will be generated using randomization.com, with the seed 
recorded for replicability.   
   
Blinding process  
This process will be carried out by a QIB scientist who is not part of the study team. 
Wendy Hollands (QIB FIH scientist) will be responsible for this process, and 
therefore ensures the trial remains blinded to the study participants, Chief  
Investigators and study scientists/advisors. Below is a summarised overview of how 
the blinding process will be implemented:  
  
Step 1: Test capsules will be filled with phytin and placed in a HDPE bottle labelled  
“Phytin”  
Step 2: Placebo capsules will be filled with MCC and placed in a HDPE bottle 
labelled “Placebo”  
Step 3: Each participant will receive either a batch of test or placebo capsules, 
therefore the capsules will be divided into 14 sets (as n=14 for this study). Again, 
HDPE bottles will be used (these bottles will NOT be labelled at this stage)  
Step 4: The 14x “Phytin” HDPE bottles will be placed in a box labelled “Phytin”  
Study protocol          EPoM                Version 4     21.Nov.18         IRAS ID 251932 
201  
Step 5: The 14x “Placebo” HDPE bottles will be placed in a box labelled “Placebo” 
Step 6: Both boxes will be given to Wendy Hollands and she will assign both boxes 
with the letters, “A” or “B”   
Step 7: Boxes “A” and “B” will be given back to Miss Bhavika Parmanand and each 
bottle subsequently labelled with the details below  
  
  EPoM study:  Treatment A/Treatment B  
Volunteer code:                        Date opened:  
 
   Two capsules to be taken three times a day, with a meal    
 
Store at room temperature  
Keep out of reach of children/pets    
For food trial use only Date of 
manufacture:  
     
Quadram Institute, James Watson Road, Norwich, NR4 6UQ. Tel:  
01603 255000  
  
Figure 5: Labelling for capsule containers  
  
Next, Miss Bhavika Parmanand will allocate the participants to either study arm “AB” 
or “BA”.   
  
Participants of the study, Chief Investigators and Study Scientists/Advisors will 
remain blind to this allocation throughout the trial as well as during analyses of 
samples taken from participants to ensure an unbiased approach is adopted to the 
evaluation of results. However, the code may be broken in the event of a medical 
emergency as deemed appropriate and necessary by the QI CRF Research Nurse. 
All personal information will be kept confidential and known only to the chief 
investigator, members of the study team, QI CRF Research Nurse and the 
participant’s GP.  
Note: to ensure uniformity of phytin dosage with capsules, as and when the capsules 
are being divided into individual HDPE pots, a subset of capsules will be removed 
and quantified for phytin concentration levels.   
  
Inclusion criteria  
• Men and women aged between 18 and 50  
• Non-smokers (e-cigarette/vape users are able to participate)  
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• Those with a body mass index (BMI) between 19.5 and 30 kg/m2 • Those that 
live within a 40-mile radius of Norwich  
  
Exclusion criteria  
You will not be able to take part if you(r):  
• results of our screening test indicate you are not suitable to take part in this 
study  
• are pregnant, have been pregnant in the last year or are lactating and/or 
breast feeding  
• are currently suffering from, or have ever suffered from, any diagnosed 
gastrointestinal disease, gastrointestinal disorders including regular diarrhoea 
and constipation (excluding hiatus hernia unless symptomatic), and/or have 
undergone gastrointestinal surgery, or the study intervention/procedure is 
contraindicated  
• have been diagnosed with any long-term medical condition that may affect the 
study outcome (e.g. cancer, diabetes, haemophilia, cardiovascular disease, 
glaucoma, anaemia). These will be assessed on an individual basis  
• have been diagnosed with any long-term medical condition requiring 
medication that may affect the study outcome  
• regularly taking over the counter medications for digestive/gastrointestinal 
conditions  
• are on long-term antibiotic therapy. You may be able to participate if 4 weeks 
has passed from the end of a course of antibiotics (this will be assessed on an 
individual basis)  
• regularly take laxatives (once a month or more)  
• take certain dietary supplements or herbal remedies and are unwilling to stop 
taking them for one month prior to and during study period. This will be 
assessed on an individual basis  
• take pre- or pro-biotic drinks &/or yoghurts on an occasional basis, unless 
willing to abstain for one month prior to and during the study period. (if you 
regularly take pre-&/or pro biotics (3+ times a week, and for more than one 
month) and will continue throughout the study then you will not be excluded) • 
are on or plan to start a diet programme that may affect the study outcome 
(e.g. 5:2 fasting diet) unless willing to abstain for 1 month prior to and during 
study period. This will be assessed on an individual basis  
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• recently returned to the UK following a period abroad, and who have suffered 
gastric symptoms during the period abroad or on return to the UK. These will 
be assessed on an individual basis  
• regular/recent (within 3 months) use of colonic irrigation or other bowel 
cleansing techniques  
• are involved in another research project that includes dietary intervention or 
involving blood sampling   
• record blood in your stools or have two or more episodes of constipation or 
diarrhoea (type 1, 2, or 7 stools) during the study  
• are unwilling to provide GPs contact details  
• are unable to provide written informed consent.  
• regularly consume more than 15 units (women) or 22 units (men) of alcohol a 
week  
• Regularly taking iron supplements  
• Those unable to swallow capsules  
• Those with abnormal blood pressure measurements (160/100 will be 
regarded as an exclusion value)  
• Are related to someone in the study (e.g. spouse, partner, immediate family 
member)  
  
Study Intervention  
Participants will receive both phytin-rich and placebo capsules as part of their normal 
diet for four weeks during the study. The order in which they will consume these 
capsules will be randomly assigned.  
  
Placebo capsules   
Microcrystalline cellulose (MCC) is a purified, partly depolymerised cellulose with 
shorter, crystalline polymer chains. Its strong binding performance make MCC one of 
the most commonly used fillers and binders in drug formulations. The product is 
manufactured by controlled partial hydrolysis of high purity wood pulp, followed by 
purification and drying. Pharmaceutical MCC will be purchased from DFE Pharma 
(https://www.dfepharma.com/en/excipients/mcc.aspx) and all related documents can 
be found in Annex 14, Catalogue A2, documents A2.1-2.8.  
  
Phytin capsules   
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Dose of phytic acid (phytin)  
The dose of phytin to be administered was calculated on the basis that it would be 
sufficient to chelate most of the iron that enters the colon. Phytin (MW=847 g/mol) is 
a salt form of phytic acid (MW=660 g/mol). Literature data refers to phytic acid and 
this MW has been used in calculations. On average, an estimated 15 mg of iron is 
consumed by men via the diet on a daily basis [19, 48]; intakes in women are lower  
(8-9 mg/day). Of this amount, approximately 15% is absorbed in the small intestine. 
Therefore, on average, 13 mg (0.233 mmoles; MW of iron – 55.8 g/mol) of iron 
travels through to the colon and is found in daily faecal matter [5].   
  
A significant molar excess of phytin is required to ensure that a substantial fraction of 
the iron in the colon is bound to phytin and not available for use by pathogenic 
colonic bacteria. We used data from human studies that investigated how increasing 
phytic acid : Fe ratios affected the absorption of iron from the small intestine to 
determine the effective dose of phytin. The report of Tuntawiroon et al., [49] shows 
that increasing the phytic acid : Fe ratio from 3:1 to 14:1 substantially reduced iron 
absorption from 22% to 7%. Taking an average phytic acid daily ingestion in the UK 
of 700 mg, assuming 50% is degraded during digestion in the upper intestine, 350 
mg (=0.530 mmoles) will reach the colon, along with an average of 13 mg (=0.233 
mmoles) of Fe, giving a molar ratio of 2.27 phytic acid : Fe. To increase the ratio to 
>14:1, we will supplement with an amount of phytin that alone achieves a PA : Fe 
ratio of 12 : 1. Therefore, the quantity of phytic acid in the supplement will be 12 x 
0.233 = 2.8 mmoles, which is 1845 mg of phytic acid (MW-660 g/mol), and 2368 mg 
of phytin (MW=847 g/mol), rounded up to 2.4 g phytin (equivalent to 1870 mg of 
phytic acid).   
  
Preliminary work has shown that a maximum of 0.4 g phytin can be filled into 1x size 
00 capsule. Therefore, participants will be required to consume two capsules (00) 
containing 0.4 g phytin 3x a day in conjunction with any 3 meals. Therefore, the total 
daily intake of phytin delivered is 2.4 g, and the total daily intake of phytic acid 
delivered is 1.87 g.   
  
Safety considerations  
The product to be administered is TSUNO Rice Fine Chemicals IP6-phytin (phytin) 
which is a salt form of phytic acid (C6H6O24P6Mg4CaNaKCa). There are no studies of 
the safety of consuming this particular product. The quantities of Mg, Na, K, and Ca 
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delivered by 2.4 g phytin are not considered toxic. The phytin has been tested for 
heavy metals by Eurofins Food Testing UK, with no concerning levels identified and 
the results are provided in Annex 14, Catalogue A1. The safety of consuming 1870 
mg per day of additional phytic acid was assessed.  
  
First, the proposed 1870 mg per day dose was compared with estimates of average 
daily phytic acid consumption from the scientific literature. A review on phytic acid by 
Schlemmer et al., [33] provides an extensive list of estimates of phytic acid intakes.  
Phytic acid intakes vary according to differences in diets, and intakes in African and 
Asian countries are higher than those in the UK and other countries in Europe, and 
intakes in vegetarians and vegans are higher than those in omnivores. Schlemmer et 
al., [33] reports estimates of mean phytic acid daily intakes varying from 504 to 844 
mg for adults in earlier studies [50], while a recent study calculated the mean daily 
phytic acid intake in men (aged 40 years) at 1436 ± 755 mg [51]. The more recent 
estimate (1436 ± 755, mean ± SD) is about twice the mean from earlier studies, but 
similar to that reported for Swedish vegetarians (mean = 1146 mg/day, range = 
5002927 mg/day), US male vegetarians (1550 ± 550 mg / day), males and females 
aged 20-45 in India (1560-2500 mg / day) and Nigerians (mean = 2200 mg / day). 
Here we use the more recent UK estimate (1436 ± 755). The proposed dose of 1870 
mg phytic acid per day is approximately 1.3-fold greater than the estimated average 
intake in UK males, and about 2.7-fold higher than the 700 mg / day reported in 
earlier studies. Inputting the 1436 ± 755 (mean ± SD) data into a normal distribution 
calculator (http://onlinestatbook.com/2/calculators/normal_dist.html) and calculating 
the proportion of the population ingesting >1870 mg phytin per day gives 28.3% (i.e. 
28% of men in the UK consume 1870 mg / day phytic acid or more). The 99th 
percentile is around 3192 mg / day.   
  
If we then consider that we might recruit a participant with average phytic acid 
consumption, then total phytic acid daily intake would be 3306 mg (1870 + 1436). 
Considering a male participant at the high end of phytate intake from their normal 
diet (2000 mg / day), then total phytic acid intake would be 4270 mg / day (2400 + 
1870). It is therefore possible that a subject may consume more phytic acid than is 
normal in the UK, but not more than has been reported as normal intakes in several 
vegan/vegetarian populations around the world.   
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Second, we reviewed the evidence for toxicity of consuming high doses of phytic 
acid. We could find no reports that phytic acid ingested in normal diets has caused 
toxic effects in humans, with reported consumption as high as 5.6 g / day. We found 
a number of Safety Data Sheets from suppliers of phytic acid (e.g. Santa Cruz, 
Carbosynth, TCI America) and none of these indicated adverse effects associated 
with oral consumption. Statements include “no significant acute toxicological data 
identified in literature”. Phytic acid has been approved as ‘generally regarded as safe  
(GRAS) when used in accordance with good manufacturing or feeding practice’. No 
reports of studies to investigate possible toxicity of phytic acid in humans were 
found. There are a few reports looking at toxicity in animal models and some LD50 
(dose causing 50% death), but none of these are for oral ingestion (they all involve 
injection, e.g. intraperitoneal), and they were not considered relevant.  
  
Finally, phytic acid is a metal chelator and is especially effective at chelating iron but 
also other minerals like zinc. Phytic acid-bound minerals such as iron and zinc are 
not available for absorption from the gut and phytate is therefore regarded as an 
anti-nutrient. However, as the phytin is being administered in specially prepared 
capsules that resist stomach / small intestinal digestion and release their contents 
only once they reach the colon, and significant mineral absorption only occurs in the 
small intestine (not colon), the intervention is not expected to reduce mineral uptake 
in the participants.    
  
In summary, phytic acid is an approved food additive and there are no 
known/reported toxic effects in humans. The intended dose is above the mean daily 
intake in the UK population, but at a level reported in several population sub-groups 
around the world such as vegetarians and vegans, and in people consuming some 
African and Asian diets. Considering the available evidence, we do not anticipate the 
intended dose of phytin causing adverse effects in the target group of study 
participants. However, as the dosage used for this trial has not been investigated 
before, this trial is testing this specific dose of phytin for the first time.  
  
Study Materials  
IP6, also known as phytin mineral salt, will be purchased from TSUNO Rice Fine 
Chemicals Company Limited, in Japan 
(https://www.tsuno.co.jp/en/products/finechemicals/ip6-biz/). IP6 from TSUNO is of 
food grade standard and therefore safe for human consumption. All factories 
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received ISO 9001 in 1998 followed by ISO 14001 in 2001 (Annex 14). A list of 
accreditation scopes can also be found in the documentation (Annex 14). TSUNO 
Rice Fine Chemicals obtained ISO 22000 in 2012 
(https://www.tsuno.co.jp/en/aboutus/history/).  
  
All other documentation regarding phytin can be found in Annex 14, Catalogue A1.  
  
Phloral® Coating for Targeted Colonic Release  
To ensure that phytin degradation does not occur in the stomach or small intestine, 
the study team has decided to encapsulate phytin with Phloral®. Phloral® is a new 
technology invented for the precise and consistent delivery of compounds to the 
colon, and has successfully completed Phase 3 clinical studies, registered at 
Clinicaltrials.gov (NCT01903252) [52]. It exploits changes in gastrointestinal pH in 
combination with the enzymatic activity of the microbiota as independent but 
complementary release mechanisms to guarantee site-specific release (Figure 6).  
  
 
  
Even though the pH in the GI tract varies, the polysaccharide component is 
independently digested by enzymes secreted by the trillions of bacteria naturally 
residing in the colon. This additional fail-safe mechanism overcomes the limitations 
of conventional polymer coatings. Furthermore, Phloral® was evaluated against a 
widely used conventional pH sensitive coating in 8 human subjects. Radiolabelled 
tablets were administered under various feeding regimens. Transit and disintegration 
was tracked by gamma scintigraphy, and results demonstrated that all Phloral® 
coated tablets were successfully released in the colon, whereas 3/8 conventional pH 
sensitive polymer coated tablets failed to release and were excreted intact (Figure  
Single film coating combining  
pH - responsive polymer and  
polysaccharide  
Polysaccharide digested by  
enzymes secreted by colonic  
microbiota   
Polymer dissolves at higher pH  
towards the colon     F igure 6 . The concept of Phloral® 
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7). Further information on the raw materials used for this formulation can be found in 
Annex 14, Catalogue A3, documents A3.1-3.7. A signed document regarding the 
safety of Phloral® formulation can also be found in Annex 14, Catalogue A3, 
document A3.8  
 
Figure 7. Testing of Phloral® in 8 human subjects. Tablets illustrate the site 
of disintegration in individual subjects. Data reported in the fed state. 
Conventional tablets remained intact in subjects 4, 5 and 7 and were excreted 
via the stools. https://www.intractpharma.com/phloral   
Encapsulation of phytin/MCC with Phloral®  
A fully organic coating suspension will be used to coat capsules to be consumed 
during the human trial. Empty, size 00 Hydroxypropylmethylcellulose (HPMC) 
capsules will be purchased from Qualicaps, Spain (Annex 14, Catalogue B, 
documents B1.1-1.3). HPMC capsules are derived from vegetable cellulose and are 
100% natural. HPMC capsules contain no gelatine, wheat, gluten, preservatives, 
animal by-products or starch and are made from pure cellulose of either poplar or 
pine, therefore allowing vegans, vegetarians and those that are intolerant to wheat or 
gluten, to participate in the study.   
  
A mini coating machine (Caleva Mini Coater Drier) located at Intract Pharma 
(London) will be used to coat 2500 size 00 HPMC capsules. These capsules will be 
separated so that the caps and bodies are coated separately to the required coating 
thickness. Once the bodies and caps of a total of 2500 capsules have been coated, 
the capsules will be left overnight to dry.   
  
To ensure the Phloral®-coated capsules are safe for consumption, these capsules 
will be prepared by Miss Bhavika Parmanand under sterile conditions, with fresh 
ingredients used for the coating suspension. A subset of the trial capsules will then 
Study protocol          EPoM                Version 4     21.Nov.18         IRAS ID 251932 
209  
be sent to Eurofins Food Testing (Wolverhampton, UK) for toxicology tests and 
microbial testing to ensure coated capsules are free from bacterial contamination 
and other contaminants, therefore safe for human consumption (Annex 14, 
Catalogue C). Once results from toxicological and microbial testing are available, 
capsules (bodies and caps separated) will be delivered to the QI CRF directly in 
appropriate containers. The bodies will then be filled with either phytin or MCC and 
capped when complete. This process will be carried out at the QI CRF. Once all 
bodies have been filled with either phytin or MCC and capped, the closed capsules 
will be stored in the containers outlined in the next section and kept at the QI CRF. 
Again, a subset of the trial capsules will then be sent to Eurofins Food Testing for 
toxicology tests and microbial testing to ensure filled capsules are free from bacterial 
contamination and other contaminants, therefore safe for human consumption. To 
ensure uniformity of the phytin dose within the capsules, a subset of the filled 
capsules will be analysed to quantify and confirm phytin concentrations.  
  
Capsule Management and Distribution  
During the course of the study, the capsules that will be provided to the participants 
will be kept at the QI CRF, accessed only by the QI CRF Research Nurse. The 
capsules will be stored in HDPE containers.   
  
Two boxes (one each for test and placebo capsules) will be labelled “A” and “B”  
(please refer to section “Randomisation process” for details). Once the test and 
placebo capsules have been placed in the containers, the containers will be stored at 
the QI CRF at room temperature, food grade room.  
  
The QI CRF Research Nurse will be responsible for dispensing the capsules, 
randomly allocated to the participants. The QI CRF Research Nurse will be provided 
with the list generated by Miss Bhavika Parmanand, which links the participant code 
number to either “AB” or “BA”. An inventory log will be kept by the QI CRF Research 
Nurse to ensure that capsule numbers are recorded. This, in conjunction with 
dispensing records will allow the QI CRF Research Nurse to keep track of how many 
capsules have been distributed and to which participant.    
  
Assessment of Compliance  
Although participants have not been asked to make any changes to their habitual 
diets throughput the entirety of this study, each participant will be asked to complete 
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a Food Frequency Questionnaire (Annex 15) upon completion of each of the test 
phases. This will be used to assess participant’s habitual diet over the trial period 
and whether their food habits correlate with, or are reflected in, the outcome. It will 
also give an indication of any participants with a naturally high, phytin-based diet.   
  
Furthermore, to assess compliance with the phytin-rich intervention, participants will 
be provided with a capsule checklist (Annex 16) and asked to mark down each time 
they ingest the capsules. This will help them to remember if they have taken the 
dose at the appropriate times points as well as serving as a measure of compliance. 
Also, at the end of each treatment phase, participants will be asked to return the 
bottle containing any unused capsules. These will be counted and then stored for 
reanalysis should any issue arise in the future.  
  
Study procedures after Study Talk (Visit 1) and Eligibility Screening 
(Visit 2):  
  
Faecal sample collection kit pick-up (Visit 3)  
Participants will be invited to take part in this study if the blood and urine tests from 
the eligibility screening are satisfactory, and they meet all the listed participation 
criteria.   
Participants will be asked to collect a faecal sample collection kit, along with a 
detailed sheet on how we would like them to collect and store their faecal sample 
buntil they can deliver it to the QI CRF. Everything the participant needs to collect 
the sample will be provided in the kit.   
  
Faecal sample drop-off (Visit 4)  
Participants will be asked to bring their faecal sample to the QI CRF in the collection 
kit that they were given during Visit 3. Alternatively, if need be, it can be arranged for 
the sample to be collected by a member of the study team. This faecal sample will 
provide a baseline gut microbial profile of the participant. After this faecal sample has 
been provided, the study team will arrange a time and date for the participant to start 
the trial.  
  
Phase 1 (Visit 5, Days 1 – 14)  
When the participant visits the QI CRF, they will be asked to provide a faecal sample 
if they have not already done so during Visit 4. The participants will be asked 
Study protocol          EPoM                Version 4     21.Nov.18         IRAS ID 251932 
211  
whether they are happy to continue with the study, and whether they have had any 
changes to their health in the form of a follow-up health questionnaire. A QI CRF 
Research Nurse will take a 15 mL blood sample (to test for ferritin and CRP levels). 
The participant will receive either “AB” or “BA”, dependent on what group they have 
been randomly assigned to for Phase 1. The first 2 capsules must be consumed at 
the QI CRF and participants must remain here for a minimum of 20 minutes. Food 
will be provided for participants on this occasion. After the participants have 
consumed the first 2 capsules, those randomly assigned to the test capsule will 
receive a bottle of capsules (this takes into account for any capsules that may be 
lost/misplaced by the participant), each containing 0.4 g phytin. Those randomly 
assigned to placebo capsule will also receive a bottle of capsules (accounting for 
lost/misplaced capsules), each containing 0.4 g microcrystalline cellulose. 
Participants will be informed that capsules must be stored in a cool, dry place dry 
place. The participants will be reminded that they are to consume 2x capsules 3 
times a day, in conjunction with a meal, for a period of two weeks.   
All participants will also be provided with the following forms: (i) food frequency 
questionnaire, (ii) stool chart and (iii) capsule checklist. The first two forms will need 
to be filled out for a consecutive 7 days; the final form is to remind participants to 
consume the capsules and tick the relevant box to show that they have taken the 
capsules.   
Finally, before they leave the QI CRF, they will be provided with a new faecal sample 
collection kit for the next stool sample.  
  
Mid-Phase 1 faecal sample drop-off (Visit 6, Day 7)  
Once the participants are halfway through Phase 1, they will be asked to provide a 
faecal sample and drop it off at the QI CRF in the faecal collection kit they were 
given at the end of Visit 5. Once this sample has been dropped off, they will be 
provided with a new faecal collection kit and asked to continue with the remaining of 
Phase 1.   
  
End of Phase 1 (Visit 7, Day 14)  
At the end of Phase 1, participants will be asked to deliver a faecal sample to the QI 
CRF in the faecal collection kit provided during Visit 6. When they are at the QI CRF, 
a QI CRF Research Nurse will take a 15 mL blood sample (to test for ferritin and 
CRP levels). Participants will be asked to return the bottle containing the capsules 
that was given to them at the beginning of Phase 1, including any capsules that have 
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not been consumed. Also, the participants will be asked to return the completed 
forms (food frequency questionnaire, stool chart and capsule checklist). Finally, a 
new faecal collection kit will be provided to the participants for the next stool sample.  
  
Washout Phase (Days 15-28)  
A wash-out phase lasting for 2 weeks was decided upon based on previous human 
studies carried out looking at various dietary interventions. An average of 2 weeks 
was deemed sufficient for the gut microbiota to normalise to its baseline levels 
before the start of the treatment [53, 54]. Participants will be asked to provide a 
faecal sample (as described in Study procedures: Faecal collection) after a minimum 
of two weeks following the end of Phase 1, i.e. the end of the washout phase. They 
will be asked to deliver this sample on Day 1 of Phase 2, in the collection kit provided 
during Visit 7. If, shortly after this 2-week period, the participant has not contacted 
the study team, a member of the study team will contact the participant to ascertain 
whether the participant would like to continue with the study.   
  
Phase 2 (Visit 8, Days 29-42)  
Participants will be asked to deliver a faecal sample before starting Phase 2. As 
before, they will be given an opportunity to produce this sample at the QI CRF if they 
were unable to do so before. Participants will be asked if they are happy to continue 
on with the study, and whether they have had any changes to their health since the 
end of Phase 1, and this will be addressed in the form of a follow-up health 
questionnaire. A QI CRF Research Nurse will take a 15 mL blood sample for ferritin 
and CRP analysis. For Phase 2, participants will be given a bottle containing the 
alternative set of capsules to what they consumed during Phase 1. All other aspects 
of Phase 2 are identical to Phase 1 – please refer to ‘Phase 1’ for these details.  
  
Mid-Phase 2 (Visit 9, Day 35)  
Please refer to section titled ‘Mid-Phase 1 Faecal sample drop-off’ for more details.  
  
End of Phase 2 (Visit 10, Day 42)  
At the end of Phase 2, the participants will be asked to deliver a final faecal sample 
to the QI CRF in the faecal collection kit provided during Visit 9. When the 
participants are at the QI CRF, a QI CRF Research Nurse will take a final 15 mL 
blood sample to test for ferritin and CRP levels. The participants will be asked to 
return the bottle containing the capsules that was given to them at the beginning of 
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Phase 2, including any capsules that have not been consumed. Also, the participants 
will be asked to return the completed forms (food frequency questionnaire, stool 
chart and capsule checklist), and this will mark the end of the study.   
  
Note: if a participant is unexpectedly unable to attend a pre-arranged assessment at 
the end of a 2-week treatment period, depending on their next availability, they will be 
asked to come in either a couple days before/after the scheduled visit. If the 
participant is not available till after more than 3 days of the scheduled visit, they may 
be asked to repeat the treatment. Furthermore, if the participant intends to go on 
holiday/travel whilst taking part in this study, we will require them to remain in the UK 
during both Phase 1 and 2. They may travel during the washout phase.  
Below is a brief breakdown of the overall samples/forms that will be collected from 
the participant through the course of this study:  
  
Blood samples (all taken at QI CRF by QI CRF Research Nurse)  Total 
number: 5 samples, amounting to 80 mL (16 teaspoons)  
- Sample 1: Eligibility screening, 20 mL, results sent to GP. Analysed by NNUH 
Pathology Laboratories. Testing for ferritin, CRP, full blood count and HBA1c.  
- Sample 2: Start of Phase 1, 15 mL, results analysed in QIB laboratories. 
Testing for ferritin and CRP  
- Sample 3: End of Phase 1, 15 mL, results analysed in QIB laboratories. 
Testing for ferritin and CRP  
- Sample 4: Start of Phase 2, 15 mL, results analysed in QIB laboratories. 
Testing for ferritin and CRP  
- Sample 5: End of Phase 2, 15 mL, results analysed in QIB laboratories. 
Testing for ferritin and CRP  
  
Faecal samples  
Total number: 6 samples  
- Sample 1: Before starting Phase 1  
- Sample 2: Midway Phase 1  
- Sample 3: End of Phase 1  
- Sample 4: End of washout phase/before starting Phase 2  
- Sample 5: Midway Phase 2  
- Sample 6: End of Phase 2  
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Stool charts  
Total number: 2 charts, each recording 7 consecutive days from Phase 1 and 2  
- Stool chart 1: During Phase 1  
- Stool chart 2: During Phase 2  
  
Capsule checklist  
Total number: 1 checklist for entire study  
  
Food frequency questionnaires   
Total number: 2 questionnaires, each recording 7 consecutive days from Phase 1 
and 2  
- Questionnaire 1: During Phase 1  
- Questionnaire 2: During Phase 2  
  
Sample/Form collections  
  
Blood collection  
For the eligibility screening, a venous blood sample (20 mL) will be taken by a QI 
CRF Research Nurse for assessment of a full blood count, HbA1c, CRP and ferritin 
levels. Eligibility screening bloods will be sent to NNUH Pathology Laboratories for 
analysis. All eligibility screening results will be sent to the participant’s GP. The 
blood samples taken during the course of the study (4 x 15 mL samples) will be 
used for research purposes. These blood samples will be used to ascertain iron 
status (serum ferritin) and to confirm lack of chronic inflammation/infection (CRP).  
These samples will be analysed at QIB laboratories.   
  
Faecal collection  
The faecal collection kit will consist of a bag containing a faecal collection pot, an 
autoclavable sample bag for collecting the faeces in, a plastic clip (for sealing the 
autoclavable bag), nappy sack and an insulated container for transporting the 
sample securely back to QI CRF. The participant will also be provided with study 
specific instructions (Annex 17) as to how to collect and store the faecal sample and 
how to contact members of the study team or QI CRF Research Nurse regarding 
arrangements for collection or delivery of the faecal sample to the QI CRF. These 
samples will be analysed at QIB laboratories  
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Detailed instructions will be provided as to how to collect their faecal sample directly 
into the labelled plastic autoclavable sample bag in the collection pot. Once the 
sample has been collected the autoclavable sample bag should then be sealed 
closed with the plastic clip, removed from the collecting pot and placed into the 
nappy sack which should be closed by tying the handles in a double knot. The tied 
nappy sack, containing the sample should then be sealed shut in the insulated 
container. Participants will be advised to wash their hands after collecting the 
samples. Participants will be asked to write the date and time of sample collection on 
a label on the lid of the insulated container and contact a member of the study team 
to arrange delivery or collection of the sample. Should the participant forget to bring 
the sample with them, they will be given the opportunity to produce one at the QI 
CRF. If they are unable to deliver the faecal samples themselves on assessment 
days, arrangements will be made for a member of the study team to collect the 
sample from the participant at a convenient time.   
  
All containers used for faecal collections will be sterilised prior to being given to the 
participant, to prevent contamination and minimise infection risk. The importance of 
hand washing after sample collection by participants will be reiterated in the faecal 
collection instruction sheet.  
  
It is hoped that the participants will be able to bring their faecal sample to a member 
of the study team at the QI CRF, however it may be that a participant requires a 
member of the study team to collect their faecal sample, and this will be arranged on 
an individual basis.   
  
When receiving a faecal sample, a member of the study team will collect the entirety 
of the faecal collection kit from the participant, except for the sample collection pot 
which will have been disposed of.   
  
Identical faecal collection kits and instructions will be provided to the participants 
prior to the collection point of all further faecal samples, and participants will be 
asked to collect the faecal samples in an identical manner to the first faecal sample. 
Should any participant suffer from diarrhoea during the study, they will be required to 
contact a member of the study team and will be asked to refrain from collecting a 
faecal sample for a minimum of 48 h after the last episode of diarrhoea. Should the 
diarrhoea persist for more than 72 h, the participant may be advised by the QI CRF 
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Research Nurse to speak to their GP. The participant may be excluded from the 
study and this decision will be at the discretion of the QI medical advisor.  
  
Stool chart  
During the study the participants will be asked to keep a record of the frequency and 
consistency of their bowel movements using the Bristol Stool Chart as a guide 
(Annex 18). The participants will be asked to keep this record for a period of seven 
consecutive days during each of the two Phases. These scores will be used as an 
estimate of gut function. If the participant’s stool chart indicates an abnormal stool 
pattern, they may be advised by the QI CRF Research Nurse to speak to their GP, 
who will receive a copy of the participants stool chart. Any participant who records 
two or more episodes of type 1, 2 or 7 stools, or the presence of blood in their stools, 
on their stool chart, will be excluded and a copy of their stool chart will be sent to 
their GP. The participant may be excluded from the study and this decision will be at 
the discretion of the QI medical advisor.  
  
Food Frequency Questionnaires  
The participants will be asked to complete 2 food frequency questionnaires, one 
during each treatment Phase. They will need to complete both these questionnaires 
for a period of 7 consecutive days. This will be used to assess participant’s habitual 
diet over the trial period and whether their food habits correlate with, or are reflected 
in, the outcome. It will also give an indication of any participants with a naturally high, 
phytin-based diet.  
  
Capsule Checklists  
The participants will be asked to complete a capsule checklist for the entirety of the 
study. This will (i) help them to remember to take the capsules at the appropriate 
time-points and (ii) serve as a measure of compliance.  
  
Completion of the study  
Upon completion of the study, the general findings of the study will be reported back 
to the participants in the form of a basic summary.  
  
Withdrawal from the study  
Participants will be withdrawn from the study if the participant, for any reason, loses 
capacity to consent during the study, or their medical situation changes. Identifiable 
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data or samples already collected with consent would be retained and used in the 
study. No further data or sample would be collected, or any other research 
procedures carried out on or in relation to the participant. If at any point during the 
study the participant wishes to withdraw, they may do so without giving a reason and 
their clinical care and participation in future studies at QIB will not be affected. The 
participant will be sent a withdrawal letter (Annex 19) explaining this and thanking 
them for their participation so far. Again, any samples or data collected up to the 
point of withdrawal will be kept and used in the study if possible.  
  
Adverse event (AE) and Serious adverse events (SAE)  
This study will comply with the NNUH Trust system for reporting adverse events and 
will adhere to the NNUH SOP 206 (Adverse Events: Identifying, Recording and 
Reporting adverse events for Non-CTIMP Healthcare Research Studies). AEs will be 
evaluated in terms of seriousness, relatedness and expectedness by QI CRF nurse 
and QI medical advisor. All adverse events/reaction that are not considered serious 
will be documented on the relevant case report forms (CRFs) (Annex 20). The 
completed form will be filed along with the other CRFs for the study and a copy 
provided to the Sponsor. SAEs/SARs will be reported on the NNUH SAE form 
(Annex 21). SAEs will be notified by the CI to the Sponsor within 24hrs of the CI 
becoming aware of the event. This will be followed within 48hrs of becoming aware  
of the event by a detailed, written report provided by the QI medical advisor. SAEs 
will be notified by the CI to the REC where in the opinion of the QI medical advisor it 
was possibly, probably or definitely related, within 15 days of the CI becoming aware 
of it. The CI will report all logged events to the REC annually as a Safety Report; a 
copy of this report will be provided to the QIB HRGC. The CI will report all logged 
events to the NNUH R&D. All SAEs will be followed up by the QI medical advisor 
until satisfactory resolution, and this should be recorded as a Follow Up report on the 
SAE form, and on the SAE log. At each stage of follow up the QI medical advisor will 
sign and date the form.   
  
A serious adverse event (SAE) is defined by ICH GCP as an untoward occurrence 
that:  
• Results in death  
• Is life threatening  
• Requires hospitalisation or prolongation of existing hospitalisation  
• Results in persistent or significant disability or incapability  
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• is otherwise considered medically significant by the QI medical advisor  
  
The participant will only be deemed to have suffered an adverse event/reaction or a 
serious adverse event/reaction if the participant has taken part in any stage of the 
intervention.   
  
Methods  
  
Gut microbiome analysis  
The faecal samples produced by the participant will either be delivered to the QI CRF 
by the participant, or a member of the study team will arrange to go and collect the 
samples. Samples delivered at the QI CRF will be safely transported to the QIB 
laboratories facilities located within the same building. Upon receipt of a faecal 
sample, part of it will be divided up into aliquots totalling no more than 10g and 
stored at –80°C until analysis. The DNA will be extracted from faecal aliquots using 
the FastDNA spin kit for soil (MP Biomedicals) according to the method of Maukonen 
et al [55] and stored at –20°C. Part of the extracted DNA from the faecal samples will 
have the 16S rRNA genes amplified by PCR, followed by sequencing using a Next 
Generation platform such as Illumina, in-house at QIB. Faecal bacterial phylogenetic 
analysis will give both the bacterial genera present and the relative proportions of 
each genus within the sample. This will make it possible to observe shifts in the 
proportions of various bacterial taxa, namely Enterobacteriaceae and 
Bifidobacteriaceae, in the faecal microbiome of each participant, due to a) the 
consumption of the different capsules (either test or placebo) compared to one 
another, and b) the consumption of the different capsules (either test or placebo) 
compared to the baseline sample obtained at the start of the study. This information 
can then be compared with the iron quantification data and used to try and determine 
whether the faecal microbiome composition correlates to the concentrations of iron.  
  
Faecal metabolite analysis   
Short chain fatty acids are bacterial waste products that are beneficial to the host, 
and as such can be considered a biomarker of good gut health. Nuclear magnetic 
resonance spectroscopy (NMR) or MS-based techniques such as HPLC or LC-MS 
will be used to determine the profile of metabolites, such as short chain fatty acids, 
from faecal aliquots. Faecal aliquots of 0.2 g will be diluted using 12 x volume of 
NMR buffer and homogenised. This will then be centrifuged at 3200 xg for 15 mins at  
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4oC, before 700 µl of the supernatant is added to an NMR tube for spectral 
acquisition. Data analysis will be performed at the QIB.  
  
Faecal calprotectin analysis   
The inflammatory status of the patient at the time of faecal sample collection will be 
assessed. Calprotectin is a biomarker that is present in the faeces when intestinal 
inflammation is present. An aliquot of the faecal sample provided by the participant 
will be used to determine calprotectin levels using a commercially available kit. 
Briefly, the faecal aliquot will be placed in disposable vials. After homogenisation and 
centrifugation, an extraction buffer will be added to the aliquots as per manufacturers 
instruction and analysed using a commercial ELISA kit at OD 405 nm against a 
standard curve. These samples will be analysed at QIB laboratories.  
  
Faecal iron analysis   
A 20 µL aliquot of the faecal water will be used to quantify iron concentrations of the 
faecal samples using the ferrozine assay as per manual instructions (Iron Assay Kit 
ab83366, Abcam, UK). Briefly, iron in the sample is reduced using an Fe reducer, 
provided by the kit, after which iron reacts with Ferene S (an iron chromogen) to 
produce a stable coloured complex. Absorbance measurements will be taken at 593 
nm. These samples will be analysed at QIB laboratories.  
  
Faecal phytin analysis   
Faecal aliquots will be used to determine faecal phytin levels using a commercial kit 
(Total Phosphorus Assay kit; Megazyme). These samples will be analysed at QIB 
laboratories.  
  
Blood analysis  
A venous blood sample (20 mL) will be taken by a QI CRF Research Nurse and sent 
to NNUH Laboratory for assessment of iron status and to confirm lack of chronic 
inflammation/infection (haemoglobin, ferritin, and C-reactive protein) for the sample 
taken for the eligibility screening. For the remaining blood samples taken throughout 
the study, bloods (15 mL) will be analysed within QIB laboratories. A total of 80 mL 
(16 teaspoons) of blood will be taken from each participant throughout the course of 
this trial.   
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The data analyst will be blind to the conditions of the study until all analysis is fully 
completed.  
  
Statistics:  
Statistical analysis:  
The primary outcome measure (relative abundance of Enterobacteriaceae) will be 
compared between placebo and treatment phases within each patient using a linear 
mixed model regression analysis, with appropriate transformations to ensure 
normality of residuals. The faecal samples collected during Phase 1 and 2 (mid and 
post samples for each phase) for each participant will be included as data points. 
Models will include the fixed effects of time period, (Phase 1 vs Phase 2) and 
treatment (placebo vs active), and the random effect of participant. The primary 
hypothesis will be tested with a two-sided test at p<0.05.  
Power calculations:  
Prior data from our lab using the same outcome measure and similar participant 
criteria suggests that the within-person variation in Enterobacteriaceae abundance 
has a standard deviation of 1.743 on the logit scale. Using two samples per-person 
per-treatment, this means that the within-participant difference between mean active 
vs mean placebo abundance will also have a standard deviation of 1.743 across 
participants. With a sample size of 14 completers there will be 80% power to detect a 
within participant difference of 1.41 on the logit scale. Although there are no directly 
comparable prior estimates of these effects, our in vitro data suggests the change in 
the abundance of Enterobacteriaceae upon phytin is around 1.91.  Allowing for 
uncertainty in the precision and applicability of these estimates and the possible 
occurrence of unusable data due to technical failure we will aim to recruit 14 
participants.  
Power calculations were conducted using R statistical software version 3.5.0.  
Data Protection and Participant Confidentiality  
Participants who are successfully recruited onto the study will be assigned a unique 
code number which will be kept in a secure file. A lockable filing cabinet or cupboard 
will be used to keep paper documents that include the file linking the participant to 
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the code and personal information. All electronic data will be stored on a password 
protected shared data file. Confidential data will be accessed only by the study team.  
Participants’ personal data will be held in a locked cabinet in QI CRF. Participants’ 
personal data will also be held in a locked cabinet or password protected electronic 
file in QIB. Only the study team will have access to these data. The samples will be 
known only by their code number. All data collected will also be identified by code 
only. Data will be stored for 15 years after completion or discontinuation of the study. 
These data will not be used to contact research participants after the study is 
completed. The data will be stored in the QIB human studies archive. Access to 
archived data will be limited to the study scientist and Chief Investigators (CI) of the 
study or the CI's successor. The quality assurance auditors may also be allowed 
access with the permission, and in the presence, of the CI. The main computer 
storage will be on one main QIB computer, but as part of a password protected 
shared network. All QIB computers are individually password protected and the 
shared network access is limited to those working within the research area. Only the 
study scientists will have access to the file linking personal data to the participants’ 
unique code. Manual files/folders will consist of separate named and numbered files 
for each participant. No data with the participants’ name will be filed in the numbered 
file and vice versa.  
  
Data Sharing and Access  
The research protocols will be registered in a publicly accessible database after 
gaining favourable ethical opinion. Registration to ClinicalTrials.gov Protocol 
Registration and Results System (PRS) using QIB account will allow us to be 
transparent in our work.  
  
Definition of End of Study  
The end of the study is the date of the last visit of the last participant  
  
Ethical considerations:  
  
Informed Consent  
 
Before participation in the intervention study, all participants will be asked to give 
written informed consent for study participation, and the long-term storage of 
samples at the Norwich Biorepository. Prior to consent being given, the participant 
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will be provided with the Participant Information Sheet by the QIB Volunteer 
Database Manager, which provides all the information about their involvement in the 
study and we will ensure that all their questions are answered. The ability of 
participants to give informed consent will depend on them receiving enough 
information about the study, the participant exercising their right to choose, the 
participants ability to understand the information and the ability of the participant to 
make a decision.   
  
Use of samples in future research:  
Participants will sign a consent form agreeing to store their samples long-term at the  
Norwich Biorepository (Annex 7), which holds a Human Tissue Authority licence  
(IRAS no: 130478, East of England - Cambridge East Research Ethics Committee 
08/h0304/85+5). Once the study has ended, blood and stool samples will be 
transferred to the Norwich Biorepository by the study team. Participants will be able 
to take part in the study even if they do not want their samples to be stored at the 
Norwich Biorepository. Storage of samples at the Norwich Biorepository after this 
study has ended will enable further data collection from this study (if needed) and 
use of the samples in future research. It is important to stress that any further 
analysis will be carried out in compliance with ethical requirements.  
  
Data Protection  
This study will comply with the new EU General Data Protection Regulation (GPDR), 
which came into force in the UK on 25 May 2018 and the UK Data Protection Act 
(DPA) 2018, with regards to the collection, storage, processing and disclosure of 
personal information and will adhere to the GPDR and DPA core principles to 
maintain confidentiality.   
  
Procedures for any harm experienced by participants  
If, throughout the period of this human intervention trial, any participant is harmed by 
taking part, there are no exclusive compensation privileges. If, due to negligence, 
harm is caused to the participant and there are grounds for legal action, the 
participant will likely have to pay for these legal costs.   
We appreciate that under specific circumstance, participants may still wish to file a 
complaint, and in this case, a confidential service which is designed to support 
patients, relatives and carers will be available to them. This service is the Patient 
Advice and Liaison Service (PALS) and the website can be found here:  
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http://www.nnuh.nhs.uk/patients-visitors/help-support/pals/. QIB has liability 
insurance (Annex 22) with regards to research involving human participants. Please 
note that the Institute will not fund any legal costs arising from any action unless 
awarded by a court.  
  
Furthermore, as this study involves the QI CRF, which is an NHS facility, indemnity is 
provided through NHS schemes.  
  
Participant wellbeing throughout the trial  
Throughout the study, the participant will be frequently asked whether any health 
situations have risen since their participation in the study, in the form of an 
‘Assessment Day Checklist’ (Annex 23), usually at the start and end of each Phase. 
If any participant becomes unwell at any stage of the study, the first point of action 
will be to see their GP or A&E. GPs will be informed about the participants’s 
involvement in this study by letter and will receive copies of the PIS. The PIS will 
advise participants to contact the emergency service (via 999) in case of a medical 
emergency, and ensure that study team is contacted as soon as practically possible.  
The decision to exclude the participant from the study will be taken by the QI medical 
adsvisor.   
  
Capsule safety   
The QI CRF follows local Environmental Health Guidelines for the preparation and 
storage of capsules for study participants. All staff handling, preparing or delivering 
capsules for the participants will hold Level 2 Food Safety.  
  
Toxicity   
No cases of phytin toxicity has been reported, but please refer to ‘Dosage and  
Toxicity’ for more information regarding this.  
  
Participant’s expenses/inconvenience payments     
 Eligibility screening urine sample (x1)                                     £2  
 Individual stool collection (x6)  6 x £5                                    £30  
14-day Stool chart  14 days at £2 per day completed                                        £28  
168x capsule consumption  168 capsules at £1 per capsule consumed           £168  
Blood samples (x5)  5 x £10                                                                               £50  
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 TOTAL   =   £278  
  
Participants will receive £278 as an inconvenience payment if the study is 
completed; if the participant withdraws or is excluded from the study, payment will be 
pro-rata. However, if the participant undergoes rescreening the inconvenience 
payment could total £280. Participants travelling by car will be reimbursed travel 
expenses to and from the QI CRF. This will be reimbursed at the QIB's current 
mileage rate. Those participants travelling by public transport will be reimbursed 
costs on production of a ticket or receipt. If participants require transport, the study 
can provide a taxi to and from QI CRF. This is paid for by the study.  
  
Study partners  
The study will be sponsored by the QIB and funded through the Biotechnology and  
Biological Sciences Research Council (BBSRC); this study was funded by the 
BBSRC Institute Strategic Programme Food Innovation and Health QIB.  
  
The study will be led by Professor Arjan Narbad. All aspects of the study will be 
managed by Miss Bhavika Parmanand with assistance from Dr Lee Kellingray and 
Professor Susan Fairweather-Tait where necessary.  
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[Insert Date] 
 
Dear_____________________________, 
 
Thank you for your interest in research studies at the Quadram Institute Bioscience. 
 
 
I have sent you the details of, 
 
 
Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
 
which is one of the studies in progress at present, as your details currently held on the database 
indicate that you may fit the criteria for this study. If you are interested in participating in this study, 
please complete and return the reply slip in the enclosed participant information sheet. If you have 
any further questions, please contact the study manager concerned, Miss Bhavika Parmanand on 
01603 255021 or bhavika.parmanand@quadram.ac.uk as stated on the enclosed participant 
information sheet. 
 
If, however, any of your details have changed or change in the future, or you would prefer to no 
longer remain on the database please could you inform the QIB Volunteer Database Manager on 
01603 255051. 
 
Thank you.  
 
Yours sincerely, 
 
Wendy Hollands 
QIB Volunteer Database Manager 
Wendy.hollands@quadram.ac.uk 
 
Quadram Institute Bioscience is a registered charity (No. 1058499)  
and a company limited by guarantee (registered in England and Wales No. 03009972).  
VAT registration No. GB 688 8914 52 
 
IRAS ID 251932 
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Participant Information Sheet 
 
 
Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study)  
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve for you. Please take time to read the following information carefully. Talk to 
others about the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen if you take part 
Part 2 gives you more detailed information about the conduct of the study 
 
Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. This 
information sheet is yours to keep. 
Thank you for reading this. 
 
This study is funded through Biotechnology and Biological Sciences Research Council 
(BBSRC); this study was funded by the BBSRC Institute Strategic Programme Food 
Innovation and Health QIB. 
 
Chief Investigator 
Professor Arjan Narbad  
Contact number: 01603 255131 
Arjan.narbad@quadram.ac.uk  
 
Study Team 
Study Manager 
Miss Bhavika Parmanand 
Contact number: 01603 255021 
bhavika.parmanand@quadram.ac.uk 
 
Study Scientist - Dr Lee Kellingray, 01603 255070, lee.kellingray@quadram.ac.uk 
Study Advisor - Professor Susan Fairweather-Tait, 01603 591304, s.fairweather-tait@uea.ac.uk  
Study Mobile number (to be included when available) 
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PART 1
 
What is the purpose of the study? 
Within many plants, such as seeds, nuts and 
cereals, there is a compound called phytic 
acid. Phytic acid has many beneficial 
properties, including producing molecules 
which slows down the damage that can be 
caused to other molecules within the body. 
Phytic acid has also been known to help in the 
treatment of cancer.  
 
Phytic acid binds 
iron very strongly. 
Iron is an extremely 
important nutrient 
not only for humans, but also for a lot of 
bacteria. In humans, iron is absorbed in the 
small intestine. Unfortunately, iron does not 
get absorbed very well and so a lot of it 
travels into the large intestine. The large 
intestine contains trillions of bacteria and a lot 
of these bacteria use iron as food. However, 
not all bacteria in the large intestine are ‘good 
bacteria’. Some bacteria, such as 
Enterobacteria, can be harmful to people’s 
health. For this reason, if iron is kept away 
from these ‘bad bacteria’ through the binding 
of phytic acid and iron, it could prove to be 
beneficial to human health.  
 
In general, our gut 
contains trillions of 
bacteria, many of 
which help us to 
unlock extra nutrients 
from the food we eat. Some bacteria, such as 
Bifidobacteria, are often referred to as ‘good 
bacteria’ and are added to foods such as 
yoghurts. Many ‘good bacteria’ are able to 
survive without iron and this makes it even 
more important to make sure the ‘bad 
bacteria’ have limited access to iron. 
Otherwise, we could find ourselves with a 
large intestine that has more harmful bacteria 
than beneficial bacteria.  
In this study, we will ask you to consume 
either the test capsule, which contains phytin 
(a salt form of phytic acid), or a control 
capsule, which contains a powder resembling 
phytin but is actually an inactive substance. 
We are interested in whether consuming 
these capsules will decrease Enterobacteria 
(one of the ‘bad bacteria’ in the large 
intestine).  
 
 
 
 
 
What we aim to do 
Along with looking at whether these capsules 
cause a change in the number of 
Enterobacteria, we will also be looking to see 
whether this in turn increases the number of 
‘good bacteria’, such as Bifidobacteria.  
 
Furthermore, we want to make sure that the 
capsules only take effect in the large intestine. 
This is why we have made capsules that act in 
the large intestine only. As mentioned before, 
we know that phytic acid binds iron. 
Therefore, to double check that the phytic 
acid hasn’t been released before the large 
intestine, we will take blood samples 
throughout the study to check your iron 
levels. 
 
Finally, not only do we want to look at 
Enterobacteria and Bifidobacteria – we want 
to take a look at your gut bacteria as a whole 
community (like we said, there are trillions of 
bacteria!). So, to do this, we will ask you to 
provide us with faecal samples throughout 
the study. We will then extract the bacterial 
DNA from these samples (your own DNA will 
not be looked at, only bacterial DNA) and use 
this data to find out whether other types of 
bacteria in your large intestine are affected by 
the capsules. At the same time, we will also 
measure the levels of iron in your faecal  
samples to see if there is a relationship 
between iron and phytin levels.  
 
Why have I been invited? 
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You have received this information sheet 
because either you have responded to an 
advertisement about this study, or your 
details are currently held on the Quadram 
Institute Bioscience (QIB) volunteer database. 
 
Who can take part in the study? 
We are aiming to recruit a total of 14 
volunteers (male and female) who meet the 
following requirements: 
 
• Aged between 18 and 50 
• Non-smokers (e-cigarette and vape 
users are able to partake in the study) 
• Have a body mass index (BMI, kg/m2) 
between 19.5 and 30 
• Do not fall in the study exclusion 
criteria (found in the next section) 
 
If you register an interest in taking part, and 
we are near to the 14-participant point, we 
may ask you if you are happy to be placed on 
a standby list. If you are put on the list, there 
will be no guarantee that you will be required 
to take part in the study, but we will keep you 
informed, and you are entitled to ask to be 
removed from the standby list at any time. 
 
Who cannot take part in the study? 
You will not be able to take part if you(r): 
• results of our screening test indicate 
you are not suitable to take part in 
this study 
• are pregnant, have been pregnant in 
the last year or are lactating and/or 
breast feeding 
• are currently suffering from, or have 
ever suffered from, any diagnosed 
gastrointestinal disease, 
gastrointestinal disorders including 
regular diarrhoea and constipation 
(excluding hiatus hernia unless 
symptomatic), and/or have 
undergone gastrointestinal surgery, or 
the study intervention/procedure is 
contraindicated 
• have been diagnosed with any long-
term medical condition that may 
affect the study outcome (e.g. cancer, 
diabetes, haemophilia, cardiovascular 
disease, glaucoma, anaemia). These 
will be assessed on an individual basis 
• have been diagnosed with any long-
term medical condition requiring 
medication that may affect the study 
outcome. 
• regularly taking over the counter 
medications for 
digestive/gastrointestinal conditions. 
• are on long-term antibiotic therapy. 
You may be able to participate if 4 
weeks has passed from the end of a 
course of antibiotics (this will be 
assessed on an individual basis). 
• regularly take laxatives (once a month 
or more). 
• take certain dietary supplements or 
herbal remedies and are unwilling to 
stop taking them for one month prior 
to and during study period. This will 
be assessed on an individual basis. 
• take pre- or pro-biotic drinks &/or 
yoghurts on an occasional basis, 
unless willing to abstain for one 
month prior to and during the study 
period. (if you regularly take pre-&/or 
pro biotics (3+ times a week, and for 
more than one month) and will 
continue throughout the study then 
you will not be excluded) 
• are on or plan to start a diet 
programme that may affect the study 
outcome (e.g. 5:2 fasting diet) unless 
willing to abstain for 1 month prior to 
and during study period. This will be 
assessed on an individual basis 
• recently returned to the UK following 
a period abroad, and who have 
suffered gastric symptoms during the 
period abroad or on return to the UK. 
These will be assessed on an 
individual basis 
• regular/recent (within 3 months) use 
of colonic irrigation or other bowel 
cleansing techniques 
• are involved in another research 
project that includes dietary 
intervention or involving blood 
sampling 
• record blood in your stools or have 
two or more episodes of constipation 
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or diarrhoea (type 1, 2, or 7 stools) 
during the study 
• are unwilling to provide GPs contact 
details 
• are unable to provide written 
informed consent 
• are related to or living with any 
member of the study team 
• regularly consume more than 15 units 
(women) or 22 units (men) of alcohol 
a week 
• Regularly taking iron supplements 
• Those unable to swallow capsules 
• Those with abnormal blood pressure 
measurements (160/100 will be 
regarded as an exclusion value) 
• Are related to someone in the study 
(e.g. spouse, partner, immediate 
family member) 
Do I have to take part? 
It is up to you to decide whether you would 
like to take part or not. We will describe the 
study in this information sheet and if, after 
reading it, you are interested in participating 
and meet the study criteria, please complete 
the response form using the pre-paid 
envelope enclosed. On receipt of the 
response form, a member of the study team 
will contact you by telephone to arrange a 
study talk with you at the QI CRF in Norwich 
and give you the opportunity to ask any 
questions you may have at this time. 
 
You may also contact the study team by 
telephone, Bhavika Parmanand on 01603 
255021; Dr Lee Kellingray on 01603 255070 or 
by email bhavika.parmanand@quadram.ac.uk 
or  lee.kellingray @quadram.ac.uk if you have 
any questions before or during the study. 
Please feel free to say no simply by not 
responding to this letter. Do not worry, no 
one will contact you or try to persuade you to 
join the study. If you are on the QIB volunteer 
database, a decision to withdraw or not to 
take part will not affect your participation in 
future studies. Finally, an expression of 
interest does not commit you to taking part.  
 
What happens if I decide to take part? 
If you decide to take part, your involvement in 
the study will last about 8 weeks depending 
on your availability for the study visits. You 
will be required to visit the QI CRF on 10 
separate occasions (4 visits before the study 
starts and 6 visits during the study). Where 
possible, appointments will be made at your 
convenience but will take place on a weekday 
during QI CRF opening hours. 
 
Below are the QI CRF visits outlined in more 
detail, explaining the study along the way. The 
QI CRF is located at James Watson Road, 
Norwich, NR4 6UQ. 
 
Pre-study talk (Visit 1) 
This meeting will last approximately an hour. 
A member of the study team will go through 
this information sheet with you and answer 
any questions you may have. After this 
meeting, you will be given as long as you need 
to decide whether or not you wish to take 
part in the study. This period will be a 
minimum of 72 hours. If you decide to take 
part in the study, you will need to contact a 
member of the study team (details on front 
page of this information sheet) to arrange an 
appointment for the next visit. 
 
After the talk, you will be given a copy of the 
Bristol Stool Chart and a small container for 
urinalysis. Should you decide not to take part 
in the study, you may dispose of these as you 
see fit. If you do join the study, we would like 
you to use the Bristol Stool Chart to identify 
what your typical stool type is, as you will be 
asked this at your screening visit by the QI CRF 
research nurse. The container will be used for 
a urine sample, which you will need to bring 
to your next visit. 
Note: Where possible, for females, the 
screening visit will be arranged for 7 days 
after their last period. 
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Eligibility screening and Informed Consent 
(Visit 2) 
This visit can last up to 1.5 hours. You will 
need to bring a midstream urine sample in the 
container that we gave you during Visit 1. If 
you use any other container, this could affect 
your results and therefore your eligibility to 
take part in the study. If you have lost the pot, 
we will provide you with another at your 
appointment and give you the opportunity to 
produce a urine sample during the visit.   
 
Before we carry out the eligibility assessment, 
you will be asked to sign two consent forms 
agreeing to (i) participate in the study and (ii) 
have your samples stored in the Norwich 
Biorepository. These forms will also be signed 
by a member of the study team (study 
manager or study scientist) or the QI CRF 
Research Nurse. You will also complete a 
medical declaration form with the QI CRF 
Research Nurse, which you will be given a 
copy of. Once you have signed the consent 
forms you are still free to withdraw at any 
time without giving a reason. 
 
After you have signed the consent forms, the 
QI CRF research nurse will carry out a urine 
dipstick test on your urine sample. The results 
of this will be known immediately and the CRF 
Research Nurse will discuss the results with 
you. Depending on your urine dipstick test 
results you may be excluded from the study or 
offered a re-screen and advised to speak to 
your doctor or surgery nurse about your 
results. All abnormal results will be referred to 
the QI CRF Medical Advisor. In an event of 
flagged urinalysis result, the decision to 
exclude you from the study will be taken by 
the QI medical advisor. 
A QI CRF research nurse will then complete a 
brief eligibility screening questionnaire with 
you and also measure and record the 
following: 
 
• Blood pressure 
• Pulse rate 
• Height 
• Weight 
• BMI 
 
Your height and weight will be used to 
calculate your BMI. BMI is a measure of 
whether you are a healthy weight for your 
height. If your BMI is outside the range of 19.5 
and 30 kg/m2 you will not be able to take part 
in the study. 
 
The QI CRF research nurse will then take a 20 
mL (roughly 4 teaspoons) blood sample from 
a vein in your arm. This blood test will 
measure your full blood count, iron levels, 
CRP (a marker for inflammation) and blood 
sugar levels. These will be assessed for 
anything outside the standard reference 
ranges and ensure you are eligible to 
participate in the study. Bloods will be tested 
at the NNUH Pathology Laboratories. The 
turnaround time for the results is roughly a 
week.  
 
We will send copies of all your clinical results 
(urine and blood results, blood pressure, 
pulse, BMI and weight) to your GP. If any of 
your clinical results are outside the standard 
reference ranges, we may recommend that 
you speak to your GP about the results. Any 
results outside the reference ranges will be 
checked by the QI medical advisor and will be 
in charge of making any decisions regarding 
blood/urine abnormalities. The QI medical 
advisor will also advise whether we will offer 
you the opportunity to re-screen in the event 
of abnormal results. If, on the second 
occasion, your results fall outside the 
standard reference ranges, you may be 
excluded from the study based on the results 
flagged. We cannot tell you what your results 
means as we are not medically trained to do 
so. Finally, please remember, these tests are 
performed to determine if you are suitable for 
the study, not to find out if you are healthy. 
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Please note, if you do not commence the study 
within 3 months of your eligibility screening, 
you will have to be re-screened should you 
wish to take part. 
 
Faecal sample collection kit pick-up (Visit 3) 
This visit will last for approximately 20 
minutes. You will be invited to take part in this 
study if the blood and urine tests from the 
eligibility screening is satisfactory, and you 
meet all the listed criteria for participation. 
You will be asked to collect a faecal sample 
collection kit, along with a detailed sheet on 
how we would like you to collect and store 
your faecal sample until you can deliver it to 
us, or it can be collected by a member of the 
study team. Everything you need to collect 
the sample will be provided within the kit. 
 
Faecal sample drop-off (Visit 4) 
This visit will last for approximately 10 
minutes. You will be asked to bring a faecal 
sample to the QI CRF in the faecal collection 
kit provided during Visit 3. After you have 
given us your first faecal sample, which will be 
used to give us an idea of the bacteria present 
in your large intestine, we will arrange a time 
and date for you to collect the first batch of 
capsules and commence the study. 
 
The study 
There are three phases in this study, and you 
do not need to be fasted on any days during 
any of these phases. Each phase will last for a 
period of 14 days. These phases are described 
below: 
 
Phase 1: 2 capsules containing either 0.4 g 
phytin or control powder, 3 times a day. 
Therefore, a total daily intake of phytin 
consumed during Phase 1 is 2.4 g. 
Washout phase: no capsules consumed 
during this phase 
Phase 2: 2 capsules containing either 0.4 g 
phytin or control powder, 3 times a day. 
Therefore, a total daily intake of phytin 
consumed during Phase 2 is 2.4 g. 
 
The order in which you consume either the 
phytin or control capsules will be ‘randomly’ 
assigned by a computer. By this, we mean 
that the order is assigned by a method similar 
to being picked out of a hat. Neither the study 
scientist nor you will know in which order you 
are consuming the capsules. Also, both types 
of capsules will look identical.  
 
During Phase 1 and Phase 2, you will be asked 
to complete two forms, for a consecutive 7 
days each. The first is a stool chart and the 
second is a food frequency questionnaire. The 
stool chart will help us gauge the frequency 
and consistency of the stools you produce. 
The food frequency questionnaire will be used 
to assess your habitual diet over the study 
period and whether your food habits correlate 
with, or are reflected in, the study outcome. 
 
Phase 1 (Visit 5, Days 1-14) 
This visit will last for approximately an hour. 
When you visit the QI CRF to begin Phase 1, 
you will be asked to provide a faecal sample if 
you have not done so already (Visits 3 and 4). 
You will be asked if you are happy to continue 
with the study, and whether you have had any 
changes to your health (this will be addressed 
in the form of a follow-up health 
questionnaire) or medication since your 
screening appointment which may affect the 
study data. A QI CRF research nurse will take a 
15 mL blood sample (to test for iron and CRP). 
 
As mentioned earlier on in “The Study”, you 
will be required to consume 2 capsules 
(randomly assigned), 3 times a day with a 
meal. The first 2 capsules of each phase must 
be consumed at the QI CRF and remain at the 
QI CRF for a minimum of 20 minutes (food will 
be provided on this occasion). After you have 
consumed the first 2 capsules, you will be 
provided with a bottle containing the rest of 
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the capsules required for Phase 1. This bottle 
will include extra capsules in case any are 
lost/misplaced.  
 
You will be given a new faecal collection kit 
before you leave the QI CRF for the next stool 
sample you will provide. You will also be given 
a form with the Bristol Stool Chart to record 
your stool frequency and consistency, along 
with a food frequency questionnaire. Please 
remember to fill both these forms for a 
consecutive 7 days during Phase 1 (these can 
be any 7 days you wish). Finally, you will be 
given a Capsule Checklist, where you need to 
tick the relevant box to show you have taken 
the capsules. 
 
Mid-Phase 1 Faecal Sample Drop-off (Visit 6, 
Day 7) 
This visit will last for approximately 10 
minutes. Once you are halfway through Phase 
1, we will need you provide us with a faecal 
sample. The faecal collection kit given at the 
end of your last visit (Visit 5) should be used 
to collect this sample. Once you have dropped 
this sample off, you will be provided with a 
new faecal collection kit for the next sample.  
 
End of Phase 1 (Visit 7, Day 14) 
This visit will last for approximately 30 
minutes. At the end of Phase 1, you will be 
asked to deliver a faecal sample to the QI CRF 
in the faecal collection kit provided during 
Visit 6. When you are at the QI CRF, a QI CRF 
research nurse will take a 15 mL blood sample 
(to test for iron and CRP). You will also be 
asked to return the bottle containing the 
capsules that was given to you at the start of 
Phase 1, including any capsules that were not 
consumed during Phase 1. The completed 
food frequency questionnaire, capsule 
checklist and stool charts will be collected 
from you and finally, a new faecal collection 
kit will be provided. 
 
Washout Phase (Days 15-28) 
During the washout phase, you will continue 
your normal diet with no capsule 
consumption. At the end of this phase, you 
will be asked to provide us with a stool 
sample, delivered when you next visit the QI 
CRF. 
 
Phase 2 (Visit 8, Days 29-42) 
This visit will last for approximately 30-45 
minutes. You will be asked to deliver a faecal 
sample before starting Phase 2. As before, 
you will be given an opportunity to produce a 
faecal sample at the QI CRF if you were unable 
to do so before. You will be asked if you are 
happy to continue with the study, and 
whether you have had any changes to your 
health (this will be addressed in the form of a 
follow-up health questionnaire) or medication 
since the end of Phase 1 which may affect the 
study data. A QI CRF Research Nurse will take 
a 15 mL blood sample (to test for iron and 
CRP). For Phase 2, you will be given a bottle 
containing the alternative set of capsules to 
what you consumed during Phase 1. All other 
aspects of Phase 2 are identical to Phase 1. 
Please refer to the section titled ‘Phase 1’ for 
details.  
 
Mid-Phase 2 Faecal Sample Drop-off (Visit 9, 
Day 35) 
This visit will last for approximately 10 
minutes. Please refer to section titled ‘Mid-
Phase 1 Faecal Sample Drop-off’ for more 
details. 
 
End of Phase 2 (Visit 10, Day 42) 
This visit will last for approximately 30 
minutes. At the end of Phase 2, you will be 
asked to deliver a faecal sample to the QI CRF 
in the faecal collection kit provided during 
Visit 9. When you are at the QI CRF, a QI CRF 
research nurse will take a 15 mL blood sample 
(to test for iron and CRP). You will also be 
asked to return the bottle that was given to 
you at the start of Phase 2, including any 
capsules that were not consumed during 
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Phase 2. Finally, the completed food 
frequency questionnaire, capsule checklist 
and stool charts will be collected from you 
and this will mark the end of the study.  
Please note, if you intend to go on 
holiday/travel whilst taking part in this study, 
we will require you to remain in the UK during 
both Phase 1 and 2. You may travel during the 
washout phase. If you are unexpectedly 
unable to attend a pre-arranged assessment 
at the end of a 2-week treatment period, 
depending on their next availability, you will 
be asked to come in either a couple days 
before/after the scheduled visit. If you are not 
available till after more than 3 days of the 
scheduled visit, you may be asked to repeat 
the treatment.  
 
Below is a brief breakdown of the overall 
samples/forms that will be collected from you 
through the course of this study: 
 
Blood samples  
Total number: 5 samples, amounting to 80 mL 
(16 teaspoons) 
- Sample 1: Eligibility screening, 20 mL, 
results sent to GP. Analysed by NNUH 
Pathology Laboratories. Testing for 
iron, CRP, full blood count and blood 
sugar. 
- Sample 2: Start of Phase 1, 15 mL, 
results analysed in QIB laboratories. 
Testing for iron and CRP 
- Sample 3: End of Phase 1, 15 mL, 
results analysed in QIB laboratories. 
Testing for iron and CRP 
- Sample 4: Start of Phase 2, 15 mL, 
results analysed in QIB laboratories. 
Testing for iron and CRP 
- Sample 5: End of Phase 2, 15 mL, 
results analysed in QIB laboratories. 
Testing for iron and CRP 
Faecal samples 
Total number: 6 samples 
- Sample 1: Before starting Phase 1 
- Sample 2: Midway Phase 1 
- Sample 3: End of Phase 1 
- Sample 4: End of washout 
phase/before starting Phase 2 
- Sample 5: Midway Phase 2 
- Sample 6: End of Phase 2 
Stool charts 
Total number: 2 charts, each recording 7 
consecutive days from Phase 1 and 2 
- Stool chart 1: During Phase 1 
- Stool chart 2: During Phase 2 
Capsule checklist 
Total number: 1 checklist for entire study 
Food frequency questionnaires  
Total number: 2 questionnaires, each 
recording 7 consecutive days from Phase 1 
and 2 
- Questionnaire 1: During Phase 1 
- Questionnaire 2: During Phase 2  
 
A flowchart summarising the outline of this 
study can be found on page 14. 
 
What happens if I become unwell during the 
study? 
If you become unwell during the study, we 
may ask you to stop taking the capsules and 
repeat the Phase that you are in once you are 
better. This will, of course, depend on the 
nature of the illness and whether or not it will 
affect the study outcome. 
In a medical emergency, you should contact 
the emergency service (via 999) and please 
ensure that your GP and the study team are 
informed as soon as practicably possible. 
 
Access to your personal information 
When you are screened for the study, you will 
be given a code number. This code number is 
unique to you and will be used to protect your 
identity and make your samples anonymous. 
Access to any information about you will be 
restricted to the research team, nurses at the 
QI CRF and your GP. There is more 
information about this in Part 2. 
Expenses and payments 
Participating in these studies is on a voluntary 
basis. However, we do recognise that taking 
part can cause some inconvenience and there 
are associated travel costs. Thus, you will 
receive £268 as an inconvenience payment; if 
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you withdraw or are excluded from the study, 
payment will be pro-rata. This means that you 
will be paid up until the point of 
withdrawal/exclusion from study. Travelling 
expenses to and from the QI CRF will be 
reimbursed on presentation of a receipt for 
buses or trains, or at the current QIB mileage 
rate for private cars. If you require transport 
to and from the QI CRF, please let us know 
and we will arrange and pay for a taxi. 
 
All payments are liable to tax and you are 
responsible for declaring your own payments 
for tax purposes. Members of staff at QIB are 
free to participate in this study provided they 
meet the study criteria; however, we would 
like to point out that their inconvenience 
payment will be taxed at source in accordance 
with BBSRC and QIB rules and HM Revenue 
and Customs (HMRC). If you are in receipt of 
benefits this payment may affect your 
benefits. 
 
What are the risks/side effects of 
participating in this study? 
As with any pressure measurement (like blood 
pressure) the inflation of the blood pressure 
cuffs may cause slight discomfort and a 
reddening of the arm where the cuff is placed, 
but this affects some people more than 
others. 
There can be a small amount of discomfort 
when taking blood samples. As mentioned 
before, this may affect some people more 
than others but generally, any discomfort 
occurs on insertion of needle. You may 
develop a small bruise at the site of injection, 
but as with any bruise, this will fade. 
 
What are the potential benefits of taking 
part? 
For you, there are no direct benefits however, 
your participation and subsequent results will 
help us to understand if there are any effects 
of iron limitation on the gut bacteria. 
 
Who will carry out the medical procedures? 
The study will be carried out in collaboration 
with the QI CRF. The QI CRF is an NHS-
governed facility and all clinical procedures 
for this study will be carried out by the QI CRF 
team following NNUH standard operating 
procedures. Clinical assessment and 
procedures will be performed by two 
members of the CRF team when you are 
attending the CRF. This will include a 
registered nurse and another member of staff 
who is trained in NNUH emergency 
procedures. When no clinical assessment or 
interventions are to be performed (for 
example in the case of an appointment for 
consent), two members of the QI CRF team 
will also be present. This will include a 
Healthcare professional who is trained n 
NNUH emergency procedures and a second 
designated member of staff to provide 
support. 
 
Will my taking part be kept confidential? 
Yes – we follow Good Clinical Practice (GCP) 
and strict ethical and research governance 
rules. All information about you will be 
handled in confidence. More details about this 
are included in Part 2. 
Data will be managed by the study team in 
compliance with EU General Data Protection 
Regulation (GPDR) and the UK Data Protection 
Act (DPA; 2018).  
This completes Part 1 of the information 
sheet. If the information in Part 1 has 
interested you and you are considering taking 
part, it is important that you read the 
additional information in Part 2 before 
making any decision. 
 
PART 2 
 
What if relevant new information becomes 
available or changes to the study are made? 
If there are changes to the study or new 
information becomes available, we will tell 
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you. If these changes are significant, you may 
be asked to sign another consent form. 
 
What will happen if I don’t want to carry on 
with the study? 
You are free to withdraw from the study at any 
time without giving a reason. However, a study 
team member will need to be informed of your 
decision to withdraw. If you withdraw from the 
study, we will analyse your samples collected 
up to the point that you leave the study with 
those we obtain from all the volunteers, unless 
you decide otherwise. You will receive 
payment pro-rata for any samples, diaries etc. 
you have contributed. 
 
How safe is it for me to ingest these 
capsules? 
Phytic acid has been approved as a food 
additive and has been given ‘generally 
regarded as safe’ (GRAS) status for human 
consumption. There are no known reports of 
phytic acid toxicity via oral consumption in 
humans. The particular form of phytic acid 
(phytin) in the capsules that we will provide 
has not been directly tested for its safety, and 
is therefore the first trial, but it is regarded as 
just one of several forms of phytic acid and 
similar to numerous closely related forms that 
are widely consumed. 
 
The daily dose of phytic acid you are being 
asked to consume is above the average daily 
intake in the UK population, which is around 
0.7 g/day, although some people consume 
much more than this. The dose is similar to 
the amounts consumed by specific population 
groups such as vegans and vegetarians, and in 
other parts of the world (e.g. regions of Africa 
and Asia). The highest reported average 
intakes were 5.6 g/day. 
 
What if there is a problem? 
If you have any concerns about the study, you 
should ask to speak to the study manager, 
Bhavika Parmanand on 01603 255021 who 
will do her best to answer your questions. If 
you are still unhappy, and wish to complain 
formally, you can do this through the 
chairperson of the QI Human Research 
Governance Committee (HRGC) – Dr 
Antonietta Melchini on 01603 255030. 
 
What if something happens to me while I am 
on the study? 
QIB accepts responsibility for carrying out 
trials and as such will give consideration to 
claims from participants for any harm suffered 
by them as a result of participating in the trial, 
with the exception of those claims arising out 
of negligence by the participant. QIB has 
liability insurance in respect of research work 
involving human volunteers. Please note that 
the Institute will not fund any legal costs 
arising from any action unless awarded by a 
court. 
If you wish to complain or have any concerns 
about the way you have been treated whilst 
taking part in this study at the QI CRF, there 
will be a local hospital complaints procedure 
that you can follow. If you wish to complain 
you should contact the Patient Advice and 
Liaison Service (PALS) at the NNUH on 01603 
289036 (email: pals@nnuh.nhs.uk). Their 
offices are located next to Kimberley Ward, 
East Block Level 2 or please ask at the main 
reception desks at the Inpatient and 
Outpatient NNUH hospital entrances. The 
office has an answerphone which is available 
24 hours a day and messages will be 
responded to as quickly as possible. As this 
study involves the QI CRF, which is an NHS 
facility, indemnity is provided through NHS 
schemes.  
 
Will my taking part in this study be kept 
confidential? 
All information collected about you during the 
course of the study will be kept strictly 
confidential. Any information leaving QIB, 
such as bacterial DNA extracted from stool 
samples for phylogenetic analysis, will be 
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anonymous. Study information will be stored 
in locked filing cabinets at the QIB. Personal 
data collected will be processed by computer, 
however only personal information that is 
essential for the study will be collected. 
 
When you are screened for the study, you will 
be given a unique code number (volunteer 
code number). This number will be used to 
identify your samples and prevents anyone 
from working out whose samples are whose. 
Access to your personal records is restricted to 
the study team, the QI CRF Research Nurse and 
your GP.  
 
The Quadram Institute Bioscience is the 
sponsor for this study based in the United 
Kingdom. We will be using information from 
you in order to undertake this study and will 
act as the data controller for this study. This 
means that we are responsible for looking 
after your information and using it properly. 
QIB will keep identifiable information about 
you 15 years after the study has finished. 
 
Your rights to access, change or move your 
information are limited, as we need to 
manage your information in specific ways in 
order for the research to be reliable and 
accurate. If you withdraw from the study, we 
will keep the information about you that we 
have already obtained. To safeguard your 
rights, we will use the minimum personally-
identifiable information possible. 
 
You can find out more about how we use your 
information by contacting the QIB Data 
Protection Officer [Mr Mohamed Imran, 
mohamed.imran@nbi.ac.uk] or QIB Human 
studies coordinator [Dr Antonietta Melchini, 
antonietta.melchini@quadram.ac.uk].  
The only people in QIB who will have access to 
information that identifies you will be people 
who need to contact you to under emergency 
unblinding procedures or audit the data 
collection process. The people who analyse 
the information will not be able to identify 
you and will not be able to find out your name 
or contact details. 
 
QIB will keep identifiable information about 
you from this study for 15 years after the 
study has finished. 
 
Data will be managed by the study team in 
compliance with EU General Data Protection 
Regulation (GPDR) and the UK Data Protection 
Act (DPA; 2018). 
 
All research is subject to inspection and audit. 
Although your records may be accessed for 
this purpose, any personal information 
remains confidential. Please note, QI has CCTV 
cameras in use for security purposes.  
 
Will my GP be informed?  
Yes, it is routine practice to inform your GP 
that you are taking part in a study at the QIB 
and we will send them: 
• Details of the study (including the PIS) 
• Your eligibility screening results 
including the dipstick urine test, blood 
test, blood pressure, pulse, weight 
and BMI  
• Any stool charts that indicate 
abnormal stools or the presence of 
blood 
 
This is one of the things you agree to when 
signing one of the consent forms (study 
participation). Any screening results which fall 
outside standard reference ranges will be 
assessed by the QI medical advisor. We are 
unable to discuss test results with you; 
however, you will be advised to speak to your 
GP about the results if deemed necessary. 
What will happen to the samples I give? 
The urine sample at QI CRF during the 
screening will be used immediately for a urine 
dipstick test and then discarded. The 20 mL 
blood sample you provide at the eligibility 
screening (Visit 2) will be sent to NNUH 
Pathology Laboratories for a full blood count, 
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iron levels, CRP levels and blood sugar levels. 
The purpose of this is to check for anything 
outside the reference ranges which may affect 
your well-being if you took part but also to 
make sure you fit the criteria for the study.  
 
The blood and faecal samples that you 
provide during the course of the study (Phase 
1 and Phase 2) will be used for research 
purposes. The blood samples taken 
throughout the study will be used to measure 
your iron levels. These measurements will be 
used as a baseline sample to ensure that iron 
levels are not affected by early release of 
capsules. CRP levels will also be analysed to 
ensure no systemic inflammation is present. 
The bacteria from your faecal sample will be 
collected and the different types of bacteria 
present will be determined by extracting 
bacterial DNA. As mentioned earlier on, your 
own DNA will not be looked at, only bacterial 
DNA. The faecal samples will also be used to 
examine changes in gut metabolites (these 
are substances that the body produces that 
are needed for cell survival) using nuclear 
magnetic resonance spectroscopy (NMR). 
NMR is a method that is able to separate the 
components of a mixture.  
 
Once all the samples have been analysed, 
samples will be put into long-term storage at 
the Norwich Research Park Biorepository (this 
is the second consent form you would have 
signed at screening) ; which holds a Human 
Tissue Licence for this purpose (IRAS no: 
130478, East of England - Cambridge East 
Research Ethics Committee 08/h0304/85+5). 
Samples may then be extracted from the 
Biorepository for use in future research 
projects where approval is ethically sought. 
What will happen to the results of the 
research study? 
As a volunteer you are valuable to us, but we 
are unable to tell you any of your individual 
results. The data resulting from the study may 
be published in scientific journals or 
presented at meetings with our funders. At 
the end of the study we will provide you with 
some feedback about what we have found as 
a result of your help and what it may mean for 
future research. Please note that the data is 
presented as a whole and is anonymous. Your 
name will not appear anywhere in any of the 
results presented, shared or published.  
 
Who is organising and funding this study? 
This study is funded through Biotechnology 
and Biological Sciences Research Council 
(BBSRC); this study was funded by the BBSRC 
Institute Strategic Programme Food 
Innovation and Health QIB. 
 
Who has reviewed this study? 
At QIB this research project has been 
reviewed by the QIB Human Research 
Governance Committee (HRGC), as well as an 
external Local Research Ethics Committee 
(REC). These are groups of independent 
people who review research to protect your 
safety, rights, well-being and dignity. This 
study has been reviewed by all committees 
and given a favourable opinion. Following 
ethical approval, the study protocol will also 
be registered at Clinicaltrials.gov.  
 
Further information-what we need you to 
tell us 
We need you to tell us some things for your 
safety and for the success of the study. 
 
Please tell us if you: 
• Have any episodes of illness, even if it 
is just a headache 
• Are injured in any way 
• Feel unwell during or after a visit to the 
unit 
• Become pregnant 
 
Some medicines affect the information we are 
collecting. Please tell us if you take any 
medication including those you purchase at 
the chemist or supermarket (e.g. 
paracetamol). 
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You should bring details of any medication 
(i.e. name of the medicine and the dose 
taken) you are taking when you come for your 
screening visit (Visit 1). 
 
Taking part in the research is entirely 
voluntary! You are free to withdraw from the 
study at any time without giving a reason. 
 
For further information or to arrange a study 
appointment, please contact a member of 
the study team or complete the attached 
response slip and return to us using the  
prepaid envelope enclosed. Thank you! 
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Outline of Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-study talk 
Visit 1 (~1 hr) 
Eligibility Screening 
Visit 2 (~ 1.5 hr) 
Faecal Sample Collection 
kit pick-up 
Visit 3 (~20 min) 
Faecal Sample Drop-off 
Visit 4 (~10 min) 
Phase 1 – Visit 5, Days 1-14 
Days 1-7 
2x capsules 3 
times a day 
with meal 
Day 7 – Visit 6 
Mid-phase 
faecal sample 
drop-off 
Days 7-14 
2x capsules 3 
times a day 
with meal 
End of Phase 1 faecal and blood 
sample – Visit 7 
Washout Phase (Days 15-28) 
End of washout phase faecal and blood 
sample – Visit 8 
Phase 2 – Visits 8-10, Days 29-42 
Identical to Phase 1 above 
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Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
I am interested in taking part and/or finding out more information about this study (please complete 
the personal details below). 
 
Name: ………………………………………………………………………………………………………………. 
 
Address: …………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………………………. 
 
…………………………………………………………………………………………………………………………. 
 
…………………………………………………………………………………………………………………………. 
 
Daytime telephone ……………………………………………………………………………………….… 
 
Evening telephone ………………………………………………………………………..………………… 
 
Mobile .................................................................................................................. 
 
I am happy for a message to be left via my daytime/evening/mobile number: YES/NO 
*please circle as applicable 
 
Preferred number/time to call: ……………………………………………………………………… 
 
E-mail address ………………………………………………………………………………………………… 
 
Please return this form in the FREEPOST envelope provided, to: 
 
Miss Bhavika Parmanand 
Quadram Institute Bioscience 
FREEPOST XXX 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Expressing an interest does not commit you to taking part in the study 
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WE NEED YOUR HELP ON 
 Effect of Phytin on Human Gut 
Microbiome 
The EPoM Study 
 
There is evidence that regularly eating foods containing phytin, such as cereals 
and legumes, may decrease the number of ‘bad’ bacteria in your gut. 
 
We need to recruit: 
Men and women aged between 18 - 50 years old for an 8-week study 
 
You would have to: 
 Consume capsules containing phytin  
 Provide biological samples such as urine, stools and blood  
 
We will:    Reimburse your expenses 
         Provide recompense for taking part in the study 
 
If you live within 40 miles of Norwich and would like further information on 
the study, please contact:  
Miss Bhavika Parmanand 
01603 255021 
Bhavika.parmanand@quadram.ac.uk  
       
      Dr Lee Kellingray 
             01603 255070 
            Lee.kellingray@quadram.ac.uk 
 
The study will be sponsored by the QIB and funded through the Biotechnology and Biological Sciences Research Council (BBSRC); this 
study was funded by the BBSRC Institute Strategic Programme Food Innovation and Health ISP. 
An expression of interest does not commit you to participation.  
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WE NEED YOUR HELP ON 
Effect of Phytin on Human Gut 
Microbiome 
The EPoM Study 
There is evidence that regularly eating 
foods containing phytin, such as cereals and legumes, may decrease the number of ‘bad’ 
bacteria in your gut. 
 
We need to recruit: 
Men and women aged between 18 - 50 years old for an 8-week study 
 
You would have to: 
 Consume capsules containing phytin 
 Provide biological samples such as urine, stools and blood 
 
We will:    Reimburse your expenses 
        Provide recompense for taking part in the study 
 
If you live within 40 miles of Norwich and would like further information on the study, please 
contact:         Miss Bhavika Parmanand 
01603 255021 
Bhavika.parmanand@quadram.ac.uk  
                  Dr Lee Kellingray  
                 01603 255070 
               Lee.kellingray@quadram.ac.uk 
The study will be sponsored by the QIB and funded through the Biotechnology and Biological Sciences Research Council (BBSRC); this study was funded by the BBSRC 
Institute Strategic Programme Food Innovation and Health ISP. 
                                                                          An expression of interest does not commit you to participation.  
Please take a tear off slip  
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Colney 
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UK 
 
www.quadram.ac.uk 
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[Insert Date] 
 
Dear_____________________________, 
 
Thank you for your interest in the following research study: 
 
Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
at the Quadram Institute Bioscience, study location Quadram Institute Clinical Research 
Facility (QI CRF). 
 
I have sent you the details of this study, which is in progress at present, as you have 
responded to an advert about the study and you may fit the criteria for this study. If you 
have any further questions about the study, please contact, Miss Bhavika Parmanand on 
01603 255021 or bhavika.parmanand@quadram.ac.uk as stated on the enclosed 
participant information sheet. 
 
If you are interested in taking part or getting more information about the study, please fill out 
the reply slip on page 14 of your participant information sheet, return it to the Quadram 
Institute in the freepost envelope provided and a member of the study team will be in touch. 
 
Thank you.  
 
Yours sincerely, 
 
 
 
Miss Bhavika Parmanand,  
EPoM study manager 
 
Quadram Institute Bioscience is a registered charity (No. 1058499)  
and a company limited by guarantee (registered in England and Wales No. 03009972).  
VAT registration No. GB 688 8914 52 
 
IRAS ID 251932 
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 INFORMED CONSENT FORM FOR RESEARCH STUDY 
  
IRAS ID: [251932] 
Study Number: [19/EE/0005] 
Participant Identification Number for this trial: 
248 
 
 
Study Title: A human intervention trial investigating the effects of phytin on the human gut microbiota 
Chief Investigator: Professor Arjan Narbad 
         Volunteer please initial each box 
 
I confirm that I have read the information sheet dated.................... (version............) for the above study.  
I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.  
   
With who have you discussed the information for this research study? 
Name:  ……………………………………………………….……  Role: EPoM Study Manager/Study Scientist/Research Nurse 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any time (i) without giving any reason, 
 (ii) without my medical care or legal rights being affected, and (iii) without my withdrawal affecting future participation 
 in other research studies at QIB and at the QI CRF and NNUH hospital 
 
 
I agree that I do not fall within the basic exclusion criteria listed for this research study     
 
 
I understand that relevant sections of my medical notes and data collected during the study may be looked at by 
 individuals from QIB, from regulatory authorities or from the NHS Trust, where it is relevant to my taking part  
in this research. I give permission for these individuals to have access to my records.                                                           
 
 
I understand that my personal information and data will be held confidentially at QIB and that it will be destroyed 
 after 15 years.                                                      
 
 
I understand that the information collected about me will be used to support other research in the future and may be 
 shared anonymously with other researchers. 
 
 
I agree to my General Practitioner being involved in the study, including any necessary exchange of information about  
me between my GP and the research team. 
 
Name and address of your General Practitioner:  …………………………………………………………………………………………
 …………………………………………………………………………………………………..…………………………………………. 
 
I understand that all research is subject to inspection and audit.       
NB: although your records may be accessed for this purpose your personal information remains confidential 
 
 
 
I agree to take part in the above study. 
 
Signed:  ……………………………………………………………………………………………………………… (Name in BLOCK letters) 
Date:  ………………………………………………………… Date of Birth: ………………..…………………………… 
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INFORMED CONSENT FORM FOR RESEARCH STUDY 
IRAS ID: 251932 
Study Number: [to insert after HRA submission] 
Participant Identification Number for this trial: 
 
1 copy of the signed consent form must be given to the volunteer to keep.  
1 copy of the signed consent form must be kept in the study records at QIB and QI CRF notes  
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I confirm that the volunteer above has been given a full verbal and written explanation of the 
study. 
Signed: ……………………………………………………………………………………………………………… (Name in BLOCK letters) 
Role:  ………………………………………………… (in BLOCK letters)  Date:  ………………………………………………… 
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The Norwich Biorepository 
 
The donation, collection, storage and use of samples of tissue 
and/or fluids and/or other material from a healthy adult donor for 
research 
 
Information sheet for healthy donors - Version 15 
(21 February 2014) 
 
Thank you for considering giving a sample for biomedical research. This information 
sheet provides a brief summary to help you to understand what this means and 
involves. 
 
There is a consent form after the information sheet. It is important that you complete 
and sign it, if you decide to give a sample. Please complete all parts of the consent form. 
 
Doctors and other health professionals may take samples (which may be blood, other fluids, 
small biopsies, or something else) from patients to help make a diagnosis and decide how best 
to treat them. 
 
They may also ask to take similar samples from healthy donors, like you, specifically for 
research purposes. They use those samples to learn more about health and/or illness, how 
disease happens and how to treat it, and sometimes to help develop new medicines. 
 
For the purposes of medical research you do not need to be in perfect health. We may 
need to ask you some questions to confirm that you do NOT suffer from the medical 
condition which is being studied. 
 
Samples from healthy volunteers, like you, will include only those that can be obtained 
externally, or by normal routes (e.g., saliva, urine, faeces), or by minimal invasion involving 
very little risk to the donor (e.g., blood taken from a vein close to the surface, or a throat swab). 
Such minimally invasive procedures include those that might be undertaken during a routine 
visit to a general practitioner. Nothing more invasive than that is permitted using this consent 
form. 
 
Samples donated (given) to the Norwich Biorepository are not: 
 
• Normally used in animal research. It will be made clear to you if animal research is an 
integral part of the project for which we are seeking a donation. 
 
Continued………… 
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• Used in cloning experiments. However, the Biorepository would consider the use of 
donations in non-reproductive cloning experiments based on their scientific value and 
in the context of prevailing law and ethical standards. It will be made clear to you if 
cloning experiments are part of the research project for which we are seeking a 
donation. 
 
To undertake research on the sample(s) that you are considering donating, we need your 
permission and signed consent. 
 
If you give permission for a sample to be taken – 
 
• The Hospital will own the sample 
 
• The sample may be stored, usually in a deep freezer, until it is used. The freezer is 
referred to as a tissue bank in the consent form 
 
• Nobody involved in the research will know where the sample has come from. 
 
• The sample will be used only in experiments that are ethical and to help other people. 
Please see the section entitled ‘Scientific and ethical approval’ below to understand 
what we mean by ethical. 
 
• Your donated sample(s) and any genetic material derived from it (them) may be stored 
indefinitely for future research projects, which may include whole genome sequencing. 
Whole genome sequencing means reading your total DNA code (your genetic blueprint) 
in a single assessment. 
 
• We might give some or all of the sample to other doctors or researchers for their 
experiments, if they are ethical and to help other people. Some of these people might 
work in companies in this country or abroad 
 
• Data derived from your sample(s) may be placed anonymously in an international 
database for future research. While we will take all possible steps to maintain your 
anonymity and protect your privacy, there is a very small risk that genetic information 
produced in the research and stored on databases could lead to your identification by 
being linked to other stored information. 
 
• We will keep some facts about you on our Biorepository database 
 
• Although these facts might be given to the research doctors or scientists to help their 
experiments, we will NOT tell them your name or other details that would let them know 
who you are 
 
• Doctors in the Hospital might also read your hospital records to help them understand 
what the doctors or researchers find out in the experiments. This is possible because 
your hospital records can be linked to the anonymous research sample without loss of 
confidentiality as far as the researchers are concerned. If the research results are 
important for you, it might be possible using this linkage to feed back the information 
to your doctor, so that any appropriate action can be considered. 
 
The next sections give more detailed information. If you have any questions, please 
ask the person who is asking for your consent. 
Continued………… 
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WHAT WILL HAPPEN 
 
Tissue, blood or other samples taken from you will be sent either to the Norwich Biorepository 
or to a research laboratory. Only as much sample as is needed for  research will be 
removed. 
 
The donation of a sample for research is designed to be as safe as possible. It is most 
unlikely that you will come to any harm as a result of this donation (though we cannot 
give any guarantees). Potential physical problems depend on the type of donation. They 
might include, for example, discomfort or pain, bleeding, or infection. The person collecting 
the donation will be properly trained in the procedure. You will be asked to give your 
written consent before donation. 
 
While we will take all possible steps to maintain your anonymity and protect your 
privacy, there is a very small risk that genetic information produced in the research and stored 
on databases could lead to your identification by being linked to other stored information. 
 
 
MEDICAL RESEARCH AND WHY THIS PROGRAMME IS IMPORTANT 
Some of your sample, or material extracted from it, will be stored in a local tissue bank. This is 
part of a research programme which now includes the Norfolk and Norwich University Hospitals 
NHS Foundation Trust, the James Paget University Hospitals NHS Foundation Trust, the 
University of East Anglia (UEA), and the Institute of Food Research (IFR). Your donation may 
be used by ourselves or by researchers from other centres at a later date. Some of this 
research may involve an assessment of genetic material (DNA and/or RNA) to help us 
understand the genetic basis of health and disease. 
 
The purpose of this research is to understand more about human health and disease. It may 
also allow us to develop new methods of disease prevention or new treatments for the benefit 
of future patients. Some of these research programmes could lead to the development of new 
products and processes, which may be developed commercially for the improvement of patient 
care. In that case, there would be no financial benefit to you. 
 
Medically qualified doctors or other suitably qualified staff at the hospital may need to review 
your hospital case records, including hospital notes, if any, to help understand how the 
research findings made by other doctors or researchers using your donated samples fit with 
what is known of your medical history. It may be important to be able see how their research 
findings relate to past events in your health record. The hospital doctors will not give your name 
to those doing the research. 
 
The research may also involve training doctors and scientists in scientific medicine, and may 
lead to higher qualifications for them (e.g., PhD or MD degrees). This is important for future 
research into diseases and for looking for new, more effective, treatments for them. 
 
 
LINKS WITH OTHER ORGANISATIONS 
If you agree, we may send stored samples or products derived from them to other approved 
tissue banks or companies in this country or abroad. This would be to support their research 
programmes or the research programmes of those companies’ clients. 
 
Continued………… 
 253  
Such outside organisations will provide financial support for the Norwich Biorepository (our 
tissue bank), to help it recover its operating costs. We are not, however, allowed to sell the 
stored samples in order to make any financial profit from these commercial links. 
 
 
SCIENTIFIC AND ETHICAL APPROVAL 
The Norwich Biorepository acts as a custodian of the samples it holds. It releases them only 
to individuals or organisations that have an acceptable scientific background and work to high 
ethical standards. We require that all such medical research has been approved by a properly 
constituted Research Governance Committee before it starts. It must also be approved by a 
Research Ethics Committee or on behalf of the Research Ethics Committee that oversees the 
work of the Norwich Biorepository under the terms of the Biorepository’s own Research Ethics 
Committee approval. That committee is the Cambridge East Research Ethics Committee. 
These committees look particularly at the purpose and validity of the research proposal, the 
welfare of any participants and issues of consent and confidentiality. We will release samples 
to commercial companies only if they work to appropriate ethical and scientific standards. 
 
 
YOUR RIGHTS 
When your samples are obtained, some information about you will be kept on a computer in 
the Norwich Biorepository. This will help us understand how what we find in the laboratory 
relates to you as a person. You are entitled to ask to see what is recorded about you by 
applying to the Chairman of the Norwich Biorepository Committee, Norfolk & Norwich 
University Hospital, c/o Dept. of Histopathology, The Cotman Centre, Colney Lane, Norwich, 
NR4 7UB. No one other than you has the right to see these records. Any information needed 
for research purposes will be made anonymous before it is given to the researcher. 
 
The researchers will not be able to find out your name or any personal details about you 
from the information that they receive. 
 
You will have the opportunity to discuss with a doctor or researcher issues relating to the 
possible use of your samples for research purposes now or at the time the sample(s) is (are) 
collected. He or she will answer any questions you may have. 
 
MAKING A DONATION (GIFT) OF A SAMPLE FOR RESEARCH 
 
If you decide that you want your sample to be donated for research purposes, you will 
be asked to sign a special consent form. This will confirm your decision and state that 
you have read and understood this information sheet. When you sign the form you will 
give the ownership of the sample(s) to the Norfolk & Norwich University Hospitals NHS 
Foundation Trust. The sample(s) will then belong to the Trust. It will store the sample(s) for an 
indefinite period of time and will able to decide how it (they) should best be used for research. 
It will also have the right to dispose of unused stored material in an appropriate legal and ethical 
manner following normal procedures. 
 
If you do not want to donate a sample to be stored in the tissue bank or used for research, 
please tell us and do NOT sign the special Consent Form. If you do not sign this form, the 
donation will not proceed. 
Continued………… 
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I agree (Please initial small box) that the following sample(s) may be used for 
research, including genetic (DNA and/or RNA) studies and for the possible development of 
commercial products for the improvement of patient care, from which I would receive no 
financial benefit: 
  
 
I also agree that (Please initial small boxes, as appropriate): 
These samples become the property of the Norfolk & Norwich University Hospitals 
NHS Foundation Trust ("the Trust") 
 
The Trust may store these samples in a tissue bank / biorepository 
 
The Trust may use these samples at its discretion in properly approved research 
programmes 
 
The Trust may pass on these samples to other approved tissue banks and/or 
companies, which may be in this country or abroad, in properly approved 
research programmes 
 
My genetic material and donated sample(s) may be stored for an indefinite amount of 
time for future research projects, which may include whole genome sequencing 
 
Information about my case may be kept on the Norwich Biorepository database 
 
Anonymous data derived from my sample(s) may be placed in an international 
database for future research 
 
Such information may be passed in an anonymous form to persons outside the Trust 
In connection with research and may be published with any research findings 
 
I agree that appropriately qualified staff employed by the Trust may review my 
hospital records, including case notes, as appropriate, for the purposes of research 
using the donated samples 
 
Continued………… 
List sample(s) 
for research: 
No 
Yes 
Complete the following details: 
 
Donor’s name……………………….................. 
Date of birth……………………………………… 
Address …………………………………………. 
……………………………………………………. 
.…………………………………………………… 
The Norwich 
Biorepository 
Consent for the collection, 
storage and release of human 
samples for research 
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I also agree that (Please initial small boxes, as appropriate): 
These samples may be used in ethically approved animal research 
These samples may be used in ethically approved cloning research 
I confirm that: 
 
1) I have read and understand the Information Sheet for healthy donors, Version 15, 
dated 21 February 2014 
 
2) The issues have been explained to me, and that I have had the opportunity to ask 
questions. 
 
Signed  _  _ (Donor) Date  _ 
 
 
 
 
 
I have explained the request for sample for research purposes and have answered 
such questions as the donor has asked. 
 
Signed  _ Print name    
 
Doctor / Nursing Practitioner / Researcher / Other   
(Please delete as appropriate / indicate Other status) 
 
Date  _  _ 
No 
Yes 
No 
Yes 
Complete the following details: 
 
Donor’s name……………………….................. 
Date of birth……………………………………… 
Address …………………………………………. 
……………………………………………………. 
.…………………………………………………… 
The Norwich 
Biorepository 
Consent for the collection, 
storage and release of human 
samples for research 
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 MEDICATION/MEDICAL CONDITIONS DECLARATION  
AGREEMENT 
 
 
Certain illnesses and medication may affect the outcome of research studies. 
Therefore, we would like you to inform the study organisers if you 
• start taking medication 
• suffer from any illness 
 
                                  OR 
 
• become pregnant 
 
 
Please sign below to confirm that you have agreed to this request. 
 
 
 
I……………………….consent to inform the study organiser of the 
 
      commencement of any medication/medical changes whilst participating in the 
 
      study 
 
 
                                                              OR 
 
 
    If I think I may be pregnant whilst participating on the study. 
 
 
 
 
   Signature of volunteer……………………………………………. 
 
 
   Date……………………….. 
 
 
 
  Signature of scientist/member of QI CRF team ………………………………………. 
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CONFIDENTIAL Participant Eligibility Screening Questionnaire EPoM 
 
Participant code number……………………..                     Sex: Male / Female 
 
Date of birth: …………………………………….      Age: …………………………………years 
 
Height: …………………cms  Weight: ………………………Kg Body Mass Index (BMI, kg/m2) ……………  
 
Blood Pressure: Right arm……………………..Left arm…………………….. Pulse: …………………….. 
 
Urinalysis: see page 4 
 
Have you ever had any of the following?  If yes give details below each relevant section. 
 
Angina/heart disease:    Y N   Thrombosis:      Y N 
……………………………………………………………….                             ………………………………………………………………. 
……………………………………………………………….                             ………………………………………………………………. 
 
High Blood Pressure:     Y N    High Cholesterol:     Y N 
……………………………………………………………….                           ………………………………………………………………. 
……………………………………………………………….                             ………………………………………………………………. 
 
Chest problems:            Y N   Diabetes:              Y        N 
……………………………………………………………….   ………………………………………………………………. 
……………………………………………………………….   ………………………………………………………………. 
 
Depression or anxiety:   Y N   Digestive/Gastrointestinal disorders: 
                                                                                                                                                                   Y         N 
………………………………………………………………    …………………………………………………………….                                                        
……………………………………………………………….                                      ……..……………………………………………………….. 
……………………………………………………………….   ………………………………………………………………. 
Skin conditions:           Y N   Inflammatory disease:  E.g. rheumatoid 
……………………………………………………………….   arthritis                               Y         N 
……………………………………………………………….   ………………………………………………………………. 
        ………………………………………………………………. 
Liver problems:   Y N     
……………………………………………………………….   Other medical conditions:                 
……………………………………………………………….                                                               Y         N 
………………………………………………………………. 
Kidney/Renal problems:  Y N   ………………………………………………………………. 
………………………………………………………………. 
……………………………………………………………….       
 
Anaemia:                                         Y           N 
………………………………………………………………. 
……………………………………………………………….                                 
 
Are you currently on any of the following? 
If yes, give details below each relevant section of brand, dosage, frequency, when started etc. 
 
Prescribed medication:     Y         N   
……………………………………………………………….……………………………………………………………………………………………….…. 
Exclude if on medication for gastrointestinal problems 
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Colonic irrigation/bowel cleansing/ laxative/diarrhoea treatments:     Y         N   
……………………………………………………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………………………………………………. 
Exclude if on medication/treatment for diarrhoea, constipation, bowel discomfort/disorder (includes over the counter 
medications). 
          
Dietary Supplements:  Y N   Herbal remedies:  Y N 
……………………………………………………………….   ………………………………………………………………. 
……………………………………………………………….   ………………………………………………………………. 
……………………………………………………………….   ………………………………………………………………. 
If taking supplements/herbal remedies which may affect the study data and the participant is not willing to discontinue use for one month 
before and during the study, please exclude.  Check supplements/Herbal remedies with scientist 
 
WOMEN ONLY SECTION 
Are you/could you be pregnant?                                       Y         N          
Have you been pregnant within the last 12 months?       Y         N 
Are you breast-feeding?        Y         N 
When was your last period?     ………………………………………..                                                                   
End of women only section 
 
Have you had a major physical injury/operation? If yes give details below:          Y         N 
……………………………………………………………….……………………………………………………………….………………………………………………….. 
……………………………………………………………….……………………………………………………………….…………………………………………………… 
Are you currently suffering from any illness/injury? If yes give details below:       Y          N 
……………………………………………………………….……………………………………………………………….………………………………………………….. 
……………………………………………………………….……………………………………………………………….………………………………………………….. 
SMOKING:  
Are you currently a: Non-smoker / Current smoker / Ex-smoker / Lifelong smoker (circle appropriate) 
What do/did you smoke? (E.g. cigarettes, roll ups, cigars, pipe etc.)………………………………………………………………….…… 
If a non-smoker/Ex-smoker, have you ever smoked? Y N    
If yes, how long since you stopped smoking?...................How many did you smoke each day?.................... 
If currently a smoker/lifelong smoker: How many years have you been smoking? ……………………………………….…... 
DRINKING:  
Do you drink alcohol:            Y          N           How many units do you drink per week? ………………….…………………………… 
A unit of alcohol is approximately half a pint of beer or lager, a single pub measure of spirit e.g. gin/vodka or a small glass of 
wine (125mL). 
Exclude participants who appear to binge drink or regularly consume >15 units (women) or >22 units (men) per week.  
 
DIETARY QUESTIONS: 
Are you a vegan or vegetarian?                             Y N 
Do you have any special dietary requirements:  Y N 
If yes state:…………………………………………………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………..………………………………………………………………………… 
Have you any known allergies:                             Y N 
Food: ………………………………………………………………………. Drugs: ……………………………………………………………………………………. 
          ………………………………………………………………………..         …………………………………………………………………………………… 
Other: ……………………………………………………………….………………………………………………………………………………………………………. 
             ……………………………………………………………….………………………………………………………………………………………………………. 
Are you currently on/or plan to start a diet programme?                          Y   N 
If yes state which:……………………………………………………………………………………………………………………………………………………….. 
If on a diet programme which may affect the study data and the participant is not willing to discontinue for one month before and during 
the study, please exclude.  Check diet programmes with scientist                                                                                                                                
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BLOOD DONOR: 
Are you a regular blood donor?                            Y   N 
If yes, when did you last donate blood? ……………………………………………………………………………………………………………………. 
                                                                                                                                                                         
Do you take prebiotics or probiotics? These may be in a drink, yoghurt or other products. 
If yes, which products?...................................................................................................................................................... 
How frequently?................................................................................................................................................................. 
If taking regularly (3+ times a week) and willing to continue throughout the study, then include. 
If taking occasionally (<3 time a week), participant will have to discontinue use for at least 1 month before starting the 
intervention and throughout the study.  If participant not happy to do so, please exclude from study. 
 
GUT FUNCTION: 
On average, how many times do you open your bowels per day? …………………………………………………………………………….. 
Do you typically need to strain when opening your bowels?                                                             Y    N 
What is the typical colour of your stools? ………………………………………………………………………………………………………………….. 
What is your typical stool type? (refer to Bristol Stool Chart):  
Type:          1          2          3          4          5          6          7                                    (circle appropriate)                                        
If participant typically passes stool types 1, 2, or 7, exclude from study. 
Do you typically suffer from any pain/discomfort when passing stools?                            Y   N 
If yes, would you describe it as typically being: Mild / Moderate / Severe        (circle appropriate) 
Have you ever seen blood in your stools?                                                                    Y           N 
If yes, when did you last see blood in your stools? …………………………………………………………………………………………………….. 
If the participant did not seek medical advice on blood in their stools, exclude from study. 
 
GENERAL PRACTITIONER: 
Do you agree to us informing your General Practitioner of your participation in the study or of any results found?   
Y  N 
If you have answered NO to this question then we are unable to accept you on this study. 
 
Name and Address of your General Practitioner: 
………………………………………………………………………………………………………………………………………………………………………………… 
 
………………………………………………………………………………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………………………Telephone number:……………………………….. 
 
 
As far as you know are you related to or living with any member of study team?               Y                 N 
 
Are you currently participating in another research study?                                                      Y                 N   
If yes check with participant whether it involves dietary intervention– refer to QI CRF Research Nurse or scientist 
 
Are you currently undergoing any GP/Hospital investigations?                                               Y                 N 
 
 
 
 
Form completed by (print name):…………………………………………….............Signature:………………………………………… 
 
Designation:……………………………………………….                      Date: ………………………………………..  
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URINE DIPSTICK TEST RESULTS 
Attach to screening questionnaire to be kept at Study centre 
     
Study Title:     
 
Participant code number (NOT NAME):……………………………….   Date of Birth:……………………………………    Male/Female (circle) 
 
Date of sample:……………………………………………    Time of sample:………………………………. 
 
Multistix Dipstick urine test reults:      
 
Protein:…………         Glucose:…………         Ketones:…………        Bilirubin:………..    Urobilinogen:………...         Blood:…………… 
 
Specific Gravity………………   pH: ………………………………… 
             
 
Test performed by:   
 
Signature:  
 
Date:   
 
Time:  
 
Menstruating:     Y    N   N/A (circle as appropriate)  If menstruating do not refer to GP repeat urine test 5 days after finishing  
                                                                                                            Menstruation. If blood indicated on this occasion refer to GP as flagged          
                                                                                                            urine. 
 
Repeat urine dipstick test results. 
 
pH………….Protein:…………Glucose:……………Ketones:………          Bilirubin:…………. 
 
Urobilinogen:………..                       Blood:………….                  Specific Gravity…………. 
 
 
Test performed by:   
 
Signature:  
 
Date:   
 
Time:  
 
 
 
 
Comments:…………………………………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………………………………… 
 
Please note a copy of these results must be sent to the participant’s G.P on the Eligibility Screening Results Form.   
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BLOOD TEST RESULTS 
Attach to screening questionnaire to be kept at Study centre 
 
                                                                                                  
Study Title:     
 
Participant code number (NOT NAME):……………………………….   Date of Birth:……………………………………    Male/Female (circle) 
 
Date of sample:……………………………………………    Time of sample:………………………………. 
 
 
Serum ferritin ………………….. 
 
HbA1c …………………………….. 
 
Full blood count ………………      
 
CRP ………………………………… 
 
Test performed by:   
 
Signature:  
 
Date:   
 
Time:  
 
 
Comments:…………………………………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………………………………… 
 
Please note a copy of these results must be sent to the participant’s G.P on the Eligibility Screening Results Form.   
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Study Title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
Participant’s Name:……………………………………………………………   
 
Date of Birth:………….               Male/Female:………….. 
                           
Multistix Dipstick urine test reults:      
 
pH………………Protein:………… ….Glucose:………… Ketones:………        Bilirubin:……….. 
60 seconds              60 seconds              30 seconds              40 seconds                30 seconds 
 
Urobilinogen:………...       Blood:………………..      Specific Gravity……………… 
60 seconds                                   60 seconds                   45 seconds 
 
Menstruating:     Y    N   N/A (circle as appropriate)    
 
Test performed by (print name):……………….. Signature:…………………. Date:……… Time:…… 
 
Repeat test required at surgery prior to re-screen:  Y    N    N/A      (circle as appropriate)   
 
Repeat urine dipstick test results (QI CRF).  Tested using Urine dipstick test strips/guide times as above  
 
pH………….Protein:…………Glucose:……………Ketones:………          Bilirubin:…………. 
 
Urobilinogen:………..                       Blood:………….                  Specific Gravity…………. 
 
 
Test performed by (print name):……………….. Signature:…………………. Date:……… Time:…… 
 
Observations: 
 
Blood Pressure: Right arm:……………Left arm:……………. Pulse:    Rt………  Lt……. 
 
Weight(kg): ……………… BMI(kg/m2):………… Reference range for study:  >19.5 - <30  
 
Copies of screening blood results attached:   Yes            No           Not applicable   (circle as appropriate) 
 
The ……………………………………. (above/1st urine/repeat urine /BP/ BMI (kg/m2) –insert as appropriate) 
result(s) will / will not exclude your patient from this study. 
 
Date:………………………………………..   Signature:………………………………… 
Designation:……………………………………………….. 
 
Abnormal results are referred to the QI CRF medical advisor for comments regarding participation in the study. 
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[Insert Date] 
 
Dear_____________________________, 
 
 
Your patient, ………………………………….., date of birth …………………………….. has consented to take part 
in a dietary intervention at the Quadram Institute Bioscience (study location within the Quadram 
Institute Clinical Research Facility, QI CRF) entitled,  
 
 
Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
Following consent, it is our standard practice to screen the volunteers to exclude any health factors 
which may affect the study data or whose screening results may indicate an issue which may 
require further investigation.  We are looking for healthy people who have no chronic illness and 
are not taking any prescribed medication which may affect the study data.   
 
 
Some/none of your patient’s results fell outside the standard reference range on this occasion.   
 
 
These results will/will not affect the study data. 
 
 
Your patient will/will not be able to participate in the study. 
 
 
Yours sincerely, 
 
 
 
Miss Bhavika Parmanand  
EPoM Study Manager 
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[Insert Date] 
 
Dear_____________________________, 
 
 
 
This is to inform you that your patient ……………………………………….. date of birth……………………….has consented 
to participate in a dietary intervention study at the Quadram Institute Bioscience (study location at the Clinical 
Research Facility at Quadram Institute). The study,  
 
 
Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
 
has been approved by a Local Research Ethics Committee and the EPoM Study Manager, 
Miss Bhavika Parmanand, can be contacted on 01603 255021 or bhavika.parmanand@quadram.ac.uk if you 
require further information. 
 
It is our policy to forward to the participant’s GP copies of all screening results obtained during the study as 
well as the participant information sheet (PIS). 
 
We anticipate your patient will complete this study by………………………………………………………………….. 
 
Yours sincerely, 
 
 
 
 
 
 
 
Miss Bhavika Parmanand 
EPoM Study Manager 
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Short title: Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
 You are receiving this study summary as one of your patients has consented to participate in the 
EPoM study undertaken at the QI CRF and has undergone screening (results enclosed, which 
includes dipstick urine test results, blood test results, BP, pulse, weight and BMI). In addition, copies 
of stool charts used during the study will be sent to you, should any significant changes to your 
patients stool type be recorded throughout the study period. 
 
 The main aim of this study is to examine whether consuming phytin can modulate the gut 
microbiota and cause a decrease in the abundance of Enterobacteria. We will also be observing 
whether phytin causes an increase in the Bifidobacteria in our gut. 
 Additionally, we are interested in how the gut bacteria are affected by phytin-induced iron 
restriction. 
 Phytic acid is the principal storage form of phosphorus in many plants, such as legumes, seeds, nuts 
and cereals. 
 When phytic acid is bound to a mineral it is known as phytate (mostly in the form of phytin). Studies 
in humans report that between 37-66% of dietary phytate is degraded during digestion in the 
stomach and small intestine when the diet is rich in plant food phytases. 
 In vitro and in vivo studies have demonstrated that phytic acid forms insoluble complexes with 
several divalent minerals, thereby preventing absorption, and can potentially result in zinc and iron 
deficiencies. Once these insoluble complexes are formed, the mineral cannot be absorbed in the 
small intestine and therefore pass into the colon. 
 Notably, phytate-bound iron found in the colon is present in the insoluble form making it difficult to 
degrade suggesting a potential role for phytate in the withholding of iron from potentially 
pathogenic bacteria. 
 We aim to assess whether the iron-restricted colonic environment via phytin can explain the 
differences in the gut microbiota populations by faecal bacteria phylogeny analysis. 
 Your patient will be asked to maintain their habitual diet for the duration of the study. The patient 
will be asked to consume encapsulated phytin for 2 weeks and encapsulated placebo for 2 weeks, in 
a random order, with a 2-week washout period separating these diets. During their involvement in 
the study, your patient will be asked to provide a total of 5 blood samples and 6 faecal samples for 
serum ferritin & gut microbiota/metabolite analysis, respectively. 
 This project is funded through the Biotechnology and Biological Sciences Research Council (BBSRC); 
Food Innovation and Health QIB ISP; QIB acting as study sponsor. 
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Annex 14, Catalogue A Raw Material 
A1. Phytin 
A1.1  Phytin Food Grade Certificate 
A1.2  Phytin Certificate of Analysis 
A1.3  Phytin GMO Statement 
A1.4  Phytin Material Safety Data Sheet 
A1.5  Phytin Shelf Life 
A1.6  Phytin Heavy Metals Testing 
A1.7  TSUNO Classification Accreditation 
A1.8  TSUNO ISO 9001  
A1.9  MHRA Medicinal Status 
A2. Microcrystalline Cellulose (MCC) 
 A2.1 MCC Process Flow Sheet 
A2.2 MCC Product Information 
A2.3 MCC Material Safety Data Sheet 
A2.4 MCC GMO Statement 
A2.5 MCC Food Statement 
A2.6 MCC Ingredient Declaration 
A2.7 MCC Allergen List 
A2.8 MCC Residual Solvents Statement 
A3. Coating Formulation (Phloral®) 
 A3.1 Amylomaize Starch SDS 
 A3.2 Eudragit S100 SDS 
 A3.3 PlasACRYL T20 SDS 
 A3.4 Reagent Alcohol SDS 
 A3.5 Triethyl Citrate Specification 
A3.6 Triethyl Citrate GMO Statement 
A3.7 Triethyl Citrate Food Grade Statement 
A3.8 Phloral Food Grade Statement      
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MATERIAL SAFETY DATA SHEET  
  
  
1.CHEMICAL PRODUCT AND COMPANY IDENTIFICATION  
  
 Chemical Product Name  : IP6  
Common Chemical Name : IP6   
 Product Code(Supplier)  : 11-934  
 Supplier     : Tsuno Rice Fine Chemicals Co.,Ltd.  
        2283,Chonomachi,Katsuragi-cho Ito-gun,Wakayama,Japan  
  
 Emergency Telephone  : +81-736-22-0061,8000  
  
2.COMPOSITION/INFORMATION ON INGREDIENTS  
  
 Substance/Preparation  : None  
Information on hazardous Ingredients  
 Chemical name     CAS Number     EC Number    Symbol  R-Phrases  
 Phytin                     3615-82-5               N/A                N/A              N/A   
  
3.HAZARD IDENTIFICATION  
  
 Physical/Chemical Hazards  : None  
 Environmental Hazards  : Easily biodegradable  
 Human Health Hazards  : None  
  
  
  
  
  
  
  
 Date of issue: Jul.13 ’01        Date of printing: Oct.19 ’01              Page 1 of 6  
  
  
4.FIRST AID MEASURES  
  
 Effects and Symptoms    
   Ingestion    : None   
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   Inhalation    : None  
 Skin Contact  : None   
  
 Eye Contact  : In case of contact with eyes,rinse immediately with plenty of  
                           Water and seek medical advice.                                 
  
First Aid Measures  
  Ingestion  
  
  : Wash out mouth with water. Get medical attention.  
  Inhalation  
  
  : None  
Skin Contact  
  
  : Wash off with water. If you feel unwell, seek medical advice.  
Eye Contact   : Wash out with plenty of water with the eyelid hold wide open      
        for at least 15 minutes. Get medical attention.  
  
5.FIRE FIGHTING MEASURES  
  
Extinguishing Media  
  Suitable   : None   Not 
suitable  : None  
 Special Firefighting  : None  
Procedures  
  
  
 Date of issue: Jul.13 ’01    Date of printing: Oct.19 ’01     Page 2 of 6  
  
 Unusual Fire/Explosion  : None  
  
 Hazardous Thermal  : None  
  
Protection of Firefighters : No special protection is needed.   
  
  
6.ACCIDENTAL RELEASE MEASURES  
  
 Personal Precautions  : None  
  
Environmental Precautions: No special precaution required.  
  
 Methods Cleaning Up  : Wash with plenty of water.  
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7.HANDLING AND STORAGE  
  
 Handling    : No special precaution required.  
  
 Storage     : Keep container tightly closed and store in a cool place.  
  
Packing Materials  
   Suitable    : Fiber drum.  
  
  
8.EXPOSURE CONTROLS/PERSONAL PROTECTION  
  
 Engineering Measures  : No specific regulation required.  
  
 Hygienic Measures  : No specific regulation required.  
  
  
Date of issue: Jul.13 ’01    Date of printing:Oct.19 ’01              Page 3 of 6 
Occupational Exposure Limits  
   Chemical Name : Phytin  
Personal Protective Equipment  
  Respiratory System  : None   Skin 
and Body   : None  
   Hands     : Suitable gloves  
   Eyes     : None  
  
9.PHYSICAL AND CHEMICAL PROPERTIES  
  
 Physical State    : Powder  
 Color      : White or yellowish white  
 Odor      : Odorless  
Boiling Point   : N/A pH 
     : N/A  
 Solubility in Water  : Hardly soluble  
 Vapor Density(Air=1)  : Not datermined  
 Flash point    : N/A  
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Auto ignition Temperature : N/A 
Lower Explosion Limit  : N/A 
Upper Explosion Limit  : N/A  
  
10.STABILITY AND REACTIVITY  
  
 Stability     : Stable under normal condition.  
 Conditions to avoid  : Open air and sunlight  
 Materials to avoid    : None  
Hazardous Decomposition   
  Products          : None  
  
  
  
  
 Date of issue: Jul.13 ’01    Date of printing:Oct.19 ’01        Page 4 of 6  
  
11.TOXICOLOGICAL INFORMATION  
  
Comment    : There is no toxicological data available on the preparation.  
Chemical Name   : Phytin  
Acute Toxicity      
  Oral    : No oral toxicity is known.  
  Dermal   : No dermal toxicity is known.  
  Inhalation  : No inhalation toxicity is known.  
Skin Irritation    : No data available  
Eye Irritation    : No data available  
Sensitization    : No data available  
Chronic Toxicity   : No chronic toxicity is known.  
Carcinogenicity    : No carcinogenicity is known.  
  
12.ECOLOGICAL INFORMATION  
  
 Comment    : Easy biodegradable   
 Chemical Name   : Phytin  
 Ecotoxicity    : No ecotoxicity is known.  
  
  
13.DISPOSAL CONSIDERATIONS  
  
 Methods of Disposal  : Disposal according to the local legislation.   
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14.TRANSPORT INFORMATION  
  
 UN Number    : None  
  
Date of issue: Jul.13 ’01    Date of printing:Oct.19 ’01         Page 5 of 6 
Land Road/Railway    
  ADR/RID Class   : N/A   
ADR/RID Item Number : N/A Inland 
Waterways    
   ADNR Class    : N/A  
 Sea        
   IMDG Class    : N/A  
   IMDG Page Number  : N/A  
 Air        
  IATA-DGR Class  : N/A National 
Transport  : N/A  
Regulations  
  
15.REGULATORY INFORMATION  
  
EC Regulations           : None      
EC Classlfication          : None  
 Label Name    : Phytin(RICE BRAN EXTRACT)  
 Hazard Symbols   : None  
   
16.OTHER INFORMATION  
  
  
HISTORY  
 Date first issue    : Jul.13,2001  
Date previous MSDS  : Jul.13,2001 
Date of issue    : Jul.13,2001  
 Version     : 1  
  
MSDS prepared by : Tsuno Rice Fine Chemicals Co., Ltd  2283,Chonomachi,Katsuragi-cho,Ito-
gun,Wakayama,Japan  
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 PO Number QIB0118056A 
Bhavika Parmanand 
Quadram Institute Bioscience 
Norwich Research Park 
Colney 
Norfolk 
NR4 7UA 
AR-18-UD-329004-01 
 Reported on 28/08/2018 
 Reported by   Antony Bagshaw, ASM - Interim 
Page 1 of 1 
Certificate Of Analysis 
Sample number 400-2018-20105980 Received on 21/08/2018 
Your sample reference Phytin - Extract From Rice Your sample code BP_Phy_HM 
Test Code Analyte Result SOP No. 
Toxic Elements 
 UD401 Arsenic (As) 0.013 mg/kg   ICPMS/010 
UD033 Cadmium 0.664 mg/kg   ICPMS/010 
UD032 Lead 0.026 mg/kg   ICPMS/010 
UD579 Mercury 0.006 mg/kg   ICPMS/010 
Unless stated, all results are expressed on a sample as received basis. 
† Indicates that this test was subcontracted Key:  cfu colony forming units 
< denotes less than 
> denotes greater than 
* Indicates that this parameter is not included in the UKAS accreditation schedule for the laboratory. 
Opinions and/or interpretations within this report are outside our accreditation scope. 
 ~ estimated value 
Eurofins Food Testing UK 
Ltd i54 Business Park Valiant 
Way 
Wolverhampton 
WV9 5GB 
0342 
www.eurofins.co.uk 
T +44 (0) 845 2666522 
F +44 (0) 845 6017470 
Regd Office: i54 Business Park 
Valiant Way 
Wolverhampton WV9 5GB 
Regd in England No: 5009315 
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 Classification of accreditation scopes  
Agriculture, forestry and fishing  
Mining and quarrying  
Food products, beverages and tobacco  
Textiles and textile products  
Leather and leather products  
Wood and wood products  
Pulp, paper and paper products  
Publishing companies  
Printing companies  
Manufacture of coke and refined petroleum products  
Nuclear fuel  
Chemicals, chemical products and fibres  
Pharmaceuticals  
Rubber and plastic products  
Non-metallic mineral products  
Concrete, cement, lime, plaster, etc.  
Basic metals and fabricated metal products  
Machinery and equipment  
Electrical and optical equipment  
Shipbuilding  
Aerospace  
Other transport equipment  
Manufacturing not elsewhere classified  
Recycling  
Electricity supply  
Gas supply  
Water supply  
Construction  
Wholesale and retail trade; Repair of motor vehicles, motorcycles and personal and household goods 30 
Hotels and restaurants  
Transport, storage and communication  
Financial intermediation; real estate; renting  
Information technology  
Engineering services  
Other services  
Public administration  
Education  
Health and social work  
Other social services  
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Quadram Institute 
Norwich 
NR4 7UA 
UK 
Bhavika.parmanand@quadram.ac.uk 
 
 
 
 
  
 
Our Ref: 2018/000735 
 
25 September 2018 
 
MHRA 
10 South Colonnade 
Canary Wharf 
London 
E14 4PU 
United Kingdom 
 
www.gov.uk/mhra 
Dear Miss Parmanand, 
 
Product: Phytin Mineral Salt   
 
I have reviewed the product listed above based on the information provided. Advice regarding this 
product is detailed below. 
 
Medicines legislation 
 
In the UK, as in the rest of the EC, medicinal products which are placed on the market are required 
to have marketing authorisations (formerly product licenses) in accordance with Regulation 46 (1) of 
the regulations. Amongst other things these provide that, unless exempt, no medicinal product shall 
be placed on the market unless an appropriate authorisation has been granted in accordance with 
Community provisions by the licensing authority or the European Commission.  
 
It is an offence to sell or supply or to advertise a medicinal product which does not have 
authorisation. 
 
 
A relevant “medicinal product” is defined in Regulation 2 of S.I. 2012/1916 as: 
 
a) any substance or combination of substances presented as having properties of preventing or 
treating disease in human beings; or  
 
(b) any substance or combination of substances that may be used by or administered to human 
beings with a view to- 
 
(i)  restoring, correcting or modifying a physiological function by exerting a 
pharmacological, immunological or metabolic action, or  
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(ii) making a medical diagnosis. 
 
If it satisfies either of the above criteria, it may be classed as a medicinal product. In broad terms, 
when classifying a product, the Agency looks at the way it is presented and its actual or perceived 
function, that is, its effects (when administered) on human physiology. 
 
Advertising 
 
Regulation 279 of the Human Medicines Regulations 2012 states: 
 
“A person may not publish an advertisement for a medicinal product unless one of the following is in 
force for the product- 
 
(a) a marketing authorisation; 
(b) a certificate of registration; 
(c) a traditional herbal registration; or 
(d) an Article 126a authorisation. 
  
"Advertisement" is defined in Regulation 277 to cover "every form of advertising whether in a 
publication or elsewhere." Unfortunately, what constitutes a "medicinal claim" is not closely defined 
in the legislation but as a rough guide unacceptable medicinal claims include the following: 
 
- references to medical conditions such as colds, headaches, cuts and bruises, spots, skin 
disorders, headlice, hangovers, smoking addiction, obesity, arthritis, depression, stress and all 
childhood disorders and serious diseases etc. 
 
- references to treatment or alleviation of adverse conditions such as decongests, relieves pain, 
reduces inflammation, calms, stops itching, cures insomnia etc. 
 
- references to interference with the normal operation of a physiological function such as burns 
fat, increases metabolism, reduces blood pressure, lowers cholesterol levels, prevents jet-lag etc. 
 
Marketing 
 
You should note that the following forms of marketing are unacceptable in products that are 
unlicensed: 
 
• References to medical conditions. 
• Comparison with licensed medicines. 
• References to interference with the normal operation of a physiological function. 
• Product names which refer to adverse medical conditions. 
• References to medical and / or clinical research and testing. 
• References to the health risks of not taking a particular product. 
• Editorial medicinal claims. 
• Testimonials that include/imply medicinal claims. 
• Graphics that imply medicinal uses. 
• References to, or reproduction of "generic" information. 
• Juxtaposing with any examples of the above. 
 
Food law 
 
The Food Labelling Regulations contain detailed provisions for both the labelling and advertising of 
food. In particular, any claim that a food has the property of preventing, treating or curing human 
disease is prohibited. This prohibition covers any implication that a foodstuff is capable of protecting 
against disease, infection or other adverse condition or relieving symptoms. Food safety law is 
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administered and enforced locally on behalf of the Food Standards Agency by the Trading 
Standards Service.  
 
In addition, health claims must now be approved under The Nutrition & Health Claims (England) 
Regulations 2007 
 
Your Product 
 
Phytin Mineral Salt   
 
The MHRA takes the view that, based on the information provided, Phytin Mineral Salt falls outside 
of the definition of a medicinal product. 
 
However, please be aware that the opinion expressed in this message does not provide authority to 
place the product on the market as a Food. Food law is administered by the Trading Standards 
Service and we would recommend that you contact your local service for guidance, if you have not 
already done so. 
 
The Agency reserves the right to change its view in the event of any information or evidence which 
has a bearing on the status of the product, including the way in which it is packaged, promoted or 
presented. The Agency can give no assurance that any particular product, including products under 
development, will not subsequently be classified as a medicinal product. It is the responsibility of 
those marketing a product to ensure that it is marketed in accordance with the relevant legislation. 
 
 
 
Yours Sincerely 
 
 
 
William Whitfield 
Classifier, Medicines Borderline Section 
 
T +44 (0)20 3080 6163 
E william.whitfield@mhra.gov.uk 
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SAFETY DATA SHEET  
MAIZE STARCH AMYLO N-400  
  
SECTION 1: Identification of the substance/mixture and of the company/undertaking  
  
1.1 Product identifier:  
  
Product name: MAIZE STARCH AMYLO N-400  
 Chemical name:  Amylose  
 REACH Registration No.:   Exempted  
CAS-No.:  9005-82-7 EC No.:  232-685-9 INCI Name: 
   
  
1.2 Relevant identified uses of the substance or mixture and uses advised against:  
  
Identified uses:  Uses advised against:  
Industrial. , Food. , Animal Feed. , Pharmaceuticals.   No data available.  
  
1.3 Details of the supplier of the safety data sheet:  
  
Supplier:   
 ROQUETTE FRERES  Telephone: +33 3 21 63 36 00  
 1 Rue de la Haute Loge  Fax: +33 3 21 63 38 50  
 62136 LESTREM - France  E-mail: sds@roquette.com  
  
1.4 Emergency telephone number: NPIS (24/24) : 844 892 0111   
  
SECTION 2: Hazards identification  
  
2.1 Classification of the substance or mixture:  
  
The product has not been classified as dangerous according to the legislation in force : CLP Regulation (EC) No 1272/2008.  
  
2.2 Label elements:  Not applicable  
    
  
2.3 Other hazards:  Dust may form an explosive mixture in the atmosphere.  
Not fulfilling PBT (persistent/bioaccumulative/toxic) criteria  
Not fulfilling vPvB (very persistent/very bioaccummulative) criteria  
  
  
SECTION 3: Composition/information on ingredients   
Catalogue A                      Document 3.1                          Amylomaize starch SDS                                  EPoM   
Version: 1.2  IRAS ID 251932 
Revision date: 11/27/2017  
Product name: MAIZE STARCH AMYLO N-400    
SDS_GB / EN - Conforms to regulation (EU) 2015/830    299 
  
  
  
  
  
3.1 Substance:   
  
   
Chemical name  Concentration  CAS-No.  EC No.  REACH Registration No.  
Amylose  >=88%  9005-82-7  232-685-9   Exempted  
  
     
SECTION 4: First aid measures     
  
4.1 Description of first aid measures:  
Inhalation:   
  
Move the exposed person to fresh air at once. Get medical attention if any 
discomfort continues.   
Eye contact:  Flush thoroughly with water. If irritation occurs, get medical assistance.   
  
 Skin contact:  Wash with soap and water.   
  
 Ingestion:  Get medical attention if symptoms occur.   
  
4.2 Most important symptoms  Dust may irritate the eyes and the respiratory 
system.  and effects, both acute and delayed:  
  
4.3 Indication of any immediate medical attention and special treatment needed:  
  
 Treatment:  Treat symptomatically.   
  
SECTION 5: Firefighting measures  
  
5.1 Extinguishing media:  
  
Suitable extinguishing 
media:  
  Water spray.   
Unsuitable extinguishing 
media:  
  
Dry chemicals or foams.   
5.2 Special hazards arising 
from the substance or 
mixture:  
Fire or excessive heat may produce hazardous decomposition products. Dust 
may form an explosive mixture in the atmosphere. See Section 10.   
  
5.3 Advice for firefighters:  
  
Special Fire Fighting 
Procedures:  Prevent dust cloud.   
  
Special protective 
equipment for fire-fighters:  
  
Firefighters must use standard protective equipment including flame retardant 
coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, 
SCBA.   
SECTION 6: Accidental release measures  
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6.1 Personal precautions, 
protective equipment 
and emergency 
procedures:  
See Section 8 of the SDS for Personal Protective Equipment.   
  
6.2 Environmental 
precautions:  
  
Avoid discharge to the aquatic environment.   
6.3 Methods and material for 
containment and cleaning 
up:  
  
Remove material, as much as possible, using mechanical equipment. Prevent 
dust cloud. Collect and dispose of spillage as indicated in section 13 of the 
SDS.   
6.4 Reference to other 
sections:  
  
For waste disposal, see section 13 of the SDS.   
SECTION 7: Handling and storage  
  
7.1 Precautions for safe  Avoid generation and spreading of dust.  handling:  
  
7.2 Conditions for safe 
storage, including any 
incompatibilities:  
  
Keep containers tightly closed. Store in original container.   
7.3 Specific end use(s):  Industrial., Food., Animal Feed., Pharmaceuticals.,   
  
SECTION 8: Exposure controls/personal protection  
  
8.1 Control parameters:  
  
Occupational exposure limits:  
    
This product does not contain any component with occupational exposure limits  
  
Chemical name  Type  Exposure Limit Values  Source  
Dust - Inhalable dust.  TWA   10 mg/m3  UK. EH40 Workplace Exposure Limits (WELs) (2007)  
Dust - Respirable dust.  TWA   4 mg/m3  UK. EH40 Workplace Exposure Limits (WELs) (2007)  
  
8.2 Exposure controls:  
  
Appropriate engineering 
controls:  
Ventilate as needed to control airborne dust. Use explosion-proof ventilation 
equipment if airborne dust levels are high.   
  
Individual protection measures, such as personal protective equipment:  
  
Eye/face protection:  
  
Skin protection:  
  
Wear dust-resistant safety goggles where there is danger of eye contact.   
Hand Protection:  No special precautions.  
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Other:  
  
No special precautions.   
Respiratory Protection:  
  
In case of inadequate ventilation or risk of inhalation of dust, use suitable 
respiratory equipment with particle filter (type P1).   
Hygiene measures:  
  
Handle the product in accordance with the good hygiene practices and 
safety instructions.   
Environmental exposure 
controls:  
Avoid discharge to the aquatic environment.   
  
SECTION 9: Physical and chemical properties  
  
9.1 Information on basic physical and chemical properties:  
  
Physical State:  solid  
Form:  Powder  
Color:  Off-white  
Odor:  Odorless   
pH:  ~ 5.6 at 20 %   
Melting Point:  No data available.  
Boiling Point:  Not Applicable   
Flash Point:   Not Applicable   
Vapor pressure:   Not Applicable   
Vapor density (air=1):  Not Applicable    
Relative density:  ~ 0.5   
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 Solubility in Water:  Insoluble in water at 20 °C   
~ 150 g/l at 90 °C    
Explosive properties: - INERIS -Data from similar product.  
 Ignition Temperature:  ~ 480 °C (Godbert-Greenwald)  MIT in Cloud.  
MIE (Minimum Ignition Energy):  ~ 225 mJ (EN 13821 (Without Inductance))  
Sensitive to ignition by an electrostatic phenomenon.     
dP/dtmax (Maximum Rate of explosion Pressure 
rise):  
~ 460 bar/s (EN 14034-2)  
Pmax (Maximum Explosion OverPressure) ±10%:  ~ 8.5 bar (EN 14034-1)  
Kst value (±20%):  ~ 124 barm/s (EN 14034-2)  
Dust Explosion Class:  st 1 (VDI 3673)    
Volume resistivity:  7,5x10^13 Ω.cm (IEC 61241-2-2 / Group IIIB 
nonconductive dust.)    
Moisture:   ~ 12.38 % (ISO 589)  
Mv (Median value):  ~ 18 µm (NFX 11-666)  
Other Data:  
  
9.2 Other information:  
  
LEL (Lower explosion limit) : 30-60 g/m3  
  
 BZ (Combustion class) : 3 (VDI 2263-1)  
SECTION 10: Stability and reactivity   
  
10.1 Reactivity:  
  
Oxidizing agents.   
10.2 Chemical stability:  
  
Material is stable under normal conditions.   
10.3 Possibility of hazardous reactions:  
  
No hazardous reactions under ordinary conditions of use and 
storage.   
10.4 Conditions to avoid:  
  
Prevent dust cloud. Dust clouds may be explosive under certain 
conditions. Avoid dust close to ignition sources.   
10.5 Incompatible materials:  
  
Strong oxidizing substances.   
10.6 Hazardous decomposition products:  
  
Carbon Dioxide. Carbon Monoxide.   
SECTION 11: Toxicological information  
  
  
11.1 Information on toxicological effects:  No data available.  
  
Remarks:  The ingredients of this product are not classified as carcinogenic by the  
ACGIH, the CIRC, the OSHA or the NTP. No data on possible toxicity effects 
have been found.   
  
SECTION 12: Ecological information  
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There are no data on the ecotoxicity of this product.   
  
12.1 Toxicity:  No data available.  
  
12.2 Persistence and degradability:  No data available.  
  
  
12.3 Bioaccumulative potential:  
  
No data available.  
12.4 Mobility in soil:  No data available.  
  
 12.5 Results of PBT and vPvB assessment:  Exempted   
  
 12.6 Other adverse effects:  None known.  
  
SECTION 13: Disposal considerations  
  
13.1 Waste treatment methods:  
  
 Product:  Dispose of waste in an appropriate authorised treatment facility in  
accordance with regulations in force and product characteristics at time of 
disposal. (for example, energy recovery).  
  
 Packaging material:  Single use packaging. Collect for salvage or disposal.   
  
SECTION 14: Transport information  
  
The product is not covered by international regulation on the transport of dangerous goods (IMDG, IATA, 
ADR/RID).  
  
14.5 Environmental hazards:  Not regulated.  
  
 14.6 Special precautions for user:  No special precautions.  
  
 14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code:  Not applicable.  
  
SECTION 15: Regulatory information  
  
15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:  
  
This Safety Data Sheet is not mandatory according to the requirements of regulation (EC) N°1907/2006 (REACH) article 31 and 
is provided for information.  
  
 15.2 Chemical safety assessment:  Exempted  
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SECTION 16: Other information  
  
Revision Information:  Not relevant.  
  
Key literature references and  No data available.  
sources for data:  
  
Abbreviations and acronyms used in the SDS.:  
CAS: Chemical Abstracts Service (division of the American Chemical Society) CLP 
: Classification, Labelling and Packaging.  
PBT: Persistent, Bioaccumulative and Toxic  
REACH : Registration, Evaluation, Authorisation and Restriction of Chemicals. 
vPvB: very persistent and very bioaccumulative substance.  
  
  
  
Disclaimer:  The information provided in this Safety Data Sheet (SDS) relates only to the 
specific product designated and may not be applicable when such product is 
used in combination with other materials or in any process. It is the  
responsibility of the user to be aware of and to follow the regulations applying to 
our product for its possession, handling and use.  
The information given is designed only as a guidance and is not to be 
considered a warranty or quality specification.  
All information and instructions provided in this SDS are based on the current 
state of our knowledge at the latest revision date indicated.  
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 SAFETY DATA SHEET (EC 1907/2006)    
EUDRAGIT S 100 / 20 KG  
Version:  
Revision date:  
Issue date:  
replaces version:  
Page:  
1.1 / GB  
30.11.2017  
19.05.2016  
1.0  
1 / 9  
VA-No.    
  
  
  
  
SECTION 1: Identification of the substance/mixture and of the company/undertaking  
  
 1.1.  Product identifier  
  
Trade name  
  
: EUDRAGIT S 100 / 20 KG  
Chemical Name  : Acrylic polymer  
  
  
  
 1.2.  Relevant identified uses of the substance or mixture and uses advised against  
  
Relevant applications  : pharmaceutical and cosmetic excipient for oral and dermal use identified  
  
 Applications which are not  : None known.  
 advised    
  
  
 1.3.  Details of the supplier of the safety data sheet  
  
Company  
  
: Evonik Nutrition & Care GmbH   
Health Care   
Kirschenallee   
D-64293 Darmstadt  
Telephone  
  
: +49 (0)201 173-01  
Telefax  
  
: +49 (0)201 173-3000  
E-mail  : productsafety-cs@evonik.com  
  
 1.4.  Emergency telephone number  
  
+49 (0)2365 49-2232 (TUIS - Interpreting service available)  
  
+49 (0)2365 49-4423 (TUIS - Fax)   
 
  
SECTION 2: Hazards identification  
  
2.1.  Classification of the substance or mixture   Classification according to Regulation (EC) No. 1272/2008 [CLP]  
 Not a hazardous substance or mixture.  
  
 2.2.  Label elements  
 The product does not require a hazard warning label in accordance with GHS. The normal safety precautions for the 
handling of chemicals must be observed.   
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 2.3.  Other hazards  
   None known.  
  
 
  
SECTION 3: Composition/information on ingredients  
 Acrylic polymer  
  
 3.1.  Substances  
  
  
  No hazardous ingredients  
  
  
  
 3.2.  Mixtures  
   -  
  
EU-GHS(R11/011) / 10.08.2018 14:55  
  
 
 SECTION 4: First aid 
measures  
  
 4.1.  Description of first aid measures  
  
General advice  
  
: Remove soiled or soaked clothing immediately  
Inhalation  
  
: Ensure supply of fresh air.  
In the event of symptoms seek medical advice.  
Skin contact  
  
: In case of contact with skin wash off immediately with soap and water 
In the event of symptoms seek medical advice.  
Eye contact  
  
: In case of contact with eyes rinse thoroughly with water. In 
the event of symptoms seek medical advice.  
Ingestion  : Thoroughly clean the mouth with water  
In the event of symptoms seek medical advice.  
  
 4.2.  Most important symptoms and effects, both acute and delayed  
  Symptoms  : Up to now no symptoms are known.  
   
 4.3.  Indication of any immediate medical attention and special treatment needed  
  
Treat symptomatically.  
   
 
 SECTION 5: Firefighting 
measures  
  
 5.1.  Extinguishing media  
  Suitable extinguishing media  : foam, carbon dioxide, dry powder, water spray.  
  
Unsuitable extinguishing  : Full water jet media  
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 5.2.  Special hazards arising from the substance or mixture  
   In the event of fire the following can be released:   
-
 
carbon dioxide, carbon monoxide   
Under certain conditions of combustion traces of other toxic substances cannot be excluded   
   
 5.3.  Advice for firefighters  
 Do not inhale explosion and/or combustion gases Use 
self-contained breathing apparatus  
  
 
  
SECTION 6: Accidental release measures  
  6.1.  Personal precautions, protective equipment and emergency procedures  
  
High risk of slipping due to leakage/spillage of product.   
Use personal protective equipment.   
Avoid dust formation.  
  
 6.2.  Environmental precautions  
  Do not allow to enter drains or waterways Do 
not discharge into the subsoil/soil.  
  
 6.3.  Methods and material for containment and cleaning up  
   Pick up mechanically  
Dispose of absorbed material in accordance with the regulations.  
  
 6.4.  Reference to other sections  
  
  
For further information on exposure monitoring and disposal see sections 8 and 13.   
 
  
SECTION 7: Handling and storage  
  7.1.  Precautions for safe handling  
  
Advice on safe handling  : Provide good ventilation of working area (local exhaust ventilation if necessary). Avoid the 
formation and deposition of dust.  
  Hygiene measures  : Wash hands before breaks and after work.  
Do not eat, drink or smoke when working.  
Remove soiled or soaked clothing immediately.  
  General protective measures  : Do not inhale dust/fumes/aerosols.  
Avoid contact with eyes and skin  
  
7.2.  Conditions for safe storage, including any incompatibilities   Prevention of fire and explosion  
  
  
Information  
  
: Keep away from sources of ignition  
Take precautionary measures against electrostatic loading.  
Dust can form an explosive mixture with air. Cool 
endangered containers by water spray  
Dust explosion class  
  
  Storage  
  
: St2  
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Information  
  
: Avoid contamination during sampling.  
Further information on storage 
conditions  
: Keep container tightly closed in a cool, well-ventilated place  
Protect from atmospheric moisture and water Keep 
away from direct sunlight.  
Keep in a dry place.  
Keep away from heat.  
  
 7.3.  Specific end use(s)  
  
No further recommendations.   
 
  
SECTION 8: Exposure controls/personal protection  
  
 8.1.  Control parameters  
   Contains no substances with occupational exposure limit values.  
  
  
  
DNEL  : No DNEL/DMEL values on file.  
  
  
PNEC  : No PNEC values on file.  
  
8.2.  Exposure controls  
  
 
 Eye protection  
  
: safety glasses  
 Hand protection  
  
: Protective gloves  
  
 Body Protection  
  
: protective clothing  
 Respiratory protection  : in case of formation of vapours/dusts: 
Short term: filter apparatus, Filter P3  
  
 
  
SECTION 9: Physical and chemical properties  
  
 9.1.  Information on basic physical and chemical properties  
  
Physical state  
  
: solid   
  
Form  
  
: Powder  
Colour  
  
: white  
Odour  
  
: slight, typical  
Odour Threshold  : not measured  
  
  
 pH  
  
: not measured  
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 Melting point  
  
: Melting point/range  
> 200 °C  
  
  
 Boiling point  
  
: not measured  
  
 Flash point  
  
: > 250 °C  
Method: ASTM D 1929-68  
  
  
 Evaporation rate  
  
: not measured  
  
 Flammability  
  
: not measured  
  
  
 Upper Explosion/Ignition Limit  
  
: not measured  
  
 Lower explosion limit  
  
: not measured  
  
 Vapour pressure  
  
: not measured  
  
 Relative vapour density  
  
: not measured  
  
 Relative density  
  
: not measured  
  
 Solubility(ies)  
  
: Medium: Acetone  
Remarks: soluble  
Medium: lower alcohols  
Remarks: soluble  
Medium: alkalines  
Remarks: soluble  
  
 Water solubility  
  
: virtually insoluble  
  
 Partition coefficient: 
noctanol/water  
  
: not measured  
  
 Autoignition temperature  
  
: not measured  
  
 Thermal decomposition  
  
: not measured  
  
 Viscosity, kinematic  
  
: not measured  
  
 Viscosity, dynamic  
  
: not measured  
  
 Explosive properties  
  
: not measured  
  
 Oxidising properties  
  
: not measured  
  
 Density  
  
: not measured  
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9.2.  
  
Other information   
 Bulk density  
  
: 500 kg/m3  
(20 °C)  
  
 Metal corrosion  : not measured  
  
 Ignition temperature  : > 400 °C  
Method: ASTM D 1929-68  
  
 volatile organic compounds 
 :   
   
 
  
SECTION 10: Stability and reactivity  
  
10.1. Reactivity  
  
see section "Possibility of hazardous reactions"  
  
10.2. Chemical stability  
   The product is stable under normal conditions.  
Depolymerization begins at 200 °C  
  
10.3. Possibility of hazardous reactions  
   No hazardous reactions with proper storage and handling.  
  
10.4. Conditions to avoid  
  Direct sunlight 
humidity Heat  
  
10.5. Incompatible materials  
   Unknown  
  
10.6. Hazardous decomposition products  
  
None with proper storage and handling.  
  
 
  
SECTION 11: Toxicological information  
  
11.1. Information on toxicological effects  
  
Acute toxicity (oral)  
  
: LD50  
Species: Rat  
Dose: > 5.000 mg/kg  
  
Catalogue A            Document A3.2                Eudragit S100                       EPoM Study                  12.Sep.18  
 
311 
 
SAFETY DATA SHEET (EC 1907/2006)    
EUDRAGIT S 100 / 20 KG  
Version:  1.1 / GB  VA-No.    
Revision date: 30.11.2017 Issue date: 19.05.2016  
replaces version:  1.0   
Page:  311 / 12  
   
  
 LD50  
Species: dog  
Dose: > 5.000 mg/kg  
  
Acute toxicity (inhalation)   : no data available  
Acute toxicity (dermal)  
  
: LD50   
Species: Rat  
Dose: > 2.000 mg/kg  
Method: OECD 402  
  
Irritation/corrosion of the skin  
  
: Species: Rabbit 
Result: non-irritant  
Method: OECD 404  
  
Serious eye damage/ eye  
irritation  
: Species: Rabbit 
Result: non-irritant  
Method: OECD 405  
  
  
Respiratory/skin sensitization  
  
: Buehler Test   
Species: Guinea pig  
Result: non-sensitizing  
Method: OECD 406  
  
Repeated dose toxicity  
  
: Species: dog   
Application Route: Oral   
Exposure duration: 6 weeks  
NOAEL: 2.000 mg/kg       
GLP: Yes  
  
   
  
 Species: Rat   
Application Route: Oral   
Exposure duration: 6 months  
NOAEL: 100 mg/kg       
Remarks: This information is derived from evaluation of or a test result for a similar 
compound (conclusion based on analogy).  
Genotoxicity in vitro  
  
: Ames test  
Salmonella typhimurium  
Result: negative  
  
Carcinogenicity  
  
: no specific test data available no 
evidence for hazardous properties  
(structure-activity-relationships)  
(analogy)  
Reprotoxicity / Fertility  
  
: no specific test data available no 
evidence for hazardous properties  
(structure-activity-relationships)  
(analogy)  
Specific Target Organ  
Toxicity - Single exposure  
: no evidence for hazardous properties  
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Specific Target Organ  
Toxicity - Repeated exposure  
  
: no evidence for hazardous properties  
Aspiration hazard  
  
: No aspiration toxicity classification  
Other information  : The properties of this product which are hazardous to health have been calculated 
as per regulation (EC) No. 1272/2008. See section 2 "Hazards Identification".  
  
 
  
SECTION 12: Ecological information  
  
   Ecotoxicology Assessment  
   Acute aquatic toxicity  : Based on available data, the classification criteria are not met.  
  
  
 Chronic aquatic toxicity  : Based on available data, the classification criteria are not met.  
  
    
12.1. Toxicity  
   Aquatoxicity, fish  : Species: Poecilia reticulata (guppy)  
Exposure duration: 96 h  
LC50: > 100 mg/l      
Method: OECD 203  
Remarks: The data are derived from the evaluations or test results achieved with 
similar products (conclusion by analogy).  
  
  
   
Aquatoxicity, invertebrates  : no data available  
   
  
Aquatoxicity, algae / aquatic  : no data available 
plants
  
   
  
Toxicity in microorganisms  : no data available  
   
  
chronic toxicity in fish  : no data available  
   
  
Chronic toxicity in aquatic  : no data available  
Invertebrates     
   
12.2.  
  
Persistence and degradability  
 Photodegradation  
  
: no evidence for hazardous properties  
(structure-activity-relationships) (analogy)  
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 Biological degradability  
   
: Biological degradability: 8 %  
Exposure duration: 28 d  
Result: Slightly biodegradable  
Method: OECD 302 B  
Remarks: The data are derived from the evaluations or test results achieved with 
similar products (conclusion by analogy).  
  
  
12.3.  
  
Bioaccumulative potential   
 Bioaccumulation  
  
: no evidence for hazardous properties  
(structure-activity-relationships) (analogy)  
  
  
12.4.  Mobility in soil   
  
Environmental distribution  : no evidence for hazardous properties  
(structure-activity-relationships)  
(analogy)  
  
   
12.5. Results of PBT and vPvB assessment  
  
PBT and vPvB assessment  : This substance/mixture contains no components considered to be either persistent, 
bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative 
(vPvB) at levels of 0.1% or higher.  
  
   
12.6. Other adverse effects  
  General Information  : The product is considered to be a weak water pollutant (German law).   
Do not allow to enter soil, waterways or waste water canal.  
  
  
 
  
SECTION 13: Disposal considerations  
  
13.1. Waste treatment methods  
  
 Product  : In accordance with local authority regulations, take to special waste incineration  
plant  
  
  
Contaminated packaging  : If empty contaminated containers are recycled or disposed of, the receiver must be 
informed about possible hazards.  
  
  
  
SECTION 14: Transport information  
Not dangerous according to transport regulations.    
  
14.1.  UN number:  --  
14.2.  UN proper shipping name:  --  
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14.3.  Transport hazard class(es):  --  
14.4.  Packing group:  --  
14.5.  Environmental hazards:  --  
14.6  Special precautions for user:  
  
  
No  
  
SECTION 15: Regulatory 
information 
  
15.1. Safety, health and environment 
  
  National legislation  
 Technical instructions on Air 
Quality  
al  
:  
  
regulations/legislation specific for the substance or mixture  
5.2.1  
  
  
Major Accident Hazard  
Legislation  
:  not applicable   
  
  
Water contaminating class  
(Germany)  
:  slightly water endangering Classification 
acc. to German law  
  
  
  
Other regulations  
  :  none  
15.2. Chemical safety assessment  
  
Chemical safety assessment  
  :  No chemical safety assessment was carried out for this product.  
  
SECTION 16: Other information   
List of references  
  
 Other information  : Comply with national laws regulating employee instruction.  
  
   Changes since the last version are highlighted in the margin. This version replaces all previous versions.  
  
This information and all further technical advice is based on our present knowledge and experience. However, it implies 
no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, 
especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the 
legal sense is intended or implied. We reserve the right to make any changes according to technological progress or 
further developments. The customer is not released from the obligation to conduct careful inspection and testing of 
incoming goods. Performance of the product described herein should be verified by testing, which should be carried out 
only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is 
neither a recommendation, nor does it imply that similar products could not be used.  
  
   Legend  
  
ADR  European Agreement concerning the International Carriage of Dangerous Goods by Road  
ADN  European Agreement concerning the International Carriage of Dangerous Goods by Inland 
Waterways  
ADNR  European agreement concerning the international carriage of dangerous goods by inland 
waterways (ADN)  
ASTM  American Society for Testing and Materials  
ATP  Adaptation to Technical Progress  
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BCF  Bioconcentration factor  
BetrSichV  German Ordinance on Industrial Safety and Health  
c.c.  closed cup  
CAS  Chemical Abstract Services  
CESIO  European Committee of Organic Surfactants and their Intermediates  
ChemG  German Chemicals Act  
CMR  carcinogenic-mutagenic-toxic for reproduction  
DIN  German Institute for Standardization  
DMEL  Derived minimum effect level  
DNEL  Derived no effect level  
EINECS  European Inventory of Existing Commercial Chemical Substances  
EC50  half maximal effective concentration  
GefStoffV  German Ordinance on Hazardous Substances  
GGVSEB  German ordinance for road, rail and inland waterway transportation of dangerous goods  
GGVSee  German ordinance for sea transportation of dangerous goods  
GLP  Good Laboratory Practice  
GMO  Genetic Modified Organism  
IATA  International Air Transport Association  
ICAO  International Civil Aviation Organization  
IMDG  International Maritime Dangerous Goods  
ISO  International Organization For Standardization  
LOAEL  Lowest observed adverse effect level  
LOEL  Lowest observed effect level  
NOAEL  No observed adverse effect level  
NOEC  no observed effect concentration  
NOEL  no observed effect level  
o. c.  open cup  
OECD  Organisation for Economic Cooperation and Development  
OEL  Occupational Exposure Limit  
PBT  Persistent, bioaccumulative, toxic  
PEC  Predicted effect concentration  
PNEC  Predicted no effect concentration  
REACH  REACH registration  
RID  Convention concerning International Carriage by Rail  
STOT  Specific Target Organ Toxicity  
SVHC  Substances of Very High Concern  
TA  Technical Instructions  
TPR  Third Party Representative (Art. 4)  
TRGS  Technical Rules for Hazardous Substances  
VCI  German chemical industry association  
vPvB  very persistent, very bioaccumulative  
VOC  volatile organic compounds  
VwVwS  German Administrative Regulation on the Classification of Substances Hazardous to Waters 
into Water Hazard Classes  
WGK  Water Hazard Class  
WHO  World Health Organization  
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SECTION 1: Identification of the substance/mixture and of the company/undertaking  
  
1.1.  Product identifier  
  
Trade name  
  
: PLASACRYL T20 / 5 KG  
Chemical Name  : Aqueous emulsion with fatty acid glycerides and plasticizer  
  
  
  
1.2.  Relevant identified uses of the substance or mixture and uses advised against  
  
Relevant applications  : pharmaceutical and cosmetic excipient for oral and dermal use identified  
  
 Applications which are not  : None known.  
 advised    
  
  
1.3.  Details of the supplier of the safety data sheet  
  
Company  
  
: Evonik Nutrition & Care GmbH   
Health Care   
Kirschenallee   
D-64293 Darmstadt  
Telephone  
  
: +49 (0)201 173-01  
Telefax  
  
: +49 (0)201 173-3000  
E-mail  : productsafety-cs@evonik.com  
  
1.4.  Emergency telephone number  
  
+49 (0)2365 49-2232 (TUIS - Interpreting service available)  
  
+49 (0)2365 49-4423 (TUIS - Fax)   
 
  
SECTION 2: Hazards identification  
  
2.1.  Classification of the substance or mixture   Classification according to Regulation (EC) No. 1272/2008 
[CLP]  
 Not a hazardous substance or mixture.  
  
2.2.  Label elements  
 The product does not require a hazard warning label in accordance with GHS. The normal safety precautions for the 
handling of chemicals must be observed.   
  
  
2.3.  Other hazards  
   None known.  
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SECTION 3: Composition/information on ingredients  
 Aqueous emulsion with fatty acid glycerides and plasticizer  
  
3.1.  Substances  
  -  
  
3.2.  Mixtures  
   
  No hazardous ingredients  
  
  
  
EU-GHS(R11/011) / 10.08.2018 14:52  
 
  
SECTION 4: First aid measures  
 4.1.  Description of first aid measures  
  
General advice  
  
: Remove soiled or soaked clothing immediately  
Inhalation  
  
: Ensure supply of fresh air.  
In the event of symptoms seek medical advice.  
Skin contact  
  
: In case of contact with skin wash off immediately with soap and water 
In the event of symptoms seek medical advice.  
Eye contact  
  
: In case of contact with eyes rinse thoroughly with water. In 
the event of symptoms seek medical advice.  
Ingestion  : Thoroughly clean the mouth with water  
In the event of symptoms seek medical advice.  
  
4.2.  Most important symptoms and effects, both acute and delayed  
  Symptoms  : Up to now no symptoms are known.  
   
4.3. Indication of any immediate medical attention and special treatment needed  Treat 
symptomatically.  
   
 
  
SECTION 5: Firefighting measures  
 5.1.  Extinguishing media  
  Suitable extinguishing media  : foam, carbon dioxide, dry powder, water spray.  
  
Unsuitable extinguishing  : Full water jet media  
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5.2.  Special hazards arising from the substance or mixture  
   In the event of fire the following can be released:   
- carbon dioxide, carbon monoxide   
Under certain conditions of combustion traces of other toxic substances cannot be excluded   
   
5.3.  Advice for firefighters  
 Do not inhale explosion and/or combustion gases Use 
self-contained breathing apparatus  
  
 
  
SECTION 6: Accidental release measures  
 6.1.  Personal precautions, protective equipment and emergency procedures  
   High risk of slipping due to leakage/spillage of product.   
Use personal protective equipment.   
Ensure adequate ventilation.  
  
6.2.  Environmental precautions  
  Do not allow to enter drains or waterways Do 
not discharge into the subsoil/soil.  
  
6.3.  Methods and material for containment and cleaning up  
  Take up with absorbent material (eg sand, kieselguhr, universal binder) Dispose 
of absorbed material in accordance with the regulations.  
  
6.4.  Reference to other sections  
   
For further information on exposure monitoring and disposal see sections 8 and 13.  
  
 
 SECTION 7: Handling and 
storage  
  
7.1.  Precautions for safe handling  
  
 Advice on safe handling  : Provide good ventilation of working area (local exhaust ventilation if necessary).  
  
 Hygiene measures  : Wash hands before breaks and after work.  
Do not eat, drink or smoke when working.  
Remove soiled or soaked clothing immediately.  
  General protective measures  : Do not inhale gases/vapours/aerosols.  
Avoid contact with eyes and skin  
  
7.2.  Conditions for safe storage, including any incompatibilities   Prevention of fire and explosion  
  
  Information  : No special measures required.  
  
  Storage  
  Information  : Avoid contamination during sampling.  
Catalogue A Document A3.3 PlasACRYL SDS EPoM  
  
 
320 
 
SAFETY DATA SHEET (EC 1907/2006)    
PLASACRYL T20 / 5 KG  
Version:  1.1 / GB  VA-No.    
Revision date: 30.11.2017 Issue date: 12.04.2016  
replaces version:  1.0   
Page:  320 / 10  
 Further information on storage : Keep container tightly closed in a cool, well-ventilated place conditions 
Protect from frost.  
  
7.3.  Specific end use(s)  
 No further recommendations.  
  
 
  
SECTION 8: Exposure controls/personal protection  
  
8.1.  Control parameters  
   Contains no substances with occupational exposure limit values.  
  
  
  
DNEL  : No DNEL/DMEL values on file.  
  
  
PNEC  : No PNEC values on file.  
  
8.2.  Exposure controls  
  
 
 Eye protection  
  
: safety glasses  
 Hand protection  
  
: The protective gloves to be worn must satisfy the specifications of EC Guideline 
89/686/EEC and the resulting Standard EN374.  
Specific workplace situations must be considered separately.  
  
Glove material: Nitrile rubber  
Break through time: 480 min  
Glove thickness: 0,33 mm  
  
 Body Protection  
  
: Wear suitable protective clothing.  
 Respiratory protection  : in case of formation of vapours/aerosols:  
Short term: filter apparatus, combination filter A-P2  
  
 
  
SECTION 9: Physical and chemical properties  
  
9.1.  Information on basic physical and chemical properties  
  
Physical state  
  
: liquid   
  
Form  
  
: Liquid  
Colour  
  
: white  
Odour  
  
: slight, typical  
Odour Threshold  
  
: not measured  
  
pH  
  
: 2,1 - 4,5  
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Melting point  : Freezing point  
approx. 0 °C  
  
  
    
 Boiling point  
  
: Boiling point/range 
approx. 100 °C  
  
  
 Flash point  
  
: not measured  
  
 Evaporation rate  
  
: not measured  
  
 Flammability  
  
: not measured  
  
  
 Upper Explosion/Ignition Limit  
  
: not measured  
  
 Lower explosion limit  
  
: not measured  
  
 Vapour pressure  
  
: not measured  
  
 Relative vapour density  
  
: not measured  
  
 Relative density  
  
: not measured  
  
 Solubility(ies)  
  
: not measured  
  
 Water solubility  
  
: dispersible  
  
 Partition coefficient: 
noctanol/water  
  
: not measured  
  
 Autoignition temperature  
  
: not measured  
  
 Thermal decomposition  
  
: not measured  
  
 Viscosity, kinematic  
  
: not measured  
  
 Viscosity, dynamic  
  
: not measured  
  
 Explosive properties  
  
: not measured  
  
 Oxidising properties  
  
: not measured  
  
 Density  
  
: not measured  
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9.2.  
  
Other information   
 Metal corrosion  
  
: not measured  
 Ignition temperature  : not measured  
   
 
  
SECTION 10: Stability and reactivity  
  
10.1. Reactivity  see section "Possibility of hazardous 
reactions"  
  
10.2. Chemical stability  
   The product is stable under normal conditions.  
  
10.3. Possibility of hazardous reactions  
   No hazardous reactions with proper storage and handling.  
  
10.4. Conditions to avoid  
 freezing.  
  
10.5. Incompatible materials  
 Unknown  
  
10.6. Hazardous decomposition products  
   None with proper storage and handling.  
  
 
  
SECTION 11: Toxicological information  
  
11.1. Information on toxicological effects  
  
Acute toxicity (oral)   : no data available  
Acute toxicity (inhalation)   : no data available  
Acute toxicity (dermal)   : no data available  
Irritation/corrosion of the skin   : no data available  
Serious eye damage/ eye 
irritation  
  
: no data available  
Respiratory/skin sensitization   : no data available  
Repeated dose toxicity  
  
  CMR assessment  
  
: no data available  
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Carcinogenicity   : no data available  
Mutagenicity   : no data available  
Teratogenicity   : no data available  
Toxicity to reproduction   : no data available  
Specific Target Organ  
Toxicity - Single exposure  
  
: no data available  
Specific Target Organ  
Toxicity - Repeated exposure  
  
: no data available  
Aspiration hazard  
  
: No aspiration toxicity classification  
Other information  : The properties of this product which are hazardous to health have been calculated 
as per regulation (EC) No. 1272/2008. See section 2 "Hazards Identification".  
  
 
  
SECTION 12: Ecological information  
  
  Ecotoxicology Assessment  
  
 Acute aquatic toxicity  : Based on available data, the classification criteria are not met.  
  
  
 Chronic aquatic toxicity  : Based on available data, the classification criteria are not met.  
  
  
  
12.1. Toxicity  
  
 Aquatoxicity, fish  
  
: no data available  
  
  
 Aquatoxicity, invertebrates  
  
: no data available  
  
  
 Aquatoxicity, algae / aquatic 
plants  
  
: no data available  
  
  
 Toxicity in microorganisms  
  
: no data available  
  
  
 chronic toxicity in fish  
  
: no data available  
  
  
 Chronic toxicity in aquatic 
Invertebrates  
   
: no data available  
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12.2.  
  
Persistence and degradability  
Photodegradation  : no data available  
   
  
Biological degradability  : no data available  
  
    
12.3.  
  
Bioaccumulative potential  
Bioaccumulation  : no data available  
  
  
  
12.4.  
  
Mobility in soil  
Environmental distribution  : no data available  
  
   
12.5. Results of PBT and vPvB assessment  
  
PBT and vPvB assessment  : This substance/mixture contains no components considered to be either persistent, 
bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative 
(vPvB) at levels of 0.1% or higher.  
  
   
12.6. Other adverse effects  
  General Information  : The product is considered to be a weak water pollutant (German law).  
  Do not allow to enter soil, waterways or waste water canal.  
  
  
 
  
SECTION 13: Disposal considerations  
  
13.1. Waste treatment methods  
  
Product  
  
: In accordance with local authority regulations, take to special waste incineration 
plant  
  
Contaminated packaging  : If empty contaminated containers are recycled or disposed of, the receiver must be 
informed about possible hazards.  
  
  
 
  
SECTION 14: Transport information  
Not dangerous according to transport regulations.    
  
14.1.  UN number:  --  
14.2.  UN proper shipping name:  --  
14.3.  Transport hazard class(es):  --  
14.4.  Packing group:  --  
14.5.  Environmental hazards:  -- 14.6  Special 
precautions for user:  No  
Catalogue A Document A3.3 PlasACRYL SDS EPoM  
  
 
325 
 
SAFETY DATA SHEET (EC 1907/2006)    
PLASACRYL T20 / 5 KG  
Version:  1.1 / GB  VA-No.    
Revision date: 30.11.2017 Issue date: 12.04.2016  
replaces version:  1.0   
Page:  325 / 10  
  
  
 
  
SECTION 15: Regulatory information  
  
15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture   National 
legislation  
  
  
Technical instructions on Air 
Quality  
  
: 5.2.5 (no class)  
  
Major Accident Hazard 
Legislation  
  
: not applicable   
  
Water contaminating class  
(Germany)  
  
  
: slightly water endangering  
Classification acc. to German law  
  
Other regulations  
  
15.2. Chemical safety assessment  
  
: none  
Chemical safety assessment  : No chemical safety assessment was carried out for this product.  
  
 
  
SECTION 16: Other information   
List of references  
  
 Other information  : Comply with national laws regulating employee instruction.  
  
 Classification and applied procedure to derive the classification of mixtures according to EU Regulation (EC) No. 
1272/2008 (CLP)  
  
  Changes since the last version are highlighted in the margin. This version replaces all previous versions.  
  
This information and all further technical advice is based on our present knowledge and experience. However, it implies 
no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, 
especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the 
legal sense is intended or implied. We reserve the right to make any changes according to technological progress or 
further developments. The customer is not released from the obligation to conduct careful inspection and testing of 
incoming goods. Performance of the product described herein should be verified by testing, which should be carried out 
only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is 
neither a recommendation, nor does it imply that similar products could not be used.  
  
  Legend  
  
ADR  European Agreement concerning the International Carriage of Dangerous Goods by Road  
ADN  European Agreement concerning the International Carriage of Dangerous Goods by Inland 
Waterways  
ADNR  European agreement concerning the international carriage of dangerous goods by inland 
waterways (ADN)  
ASTM  American Society for Testing and Materials  
ATP  Adaptation to Technical Progress  
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BCF  Bioconcentration factor  
BetrSichV  German Ordinance on Industrial Safety and Health  
c.c.  closed cup  
CAS  Chemical Abstract Services  
CESIO  European Committee of Organic Surfactants and their Intermediates  
ChemG  German Chemicals Act  
CMR  carcinogenic-mutagenic-toxic for reproduction  
DIN  German Institute for Standardization  
DMEL  Derived minimum effect level  
DNEL  Derived no effect level  
EINECS  European Inventory of Existing Commercial Chemical Substances  
EC50  half maximal effective concentration  
GefStoffV  German Ordinance on Hazardous Substances  
GGVSEB  German ordinance for road, rail and inland waterway transportation of dangerous goods  
GGVSee  German ordinance for sea transportation of dangerous goods  
GLP  Good Laboratory Practice  
GMO  Genetic Modified Organism  
IATA  International Air Transport Association  
ICAO  International Civil Aviation Organization  
IMDG  International Maritime Dangerous Goods  
ISO  International Organization For Standardization  
LOAEL  Lowest observed adverse effect level  
LOEL  Lowest observed effect level  
NOAEL  No observed adverse effect level  
NOEC  no observed effect concentration  
NOEL  no observed effect level  
o. c.  open cup  
OECD  Organisation for Economic Cooperation and Development  
OEL  Occupational Exposure Limit  
PBT  Persistent, bioaccumulative, toxic  
PEC  Predicted effect concentration  
PNEC  Predicted no effect concentration  
REACH  REACH registration  
RID  Convention concerning International Carriage by Rail  
STOT  Specific Target Organ Toxicity  
SVHC  Substances of Very High Concern  
TA  Technical Instructions  
TPR  Third Party Representative (Art. 4)  
TRGS  Technical Rules for Hazardous Substances  
VCI  German chemical industry association  
vPvB  very persistent, very bioaccumulative  
VOC  volatile organic compounds  
VwVwS  German Administrative Regulation on the Classification of Substances Hazardous to Waters 
into Water Hazard Classes  
WGK  Water Hazard Class  
WHO  World Health Organization  
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SAFETY DATA SHEET 
Preparation Date:  9/12/2013 Revision Date:  8/20/2018 Revision Number:  
G7 
1. IDENTIFICATION 
Product identifier  
Product code: ET108 Product Name: ALCOHOL, 190 
PROOF, USP 
Other means of identification  
 Synonyms: Alcool ethylique 190 proof (French) 
Alcohol etílico 190 proof (Spanish) 
Ethanol 190 proof 
Ethanol, undenatured 190 proof 
 CAS #: 64-17-5 
 RTECS # KQ6300000 
 CI#: Not available 
Recommended use of the chemical and restrictions on use  
Recommended use: Solvent. Perfuming agent. In pharmaceuticals. Inks. In organic synthesis. In 
beverages. 
 Uses advised against No information available 
 Supplier:  Spectrum Chemical Mfg. Corp 
14422 South San Pedro St. 
Gardena, CA  90248 
(310) 516-8000 
 Order Online At:  https://www.spectrumchemical.com   
Emergency telephone number Chemtrec 1-800-424-9300 Contact 
Person: Martin LaBenz (West Coast) 
 Contact Person:  Ibad Tirmiz (East Coast) 
2. HAZARDS IDENTIFICATION 
Classification  
This chemical is considered hazardous according to the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) 
Considered a dangerous substance or mixture according to the Globally Harmonized System (GHS) 
Serious eye damage/eye irritation Category 2 
Reproductive toxicity Category 1A 
Specific target organ toxicity (single exposure) Category 3 
Specific target organ toxicity (repeated exposure) Category 1 
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Flammable liquids Category 2 
Label elements  
 
Not Applicable 
Other hazards  
Causes mild skin irritation 
Can burn with an invisible flame 
Precautionary Statements - Prevention 
Obtain special instructions before use 
Do not handle until all safety precautions have been read and understood 
Wash face, hands and any exposed skin thoroughly after handling 
Wear protective gloves/protective clothing/eye protection/face protection 
Do not breathe dust/fume/gas/mist/vapors/spray 
Do not eat, drink or smoke when using this product 
Use only outdoors or in a well-ventilated area 
Keep away from heat/sparks/open flames/hot surfaces. — No smoking 
Keep container tightly closed 
Ground/bond container and receiving equipment 
Use explosion-proof electrical/ventilating/lighting/.../equipment 
Use only non-sparking tools 
Take precautionary measures against static discharge 
Keep cool 
Precautionary Statements - Response 
IF exposed or concerned: Get medical advice/attention 
In case of fire: Use CO2, dry chemical, or foam to extinguish. 
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If 
eye irritation persists: Get medical advice/attention. If skin irritation occurs: Get medical advice/attention 
IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor/physician if you 
feel unwell. 
Precautionary Statements - Storage 
Store locked up 
Store in a well-ventilated place. Keep container tightly closed 
Precautionary Statements - Disposal 
Dispose of contents/container to an approved waste disposal plant 
3. COMPOSITION/INFORMATION ON INGREDIENTS  
Hazards not otherwise classified (HNOC)   
Danger 
Hazard statements 
Causes serious eye irritation 
May damage fertility or the unborn child 
May cause respiratory irritation.  May cause drowsiness or dizziness 
Causes damage to organs through prolonged or repeated exposure 
Highly flammable liquid and vapor 
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Components CAS-No.  Weight % 
Ethyl Alcohol 200 proof 64-17-5  95 
Water 7732-18-5 5 
  
 4. FIRST AID MEASURES 
First aid measures 
General Advice: National Capital Poison Center in the United States can provide assistance if you 
have a poison emergency and need to talk to a poison specialist.  Call 1-800-222-
1222. 
Skin Contact: 
Wash off immediately with soap and plenty of water removing all contaminated clothing 
and shoes. Get medical attention. If skin irritation persists, call a physician. 
Eye Contact: Flush eyes with water for 15 minutes. Get medical attention. 
Inhalation: 
Move to fresh air. If breathing is difficult, give oxygen. If not breathing, give artificial 
respiration. Get medical attention. 
Ingestion: Do not induce vomiting without medical advice. Never give anything by mouth to an 
unconscious person. Consult a physician if necessary. 
Most important symptoms and effects, both acute and delayed 
 Symptoms Causes eye irritation 
May cause skin irritation 
May cause irritation of respiratory tract 
Dyspnea (Difficulty breathing and shortness of breath) 
Central nervous system effects 
Dizziness 
Drowsiness 
Headache 
Ataxia 
Staggering gait 
Nausea 
Vomiting 
May cause cardiovascular effects 
Indication of any immediate medical attention and special treatment needed 
 Notes to Physician: Treat symptomatically. 
Protection of first-aiders 
First-Aid Providers:  Avoid exposure to blood or body fluids.  Wear gloves and other necessary protective clothing.  Dispose of 
contaminated clothing and equipment as bio-hazardous waste. 
5. FIRE-FIGHTING MEASURES 
Extinguishing Media  
Suitable Extinguishing Media: Carbon dioxide (CO2). Dry chemical. Alcohol-resistant 
foam. Water spray. 
 Unsuitable Extinguishing Media: Do not use a solid (straight) water stream as it may scatter 
and spread fire. 
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Specific hazards arising from the chemical 
 Hazardous Combustion Products: Carbon Monoxide, Carbon Dioxide. 
 Specific hazards: Flammable. May be ignited by heat, sparks or flames. 
Material can burn with invisible flame. Vapor may travel 
considerable distance to source of ignition and flash back. 
Vapors may form explosive mixtures with air. Most vapors 
are heavier than air.  They will spread along the ground 
and collect in low or confined areas (sewers, basements, 
tanks). Container explosion may occur under fire 
conditions or when heated. Fire may produce irritating, 
corrosive and/or toxic gases. 
Special Protective Actions for Firefighters   
Specific Methods: 
Water mist may be used to cool closed containers. For 
larger fires, use water spray or fog.  Cool containers with 
flooding quantities of water until well after fire is out. 
Special Protective Equipment for Firefighters: 
As in any fire, wear self-contained breathing apparatus 
pressure-demand, MSHA/NIOSH (approved or 
equivalent) and full protective gear 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions, protective equipment and emergency procedures   
Personal Precautions: Ensure adequate ventilation. Keep people away from and upwind of spill/leak. Avoid 
contact with skin, eyes and clothing. Use personal protective equipment. Remove all 
sources of ignition. Pay attention to flashback. Take precautionary measures against static 
discharges. All equipment used when handling the product must be grounded. Use spark-
proof tools and explosion-proof equipment. In case of large spill, water spray or vapor 
suppressing foam may be used to reduce vapors, but may not prevent ignition in closed 
spaces. 
Environmental precautions  Prevent further leakage or spillage if safe to do so. Prevent product from 
entering drains. Prevent entry into waterways, sewers, basements or confined 
areas. 
 
Methods for containment Stop leak if you can do it without risk. Absorb spill with inert material (e.g. 
vermiculite, dry sand or earth), then place in a suitable chemical waste 
container. In case of large spill, dike if needed.  Dike far ahead of liquid spill for 
later disposal. 
Methods for cleaning up 
Use appropriate tools to put the spilled material in a suitable chemical waste 
disposal container. Use only non-sparking tools. Clean contaminated surface 
thoroughly. 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Technical Measures/Precautions: 
Provide sufficient air exchange and/or exhaust in work rooms. Remove all sources of ignition. To avoid ignition of 
vapors by static electricity discharge, all metal parts of the equipment must be grounded. Keep away from 
incompatible materials. 
Methods and material for containment and cleaning up   
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Safe Handling Advice 
Wear personal protective equipment. Use only in well-ventilated areas. Avoid contact with skin, eyes and clothing. 
Keep away from heat and sources of ignition. Do not breathe vapors or spray mist. Do not ingest. When using do 
not smoke. Handle in accordance with good industrial hygiene and safety practice. 
Conditions for safe storage, including any incompatibilities 
Technical Measures/Storage Conditions: 
Hygroscopic. Keep container tightly closed in a dry and well-ventilated place. Store at room temperature in the 
original container. Sensitive to light.  Store in light-resistant containers. Keep away from heat and sources of 
ignition. Store in a segregated and approved area. Store away from incompatible materials. 
Incompatible Materials: 
Oxidizing agents 
Acids 
Alkali Metals 
Halogens 
Caustics 
isocyanates 
Metals 
Bases 
Acid anhydrides 
Acid chlorides 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Control parameters   
National occupational exposure limits 
United States 
Components CAS-No. OSHA NIOSH ACGIH AIHA WEEL 
Ethyl Alcohol 200 
proof 
64-17-5 1000 ppm TWA 
1900 mg/m
3
 TWA 
1000 ppm TWA 
1900 mg/m
3
 TWA 
1000 ppm STEL None 
Water 7732-18-5 None None None None 
Canada 
Components CAS-No. Canada - Alberta Canada - British 
Columbia 
Canada - Ontario Canada - Quebec 
Ethyl Alcohol 200 
proof 
64-17-5 1000 ppm TWA 
1880 mg/m
3
 TWA 
1000 ppm STEL 1000 ppm STEL None 
Water 7732-18-5 None None None None 
Australia and Mexico 
Components CAS-No. Australia Mexico 
Ethyl Alcohol 200 proof 64-17-5 1000 ppm TWA 
1880 mg/m
3
 TWA 
1000 ppm TWA 
1900 mg/m
3
 TWA 
Water 7732-18-5 None None 
Appropriate engineering controls 
 Engineering measures to reduce exposure: Ensure adequate ventilation. Provide exhaust ventilation or 
other engineering controls to keep the airborne 
concentrations of vapors and mist below their respective 
threshold limit value. 
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Individual protection measures, such as personal protective equipment 
Personal Protective Equipment 
 Eye protection: Goggles or Safety glasses with side-shields 
 Skin and body protection: Chemical resistant apron 
Long sleeved clothing 
Gloves 
 Respiratory protection: Vapor respirator.  Be sure to use an approved/certified respirator or equivalent. 
Hygiene measures: Avoid contact with skin, eyes and clothing. When using, do not eat, drink or 
smoke. Wash hands before breaks and immediately after handling the product. 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Physical state: 
Liquid 
Odor: 
Pleasant. Alcoholic. Mild. Ethereal. 
Like wine or whiskey. 
Molecular/Formula weight 
(g/mole): 
46.07 
Flashpoint (°C/°F): 
17 °C/63 °F 
Lower Explosion Limit (%): 
3.3% 
Decomposition temperature(°C/°F): 
No information available 
Density (g/cm3): 
No information available 
Vapor pressure @ 20°C (kPa): 
5.93 
VOC content (g/L): 
789 
Viscosity: 
No information available 
Appearance: 
No information available. 
Taste 
Pungent. Burning. 
Flammability: 
No information available 
Flash Point Tested according to: 
Closed cup 
Upper Explosion Limit (%): 
19% 
Boiling point/range(°C/°F): 
79 °C/174.2 °F 
Specific gravity: 
0.8 @ 20 °C 
Evaporation rate: No 
information available 
Odor threshold (ppm): 
5-10 (recognition) 
84  (tolerance) 
Miscibility: 
Miscible with water 
Miscible with Acetone 
Miscible with Ether 
Miscible with Benzene 
Miscible with glacial Acetic Acid 
Miscible with many organic solvents 
Color: 
Clear. Colorless. 
Formula: 
C2-H5-OH 
Flash point (°C): 
17 
Autoignition Temperature (°C/°F): 
363 °C/685.4 °F 
Melting point/range(°C/°F): -114.1-
117.3 °C/-173.38-179.14 °F 
Bulk density: 
No information available 
pH: 
No information available 
Vapor density: 
1.59 
Partition coefficient 
(n-octanol/water): No 
information available 
Solubility: 
Very soluble in water 
10. STABILITY AND REACTIVITY 
Reactivity   
When Ethanol comes in contact with Sodium, it liberates flammable hydrogen gas 
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It can react vigorously or explosively with acid hydrides or acid chlorides 
It reacts with alkali metals to liberate flammable hydrogen gas 
It reacts with ammonia + silver nitrate to form silver nitride and silver fulminate 
It reacts with acetyl bromide to evolve hydrogen bromide 
Ethyl alcohol can react with freshly cut/etched/scratched aluminum with the evolution of heat and release of hydrogen gas.  
The Ethyl alcohol has to be on the aluminum surface as it is being cut/scratched/etched Ethyl Alcohol reacts vigorously with 
acetyl chloride. 
Ethyl alcohol reacts with silver (I) oxide + ammonia or hydrazine to form silver nitride and silver fulminate 
Ethanol ignites and then explodes on contact with the following compounds:  acetic anhydride + sodium hydrosulfate, disulfuric 
acid + nitric acid, phosphorus (III) oxide, platinum, potassium tert-butoxide + acids 
Ethanol rapidly absorbs moisture from the air.  Can react vigorously/explosively with oxidizers.  Ethanol can react 
vigorously/explosively with the following:  ammonium hydroxide & silver oxide, chlorine or chlorine oxides, perchlorates (barium 
perchlorate, chloryl perchlorate, magnesium perchlorate (forms ethyl perchlorate), nitrosyl perchlorate , potassium perchlorate, 
silver perchlorate, uranyl perchlorate), acetic anhydride, acetyl bromide (evolves hydrogen bromide), acetyl chloride, aluminum 
sesquibromide ethylate, bromine pentafluoride, calcium hypochlorite, chromic anhydride, , chromium trioxide, chromyl chloride, 
cyanuric acid + water, dichloromethane + sulfuric acid + nitrate (or) nitrite, manganese perchlorate + 2,2-dimethoxy propane, 
dioxygen difluoride, disulfuryl difluoride, fluorine nitrate, hydrogen peroxide, iodine heptafluoride, manganese heptoxide, iodine + 
methanol + mercuric oxide, iodine + Phosphorus (forms ethane iodide), mercuric nitrate, nitric acid, perchloric acid, permanganic 
acid, peroxodisulfuric acid, platinum black, potassium dioxide, potassium permanganate, potassium superoxide, potassium tert-
butoxide, ruthenium(VIII) oxide, silver +nitric acid (forms silver fulminate), silver nitrate (forms ethyl nitrate), silver peroxide, sodium 
hydrazide, hydrogen peroxide + sulfuric acid, sulfuric acid + permanganates, uranium hexafluoride, sulfuric acid + sodium 
dichromate, tetrachlorisilane + water, silver & nitric acid, tetraphosphorus hexaoxide 
Chemical stability 
 Stability: Stable under recommended storage conditions. 
Possibility of Hazardous Reactions: Hazardous polymerization does not occur 
Conditions to avoid:  Heat. Ignition sources. Incompatible materials. 
Incompatible Materials:  
Oxidizing agents 
Acids 
Alkali Metals 
Halogens 
Caustics 
isocyanates 
Metals 
Bases 
Acid anhydrides 
Acid chlorides 
Hazardous decomposition 
products:  
Other Information  
Carbon monoxide. Carbon dioxide. When heated to decomposition it emits 
acrid smoke and irritating fumes. 
Corrosivity: No information available 
Special Remarks on Corrosivity: No information available 
11. TOXICOLOGICAL INFORMATION 
Information on likely routes of exposure   
Principal Routes of Exposure: 
Ingestion. Skin. Eyes. Inhalation. 
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Acute Toxicity 
The following values are calculated based on chapter 3.1 of the GHS document 
 ATEmix (oral) 7432  mg/kg 
 ATEmix (inhalation-vapor) 131.26  mg/l 
Component Information 
Ethyl Alcohol 200 proof  
CAS-No. 64-17-5 
LD50/oral/rat =  7060 mg/kg Oral LD50 Rat 
LD50/oral/mouse =  3450 mg/kg Oral LD50 Mouse 
LD50/dermal/rabbit =  No information available 
LD50/dermal/rat =  No information available 
LC50/inhalation/rat =  124.7 mg/L Inhalation LC50 Rat 4 h 
LC50/inhalation/mouse =  39000 mg/m
3
  4 h 
Other LD50 or LC50information =  >60000 ppm Inhalation LC50 Mouse 1 h 
5900 mg/m
3
  Inhalation LC50 Rat 6 h 
20000 ppm Inhalation LC50 Rat 10 h 
5560 mg/kg Oral LD50 Guinea Pig 
6300 mg/kg Oral LD50 Rabbit 
Water  
CAS-No. 7732-18-5 
LD50/oral/rat =  > 90 mL/kg Oral LD50 Rat 
LD50/oral/mouse =  No information available 
LD50/dermal/rabbit =  No information available 
LD50/dermal/rat =  No information available 
LC50/inhalation/rat =  No information available 
LC50/inhalation/mouse =  No information available 
Other LD50 or LC50information =  No information available 
Product Information 
LD50/oral/rat = 
VALUE- Acute Tox Oral =  No information available 
LD50/oral/mouse = 
Value - Acute Tox Oral =  No information available 
LD50/dermal/rabbit 
VALUE-Acute Tox Dermal =  No information available 
LD50/dermal/rat 
VALUE -Acute Tox Dermal =  No information available 
LC50/inhalation/rat 
VALUE-Vapor =  No information available 
VALUE-Gas =  No information available 
VALUE-Dust/Mist =  No information available 
LC50/Inhalation/mouse 
VALUE-Vapor =  No information available 
VALUE - Gas =  No information available 
VALUE - Dust/Mist =  No information available 
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Symptoms  
Skin Contact: Mildly to moderately irritating to the skin. 
Eye Contact: Causes serious eye irritation. 
Inhalation May cause irritation of respiratory tract. Symptoms may include coughing 
and shortness of breath. May cause nausea and headache. It may affect 
behavior/central nervous system (ataxia, general anesthetic, drowsiness). 
May affect respiration (respiratory depression). Inhalation of high 
concentrations of vapor may cause anesthetic effects. Inhalation of high 
concentrations of vapors may cause dizziness or suffocation. May affect the 
brain. 
Ingestion Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhea. 
May cause gastritis. May cause loss of appetite. May cause flushed skin. May 
affect the cardiovascular system (change in heart rate). May affect the 
cardiovascular system (hypotension or hypertension, tachycardia, 
dysrhythmias). It may affect behavior/central nervous system (excitation, mild 
euphoria, excessive talking, fatigue, headache, dizziness, drowsiness, 
staggaring gait, ataxia, hallucinations, slurred speech, amnesia, confusion, 
release of inhibitions, agressive behavior, convulsions, coma). May affect 
respiration (dyspnea, respiratory depression). It may affect the brain. May affect 
liver. May affect the blood. May affect the endocrine system. It may affect the 
spleen. May affect urinary system (kidneys). 
Aspiration hazard 
No information available. 
Delayed and immediate effects as well as chronic effects from short and long-term exposure   
Chronic Toxicity Prolonged or repeated skin contact may cause dermatitis, and dryness and 
cracking of the skin. Prolonged or repeated ingestion may affect 
behavior/central nervous system. Prolonged or repeated ingestion may affect 
metabolism (cause anorexia, weight loss). Prolonged or repeated ingestion may 
affect the liver (fatty liver degeneration, cirrhosis of the liver. Prolonged or 
repeated ingestion may affect the cardiovascular system. 
Sensitization: 
No information available. 
Mutagenic Effects: 
For Ethyl alcohol: 
May affect genetic material 
Experiments with bacteria and/or yeast have shown mutagenic effects 
Cytogenic analysis - hamster ovary 
Cytogenic Analysis (Hamster embryo) 
Cytogenic analysis - human leukocyte 
Cytogenic Analysis: human lymphocyte 
Sister Chromatid Exchange - Hamster ovary 
Sister Chromatid Exchange (human lymphocyte) 
Carcinogenic effects: May cause cancer based on animal test data.  Equivocal tumorigenic agent by 
RTECS criteria. 
Components CAS-No. IARC ACGIH - 
Carcinogens 
NTP OSHA HCS - 
Carcinogens 
Australia - 
Notifiable 
Carcinogenic 
Substances 
Australia - 
Prohibited 
Carcinogenic 
Substances 
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Ethyl Alcohol 200 proof 64-17-5 Group 1 
Monograph 
100E [2012] in 
alcoholic 
beverages 
Monograph 96 
[2010] in 
alcoholic 
beverages 
A3 Confirmed 
Animal 
Carcinogen 
with Unknown 
Relevance to 
Humans 
Not listed Present Not listed Not listed 
Water 7732-18-5 Not listed Not listed Not listed Not listed Not listed Not listed 
ACGIH (American Conference of Governmental Industrial Hygienists) 
IARC (International Agency for Research on Cancer) 
NTP (National Toxicology Program) 
OSHA (Occupational Safety and Health Administration of the US Department of Labor) 
 Reproductive toxicity  May damage fertility or the unborn child 
Reproductive Effects: Causes adverse reproductive effects 
Developmental Effects: May cause adverse developmental 
effects May cause harm to the unborn 
child 
Teratogenic Effects: Causes birth defects (teratogenic effects) 
Specific Target Organ Toxicity  
 STOT - single exposure Respiratory system. central nervous system. 
STOT - repeated exposure Causes damage to organs through prolonged or repeated exposure. Target 
Organs: Skin. Liver. Central nervous system. Nervous system. Heart. 
 12. ECOLOGICAL INFORMATION 
Ecotoxicity 
Ecotoxicity effects: Aquatic environment. 
Ethyl Alcohol 200 proof - 64-17-5 
Freshwater Fish Species Data: 
12.0 - 16.0 mL/L LC50 Oncorhynchus mykiss 96 h static 1 100 mg/L LC50 
Pimephales promelas 96 h static 1 13400 - 15100 mg/L LC50 Pimephales 
promelas 96 h flow-through 1 
Water Flea Data: 9268 - 14221 mg/L LC50 Daphnia magna 48 h 2 mg/L EC50 Daphnia magna 48 
h 
10800 mg/L EC50 Daphnia magna 24 h 
Persistence and degradability: No information available 
Bioaccumulative potential: No information available. 
Mobility: No information available. 
 13. DISPOSAL CONSIDERATIONS 
Disposal Methods  
Waste from residues / unused products: 
Waste must be disposed of in accordance with Federal, State and Local regulation. 
Contaminated packaging: 
Catalogue A                  Document A3.4                      Reagent Alcohol SDS                      EPoM                   12.Sep.18 
 
338 
 
Empty containers should be taken for local recycling, recovery or waste disposal 
Components CAS-No. RCRA - F Series 
Wastes 
RCRA - K Series 
Wastes 
RCRA - P Series 
Wastes 
RCRA - U Series 
Wastes 
Ethyl Alcohol 200 proof 64-17-5 None None None None 
Water 7732-18-5 None None None None 
14. TRANSPORT INFORMATION 
DOT 
 UN-No: UN1170 
 Proper Shipping Name: Ethanol solution 
 Hazard Class: 3 
 Subsidiary Class No information available 
 Packing group: II 
Emergency Response Guide 127 
Number 
 
Marine Pollutant No data available 
DOT RQ (lbs): No information available 
Special Provisions 24, IB2, T4, TP1 
Symbol(s): No information available 
Description: 
TDG (Canada) 
UN1170,  ETHANOL 
SOLUTION, 3, II 
UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Subsidiary Risk: No information available 
Packing Group: II 
Marine Pollutant No Information available 
Description: 
ADR 
UN1170,  ETHANOL 
SOLUTION, 3, II 
UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Packing Group: II 
Subsidiary Risk: No information available 
Special Provisions 144, 601 
Description: 
IMO / IMDG 
UN1170,  ETHANOL 
SOLUTION, 3, II 
UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Subsidiary Risk: No information available 
Packing Group: II 
Marine Pollutant No information available 
EMS: F-E 
Special Provisions 144 
Description 
RID 
UN1170,  ETHANOL 
SOLUTION, 3, II 
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UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Subsidiary Risk: 3 
Packing Group: II 
Special Provisions 144, 601 
Description: 
ICAO 
UN1170,  ETHANOL 
SOLUTION, 3, II 
UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Subsidiary Risk: No information available 
Packing Group: II 
Description: UN1170,  ETHANOL 
SOLUTION, 3, II 
Special Provisions 
IATA 
A58, A180, A3 
UN-No: UN1170 
Proper Shipping 
Name: 
Ethanol solution 
Hazard Class: 3 
Subsidiary Risk: No information available 
Packing Group: II 
ERG Code: 3L 
Special Provisions No information available 
Description: UN1170,  ETHANOL SOLUTION, 3, II 
 15. REGULATORY INFORMATION 
International Inventories 
Components CAS-No. U.S. TSCA KOREA 
KECL 
Philippines 
(PICCS) 
Japan ENCS CHINA Australia 
(AICS) 
EINECS-No. 
Ethyl Alcohol 200 
proof 
64-17-5 Present(ACTI 
VE) 
KE-13217 Present (2)-202 Present Present Present 200-
578-6 
Water 7732-18-5 PresentACTIV 
E 
Present KE-
35400 
Present Not present Present Present Present 231-
791-2 
U.S. Regulations 
Ethyl Alcohol 200 proof 
Massachusetts RTK:  Present 
New Jersey RTK Hazardous Substance List:  0844 
Pennsylvania RTK:  Present 
Minnesota - Hazardous Substance List:  Present 
Louisana Reportable Quantity List for Pollutants:  Present (listed as Volatile Organic Compounds) 
California Directors List of Hazardous Substances:  Present 
FDA - Food Additives Generally Recognized as Safe (GRAS):  21 CFR 184.1293 
FDA - 21 CFR - Total Food Additives 169.175, 169.176, 169.177, 169.181, 172.340, 172.560, 172.580, 175.105, 176.180, 
176.200, 177.1200, 177.1650, 178.1010, 184.1293, 73.30, 73.345, 73.615 
California Prop. 65: Safe Drinking Water and Toxic Enforcement Act of 1986. 
Chemicals Known to the State of California to Cause Cancer: 
WARNING:  This product can expose you to chemicals including (see table below) which is (are) known to the State of California to cause 
cancer.  For more information go to www.p65warnings.ca.gov. 
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Chemicals Known to the State of California to Cause Reproductive Toxicity: 
WARNING:  This product can expose you to chemicals including (see table below) which is (are) known to the State of California to cause birth 
defects or other reproductive harm.  For more information go to www.p65warnings.ca.gov. 
Components CAS-No. Carcinogen Developmental Toxicity Male 
Reproductive 
Toxicity 
Female 
Reproductive 
Toxicity: 
Ethyl Alcohol 200 proof 64-17-5 carcinogen 
(Ethanol in 
alcoholic 
beverages) 
developmental toxicity 
(Ethyl alcohol in 
alcoholic beverages) 
Not Listed Not Listed 
Water 7732-18-5 Not Listed Not Listed Not Listed Not Listed 
CERCLA/SARA 
Components CAS-No. CERCLA - 
Hazardous 
Substances and 
their Reportable 
Quantities 
Section 302 
Extremely 
Hazardous 
Substances 
and TPQs 
Section 302 
Extremely 
Hazardous 
Substances and 
RQs 
Section 313 - 
Chemical 
Category 
Section 313 - 
Reporting  
de minimis 
Ethyl Alcohol 200 
proof 
64-17-5 None None None None None 
Water 7732-18-5 None None None None None 
U.S. TSCA 
Components CAS-No. TSCA Section 5(a)2 - Chemicals 
With Significant New Use Rules 
(SNURS) 
TSCA 8(d) -Health and Safety 
Reporting 
Ethyl Alcohol 200 proof 64-17-5 Not Applicable Not Applicable 
Water 7732-18-5 Not Applicable Not Applicable 
Canada 
WHIMIS 2015 - GHS Classifications 
 WHMIS 2015 Hazard Classification . 
Information: 
 Component WHMIS 2015 Hazard Classification 
 Ethyl Alcohol 200 proof Flammable liquids - Category 2: H225 Highly flammable liquid and 
  64-17-5 ( 95 ) vapour.; Serious Eye Damage/Eye Irritation - Category 2B: H320 
Causes eye irritation. 
 Water Not a dangerous product according to HPR classification criteria 
 7732-18-5 ( 5 ) 
Canada Hazardous Products Regulation This product has been classified according to the hazard criteria of the HPR (Hazardous 
Products Regulation) and the SDS contains all of the information required by the HPR 
WHMIS 1988 Hazard Class 
B2  Flammable liquid 
D2B  Toxic materials 
 
Components WHMIS 1988 
Ethyl Alcohol 200 proof B2,D2B 
Water Uncontrolled product according to WHMIS 
classification criteria 
Canada Controlled Products Regulation: 
This product has been classified according to the hazard criteria of the CPR (Controlled Products Regulation) and the MSDS 
contains all of the information required by the CPR. 
Components WHMIS Ingredient Disclosure List - 
Ethyl Alcohol 200 proof 0.1 % 
Inventory 
Components CAS-No. Canada (DSL) Canada  (NDSL) 
Ethyl Alcohol 200 proof 64-17-5 Present Not Listed 
Water 7732-18-5 Present Not Listed 
Components CAS-No. CEPA Schedule I - Toxic Substances 
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Ethyl Alcohol 200 proof 64-17-5 Not listed 
Water 7732-18-5 Not listed 
Components CAS-No. CEPA - 2010 Greenhouse Gases Subject 
to Mandatory Reporting 
Ethyl Alcohol 200 proof 64-17-5 Not listed 
Water 7732-18-5 Not listed 
EU Classification 
EU GHS - SV - CLP 1272/2008 
Components CAS-No. EU GHS - SV - CLP (1272/2008) 
Ethyl Alcohol 200 proof 64-17-5 Flammable liquids - Flam. Liq. 2: 
H225 
Highly flammable liquid and 
vapour.603-002-00-5 
Water 7732-18-5  
EU - CLP (1272/2008) 
R-phrase(s) 
R11 - Highly flammable. 
S -phrase(s) 
S 7 - Keep container tightly closed. 
S16 - Keep away from sources of ignition - No smoking. 
Components CAS-No. Classification Concentration 
Limits: 
Safety Phrases 
Ethyl Alcohol 200 proof 64-17-5 F; R11 No information S(2) S7 S16 
Water 7732-18-5  No information  
The product is classified in accordance with Annex VI to Directive 67/548/EEC 
Indication of danger: 
F - Highly flammable. 
 
16. OTHER INFORMATION 
Preparation Date: 9/12/2013 
Revision Date: 8/20/2018 
Prepared by: Sonia Owen 
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Disclaimer: 
All chemicals may pose unknown hazards and should be used with caution. This 
Safety Data Sheet (SDS) applies only to the material as packaged. If this product 
is combined with other materials, deteriorates, or becomes contaminated, it may 
pose hazards not mentioned in this SDS. The physical properties reported in this 
SDS are obtained from the literature and do not constitute product specifications. 
Information contained herein does not constitute a warranty, whether expressed 
or implied, as to the safety, merchantability or fitness of the goods for a particular 
purpose. Spectrum Chemicals & Laboratory Products, Inc. assumes no 
responsibility for results obtained or for incidental or consequential damages, 
including lost profits, arising from the use of these data. No warranty against 
infringement of any patent, copyright or trademark is made or implied. It shall be 
the user's responsibility to develop proper methods of handling and personal 
protection based on the actual conditions of use. While this SDS is based on 
technical data judged to be reliable, Spectrum assumes no responsibility for the 
completeness or accuracy of the information contained herein. 
End of Safety Data Sheet 
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3050 Spruce Street, Saint Louis, MO 63103, USA 
Website:  www.sigmaaldrich.com 
Email USA:      techserv@sial.com 
Outside USA:  eurtechserv@sial.com 
Product Specification 
Product Name: 
 
Product Number: W308302 CAS Number: 77-93-0 
Formula: C12H20O7 
Formula Weight: 276.29 g/mol 
TEST Specification 
________________________________________________________
________________ 
Appearance (Color)                     Colorless 
Appearance (Form)                     Liquid 
Refractive index at 20 ° C           1.440 - 1.444 
Infrared Spectrum                       Conforms to 
Structure 
Purity (GC)                              >_ 99.0 % 
Arsenic (As)                             <_ 3 ppm 
Cadmium (Cd)                             <_ 1 ppm 
Mercury (Hg)                             <_ 1 ppm 
Lead (Pb)                                <_ 10 ppm 
Expiration Date Period                
5 Years 
------------------------- 
Specification: PRD.1.ZQ5.100000 
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Prof. Arjan Narbad, 
Quadram Institute Bioscience, 
Norwich Research Park, 
 NR4 7UA 
Phloral® use in Human Clinical Trials 
Dear Professor Narbad, 
Phloral® is the world’s most advanced oral technology for delivering drugs to the human 
colon. Phloral coated tablets and capsules have been evaluated for both efficacy and safety 
in multiple human clinical trials. These studies include administering the formulation to 
healthy volunteers
1
, as well as disease states such as ulcerative colitis
2
 and Clostrium difficile 
infection (CDI)
3
.  
D’Haens et al (2017) evaluated a Phloral®-coated mesalazine formulation in 409 patients 
with ulcerative colitis as part of a global Phase III randomised non-inferiority study. As a 
result of successfully completing this pivotal trial, the formulation is expected to be available 
to patients in 2019, marketed by Tilllotts Pharma. 
Allegretti et al. (2018) conducted an open label dose finding study with Phloral® 
formulations containing faecal microbiota transplants (FMT). Twenty-six patients with 
recurrent CDI were administered a Phloral®-coated FMT formulation. The Phloral® 
formulations even at a low dose, significantly improved the clinical cure rate and microbial 
diversity when compared to gastric-release formations. 
In all human clinical trials using Phloral® to date, the formulation has been deemed to be 
both safe and efficacious. 
 
Bill Lindsay  
CEO  
1
 Ibekwe VC et al. Aliment Pharmacol Ther. 2008;(28):911-916 
2
 D’Haens GR et al. Aliment Pharmacol Ther. 2017;46(3):292–302 
3
 Allegretti J et al. Microbial-Based Therapy. 2018 
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HE TREND IN MARKET 
PREFERENCE FOR  
PHARMACEUTICAL  
APPLICATIONS 
 
QUALI-V®   
THE PREFERRED CHOICE FOR 
PHARMACEUTICAL  
SOLID ORAL DOSAGE FORMS 
 
QUALI-V® HPMC CAPSULES,   
THE BEST ALTERNATIVE TO GELATIN 
• Quali-V® HPMC capsules are equivalent in their dissolution profile to traditional hard gelatin capsules, with a 
similar disintegration time
1
 and release properties
2
, proving identical in-vivo performance behavior.  
• While gelatin capsules undergo cross-linking at high temperature or high relative humidity3, such conditions do 
not affect the Quali-V
®
 HPMC dissolution profile, as these capsules are chemically stable.  
JP 1st (pH 1.2) JP 1st (pH 1.2)   
40ºC –RH 75% (6 months) 
JP 1st (pH 1.2)  60ºC 
(1 week) 
JP 1st (pH 1.2)   
30ºC –RH 60% (1 year) 
 
Capsule fill formulation: Acetaminophen 35 mg, Lactose 280 mg, Croscarmellose 35 mg • Quali-V® (HPMC) • Quali-G™ (gelatin) 
Fill weight: 350 mg (Size 1 capsule) 
Dissolution test method: Paddle at 50 rpm 
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• In addition to having a lower moisture content (4.0%-6.0%), Quali-V® HPMC capsules demonstrate better 
performance than gelatin capsules in terms of brittleness. The moisture content of Quali-V
®
 can be reduced 
minimizing significantly the occurrence of brittleness
4
 that takes place when drying gelatin capsules below a certain 
threshold.  
• Moisture has more influence on static electricity in gelatin capsules than in Quali-V® HPMC capsules5. 
 
QUALI-V® CAPSULES, SUPERIOR PROPERTIES  FOR 
HYGROSCOPIC DRUGS 
• Quali-V® capsules maintain their physical stability when filled with hygroscopic materials or are exposed to low 
relative humidity conditions. They also hold many types of formulations: powders, pellets, tablets, semi-solids and 
non-aqueous liquids. 
• Quali-V® capsules are proven to be more resistant to breaking and fracturing at very low relative humidity (12% 
RH), as they are more elastic
6
.  
 BRITTLENESS TESTER (QUALICAPS®) CAPSULE BRITTLENESS 
IMPACT TEST (EMPTY CAPSULE; N=30) 
Y: Brittleness (%) 
 
 Capsule Tensile strength [N] Elongation al break (%) 
RH 45 - 50% (ambient 
humidity) 
Quali-V® 
HPMC with   
no gelling agent 
165 ± 16 
153 ± 15 
14.6 ± 2.4 
9.7 ± 0.8 
RH 12% (low 
humidity) 
Quali-V® 
HPMC with   
no gelling agent 
172 ± 21 
119 ± 40 
11.1 ± 2.0 
8.5 ± 1.2 
(size 1, N=10, Average ± SD) 
• Superior resistance to breaking and superior de-blistering performance4,6 make Quali-V® capsules the ideal option to 
safeguard encapsulated products during long-term storage, even in less than ideal conditions. 
 
QUALI-V® CAPSULES, THE PERFECT CHOICE   
FOR RAPID DISSOLVING DRUG PRODUCTS 
• Quali-V® capsules demonstrate a very rapid and 
predictable dissolving drug product profile where 
85% of the API is released in the first 15 
minutes at different pH levels.  
 
 
 
 
 
 
 
 
 
Size 0  
 
 
  
 
 
  
 
  
  
     
 
Catalogue B             Document B1.2                    Quali Caps Technical Brochure             EPoM 
351 
 
• Quali-V® capsules show high reproducibility of 
invitro performance between manufactured lots. 
Studies of Universitat de València 2012-2013 
DISSOLUTION PROFILE FOR THREE QUALI-V® BATCHES (pH 1.2)  
 
• E1101855 Mu-1 • E1102536 C-9 • E1102536 C-3 
• Quali-V® capsules have a faster release profile, with a shorter timeframe until first rupture7, 3-4 minutes less 
than other HPMC capsules on the market. Quali-V
®
 also shows quicker dissolution rates with less variation
6
. 
 
• Quali-V® capsules are specifically designed for oral pharmaceutical applications where dissolution properties are 
prioritized over mechanical properties to ensure a consistent dissolution profile in standard conditions.  
Y: % Dissolved (%) 
Quali-V® capsules for   
PHARMACEUTICAL APPLICATIONS 
P
urified water 
  JP14
J
P16 1st (pH 1.2) +9 g KCl (NON-USUAL CONDITION) 
Qualicaps® HPMC capsules for   
NON-PHARMACEUTICAL APPLICATIONS 
P
urified water 
  JP14
J
P17 1st (pH 1.2) +9 g KCl (NON-USUAL CONDITION) 
Capsule fill formilation: Caffeine 100 mg 
Capsule: Size 1 capsule  
Dissolution test method: Paddle at 50 rpm 
X: Time (min) 
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QUALI-V® CAPSULES, DESIGNED TO MEET THE DEMANDING REQUIREMENTS OF 
PHARMACEUTICAL INDUSTRY 
• 100% plant-based and preservative-free, Quali-V® is acceptable for consumption within certain dietary and 
religious limitations. Quali-V
®
 also responds to the clean label movement among today’s consumers. 
• Pharmaceutical-grade quality. The manufacturing process is carried out following strict pharmaceutical criteria 
and certified according to ISO 9001 and ISO 14001. Drug Master Files for the US and Canada have been 
registered. 
• Quali-V® capsules do not undergo any changes in physical and chemical performance throughout their 5-year 
shelf-life; all parameters meet the specifications during stability studies. 
 
 Our scientific business development  Our technical service engineers  
team can support R&D in capsule- can assist in achieving productivity based dosage 
forms yields in capsule filling 
 
References 
1 Tuleu, C., Khela, M., Evans, D., Jones, B., Nagata, S. and Basit. A., 2004. A comparative scintigraphic assessment of the dis integration of HPMC and gelatin capsules in fasting 
subjects. Poster, AAPS Meeting, Baltimore, 2004. 2 Honkanen, O., Eerikäinen, S., Tuominen, R. and Marvola, M., 2001. Bioavailability of ibuprofen from orally administered 
hydroxypropyl methylcellulose capsules compared to corresponding gelatine capsules. S. T. P. Pharma Sci., 11, 181-185. 3 Nagata, S, Tochio, S., Sakuma, S. and Suzuki, Y., 2001. 
Dissolution profiles of drugs filled into HPMC and gelatin capsules. Poster AAPS Meeting, Denver, 2001 4 Nagata, S., 2002. Advantages to HPMC capsules: a new generation’s 
capsules. Drug Del. Technol., 2(2), 34-39. 5 Satoshi Sakuma, Shinji Tochio, Shunji Nagata. Shionogi Qualicaps CO., LTD. Investigation of the Static Electrical Charging of  HPMC and 
Gelatin Capsules. Poster AAPS  Meeting, Salt Lake City, 2003 6 Evaluation of the properties of HPMC capsules manufactured using different methods. Tomo Uyama, Asami Inui, Tohru 
Kokubo. Qualicaps Co. Ltd., 321-5, Ikezawa-cho, Yamato-Koriyama, Nara 639-1032, Japan. Poster AAPS Meeting, New Orleans, 2010. 7 Ku, M.S., Lu, Q., Li, W., Chen, Y., Performance 
qualification of a new hypromellose capsule: Part II. Disintegration and dissolution comparison between two types of hypromellose capsules. Internationa Journal of Pharmaceutics, 
386 (2010) 30-41. 
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TECHNICAL  
DOSSIER 
 
Hard two-piece HPMC capsules 
produced with the consumer well-
being in mind  
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Technical Dossier 
1 Raw Material Specifications  
1.1 Hypromellose 
Nutra'V capsules are made from hypromellose that complies with the principal 
Pharmacopoeiae: the United States Pharmacopoeia (USP/NF), the European  
Pharmacopoeia (EP) and the Japanese Pharmacopoeia (JP), as well as with the 
pu-rity criteria defined for E464 (HPMC) in Commission Regula-tion (EU) No 
231/2012. 
1.2 Colourants 
The colourants used are in compliance with the EU Directives and when required 
with the requirements of the EP, USP/NF. 
1.3 Purified Water 
The water used by Qualicaps
®
 complies with the requirements of the EP, USP/NF 
and JP. 
1.4 Additives 
Nutra'V capsules contain small amounts of carra-geenan as a gelling agent and 
potassium chloride as a gelling promoter. In addition, carnauba wax is applied as 
a surface lu-bricant on the capsules. These additives comply with the re-
quirements of the  following regulations: carrageenan - the EEC food 
regulations, USP/NF, and Japanese Pharmaceutical Excipients (JPE) regulations; 
potassium chloride - the EP, USP/NF and JP; carnauba wax and/or maize (corn) 
starch - the EP, USP/NF and JP. 
2 Dimensional Specifications 
2.1 Weight 
Capsule weight can vary by ± 10% from the target value. The values are 
determined by weighing a sample of 100 capsules at the standard moisture 
content of 3.0% to 7.0%. Customers should determine tare weights for filling by 
testing samples from in-house batches. These values are not applicable to 
individual capsules but rather to the average of the batch. 
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2.2 Length 
Capsule lengths are controlled in the manufacturing process and audited for 
each batch. 
2.3 Closed Joined Length 
This value is given as a filling machine set-up recommendation and not as an 
approval/rejection criterion for empty capsules. The closed joined length has 
been calculated to ensure the correct location of the special positive locking 
features on the cap and body. If the filling machine is set so that the capsules 
are closed to a shorter length, then the cap or body may be damaged and the 
locking mechanism may fail; if longer, they may come apart. It is 
recommendable to provide this value to packaging equipment manufacturers 
prior to making a decision on blister pocket specifications.  
2.4 Outside Diameter 
The outside diameters, provided as a guideline for evaluating packaging material 
dimensions, are measured by passing the caps and bodies through calibrated 
bushes under specified conditions that simulate those of filling machines. This 
dimension should never be considered as an approval/rejection criterion. 
 
Size  00 0E 0 1 
Weight 
Target weight (mg/100 capsules) 
Weight limits (mg/100 capsules) 
120 
108-132 
110 
99-121 
90 81-99 72 64.8-
79.2 
Capacity Approximate body volume (ml) 0.93 0.76 0.67 0.48 
Outside 
diameter 
Cap diameter (mm) 
Body diameter (mm) 
Tolerance (mm) 
8.57 
8.23 
± 0.06 
7.69 
7.34 
± 0.06 
7.68 
7.34 
± 0.06 
6.92 
6.61 
± 0.06 
Length 
Cap length (mm) 
Body length (mm) 
Tolerance (mm) 
11.84 
20.17 
± 0.5 
11.99 
20.98 
± 0.5 
10.72 
18.44 
± 0.5 
9.78 
16.61 
± 0.5 
Closed  
joined  
length 
Closed joined length (mm) 
Tolerance (mm) 
23.6 
± 0.3 
24.2 
± 0.3 
21.7 
± 0.3 
19.4 
± 0.3 
Size  2 3 4 
Weight 
Target weight (mg/100 capsules) 
Weight limits (mg/100 capsules) 
61 
54.9-67.1 
49 
44.1-53.9 
38 
34.2-41.8 
Capacity 
Approximate body volume (ml) 0.37 0.28 0.21 
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Outside 
diameter 
Cap diameter (mm) 
Body diameter (mm) 
Tolerance (mm) 
6.36 
6.07 
± 0.06 
5.83 
5.56 
± 0.06 
5.33 
5.06 
± 0.06 
Length 
Cap length (mm) 
Body length (mm) 
Tolerance (mm) 
8.94 
15.27 
± 0.5 
8.08 
13.59 
± 0.5 
7.21 
12.19 
± 0.5 
Closed  
joined  
length 
Closed joined length (mm) 
Tolerance (mm) 
18.0 
± 0.3 
15.9 
± 0.3 
14.3 
± 0.3 
3 Visual Quality Specifications (AQLs) 
The visual quality of a capsule batch is determined using sampling plans defined 
in ANSI/ASQ Z 1.4–2008 (normal inspection level, single sampling plan).  
The specifications are derived from the ANSI/ASQ Z 1.4–2008 and assessed on a 
combined sample taken randomly throughout the batch from √N + 1 cartons (N 
is the total number of cartons in the controlled batch). 
Qualicaps
®
 capsules are controlled statistically to ensure conformance to the 
specifications found in the following section. 
4 Visual Acceptable Quality Level (AQL) 
AQL as defined in ANSI/ASQ Z 1.4-2008, is the maximum percent of defective 
units that for the purpose of sampling inspection can be considered satisfactory 
as a process average. A normal inspection level, single sampling plan is used. 
 Defect classification AQL 
 
 Major A 0.015% 
 Major B  0.065% 
 Minor 1.0% 
5 Classification and Descriptions of Visual 
Defects 
Visual defects are classified according to the following definitions: 
Catalogue B    Document B1.3          QualiCaps Technical Info EPoM 
 
357     
• Major A: Affects the performance of a capsule as a package for the final 
product, or could contribute to a major subjective problem in filling. 
• Major B: Would cause a problem on a capsule filling machine. 
• Minor: Has no effect on the performance of a capsule as a package; it is a 
slight blemish that makes the capsule visually imperfect.  
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MAJOR A  
Cracked A cap or body with many splits 
Double dip 
Extra thick cap due to being dipped twice which makes the capsule not 
separate properly 
Failure to separate A joined cap and body that does not separate properly 
Hole An irregular opening in the cap or body 
Joined in lock A capsule in locked position 
Long cap/body Length of cap or body 1 mm more than specified length 
Mashed A mechanically damaged capsule that has been squashed flat 
Pinched Inward cap or body pinches > 3 mm 
Short cap Cap length 1 mm less than specified length 
Short body Body length 0.6 mm less than specified length 
Split A split in the film starting from the cap or body edge > 2 mm 
Telescope 
A closed capsule with a protruding piece of either cap or body produced by a 
double split 
Thin spot (cap shoulder) A thin area in the cap shoulder that may rupture when the capsule is filled 
Trimming 
A piece > 5 mm of, or the whole trimmed end of a cap or body inside a 
closed capsule 
Uncut cap/body An untrimmed cap or body 
 
MAJOR B  
Damaged edge-large 
Roughly trimmed cap edge. The imperfection at its greatest is > 1 mm into 
the specified length 
Double cap A capsule with an additional cap covering the body end 
Different dye speck A coloured spot different from the colour of cap or body 
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Grease Mould release aid spots on the inside of capsule 
Inverted end A cap or body with the end pushed inwards > 3 mm in length 
Long joined A capsule not closed sufficiently to engage the prelock 
Small pinched Inward cap or body pinches < 3 mm 
Thin spot 
A thin area in the cap or body wall which may rupture when the capsule is 
filled 
Turned edge Folded-over edge > 2 mm on body cut line  
Unjoined A single cap or body 
 
MINOR  
Black speck A non-contaminant black spot > 2 mm 
Bubble 
An air bubble in the visible part of the capsule with a diameter  > 
0.4 mm (excluding overlapping area between cap and body) 
Chips, tails 
Small fragments of gelatin > 3 mm still attached or free within the 
capsule  
Crimp Cap or body has external surfaces crimped > 3 mm 
Damaged edge-small 
Roughly trimmed cap edge. The imperfection is V shaped and < 1 mm into 
the specified length 
Dent 
A depression formed in the end of cap or body. The dent is less than half of 
the diameter of the capsule part 
Dye speck A colour spot from the colour of the cap or body > 2 mm 
Grease light Small grease marks > 3 mm 
Scrape A scratch mark > 3 mm on the surface of a cap or body 
Starred end 
An individual imperfection of the tip of cap or body > 3 mm generated by 
turbidity or surface deformation 
Strings Strings between 3-4 mm at the cutting edge 
6 Print Quality Specifications  
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(AQLs) 
The print quality of a capsule batch is determined using statistical sampling 
plans defined in the ANSI/ASQ Z 1.4–2008 (normal inspection level, single 
sampling plan). 
The specifications are derived from the ANSI/ASQ Z 1.4–2008 and assessed on a 
combined sample taken randomly throughout the batch from √N + 1 cartons (N 
is the total number of cartons in the controlled batch). 
Qualicaps
®
 printed capsules are controlled statistically to ensure compliance 
with the specifications found in the following section. 
7 Print Acceptable Quality Level (AQL) 
AQL as defined in ANSI/ASQ Z 1.4-2008, is the maximum percent of defective 
units that for the purpose of sampling inspection can be considered satisfactory 
as a process average.  
A normal inspection level, single sampling plan is used. 
Defect classification AQL 
Major A 
Major B 
Minor 
0.010% 
0.040% 
1.0% 
8 Classification and Descriptions  
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of Print Defects 
Multipl
e 
Images  
(image 
is 
illegibl
e) 
Partial Image  
) 
Smudged Image  
(image is illegible) 
MINOR 
Ink Line/Spot (1-5 mm) 
Misplaced Image  
(off-register; still identifiable) 
Multiple Images  
(image is still legible) 
Partial Image  
(part of image is missing, but still legible) 
Smudged Image  
(image is still legible) 
MAJOR A MAJOR B  
Unprinted Ink line/Spot > 5 mm 
Incorrect Image 
Misplaced Image  
(off-register; not identifiable) 
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9 Chemical Specifications 
10 Microbiological Specifications 
Parameter 
 
Specification 
 
Total Aerobic Microbial Count (TAMC) 
103 cfu/g 
Escherichia coli Absence in 1 g 
Total Yeats and Mould Count  (TYMC) 102 cfu/g  
11 Packaging 
Qualicaps
®
 capsules are supplied in a package that has two components: 
• An inner liner made of a laminate of pharmaceutical-grade materials: 
polyester/polyethylene/aluminium foil. This is heat-sealed after inserting the capsules, 
creating a container with minimal moisture transfer properties. 
• A cuboid cardboard carton of standard dimensions. This protects the inner liner during 
transportation. 
Capsule size 00 0E 0 1 2 3 4 
Capsules per carton in 
000’s* 75 75 100 135 175 225 300 
Cartons size: 60 cm long x 40 cm wide x 75 cm high 
* Tolerance: Capsule quantity variance is ± 5% per delivered carton box 
12 Storage 
Qualicaps
® 
packaging is designed to maintain the quality of the empty capsule between 
manufacturing and filling. It is essential to read and understand the following information in order 
to ensure that Nutra'V capsules maintain their quality during this period. 
12.1 Transportation 
Nutra'V capsules are supplied in sturdy cardboard car-tons, each having heat-sealed, moisture-
proof liners. These cartons may be grouped on a European size case pallet. 
Parameter 
Moisture content/Loss on drying 
Specification 
3.0% - 7.0% 
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12.2 Warehousing conditions  
The conditions in the areas in which capsules are stored or filled can affect the machinability of 
the Nutra'V capsule. The ideal temperature for the storage of capsules should be between 15°C 
and 30°C (59°F and 86°F). The containers should be kept away from exposure to direct heat, 
sunlight and moisture. Maintaining the capsules within the liner bag (without perforations) 
safeguards them from both light degradation and loss of moisture, regardless of ambient 
humidity. Properly stored and sealed containers will provide optimum capsule performance in 
production. 
12.3 Capsule Shelf Life  
Under the aforementioned storage conditions, Nutra'V capsules will maintain their quality for five 
years from the date of manufacture. 
13 Filling Area Conditions  
The moisture content of capsules is directly related to the relative humidity of the air to which 
they are exposed. When capsules are removed from their original packaging (sealed aluminium 
liner) and exposed during the filling process, their moisture content will equilibrate to filling room 
conditions. 
The ideal conditions for a filling area are a temperature between 20°C and 25°C and a relative 
humidity between 35% and 55%, which will maintain the moisture content of the capsules within 
the desired range of 3.0% to 7.0% for Nutra'V. 
An important consideration is to expose the minimum number of capsules required for the 
process at any one time. Some filling machines can generate significant heat during running, and 
this may affect capsules in use. 
The capsule filling machine may be located in a controlled area but the climatization system may 
be operated only during the working day. Empty capsules should preferably be removed from the 
hopper on the filling and/or intermediate conveying equipment if climatic conditions vary from 
the ideal during idle hours.  
For capsule handling, it is best to avoid the use of plastic utensils because this could result in static 
electrical charging that could cause feeding problems on the filling machine. 
14 Regulatory Information 
Nutra'V capsules are made from hypromellose that conforms to current editions of EP/USP/JP 
monographs and with the purity criteria defined for E464 (HPMC) in Commis-sion Regulation (EU) 
No 231/2012. 
• Hypromellose, used as the main raw material in the manufacturing process of empty Nutra'V 
capsules, is de-rived from pine trees. 
• None of the ingredients of Nutra'Vcapsules are of bovine origin and therefore, there is no 
TSE/BSE problem associated to Nutra'V capsules. 
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• None of the ingredients of Nutra'Vcapsules are listed on Commission Regulation 881/2006, and 
therefore can be considered non-risk materials as far as contaminants mentioned in such 
regulation are concerned. 
• Nutra'V capsules do not contain GMOs (genetically modified organisms). 
• Nutra'V capsules do not contained preservatives and are not treated with either Ethylene 
Oxide nor gamma radiations. 
• Neither gluten, sugar, nor lactose are used in the manufacturing process of Nutra'V capsules. 
• The residual level of solvents in capsules fully complies with guideline CPMP/ICH/283/95 
 
 365 
 
Annex 14, Catalogue C Coated Capsules 
 C1. Microbial testing of trial capsules 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IRAS ID 251932           
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 PO Number QIB0117738A 
Bhavika Parmanand 
Quadram Institute Bioscience 
Norwich Research Park 
Colney 
Norfolk 
NR4 7UA 
AR-18-UD-247696-01 
 Reported on 03/07/2018 
 Reported by   Narinder Ramewal, Head of  
Operational Excellence 
Page 1 of 1 
Certificate Of Analysis 
Sample number 400-2018-60163259 Received on 26/06/2018 
  Analysis Started on 27/06/2018 
Your sample reference Capsules Containing inert 
powder 
Your sample code None supplied 
Test Code Analyte Result SOP No. 
Microbiology 
 UMRXB Clostridium Perfringens < 10 cfu/g EUMM3.07 
UM02R Coagulase positive staphylococcus < 20  cfu/g  EUMM3.06 
UMMKF Listeria Species Not Detected  /25 g  EUMM3.19 
UMX0I Moulds 25°C < 10  cfu/g  EUMM3.16 
UMX0I Yeast 25°C < 10  cfu/g  EUMM3.16 
UM8SQ Presumptive Bacillus cereus 30°C < 10  cfu/g  EUMM3.03 
UMPEC Presumptive Enterobacteriaceae 37°C < 10  cfu/g  EUMM3.05 
UMRJX Salmonella Not Detected  /25 g  EUMM3.28 
Unless stated, all results are expressed on a sample as received basis. 
† Indicates that this test was subcontracted Key:  cfu colony forming units 
< denotes less than 
> denotes greater than 
* Indicates that this parameter is not included in the UKAS accreditation schedule for the laboratory. 
Opinions and/or interpretations within this report are outside our accreditation scope. 
 ~ estimated value 
Eurofins Food Testing UK Ltd i54  
Business Park Valiant Way 
Wolverhampton 
WV9 5GB 0342 
 
T +44 (0) 845 2666522 
F +44 (0) 845 6017470 
Regd Office: i54 Business Park 
Valiant Way 
Wolverhampton WV9 5GB 
Regd in England No: 5009315 
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EPoM Food Frequency 
Questionnaire 
This questionnaire asks for some background information about you, especially about 
what you eat. 
Please answer every question. If you are uncertain about how to answer a question then 
do the best you can, but please do not leave a question blank. 
1. On average, how often have you eaten these foods during the intervention 
period? Please answer all questions accurately. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foods Never 1-3 
per 
week 
4 or 
more 
per 
week 
Tofu    
Wholemeal pasta    
Oat meal    
Beans inc. pinto, kidney, soybeans    
Brown rice    
Polished rice    
Chickpeas    
Lentils    
Potatoes    
Peas    
Egg (e.g. omelettes, flans, meringues, cakes, cookies, 
batter 
   
mixes, egg pasta, quorn, mayonnaise, quiches)    
Wheat (e.g. bread, cereals, pasta, pizza, cakes, pies, 
pastry) 
   
White fish (e.g. tuna, fish cakes, battered fish, fish 
fingers) 
   
Shellfish (e.g. crab, prawns, shrimps, lobster, crayfish)    
Oily fish (e.g. mackerel, salmon, sardines, pilchards,    
herring, kipper, white bait, trout, crab, FRESH tuna)    
Peanuts (e.g. Bombay mix, peanut butter, peanut 
brittle, 
   
peanut cookies, sate, some vegetarian meals)    
Tree nuts - almonds, brazil nuts, pecan nuts, hazel nuts, 
walnuts etc. (e.g. in chocolate, crunchy nut cornflakes, 
   
   
Citrus fruits (eg orange, tangerine, grapefruit, lemon, 
lime) 
   
Seeds e.g. sesame, poppy, sunflower  
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2. How many portions of fruit and vegetables do you eat daily? (1 portion is 1 fruit, 1 
bowl of salad, 2-3 tablespoons of vegetables, 1 bowl of fruit salad, a handful of dried 
fruit or a cupful of berries or grapes) 
Less than 1 portion  
1 portion  
2 portions  
3 portions  
4 portions  
5 portions  
More than 5 portions  
 
3. How many cups of coffee/tea do you drink per day? 
 
None  
1   
2   
3   
More than 3  
 
 
4. Please write any additional comments you may think will be of use to the study team: 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this questionnaire. Please hand this questionnaire 
back to a study team member. 
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EPoM Study Participant Capsule Checklist 
Below is a checklist that we require you to fill out as and when 
capsules have been consumed throughout the study. If you do 
forget to consume a capsule, please make a note of it in the space 
provided below. 
Day Date Meal 1 
(2x capsules 
to be taken 
with meal 1) 
Meal 2 
(2x capsules 
to be taken 
with meal 2) 
Meal 3 
(2x capsules 
to be taken 
with meal 3) 
Reason for 
Omission 
Example  02.02.19 x x x - 
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
14      
Please mark the relevant box when you have consumed the required number of capsules for 
each day of the study in this phase. When completed, please tick the box and date the 
statement below: 
 
I can confirm that I have consumed the capsules provided to me at the times indicated in 
the table above  
Date ……………………………………… 
PLEASE REMEMBER TO RETURN THE CAPSULE BOTTLE AT THE END OF THE PHASE 
Participant Code: 
Phase 1/2 (please delete as 
appropriate) 
Treatment A/B (please delete as 
appropriate)  
Date treatment started:  
 
 
Please use this space to provide us with any other information you may feel is relevant to the study: 
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Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
Faecal Collection Kit: 
In order to collect your faecal sample, we have provided you with a faecal collection kit. The 
kit should include: 
o An insulated container with a label on it 
o A plastic pot 
o A plastic bag  
o A nappy sack 
o A plastic clip to close the plastic bag  
o When necessary, a urine sample collection bottle will be included, and we 
would advise you to put this somewhere separate from the faecal collection kit 
until it is required. 
Please can you check your kit to ensure that you have all the items. Although we have 
checked the kit, if anything is missing please contact a member of the study team on the 
study mobile (to be included when available), Bhavika Parmanand on 01603 255021 or 
Dr Lee Kellingray on 01603 255070 before you collect your sample. 
The instructions as to how we would like you to collect your sample are on the other side of 
this piece of paper.  
Please ensure you have read and understood the instructions in advance of trying to collect 
your sample. If you have any questions please get in touch with a member of the study team.  
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Instructions for faecal collection: 
 
 
 
Day of the sample collection 
 
1. Place the labelled plastic bag into the plastic pot as though you were lining a bin, roll the 
excess bag down over the outsides of the plastic pot (note pot will be white not black as in 
picture).  
 
 
2. Collect your faecal sample directly into the labelled plastic bag in the pot. The pot is 
only used to make it easier to hold the bag. Please do not place any toilet paper into 
the pot and avoid collecting any urine in the pot if possible. 
 
3. Once the faeces is inside the labelled plastic bag, roll the top of the bag back up and 
seal the bag, close to but not touching the sample, using the plastic clip provided. 
Remove the sealed bag from the plastic pot and throw the plastic pot away in your 
normal domestic waste. 
 
4. Place the sealed bag inside the nappy sack and tie the nappy sack shut using the bag 
handles. 
 
5. Place the tied nappy into the insulated container. Close the lid of the insulated 
container and clip it shut to secure it. Wash your hands. 
 
6. Please write your volunteer number, and the date and time of collection on the label 
on the outside of the insulated container. 
 
7. Please call the study mobile (to be included when available), or a study scientist 
Bhavika Parmanand on 01603 255021 or Dr Lee Kellingray on 01603 255070 
before you deliver your sample so that we can be ready to receive it.  
 
8. If for any reason a study scientist is unable to take your call, you can contact the 
Clinical Research Facility (CRF) (to be included when available). If you call the 
CRF and the answer phone is on it means there is no one at the CRF and you will need to 
contact one of the study scientists on the numbers above.   
 
Thank you very much. 
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Effect of Phytin on Human Gut Microbiome 
(EPoM Study) 
 
Stool chart 
 
 
• This stool chart will allow us to monitor and record any changes to gut function during the 
study period.  
 
• During the periods outlined below we would like you to keep a record of each stool using the 
Bristol stool chart on page 2 to identify the type of stool. During these periods, we would also 
like you to record whether you see any blood or mucus on/in your stool and rate any 
experience of abdominal discomfort/pain, abdominal bloating, straining when opening your 
bowels (constipation), and/or flatulence for each day, leaving a gap to separate each day 
(example on page 3). 
 
• Ladies who are menstruating at the time entries are added to the stool chart should mark M in 
the box referring to stool type as this may help to interpret the data. 
 
• We would like you to keep this record for 7 days whilst consuming each of the supplied 
capsules, during both Phases  
 
 
• You can choose which days to complete, but ideally it must be 7 consecutive days.  If this is 
not possible, then the 7 days should include one weekend. 
 
• Key to gastrointestinal sensations: 
              None – no discomfort. 
Mild – minimal discomfort but not interfering with everyday activities. 
Moderate - causes interference with everyday activities. 
Severe – prevents normal everyday activities. 
 
 
 
 
 
Please call Bhavika Parmanand on 01603 255021 
or Dr Lee Kellingray on 01603 255070 
OR the study mobile (to be included when available) 
during normal working hours for any help. 
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Towards the bottom of the stool chart, which we would like you to complete, you will notice questions 
relating to any changes in medication. Should you have any changes to your medication, or start 
taking any medication of any kind, we would appreciate it if you could record what is being taken, any 
changes such as increased/decreased dose, date the medication was taken/changed, and the reason 
for taking/changing the medication. 
 
The QI CRF Research Nurse may contact you by telephone to discuss information on the stool chart 
and might advise you to speak to your GP should it be deemed necessary, as well as advising on your 
continuation or exclusion from the study.  
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If you suffer from diarrhoea during the study, we would like you to contact a member of the study 
team and you will be asked to not collect a faecal sample for a minimum of 48 h after the last episode 
of diarrhoea. Should the diarrhoea persist for more than 72 h, you may be advised by the 
QI CRF Research Nurse to speak to your GP and will be excluded from the study. 
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EPoM study stool chart example: 
 
Date Time Type 
(refer 
to 
Bristol 
stool 
chart) 
Abdominal 
discomfort 
(none, 
mild, 
moderate, 
severe) 
Abdominal 
pain 
(none, 
mild, 
moderate, 
severe) 
Type of 
abdominal 
pain (dull 
ache, 
sharp pain, 
cramping) 
Bloating 
(none, 
mild, 
moderate, 
severe) 
Constipation 
(none, mild, 
moderate, 
severe) 
Flatulence 
(none, 
mild, 
moderate, 
severe) 
Colour  
(pale 
cream, 
light 
brown, 
dark 
brown, 
black) 
Blood 
Y/N 
If yes, 
what 
colour 
(bright 
red, dark 
red) 
Mucus 
Y/N 
01/06/19 09:05 3 none none none none none none Pale cream N Y 
01/06/19 14:25 2 none none none mild none moderate Light 
brown 
Y 
Bright red 
N 
            
02/06/19 10:50 4          
M 
none none none none none none Dark 
brown 
N N 
02/06/19 17:15 2          
M 
mild       none none none        none mild        Light 
brown 
N N 
            
03/06/19 All day none moderate moderate dull ache mild severe severe n/a n/a n/a 
 
 
Have there been any changes to your medication?   Y N 
What is the medication? Senokot…………………………………………………………………………………………………………………………………………………………………… 
How has your medication changed? Took 2 tablets………………………………………………………………………………………………………………………………………. 
When did your medication change? Tuesday 01st January 2019 at 10pm…………………………………………………………………………………………………………….... 
For what reason did your medication change? I was constipated and experiencing abdominal pain ……………….................................................................. 
............................................................................................................................. ............................................................................................................................................................................. 
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[Insert Date] 
[Participant Address] 
 
 
Dear_____________________________, 
 
Re: Effects of Phytin on Human Gut Microbiome (EPoM Study) 
 
I am writing to confirm your decision to withdraw from the EPoM study. I can confirm that your 
withdrawal from this research study will not affect your clinical care and participation in future 
studies at the Quadram Institute Bioscience or Norfolk and Norwich University Hospitals. No further 
data or sample will be collected from you, however, identifiable data or samples already collected 
with consent will be retained and used in this study if possible.  
 
You will not be contacted again or be asked to provide any information in relation to the EPoM 
study, however, if you would like to discuss the withdrawal procedure in more detail, please do not 
hesitate to contact a member of the study team (contact information can be found in the participant 
information sheet and towards the end of this letter). 
 
We would like to thank you for your participation in this study. 
 
Yours sincerely, 
 
 
 
Miss Bhavika Parmanand 
Tel: 01603 255021 
Email: bhavika.parmanand@quadram.ac.uk 
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REPORT ON ADVERSE EVENT (AE)/REACTION (AR)/SERIOUS ADVERSE EVENT (SAE) 
(SAE/SUSAR-internal use only as the official NRES form will be used and signed off by Chief Investigator) 
 
Adverse Event / Adverse Reaction (circle as appropriate)  
 
Study Title: EPoM 
 
REC reference:…………………………………..  
 
Participant Code Number:………………..   Date of Birth: ………………………...      Age: ……………………. 
 
Male/Female (delete as appropriate) 
 
Date/Time of occurrence: ………………………………..  Date/Time reported: ……………………………..... 
 
Reported to (initially): …………………………………….  Place of occurrence: ………………………………    
 
 
Description of AE/AR/SAE/SUSAR: 
 
Extent of Adverse Event (delete as appropriate):        Mild       Moderate     Severe 
 
Treatment/Action:……………………………………………………………………………………………………………………. 
 …………………………………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………………………………  
Outcome (delete as appropriate):      Recovered      Not yet recovered         Unknown 
 
Description of Trial Material:  
 
Drug Reaction (delete as appropriate):  Certain    Probable    Possible    Unlikely    Unclassified  
 
Reporter details (print name):……………………………….Title:……………………………………………………………… 
 
Signature of QI CRF Medical advisor …………………………………………………………….. Date:……………………………………………….. 
 
 
 
Professional Address:   CRF, QI, James Watson Road, Norwich, NR4 6UQ    Tel. Number: to be included when available 
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Chief Investigator   Professor Arjan Narbad  
 
Signature:                                                          Date:        
 
 
Professional Address:  QIB, Colney, Norwich, NR4 7UA    Tel. Number: 01603 255131 
 
Comments by QI CRF Medical advisor:  
 
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
 
Participant’s screening questionnaire attached (circle as appropriate):   Yes   No 
 
If ‘No’ state reason:……………………………………………………………………………………….. 
 
N.B. please ensure any relevant paperwork is attached  
 
 
 
 
 
 
 
 
 
 
QI CRF medical advisor 
 
Name:............................................................................................................................................... 
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Professional Address: 
 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
Telephone No.: ……………………………………………………………………………………………. 
 
 
Signature:……………………………………… Date:………………………………………………… 
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Joint Arrangements for Research 
Serious Adverse Event report 
1. What are you reporting? 
SAE / SAR  SUSAR*  
*Note: If you are reporting a SUSAR the randomisation code for that participant will have to be unblinded 
Report Type: Initial      Follow-up Report   Follow-up Report #       
2. Study information 
Study Title: (short)       
Sponsor:       
Chief Investigator Name:      
Email Address:      
Eudract 
Number:       
(for CTIMPs only)  
R&D Reference  
Number / IRAS Number:       
Protocol title and version number:       
Site Number:       
(for multi-site studies only) 
Site Name:       
Principal Investigator 
Name:       
Email address:       
Date of site becoming aware of the event (dd/mm/yy):       
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3. Participant information 
Participant DOB: 
(dd/mm/yy) 
      
Participant initials: 
      
Participant Gender:  
Male            Female 
Participant Randomisation No:       
Evaluation of Event 
4. Event/Reaction: (keywords; e.g. body site, symptoms, severity, treatment) 
      
5. Date of onset:       
(dd/mm/yy) 
6. Date person completing form became 
aware of event:       
(dd/mm/yy) 
7. Criteria for definition as SAE *: 
 Congenital abnormality/birth defect 
 Resulted in death 
 Life threatening 
 In patient hospitalisation/prolongation of hospitalisation  
Persistent or significant disability 
* If there is more than one criterion, choose the more/most significant one. 
8. Describe event: (A summary of signs and symptoms, diagnosis, treatment of event, concurrent treatment, 
other relevant medical history, including re-challenge details if applicable. Please include the point in the study at 
which the event occurred.) 
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9. In the 
investigators 
opinion was the 
event related to a  
research 
procedure? 
 Definitely 
 Likely 
 Possibly 
 Unlikely 
 Not related 
10. Please specify 
which procedure if 
applicable 
 
11. Is the study a Clinical Trial of Investigational Medicinal Product (CTIMP)? 
 Yes Please answer questions 12-17 
 No Please go to question 18 
12. In the 
investigators 
opinion was the 
event related to the 
Investigational  
Medicinal Product? 
 Definitely 
 Likely 
 Possibly 
 Unlikely 
 Not related 
13. Action taken 
with study drug:  None 
 Dose temporarily reduced 
 Dose reduced 
 Discontinued temporarily 
 Discontinued 
14. If related to IMP was this reaction unexpected (Suspected Unexpected 
Serious Adverse Reaction – SUSAR)? 
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 Yes 
 No 
 Not applicable 
15. Did 
event/reaction 
abate after 
stopping drug? 
 Yes 
 No 
 Not applicable 
16. Did 
event/reaction 
reappear after 
reintroduction of 
drug? 
 Yes 
 No 
 Not applicable 
17. IMP & concomitant medication information 
 
(Please complete Appendix 1) 
18. Have urgent safety 
measures been 
implemented? 
 Yes 
 No 
 Not applicable 
If yes, please detail below:       
Outcome of event 
19. What is the 
outcome of the 
SAE?  
20. Date event resolved: 
(dd/mm/yy) 
21. Date patient died: 
(dd/mm/yy) 
 Recovered 
 Recovered with 
sequalae 
 Continuing 
 Resulted in death 
 Unknown 
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22. Cause of death obtained from: 
 Coroner’s inquest 
 Death certificate 
 Working diagnosis 
Contact and signatures 
Please supply contact details where further information may be obtained: 
23. Person to  
     
contact: 
24. Phone number:       
25. Email address:       
______________________ 
_ 
            
Signature (person completing  
report) 
______________________ 
Print name Date (dd/mm/yy) 
_             
PI Signature (if multicentre trial) 
______________________ 
Print name Date (dd/mm/yy) 
_             
CI Signature (if not completing  Print name Date (dd/mm/yy) 
report) 
If the study is sponsored by NNUH please send the completed form to rdsae@nnuh.nhs.uk . 
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If the study is sponsored by the University of East Anglia and Hosted by NNUH, please scan 
and email the form to researchsponsor@uea.ac.uk and rdsae@nnuh.nhs.uk.   
For R&D Office use only 
Date form RECEIVED by R&D 
team: (dd/mm/yy) ( ___ 
/___/____) 
Reviewed by:                                 Date reviewed: 
                                                        (dd/mm/yy) 
                                                       ( ___ /___/____) 
For SUSAR only: 
Date reported to the REC: ( ___ /___/____) 
Date reported to MHRA: ( ___ /___/____) 
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Appendix 1 
Section 17: IMP & concomitant medication information 
Drug details (Daily dose and generic name) Route of  
Administration  
(IV / Oral etc.) 
Therapy Start  
Date  
(dd/mm/yy) 
Therapy End  
Date  
(dd/mm/yy) 
Date of last  
Administrered  
Dose prior to  
SAE onset  
(dd/mm/yy) 
Indications for Use 
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Annex 22        Insurance Letter      EPoM     Version 1     12.Sep.18  
  
Quadram Institute Bioscience  
Norwich Research Park  
Colney  
Norwich NR4 7UA  
UK  
 www.quadram.ac.uk   
  
 
3 rd October 2018  
To Whom It May Concern  
Dear Sir or Madam,  
The PHYTIN Study — Effect of ehytin on the Human Gut Microbiome (EPoM) IRAS Number 251932.  
The Quadram Institute will maintain is current liability Insurance with the same insurer in 2018. The Institute 
has liability insurance in respect of research work involving human volunteers. The insurances comprise of:  
1. No Fault Compensation for Clinical Trials/Human Studies  
   for any one occurrence & in the annual aggregate    
2. Legal Liability for Clinical Trials/Human Studies  
 for any one occurrence & in the annual aggregate  
3. Medical Malpractice  for any one occurrence & in the annual aggregate  
No Fault Compensation for Clinical Trials/Human Studies  
Compensation for bodily injury arising out of any Human Study or Healthy Volunteer Study conducted by 
QIB or on its behalf in connection with QIB business. Claims are covered only if they are made during the 
period of insurance.  
Legal Liability for Clinical Trials/Human Studies  
Legal liability to research subjects for bodily injury arising out of any Human Study conducted by QIB or on 
its behalf in connection with QIB business. Claims are covered only if they are made during the period of 
insurance.  
o The Insured shall also include any past employee who acted for the Insured and who agrees to be 
bound by the terms of the policy.  
Quadram Institute Bioscience is a registered charity (No. 1058499)   
and a company limited by guarantee (registered in England and Wales No. 03009972).   
VAT registration No. GB 688 8914 52  
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o Any sub-contractor, doctor, consultant physician, hospital or contract research organisation or 
nurse who will be performing work for the Insured in respect of Study/Trial are covered by this 
policy excluding liability which arises out of their own act error or omission outside the terms or 
instructions of the Study/Trial protocol.  
Medical Malpractice  
Legal liability to third parties arising from medical malpractice. Claims are covered only if they are made 
during the period of insurance, excluding any claim which is the subject of insurance indemnity or  
assistance provided by any Medical Defence Organisation or arising from products supplied.  
The attached Schedule gives further details of all QIB liability insurances.  
  
Dave Foreman  
Finance Director  
Annex 23 Assessment Day Checklist  EPoM      Version 1              12.Sep.18 
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Is the participant willing to continue with the study?  
(If no, do not continue study)  
  
  
Allergies?         Y ________N______   If yes, please state   ________________________________________________  
  
 Weight    kg  
  
Has the participant developed any illnesses/medical conditions since the last study visit?   YES / NO  If 
YES:  
Symptoms  
Description  
Onset Date  
Severity:  
1= mild; 2=moderate;  
3=severe;  
4= life threatening  
A 
E  
/  
S 
A 
E   
Comments/ Action taken  
  
  
  
___ ___/___ ___/___ ___   
    
  
  
  
  
  
  
___ ___/___ ___/___ ___   
    
  
  
  
  
Has the participant started medication or changed anything about his/her current medication/supplements since  
 the last visit?                         YES / NO  
If YES:  
Medication /  
Supplements  
  
Dosage /  
Frequency 
change  
Date of Change  Reason  Comments/Action 
taken  
      
___ ___/___ ___/___ ___  
  
    
      
___ ___/___ ___/___ ___  
  
    
            
Please use this space to provide us with any other information the participant may feel is relevant to the study:  
Comments: Exclude / Postpone / Continue study day (circle)  
Name of CRF Research Nurse/Study Scientist (circle)  
(PRINT)…………………………………………………  Signature…………………………………Date ___ ___/___ ___/___ ___  
  
Effect of Phytin on Human Gut Microbiome (EPoM Study)  
Assessment day  c heck list  
  
Participant Code :   _____________   Date: ___ ___/ ___ ___/   ___ ___    Treatment: AB/BA (circle)         
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Annex24                       QIB Funding ISP Letter                             Version 1                         EPoM Study  
                
     Quadram Institute Bioscience   
Norwich Research Park   
Colney   
Norwich NR4 7UA   
                                                                                                   UK 
 www.quadram.ac.uk    
   
  
      25th July 2018   
   
To whom it may concern   
   
   
I hereby confirm that the Quadram Institute Bioscience is in receipt of £5,358,691.17 funding 
from the BBSRC, reference BB/R012512/1, for the Food Innovation and Health Institute Strategic 
Programme Grant starting 1st April 2018 and ending 31st March 2022.     
   
   
   
   
Yours sincerely   
   
   
   
Dr Mary Anderson   
Head of Contracts   
